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Abstract 
Competing risks analysis is more appropriate than standard survival analysis 
when there are two or more mutually exclusive possible events, and investigates 
which one of the events occurs first. Competing risks analysis constitutes the 
simplest form of multi-state modelling. Multi-state modelling more generally 
extends the competing risks approach to consider events of interest that can 
occur after the first event. However, competing risks and multi-state modelling 
have not been used to their full potential in health research. The aim of this 
thesis is to demonstrate the potential of multi-state modelling in an 
epidemiological and health economics context, in areas where it is not widely 
applied. Focus is on two case studies – one in epidemiology and one in health 
economics. 
The first case study is in stroke epidemiology and investigates the outcomes 
stroke recurrence and death. The research is thought to be the first to 
comprehensively examine the competing risks stroke recurrence and death 
without recurrence. It demonstrates the clinical insights that can be gained by 
decomposing a composite outcome and by studying the cumulative incidence of 
each event alongside the hazards that drive them. Furthermore, an illustration 
of the flexibility in predictions of multi-state modelling is given. Predictions at 
the start of the study and as time progresses are demonstrated. 
The second study is in health economics and is based on a technology appraisal 
submitted to the National Institute for Health and Care Excellence in the UK. An 
objective of this thesis is to compare multi-state modelling with the two 
common approaches of Markov decision-analytic modelling and partitioned 
survival. This comparison shows that the conventional decision-analytic 
modelling and multi-state modelling differ substantially when the assumptions 
vary between the approaches, but produce equivalent results when they make 
the same transition assumptions. Therefore, the greatest influence on the 
clinical and cost-effectiveness results is the choice of assumptions rather than 
the modelling approach used itself. The research highlights it is imperative to 
check that any assumptions made are realistic. The comparison of the 
approaches shows any output required from the conventional approaches can 
just as easily be produced using multi-state modelling. It is hoped this research 
will encourage further adoption of multi-state modelling, in the many areas 
where it has not yet reached its full potential. 
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 Introduction 
 Background  
Survival analysis is a well-established technique in the fields of 
epidemiology/medical statistics and health economics. It is widely applied in the 
form of standard survival analysis which involves only one event of interest. This 
typically involves investigating all-cause mortality as an outcome or a composite 
outcome comprising of a non-fatal event(s) and death. These outcomes are often 
studied as part of a randomised clinical trial in both medical statistics and health 
economics. In the former, the efficacy/effectiveness of an intervention is of 
interest while in the latter the cost-effectiveness of an intervention is of overall 
interest. However, a major component in the analysis of cost-effectiveness is 
effectiveness and, in health economic modelling that involves the outcomes 
described above, survival analysis is often used to investigate the (quality-
adjusted) life years gained from an intervention. 
Frequently however, standard survival analysis may be too restrictive to answer 
the research question of interest because more specific events are of interest. 
For instance, interest may be in specific causes of death rather than all-cause 
mortality, or in a non-fatal outcome specifically rather than a composite one. 
These scenarios are termed “competing risks” and require a different approach 
to analysis than standard survival analysis. Competing risks analysis focuses on 
identifying which of two or more mutually exclusive events occur first, and in 
that sense the risks are competing with one another to be the first to occur and 
hence the event. The competing risk that occurs precludes the other competing 
risk(s) from being the event to occur first. For example, a specific cause of 
death would be considered a competing risk for another cause of death.  An 
alternative definition of a competing risk is an event that precludes an event of 
interest, or otherwise affects the risk of it occurring. Consequently, competing 
risks scenarios need not just involve death. Non-fatal outcomes can also act as 
competing risks. For instance, hospital discharge should be treated as a 
competing risk when interest is in in-hospital infection. In another common 
scenario that arises, death should be treated as a competing risk when analysing 
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a non-fatal outcome. However, Koller et al. (2012) performed a literature 
review that found that competing risks, and the issues that require consideration 
when faced with such a scenario, were not widely recognised in the clinical 
literature. This was particularly the case in high impact clinical journals. 
Standard and competing risks survival analysis constitute the simplest forms of 
modelling under the more general multi-state modelling survival analysis 
framework. Multi-state modelling more generally extends the competing risks 
approach to also consider events of interest that can happen after the first 
event. It is therefore applicable when at least one of the events is non-fatal. In 
a multi-state modelling situation, a first event(s) that is studied as part of a 
competing risks analysis is considered to be an intermediate state(s) between 
the initial and final states, all of which are of interest. This is the case 
particularly when studying the course of a chronic and/or progressive disease. 
For instance, a competing risks analysis might involve following patients in an 
initial healthy state to see which one of the two events/states of interest non-
fatal illness or death they experience first. In a multi-state model, the non-fatal 
illness state would act as an intermediate state between the initial healthy state 
and final death state. 
One of the main advantages of multi-state modelling over standard and 
competing risks survival analysis is the flexibility in predictions it can 
accommodate. Predictions of being in different health states over time can be 
estimated as patients enter the initial health state. Furthermore, dynamic 
predictions can be carried out, that is to say predictions as time progresses, 
especially as patients progress to other health states. These latter predictions 
are particularly applicable in an epidemiological/medical statistics context, but 
do not appear to be widely applied. In a health economics context, multi-state 
modelling falls under the umbrella of state-transition modelling, a common 
approach in health economic modelling. However, as this thesis will show, multi-
state modelling is under-used in the field of health economics. Multi-state 
modelling for cost-effectiveness analysis has great potential as an alternative to 
conventional spreadsheet-based approaches. It is syntax-based providing a 
transparent record of the analysis and it makes errors easier to spot. 
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Furthermore, it explicitly allows testing of the Markov property by simply adding 
a relevant covariate and semi-Markov modelling does not require tunnel states. 
In addition, the building of Markov multi-state models is less cumbersome and 
time-consuming; such models can be created in seconds.  
 Overall aim and objectives 
The overall aim of this thesis is to demonstrate the potential of multi-state 
modelling in an epidemiological and health economics context, in areas where it 
is not widely applied. Two case studies are used to provide focus – one in 
epidemiology and one in health economics. The first case study is in stroke 
epidemiology with the outcomes recurrence and death.  
Objectives in this stroke epidemiology context are: 
 to investigate the up-to-date use in the literature of competing risks and 
multi-state modelling for analysing the outcomes recurrence and death 
 to demonstrate the added insight gained from using competing risks 
analysis and multi-state modelling over and above standard survival 
analysis. 
The second case study, which is in health economics, is based on a technology 
appraisal (TA) submitted to the National Institute for Health and Care Excellence 
(NICE) in the UK. This particular TA involved evaluating the cost-effectiveness of 
rituximab in combination with fludarabine and cyclophosphamide, compared to 
fludarabine and cyclophosphamide alone, for the first-line treatment of chronic 
lymphocytic leukaemia. The Evidence Review Group working on behalf of NICE 
had some concerns about the economic model submitted by the manufacturer 
and instigated some sensitivity analyses of their own. However, there was scope 
to show how multi-state modelling could provide an alternative to the common 
approaches adopted by modellers performing economic evaluations. 
 Objectives in the health economics context are: 
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 to explore the use of multi-state modelling in the health economics 
literature 
 to compare multi-state modelling with two common approaches applied in 
health economic modelling, namely Markov decision-analytic modelling 
and partitioned survival. 
In recent methodology guidance issued by the NICE Decision Support Unit [Woods 
et al. (2017)], the two publications that accompany this thesis have been cited 
to help raise awareness that multi-state modelling can provide an alternative to, 
or complement, cost-effectiveness analyses conducted using partitioned survival 
and more conventional Markov decision-analytic state-transition modelling. The 
guidance also outlines some of the advantages, compared to partitioned 
survival, of the conventional discrete-time approach to decision-analytic state-
transition modelling and that of continuous-time multi-state modelling. In 
particular, it highlights some benefits pertaining to conceptualising the model, 
for a decision problem involving patients who experience distinct health states 
and possible transitions  between them, as a discrete or continuous-time state 
transition model. These include, for intermediate states, incorporating 
sensitivity analyses of the effect of treatment and extrapolations that can be 
based on external data focused specifically on those health states, allowing 
assessment of clinical plausibility.  
The “cognitive dissonance” of using the partitioned survival approach when 
health states and transitions are involved also means there is not a formal 
structural link between morality and earlier intermediate events. For example, 
in an illness-death model of progression-free, progression and death, mortality 
depends on all three individual transitions, with the rate of death reflecting the 
evolving proportion of patients in the progressed state and the differences in 
mortality between progression-free and progressed patients [Woods et al. 
(2017)]. 
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Additional contributions of continuous-time multi-state modelling to the 
methodology and application of cost-effectiveness analysis emphasised in this 
thesis include: 
• The ability to test the Markov property in a straightforward manner simply 
by including in the model a covariate that represents time in a previous state, or 
a function thereof. If evidence is found that the Markov property does not hold, 
or it is not thought to hold, then analysis can progress using a semi-Markov 
approach. This explicit assessment of whether the Markov property holds can 
often be overlooked in more conventional state-transition modelling. That 
possible violations of the property can be investigated with such ease, adds 
another tool for modellers to help them decide whether a Markov or semi-
Markov is more appropriate therefore improving face validity of models. 
• The implementation of semi-Markov modelling, under the continuous-time 
approach demonstrated in this thesis, avoids the need for some of the aspects 
that make the approach more complex under the more conventional discrete-
time framework. For example, there is no need for tunnel states, matrix algebra 
involving discrete cycles or complicated microsimulation. In addition, if a 
modeller wants transitions to be based on trial data, unlike a Markov approach, 
the semi-Markov approach can be implemented without the individual patient 
level data. It only requires access to Kaplan-Meier curves that can be digitized if 
necessary. 
• The analysis only involves one software package and as such is 
streamlined while the use of coding provides transparency. All the calculations 
performed on the data can be viewed together in a file that provides a 
traceable, annotated written record of the analysis. This can make it easier to 
keep track of what aspects of the code have been updated, and avoid the 
accidental changes that can occur if a cell is inadvertently amended when using 
spreadsheet-based approaches. The model building process is quick; all aspects 
of implementation such as estimation and prediction can be run in seconds.  
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The transparency of the annotated coding also better facilitates model sharing in 
an open-source environment. This can help with reproducibility, validation and 
standardisation of models and ensure that those working in a similar area do not 
need to start from scratch. It can also satisfy the growing culture amongst 
journals of requiring syntax with submissions and the increasing popularity of 
sharing code on websites such as Github. This thesis will demonstrate that multi-
state modelling, an approach better known in other disciplines such as medical 
statistics, can easily be adapted for use in health economic modelling. It will 
illustrate that anything that can be built using the more conventional 
spreadsheet-based approach can also be similarly transparent, and it has 
provided a foundation to extend this to other health economic models in the 
future. 
 Structure of the thesis  
Chapter 2 emphasises that the presence of competing risks requires a different 
approach to analysis than standard survival analysis, and proceeds to describe 
approaches to competing risks survival analysis. Intertwined with this, it also 
highlights key issues that should be considered when faced with a competing 
risks scenario. In addition, a review of the extent to which competing risks are 
recognised is given, both in the broad clinical literature and for stroke 
recurrence and death without recurrence specifically. The latter identifies gaps 
in the research that motivates the empirical analysis of my stroke epidemiology 
case study in the next chapter. 
Chapter 3 presents competing risks analyses of the outcomes recurrence and 
death without recurrence in stroke patients. In particular, it highlights the extra 
insight that can be gained from decomposing a composite outcome into 
competing risks. Furthermore, both the cause-specific hazard and Fine and Gray 
(1999)’s proportional subdistribution hazard approaches to modelling are 
demonstrated. The greater understanding that can be gained when both the 
hazards and cumulative incidences/subdistribution hazards are investigated for 
each of the competing risks is then outlined. In addition, the bias that can be 
introduced when competing risks are not taken into account is highlighted. 
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In Chapter 4 the multi-state modelling survival analysis framework is described. 
In addition, a review is undertaken of multi-state modelling of stroke, 
recurrence and death which provides the scope for the empirical analysis in the 
following chapter.  
Chapter 5 presents illness-death modelling of stroke, recurrence and death; a 
particular type of multi-state model. The results of the effects of covariates on 
all relevant transitions between health states are shown and interpreted. 
Furthermore, illustrations are given of predictions at the time of the index 
stroke, and dynamically taking into account the time elapsed and any 
subsequent events since the stroke. In addition, the extra insight gained from 
this multi-state modelling approach over and above the competing risks analysis 
in Chapter 3 is highlighted. 
Chapter 6 summarises partitioned survival and Markov decision-analytic 
modelling, two common approaches in health economic modelling. This overview 
of the methods provides fundamental background prior to an analysis comparing 
them with multi-state modelling in the next chapter. Furthermore, a review is 
given of the contributions in the literature involving multi-state modelling in a 
health economics context. Important methodological issues and barriers to 
adoption of the approach are highlighted. Chapter 6 then discusses the 
assessment of fit of models over the observed period of a study. Finally, the 
important concept in health economic modelling of extrapolation of outcomes 
beyond the observed data in order to take a lifetime perspective is described. 
This will be taken into account in the comparison presented in the next chapter. 
In Chapter 7 a case study in a health economics context is used to illustrate and 
compare the Markov decision-analytic modelling, partitioned survival and multi-
state modelling approaches. Furthermore for the multi-state modelling, the 
primary focus of this thesis, one-way and probabilistic sensitivity analyses will be 
presented to explore any uncertainty in the conclusions with regards to cost-
effectiveness. 
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Finally, Chapter 8 summarises the main insights revealed by the analyses in the 
empirical chapters. In addition, limitations of this thesis are discussed and 
possible scope for developing this research further is outlined. 
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 Background to competing risks method 
 Introduction 
This chapter provides an overview of the competing risks methodology under the 
survival analysis framework, giving the background to the empirical analysis in 
the next chapter. As well as describing the technique, this chapter highlights key 
issues that need to be considered when faced with competing risks. Section 2.2 
emphasises that standard survival analysis is only applicable with one event of 
interest. It then proceeds to point out that if patients are at risk of two or more 
events, that affect the risk of the other(s) occurring first, then an approach that 
takes into account such competing risks is required. Since the need for a 
competing risks approach is not always recognised, section 2.2 continues by 
stressing the definition of a competing risks problem and outlines common 
scenarios when an approach that takes into account competing risks is required. 
Section 2.3 then explains why the Kaplan-Meier approach in standard survival 
analysis is not appropriate when competing risks are present. In sub-section 
2.3.1 the more appropriate competing risks cumulative incidence approach is 
introduced. Section 2.4 concentrates on describing modelling approaches with 
competing risks data. Its main focus is on the two most widely-applied methods 
of cause-specific hazards modelling and Fine and Gray’s proportional 
subdistribution hazards model. Then, section 2.5 discusses the issue that the 
effect of a covariate on the cause-specific hazard is not necessarily the same as 
its effect on the cumulative incidence. Section 2.6 is devoted to highlighting 
that the cumulative incidence can be derived from cause-specific hazard 
modelling. Next, section 2.7 considers issues related to variable selection with 
competing risks approaches. In section 2.8, two schools of thought with regard 
to the use of the two common approaches to modelling competing risks are 
outlined. The first is that the research question should drive the modelling 
approach used. The second strategy is that both the cause-specific hazard and 
cumulative incidence should be considered for each competing risk, to gain a full 
understanding of the competing risks scenario under consideration. Next, section 
2.9 emphasises the extra insight that could be gained by decomposing a 
composite outcome into each of its competing risks component parts.  
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Contributions from the literature are used in the aforementioned sections of this 
chapter to help describe the competing risks method and highlight issues that 
arise over and above standard survival analysis. Because these sections are 
discussing the key methodological issues that repeatedly appear in the 
literature, a robust search strategy was not developed to review all such 
contributions to the literature. However, for the final section of this chapter 
section 2.10, a search strategy was developed in order to review the extent of 
use of competing risks in the literature. This had a particular focus on stroke 
epidemiology to identify gaps in the existing research to motivate the empirical 
analysis of the stroke case study in the next chapter. Furthermore, throughout 
this current chapter – i.e. the background to the method, the methodological 
issues raised and the review of the extent of use in the literature – 
misconceptions and misunderstandings relating to some of the methodological 
issues are highlighted. The purpose of this is to alleviate the confusion that can 
arise from some of the conflicting messages in the literature.    
This chapter is concerned with competing risks in the standard case when all 
event times are observed exactly or are right-censored. Readers interested in 
competing risks involving interval-censored and truncated data may find the 
contributions by Hudgens et al. (2001), Hudgens et al. (2014) or Li (2016) useful.  
 Competing risks: definitions and common scenarios 
Survival analysis is a commonly-applied statistical method in medical research. It 
is used for time-to-event analysis where patients are followed up to see 
whether, and when, they experience an event of interest. In the standard (non-
competing risks) survival analysis setting there is one event of interest, such as 
any-cause mortality or a composite outcome combining a non-fatal event and 
death. Typical approaches used for analysis include the Kaplan-Meier survival 
estimator and Cox proportional hazard regression modelling. However, often 
there are situations where patients are at risk of two or more mutually exclusive 
events, which affect the risk of each other, and this requires a different 
approach. In such situations there is a competing risks scenario. The risks are 
said to be “competing” with each other to be the first event. For instance, two 
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different causes of death act as competing risks because only one of them can 
occur. Another example of competing risks are hospital discharge and in-hospital 
infection, in that discharge affects the risk of in-hospital infection by preventing 
it occurring first. 
There has been a wealth of literature that provides an overview of the 
competing risks method in both the medical statistics/clinical epidemiology field 
[e.g. Fine and Gray (1999), Putter et al. (2007), Pintilie (2007a), Lau et al. 
(2009), Varadhan et al. (2010), Allignol et al. (2011), Tai et al. (2011), Andersen 
et al. (2012), Bakoyannis and Touloumi (2012), Koller et al. (2012), Latouche et 
al. (2013)] and in the wider general clinical literature [e.g. Satagopan et al. 
(2004), Kim (2007), Dignam and Kocherginsky (2008), Pfirrmann et al. (2011), 
Dignam et al. (2012), Austin et al. (2016)]. Most of the contributions giving such 
an overview provide a formal definition of a competing risk. A commonly used 
definition of a competing risk is that it is an event that precludes an event of 
interest. This is the sole definition used in the work by Lau et al. (2009) and 
Koller et al. (2012). However, this definition does not convey every scenario in 
which competing risks can be present. It implies only deaths can be competing 
risks. Gooley et al. (1999), Satagopan et al. (2004), Mell and Jeong (2010), 
Chappell (2012) and Wolbers et al. (2014) use the more comprehensive definition 
that a competing risk is an event that precludes the event of interest, or 
otherwise modifies the probability of experiencing the event of interest. 
Therefore, they recognise that competing risks need not be limited to deaths, 
and that non-fatal events can also act as competing risks. Similarly, Bakoyannis 
and Touloumi (2012) and Austin et al. (2016) use the definition that a competing 
risk prevents the event of interest occurring first, acknowledging that competing 
risks consist of non-fatal events and/or deaths. 
To help fully understand the definition of a competing risk, common competing 
risks scenarios are illustrated in Figure 2.1. The scenarios outlined are primarily 
based on the scenarios described in the tutorial by Putter et al. (2007).  
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Figure 2.1 Common competing risks scenarios  
 
Figure 2.1 (a) shows a diagram of the standard (non-competing risks) survival 
analysis model for comparison purposes. The typical model has every patient in 
an alive/healthy state at the beginning of a study. A sole transition is of interest 
and this is often to death, also known as all-cause or any-cause mortality. More 
generally, the event in standard survival analysis need not be death but could be 
a composite outcome comprising of a non-fatal event(s) or death.  
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In contrast, competing risks scenarios involve two or more mutually exclusive 
events. Figure 2.1 (b) depicts the situation when any-cause mortality is split into 
specific causes of death. This could form the basis for two different competing 
risks scenarios. Firstly, interest might be in disease-specific mortality and other 
causes of death act as competing risks. Secondly, each specific cause of death 
may be of interest in its own right. In that situation, each cause could be seen to 
be competing with the others to become the event. It might be that interest is 
in how frequently each cause occurred, or in assessing the influence of risk 
factors for each cause separately allowing them to be compared.  
Figure 2.1 (c) shows another scenario that requires taking competing risks into 
consideration. It may be that a non-fatal outcome is the event of interest. 
Deaths would then need to be taken into account as a competing risk, because 
they would preclude the event of interest. (The only exception to this would be 
if no, or very few, deaths were observed. Then the situation could be thought of 
as involving a composite outcome of a non-fatal outcome and death, albeit with 
the number of deaths being zero. As an analysis of a composite outcome, 
standard survival analysis techniques could be employed). However, a competing 
risk can arise even without preclusion. For instance, as Putter et al. (2007) point 
out, hospital discharge can act as a competing risk when interest is in in-hospital 
infection (Figure 2.1 (d)). Hence, in that example, the competing risk is 
preventing the event of interest from occurring first. 
It is important to recognise a competing risks scenario, when one exists, as this 
requires a different approach to standard survival analysis, as explained in the 
rest of this chapter. Before leaving this section it should be noted that, while 
there are many useful contributions that define and illustrate competing risks 
scenarios, there are other articles in the literature that portray competing risks 
in a confusing and often misleading way. For example, Tai et al. (2011) state 
that “the occurrence of a specific event would preclude the competing risks 
from being observed”. This is not inaccurate in itself because a specific event is 
considered a competing risk when in fact the competing risk is treated as the 
event of interest. However, it does not follow the usual convention that it is the 
competing risk that precludes, or otherwise alters the probability of, the event 
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of interest and not the other way round. Another piece, a commentary by 
Chappell (2012), emphasises that administrative censoring can be a competing 
risk. However, reaching the end of a study does not typically involve an event 
that precludes, or otherwise alters the probability of occurrence of, an outcome 
of interest. Therefore, this is a misleading statement. In other work, Varadhan 
et al. (2010) include the semi-competing risks approach in their review of 
statistical methods for competing risks. This introduces confusion as the semi-
competing risks approach they present is not used for competing risks scenarios. 
It does not just consider the first event to occur from two or more mutually 
exclusive events. Instead, this approach also considers subsequent events. It is 
often known as an “illness-death model”, part of the more general multi-state 
modelling framework. This method is the focus of Chapter 4 (methodological 
aspects) and Chapter 5 (empirical analysis).  
 Kaplan-Meier not appropriate for competing risks: 
introduction to competing risks cumulative incidence  
The previous section highlighted that there is a need to recognise competing 
risks, when they exist, because a different approach to analysis is required. 
There is a fundamental difference between standard and competing risks 
survival analysis that gives rise to this. With standard survival analysis, there is a 
one-to-one correspondence between the hazard and survival functions. This 
means that when the hazard increases so does the probability (1-survival) of the 
event occurring. Similarly, a decrease in the hazard leads to a decrease in the 
probability of the event occurring. However, this one-to-one relationship does 
not necessarily hold in the presence of competing risks. One of the consequences 
of this is that the standard Kaplan-Meier analysis is no longer appropriate with 
competing risks, as this section will explain. 
A contentious issue with competing risks is whether survival is an appropriate 
quantity to estimate. A few authors stipulate that the ideal estimand is marginal 
or net survival [e.g. (Dignam and Kocherginsky, 2008)]. Lambert et al. (2010)    
mention that net survival is a “measure of patient survival corrected for the 
effect of other causes”. The authors also explain that, in the context of cancer, 
the net probability of death due to cancer allows comparisons to be made over 
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time or between places; which is of particular relevance because deaths due to 
other causes can also vary over time or between places and it is important that 
survival/death estimates are not influenced by these changes in mortality due to 
other causes. However the authors also mention that the net probability of 
death due to cancer (1- net survival) is not a true measure of the probability of 
death due to cancer as it assumes that deaths due to other causes do not exist. 
Therefore, in a competing risks setting, the term survival (from any one of the 
competing events) is said to only apply in a hypothetical situation. It does not 
have a meaningful interpretation in the real world scenarios that medicine 
presents, and therefore there is a general consensus that survival is not an 
appropriate term to use for any specific competing risk e.g. Bakoyannis and 
Touloumi (2012).  
The marginal or net survival alluded to above could be estimated using the 
Kaplan-Meier method commonly applied in standard survival analysis. However, 
as well as only being appropriate in a hypothetical scenario, it is widely 
recognised in the literature that the Kaplan-Meier approach is not appropriate in 
the competing risks context for the reasons explained below [e.g.  Gooley et al. 
(1999); Fine and Gray (1999), Satagopan et al. (2004), Kim (2007), Putter et al. 
(2007), Dignam and Kocherginsky (2008), Lau et al. (2009), Varadhan et al. 
(2010), Pfirrmann et al. (2011), Tai et al. (2011), Andersen et al. (2012), 
Bakoyannis and Touloumi (2012), Chappell (2012), Dignam et al. (2012), Koller et 
al. (2012), Latouche et al. (2013), Wolbers et al. (2014), Austin et al. (2016)]. 
Andersen et al. (2012) emphasise that this is one of the consequences of the 
one-to-one correspondence between the hazard and survival not holding for 
competing risks. 
In standard survival analysis, because there is only one possible event, patients 
either experience the event or are censored at the time they were last known 
not to have the event. In a competing risks scenario, analysis is undertaken for 
each specific event by treating it as the event of interest. Competing events are 
censored because they are not the event of interest. The Kaplan-Meier approach 
relies on an assumption of non-informative censoring. That is to say, at the time 
of censoring, for patients who are censored the risk of the event should not be 
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any different than that for the patients who are at risk but are still in the study 
(i.e. uncensored). In other words, the censoring mechanism should not provide 
any information that influences the distribution of event times. However, by 
censoring any competing risks, informative censoring is introduced by the very 
definition of a competing risk. This is particularly evident when death is a 
competing risk as patients censored for this reason categorically cannot 
experience the event of interest, and therefore their risk is different from the 
uncensored patients. More specifically, if the Kaplan-Meier method is used, bias 
will be introduced that inflates the probability of the event of interest. This is 
because the uncensored individuals left in the dataset are not representative of 
all those who have not experienced the event. Those not at risk of experiencing 
the event first have been removed from the risk set through censoring. Hence 
the risk set contains more patients at risk of the event than it should and 
therefore the probability of the event of interest is inflated. 
However, just like standard survival analysis, the probability at any given time of 
a specific event occurring is of interest when competing risks are present. An 
appropriate estimand for this is the cumulative incidence that takes into account 
competing risks. Briefly, the calculation of this involves not only the hazard of 
the specific event but also the hazard of each competing risk. It is explained in 
more detail in the next sub-section. There are many contributions in the 
literature that demonstrate the bias in the Kaplan-Meier approach by contrasting 
(the complement of) a Kaplan-Meier curve with a corresponding cumulative 
incidence curve that takes into account competing risks [e.g. Gooley et al. 
(1999), Kim (2007), Varadhan et al. (2010), Andersen et al. (2012), Bakoyannis 
and Touloumi (2012), Austin et al. (2016)]. By comparing the two curves, each of 
these authors illustrate the inflation of the cumulative incidence of the specific 
event that can arise if the competing risks are not taken into account 
appropriately. 
This section has emphasised that the Kaplan-Meier (KM) approach is 
inappropriate in the presence of competing risks. While there is a wealth of 
useful contributions to the literature that raise awareness of this, there are also 
articles that contain misleading statements. The papers by Kim (2007) and 
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Satagopan et al. (2004) contain statements which are representative of the 
typical errors that are made. These were educational papers and have received 
much attention, having being cited 172 (257) and 311 (431) times respectively up 
to the end of 2016 according to Web of Science (Google Scholar).  
The work by Kim (2007) begins by explaining that the Kaplan-Meier method is 
inappropriate when competing risks are present. Furthermore, it recognises that 
relapse and transplant-related mortality are two competing risks when studying 
allogeneic hematopoietic stem cell transplantation. However, the paper then 
makes the contradictory statement that “The KM estimate of cumulative 
incidence function is simple and useful for a single end point such as relapse”. 
This is however later refuted by clarifying that the cumulative incidence of 
relapse is overestimated using the KM method because there are also transplant-
related deaths. However, the contradictory statement could still lead to 
confusion. It does acknowledge that the Kaplan-Meier approach is useful for 
single end points. However, crucially, it fails to note that in a Kaplan-Meier 
analysis non-fatal outcomes such as relapse need to be combined with deaths if 
they occur. Related to this, the paper uses the term “relapse-free survival” 
when referring to the estimate using the Kaplan-Meier approach. This is an 
inaccurate description when the event of interest is relapse alone as the term 
should only be used with the composite outcome relapse or death. In addition, 
the illustration of the Kaplan-Meier method is that of the “naïve” Kaplan-Meier 
method but it is not labelled as such. Naïve Kaplan-Meier method is well-
recognised terminology in the competing risks literature when demonstrating 
Kaplan-Meier analysis in the presence of competing risks. Therefore this 
contribution by Kim (2007) is inconsistent with other research. Another piece 
that does not use the term naïve with their illustration of the Kaplan-Meier 
method is the work by Satagopan et al. (2004). The paper does however 
explicitly convey that the analysis is not taking into account the competing risk. 
In a similar manner to Kim (2007) mentioned above, this work uses the term 
haematologic malignancy-free survival when in fact the event of interest is  
haematologic malignancy alone. 
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 Cumulative incidence for competing risks 
Earlier in this section it was highlighted that there is a need to appropriately 
take into account any competing risks when calculating the cumulative incidence 
of an event of interest. It alluded to the fact that the cumulative incidence of a 
specific event must take into account the hazards of each competing event, as 
well as that for the event of interest. They are many contributions that describe 
how to calculate the cumulative incidence function (e.g. Putter et al. (2007), 
Dignam and Kocherginsky (2008), Varadhan et al. (2010), Allignol et al. (2011), 
Pfirrmann et al. (2011), Andersen et al. (2012), Bakoyannis and Touloumi (2012), 
Dignam et al. (2012)). The formal equation to calculate the cumulative 
incidence, 𝐹𝑘(𝑡), i.e. the cumulative probability of event 𝑘 having occurred in 
the presence of other competing events,  is: 
𝐹𝑘(𝑡) = Pr(failure time T ≤ 𝑡, cause= 𝑘) = ∫ 𝑆(𝑢)𝜆𝑘(𝑢)𝑑𝑢 
𝑡
𝑜
  
where 𝑆(𝑡) =survival free from any of the events up to time t 
and 𝜆𝑘(𝑡) = cause-specific hazard for the event of interest  
 (Dignam and Kocherginsky, 2008). 
The cause-specific hazard is the key driving force behind the cumulative 
incidence in the presence of competing risks. Dignam et al. (2012) describe it as 
representing the probability of failure due to cause 𝑘 at a moment in time, given 
that no failure of any kind has occurred thus far. More formally it is 
𝜆𝑘 (𝑡) = lim
Δ𝑡↓0
Prob(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡, 𝐷 = 𝑘|𝑇 ≥ 𝑡)
∆𝑡
 
                           
where 𝑇 is the time of failure and  
          𝐷 is the cause of failure                                      (Putter et al., 2007) 
 
It is the instantaneous rate of failing from cause 𝑘 in the small time interval        
[𝑡, 𝑡 + ∆ 𝑡), given that no failure of any kind occurred prior to time 𝑡.  
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The 𝑆(𝑡) element of the cumulative incidence also involves the cause-specific 
hazards. As outlined by Putter et al. (2007), 𝑆(𝑡) =exp(- ∑ Λ𝑘
𝐾
𝑘=1 (𝑡))  where 
Λ𝑘 (𝑡) = ∫ 𝜆𝑘
𝑡
0
(𝑠)𝑑𝑠.  
Therefore, 𝑆(𝑡) incorporates the cause-specific hazard of each event i.e. the 
event of interest and any competing events.  
For estimation purposes, the following non-parametric plug-in estimators can be 
used (Bakoyannis and Touloumi, 2012): 
?̂?𝑘(𝑡) = ∑ ?̂?𝑘
𝑚: 𝑡𝑚≤𝑡
(𝑡𝑚)?̂?(𝑡𝑚−1), where ?̂?𝑘(𝑡𝑚) =
𝑑𝑘𝑚
𝑛𝑚
 , ?̂?(𝑡𝑚−1) = ∏ (1 −
𝑑𝑖
𝑛𝑖
) ,
𝑚−1
𝑖=1
 
tm is the mth-ordered failure time     
dkm is the number of failures from cause k at tm 
dm is the total number of failures (from any cause) and  
nm is the number of subjects at risk at tm. 
Therefore, 𝑆(𝑡) can be estimated with the widely-applied Kaplan-Meier 
estimator. 
Furthermore, as Pfirrmann et al. (2011) emphasise, the cumulative incidence 
estimator above can be expressed as  
𝐹𝑘(𝑡𝑚) = 𝐹𝑘(𝑡𝑚−1) + ?̂?𝑘(𝑡𝑚) = 𝐹𝑘(𝑡𝑚−1) +  ?̂?𝑘(𝑡𝑚) × ?̂?(𝑡𝑚−1)          
explicitly emphasising its cumulative nature. 
Many of the authors that outline how to calculate the cumulative incidence also 
offer a step-by-step demonstration of such a calculation [e.g. Kim (2007), Putter 
et al. (2007), Pfirrmann et al. (2011), Tai et al. (2011), Andersen et al. (2012)]. 
Each of these contributions provide a useful insight into how the cumulative 
incidence is influenced by the cause-specific hazard of each event. Satagopan et 
al. (2004) also provide a step-by-step illustration of the cumulative incidence 
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calculation. In their discussion, the authors state: “One minus the cumulative 
incidence is the probability of surviving the event of interest up to a specific 
time”. However, as previously mentioned on page 14, survival is not an 
appropriate term to use for a specific event in a competing risks context. 
Instead, focus should be on the cumulative incidence, i.e. probability of having 
the event taking into account any competing risks, such as that described in this 
sub-section.     
Interest is often in comparing cumulative incidence curves between different 
groups. Gray (1988) developed a K-test for this purpose, analogous to the log-
rank text for comparing Kaplan-Meier survival curves.    
 Competing risks modelling approaches 
 Introduction 
The previous section described a non-parametric estimator of the cumulative 
incidence under the competing risks framework. It was non-parametric in the 
sense that no covariates were considered. This section describes approaches to 
modelling competing risks that can accommodate covariates. It begins by briefly 
summarising the classical latent failure times competing risks framework and 
some of its problems. This approach has largely been superseded by approaches 
based on observable quantities, a framework which is now widely considered to 
be the most acceptable way to carry out competing risks analysis. The section 
then continues by summarising the two most commonly used approaches under 
this framework, namely the cause-specific hazard Cox approach and Fine and 
Gray (1999)’s proportional subdistribution hazards model. Finally, some of the 
alternative approaches that can be taken are emphasised.     
 Latent failure times competing risk framework 
With the latent failure times approach to competing risks, each patient is 
assumed to have a potential failure time for each type of failure. Only the 
failure that occurs first is actually observed, with the other failure times 
deemed to be latent. More formally, under the latent failure times framework, 
 Chapter 2    Background to competing risks method    21                                                                                                                                                                                                  
 
it is assumed there are latent or potential failure times Y1, . . . , Ym for each of m 
failure types and that only T=min(Y1, . . . , Ym)  is observed.     
A fundamental concept in the latent failure times approach is that of the joint 
survivor function Q(y1, . . . , ym : z) = P(Y1 >  y1, . . . , Ym > ym ; z) where z is a 
covariate vector and Yi is as defined above.  A related concept is the marginal 
“survival” distribution Qj(yj: z) = Q(0, . . . , 0, yj, . . . , 0 : z). 
However, both the joint survivor function and the marginal distribution suffer 
from the problem of identifiability. They cannot be identified from the observed 
data without additional assumptions (Bakoyannis and Touloumi, 2012). One such 
assumption is independence of the different latent failure times. Furthermore, 
the assumptions are not testable. Further details of the problems with the latent 
failure times approach are detailed in the contributions by Tsiatis (1975),  Gail 
(1975) and Prentice et al. (1978).  
 
Therefore, owing to such problems with the latent failure times approach, it has 
been largely superseded by approaches based on observable quantities. Two 
such approaches are described in the following two parts of this section.   
 Cause-specific hazards Cox approach to modelling 
competing risks 
Cox proportional hazards regression modelling is a well-recognised method in 
standard survival analysis. It involves modelling, for a patient with covariate 
values Z =(Z1, …, Zp), the hazard λ(t|Z) =λ0(t)exp(βT Z)  
where β is a vector of regression coefficients and  λ0(t) is the baseline hazard. 
βTZ is shorthand for ∑ 𝛽𝑘 × 𝑍𝑘
𝑝
𝑘=1  where 𝑝 = number of parameters in the model. 
An analogous Cox regression approach can also be applied when competing risks 
are present. The approach is then called cause-specific hazards Cox regression. 
It involves fitting a separate Cox regression model of the hazard for each of the 
competing events (causes). The cause-specific hazard of cause k, for a patient 
with covariate vector Z, is  
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λk(t|Z) =λk,0(t)exp(βkT Z) 
where λk,0(t) is the baseline cause-specific hazard of cause k 
and βk  represents the covariate effects on cause k. 
The cause-specific hazard is the instantaneous rate of experiencing cause 𝑘 
amongst those who are event-free (i.e. not yet had cause 𝑘  or any of the 
competing events). A straightforward way of applying this cause-specific hazards 
approach is to fit a separate Cox model for each cause, censoring any competing 
events at their time of occurrence. An alternative way to implement cause-
specific hazard modelling is to use a “data-augmentation” method. This offers 
more flexibility and may help to overcome problems of overfitting. It allows 
inclusion of an interaction between a covariate and the cause, thereby enabling 
direct evaluation of the difference in the (relative) effect of a covariate 
between the causes. In particular, it allows for hypothesis testing of an effect of 
an interaction, aiding a decision of the modeller as to whether a common effect 
of the covariate across all causes may suffice. It also allows the effect of a 
covariate on one cause to be proportional to the effect on another cause, 
providing another solution to overfitting. The data-augmentation approach 
involves setting up the data in long format, with each patient having as many 
rows as the number of causes. Since patients can only experience one cause in a 
competing risks scenario, any competing causes are censored at the time of 
occurrence of the cause experienced. Any patients who do not experience any of 
the events have censored times in each of their rows, with the censoring 
occurring at the end of their follow-up. Covariate information is recorded for 
each cause. The original covariate values in the data are used for the cause that 
is actually experienced. For competing causes, all covariate values are set to 
zero. These cause-specific covariates allow for cause-specific modelling to be 
undertaken using one model rather than separate modelling for each cause. The 
modelling also has the flexibility to consider different covariates for each cause-
specific hazard. More details of the implementation and flexibility offered by 
the data-augmentation/cause-specific hazards approach is available in the work 
by Lunn and Mcneil (1995) and Putter et al. (2007).  
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 Fine and Gray’s subdistribution proportional hazard 
modelling approach to competing risks 
As previously mentioned in section 2.3, the one-to-one correspondence between 
the hazard and survival that exists with standard survival analysis does not 
necessarily hold when competing risks are present. As a consequence, the effect 
of a covariate on the cause-specific hazard for a particular cause may be 
different from its corresponding effect on the probability of the event occurring. 
To overcome the related problems with interpretation with the cause-specific 
hazards approach, Fine and Gray (1999) developed an alternative method that 
retains a one-to-one link. Instead of the hazard, they introduce the concept of a 
subdistribution hazard that has a one-to-one correspondence with the 
cumulative incidence of the event. The subdistribution hazard of cause k is 
defined as:  
𝜆𝑘(𝑡; 𝐙) =  lim
Δ𝑡→0
1
Δ𝑡
Pr{𝑡 ≤ 𝑇 ≤ 𝑡 +  ∆𝑡, 𝜀 = 𝑘 | 𝑇 ≥ 𝑡 ∪ (𝑇 ≤ 𝑡 ∩  𝜀 ≠ 𝑘), 𝐙} 
                     = d𝐹𝑘(𝑡; 𝐙)/d𝑡 } /{1 − 𝐹𝑘(𝑡; 𝐙)} 
                            =  −dlog {1 − 𝐹𝑘(𝑡; 𝐙)}/dt  
where T is the failure time  
              𝜀 𝜖 (1, …  , 𝐾) is the cause of failure  
             𝐙 is the 𝑝 × 1 bounded time − independent covariate vector 
    and 𝐹𝑘(𝑡; 𝐙) = Pr{𝑡 ≤ 𝑇 , 𝜀 = 𝑘 | 𝐙)   
 
The risk set associated with this subdistribution hazard is somewhat counter-
intuitive. Patients who experience a competing event are retained in the risk 
set, even though the occurrence of their event results in zero, or otherwise 
altered, probability of the event under consideration. This is in contrast to the 
cause-specific hazards approach which censors such patients at the time of 
occurrence of the competing event. However, just like standard survival analysis 
and the cause-specific hazard approach, the subdistribution hazard can be 
modelled in a proportional hazards framework via: 
λk(t; Z) =λk0(t)exp(ZT β), where λk0(t) is completely unspecified. 
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It can also be extended to time-varying covariates Z(t), using  
λk(t; Z) =λk0(t)exp(ZT(t) β)   
with 𝐹𝑘(𝑡; 𝐙) = 1 − exp[− ∫ λ𝑘0(s) exp{𝐙
𝐓(𝑠)𝛃} ds ]
𝑡
0
       
In practical terms, the method of implementation of the modelling of the 
subdistribution hazard for a particular cause depends on the reason for any 
censoring that occurs. If the censoring is purely administrative, then the 
modelling can be carried out using Cox proportional hazards regression. Any 
competing events are censored at a time just after the last observed event of 
the type under consideration. This way the competing events are retained in the 
risk set with a time for the event under consideration that is essentially infinity. 
This corresponds to the representation that the subdistribution hazard 𝜆𝑘 can be 
thought of as acting on the improper random variable T* = Ι (ε = k) × T + 
{1 − I(ε = k)} × ∞ . The cumulative incidence function 𝐹𝑘(𝑡; 𝐙)  is itself an 
improper probability distribution in that 𝐹𝑘(∞; 𝐙) < 1 i.e. it never reaches 1.  
When the censoring is instead right-censoring due to loss of follow-up, weighting 
of the censoring is used. Fine and Gray (1999) adapt inverse probability of 
censoring weighting (IPCW) techniques and incorporate them into their 
modelling of the subdistribution hazard. An estimate of the survivor function of 
the censoring distribution is used to reweight contributions to the risk set for 
events due to competing causes.  
 Other approaches to modelling competing risks 
This thesis applies the two main approaches to competing risks regression 
described above. Alternative approaches and extensions to modelling of cause-
specific hazards and of cumulative incidences are described elsewhere. 
Contributions that may be of interest include those involving extending the 
standard case, when all event times are observed exactly or right-censored, to 
interval-censored and possibly truncated data [Hudgens et al. (2001), Hudgens et 
al. (2014) and Li (2016)]. In addition, alternative approaches proposed include 
vertical modelling (Nicolaie et al., 2010) and mixture models (Lau et al., 2008). 
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Furthermore, methods that can be used when the proportional hazards 
assumption is not met include those involving flexible modelling of competing 
risks [Scheike and Zhang (2008) and Belot et al. (2010)], stratified competing 
risks regression (Zhou et al., 2011) and modelling of time-varying cause-specific 
hazard ratios (Sun et al., 2008). Lastly, extensions to modelling of the 
cumulative incidence function include using pseudo values (Klein and Andersen, 
2005) and addressing missing causes of failure (Bakoyannis et al., 2010). 
  The effect of a covariate on the cause-specific hazard 
is not necessarily the same as its effect on the 
cumulative incidence   
As previously mentioned, the one-to-one correspondence between the hazard 
and survival that exists with standard survival analysis may no longer hold when 
competing risks are present. This is a fundamental difference that affects the 
analysis and interpretation of competing risks, and it has two main 
consequences. Section 2.3 focused on the first consequence that Kaplan-Meier 
analysis is inappropriate with competing risks. This section focuses on the second 
consequence, that the effect of a covariate on the cause-specific hazard may be 
different from the corresponding effect on the cumulative incidence. There are 
many contributions in the literature that illustrate this important aspect of 
competing risks, e.g. (Putter et al., 2007, Lau et al., 2009, Allignol et al., 2011, 
Latouche et al., 2013, Wolbers et al., 2014, Austin et al., 2016). 
Table 2.1 summarises, for two competing events, the probable effects of a 
covariate on the cumulative incidences, under different scenarios of effects of 
the same covariate on the cause-specific hazards. 
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scenarios 
effect of covariate on             
cause-specific hazard 
(csh) of:  
 
probable impact on 
cumulative incidence of:  
 
event of 
interest  
competing 
event 
 
event of 
interest  
competing 
event 
covariate has no 
effect on csh of 
either event 
A1 0 0 
 
0 0 
covariate has an 
effect on csh of 
one event only 
B1 () 0 
 
() 
B2 () 0 
 
() 
B3 0 ()

 ()
B4 0 ()

 ()
covariate affects 
csh of each event 
but in opposite 
directions 
C1  ()

 ()
C2  ()

 ()
C3  ()

 ()
C4  ()

 ()
covariate affects 
csh of each event 
but in the same 
direction 
D1  

 
D2  

 
D3  

 
D4  

 
D5  

 
D6  

 
D7  

 
D8  

 
Abbreviations used:  
csh = cause-specific hazard 
     0    =  covariate has no effect 
        =  covariate associated with an increased effect 
    =  covariate associated with a more pronounced increase 
     =  covariate associated with a reduced effect 
    =  covariate associated with a more pronounced reduction 
  
Table 2.1  Effect on the cause-specific hazard versus that on the cumulative incidence: 
different scenarios     
Throughout this thesis, the hazard ratio is the effect that is being represented 
by any mention of the phrase “the effect of a covariate on the cause-specific 
hazard”. That is to say that phrase, and similar wording, is being used as 
shorthand for the effect on the cause-specific hazard of a particular level of 
covariate relative to the reference level of that covariate. 
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The scenarios can be classified as follows: 
 the covariate does not affect the cause-specific hazard 
of either event (scenario A1) 
In a situation where a covariate has no effect on either the cause-specific hazard 
of the event of interest or the competing event then, obviously, the covariate 
will not have any effect on the cumulative incidence of either event (Dignam et 
al. (2012)). However, this scenario is rarely encountered because a covariate 
that has no effect on either event is unlikely to be included in any modelling. 
 the covariate has an effect on one event only 
 (scenarios B1-B4) 
The ‘B’ section of Table 2.1 outlines scenarios where a covariate affects the 
cause-specific hazard of one event but not the other. Each row in the B section 
condenses together two different scenarios for brevity, distinguishable by 
whether the bracketed or unbracketed term is considered in those cells which 
contain both. For instance in row B1, ignoring the bracketed terms outlines the 
following scenario: the covariate decreases the hazard of the event of interest 
and has no effect on the hazard of the competing event, which in turn results in 
that covariate being associated with a probable decrease in the cumulative 
incidence of the event of interest and a probable increase in the cumulative 
incidence of the competing event. Considering the bracketed term instead of 
the unbracketed term results in the aforementioned effects on the event of 
interest being replaced by those that are more pronounced.  
When a covariate has no effect on the cause-specific hazard of a competing 
event, Allignol et al. (2011) stress that the interpretation is straightforward of 
how the effect of the covariate on the cause-specific hazard of an event of 
interest translates to a corresponding effect on its cumulative incidence  
(scenarios B1 and B2). When outlining this aspect in their simulations, the 
authors state that the direction of the effect on the cause-specific hazard 
determines the direction of the effect on the cumulative incidence. When the 
effect on the hazard is more pronounced, the impact of the effect on the 
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cumulative incidence is also larger (bracketed B1 and B2 scenarios in Table 2.1). 
However this ease of interpretation only applies to the event of interest.  
Wolbers et al. (2014) emphasise that, even though there is no effect on the 
cause-specific hazard of the competing event, the covariate can have an effect 
on the cumulative incidence of the competing event. The authors provide a 
useful clinical illustration to help explain scenarios B1 in Table 2.1. Wolbers et 
al. (2014) present an example concerned with the effect of the binary treatment 
covariate (intervention versus control) on two events. Coronary heart disease 
(CHD) death is the event of interest and non-CHD death is the competing event. 
The intervention is found to reduce the cause-specific hazard of CHD death but 
to have no effect on the cause-specific hazard of non-CHD death. The authors 
explain that the reduction seen in the cause-specific hazard of CHD death for 
those with the intervention leaves more patients vulnerable to the force that 
draws them towards non-CHD death. Therefore, even though the intervention 
does not affect the cause-specific hazard of non–CHD death, it is expected to 
increase the cumulative incidence (absolute risk) of non-CHD death. 
A similar argument explains scenarios B2 ((Lau et al., 2009, Dignam et al., 2012). 
Dignam et al. (2012) present the results of a prostate cancer trial focused on the 
effect of treatment, age and tumour grade on death due to prostate cancer and 
death due to other causes. Compared to a grade 1 tumour, having a grade 3 
tumour appears at first to have a protective effect on the cumulative incidence 
of death due to other causes. This effect is seen even though tumour grade is 
not found to have an association with the cause-specific hazard of death due to 
other causes. However, a grade 3 tumour is associated with an increase in the 
cause-specific hazard of prostate cancer death. Therefore, the lack of increase 
in the absolute risk of death due to other causes is actually due to there being 
fewer patients surviving prostate cancer to be at risk of death due to other 
causes.  
There are analogous arguments when a covariate has no effect on the cause-
specific hazard on the event of interest but does affect the cause-specific 
hazard of the competing event (scenarios B3 and B4). Specifically, the direction 
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of the effect on the cause-specific hazard of the competing event is mirrored in 
the corresponding effect on the cumulative incidence of the competing event. 
Furthermore, the covariate can have an effect on the cumulative incidence of 
the event of interest, even when it has no effect on its cause-specific hazard. 
This is typically in the opposite direction to that seen on the cumulative 
incidence of the competing event. 
Andersen et al. (2012) present an example that aids understanding by providing 
an explanation in terms of risk sets. Their example involved patients with 
chronic myeloid leukaemia who had an allogeneic stem cell transplant and 
originated from European Group for Blood and Marrow Transplantation (EBMT) 
data. The illustration investigated the effect of EBMT risk score on the events 
relapse and non-relapse mortality (NRM). It was found that there was no 
evidence of a difference between those with score 0-1 and 2 in the cause-
specific hazard of relapse, while there was an increased cause-specific hazard of 
NRM for those with score 2 compared to those with score 0-1. Of note, while 
there was no effect on the cause-specific hazard of relapse, there was a lower 
cumulative incidence of relapse for those with score 2 compared to those with 
score 0-1. The authors point out that the cause-specific hazard acts on those 
patients still in the risk set. Their explanation continues by outlining that 
because more with score 2 experience NRM, over time, the risk set of those with 
score 2 decreases faster than the risk set of those with score 0-1. Consequently, 
in absolute terms, there are fewer with score 2 having relapse and therefore the 
cumulative incidence of relapse is lower in that group. 
 the covariate affects the cause-specific hazard of each 
event but in opposite directions (scenarios C1-C4)   
Allignol et al. (2011) stress that the interpretation of how the effect of a 
covariate on the cause-specific hazards translates to effects on the cumulative 
incidences is again straightforward when the former have opposing effects for 
the two events. For each of the two events, the direction of the effect on the 
cause-specific hazard is mirrored in the direction of the effect on the cumulative 
incidence (Allignol et al., 2011, Latouche et al., 2013). Latouche et al. (2013) 
present an example involving patients aged at least 50 years old with acute 
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myeloblastic leukemia who received hematopoietic stem cell transplantation. 
The two treatment regimes investigated were reduced intensity conditioning 
(RIC) and myeloablative conditioning (MAC) and the two events of interest were 
relapse and treatment-related mortality (TRM). Treatment regime had similar 
sized effects on the two events, but in opposite directions. RIC was found to 
increase the cause-specific hazard of relapse but decrease the cause-specific 
hazard of TRM. These effects were mirrored in the corresponding results for the 
cumulative incidence of each event. Because the analyses based on the cause-
specific hazard and cumulative incidence gave consistent results, the authors 
concluded that the effect of treatment regime on the cumulative incidence of 
relapse was an actual effect and not due to an indirect effect on the competing 
event TRM. 
 the covariate affects the cause-specific hazard of each 
event in the same direction (scenarios D1-D8)      
Allignol et al. (2011) highlight that unidirectional covariate effects on cause-
specific hazards constitute the most challenging scenario in terms of 
understanding the corresponding effects on the cumulative incidences. In 
particular, they outline the situation when having a specific covariate level 
reduces the cause-specific hazard of both the event of interest and the 
competing event, but the effect for the competing event is more pronounced 
(scenario D1 in Table 2.1). Allignol et al. (2011) and Wolbers et al. (2014)  
emphasis a difficulty in interpretation that may arise from this. Wolbers et al. 
(2014) discuss an example involving the effect of an intervention on CHD death 
and non-CHD death. The intervention reduces both the cause-specific hazard of 
CHD death and non-CHD death, but that decrease is more pronounced for non-
CHD death. They highlight that the intervention may be associated with an 
increase in the cumulative incidence of CHD death, even though it was 
associated with a reduction in the cause-specific hazard of the event. This would 
likely be due to the more dramatic decrease in the hazard of non-CHD death 
meaning there would be more patients surviving to be at risk of a CHD death. 
When the more pronounced reduction in cause-specific hazard is seen for the 
event of interest (scenario D2), the analysis may indicate an increase in the 
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cumulative incidence of the competing event associated with the specified level 
of the covariate.  
Bakoyannis and Touloumi (2012) use a synthetic example to demonstrate that 
cumulative incidence curves can cross in scenario D3. They outline an 
investigation into the effect of gender on the event of interest treatment 
interruption (TI) and the competing event switching to a new regime (NH) among 
HIV seropositive patients. The authors fix the coefficient of gender (female 
versus male) at 0.531 for TI and vary the corresponding coefficient for NH 
between -0.018 and 1.75. It is shown that, as the coefficient of gender on NH 
increases, the gap between the curves narrows, and when the coefficient for NH 
becomes more and more pronounced (1.5 and 1.75) the curves actually cross. 
While the cumulative incidence of TI is initially higher for women, it is higher for 
men as time progresses. This more pronounced effect of the competing risk NH 
means more women experience NH – therefore precluding TI as the first event 
for women – leading to the crossing of the curves and the eventual higher 
cumulative incidence of TI in men.  
The crossing of curves may also be apparent when a specified level of a 
covariate is associated with a more pronounced increase in the cause-specific 
hazard of a competing event (scenario D4).  
In another illustration, Dignam and Kocherginsky (2008) describe a trial involving 
early stage breast cancer patients comparing the effect of tamoxifen versus 
placebo on the four events breast cancer recurrence, contralateral breast 
tumours, endometrial cancer and other events. It was found that the cumulative 
incidence of other events was lower in the tamoxifen arm initially, before 
becoming higher as time passed, and hence the curves crossed. The authors 
explain that this is likely due to more of those in the placebo arm having a 
recurrence or contralateral breast tumour first, whereas in the tamoxifen arm 
there are relatively more patients remaining at risk of experiencing an other 
event first. The number of susceptible patients in each group to each event, 
over time, is the likely reason for the eventual crossing of the curves. 
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When the effects of a covariate on the cause-specific hazard of each event are 
in the same direction and of similar size (scenarios D5-D8), then the effects on 
the cumulative incidences of each event are likely to be in this same direction. 
However, the effect on each cumulative incidence is likely to be attenuated 
compared to the corresponding effect on the cause-specific hazard. This is due 
to the covariate having an effect on the other event, and the stronger this 
association the more the effect on the cumulative incidence of the event of 
interest lessens. 
This section has emphasised that, when competing risks are present, the effect 
of a covariate on the cumulative incidence for a particular event is influenced 
not only by the effect on the cause-specific hazard of the event, but also by the 
effect on the cause-specific hazard of any competing events. An aspect that is 
not always highlighted in the literature is that the baseline hazard of the event 
of interest, and any competing events, can also affect the cumulative incidence 
of an event. This is not immediately apparent from an analysis of data from a 
trial or study. However, many contributions show simulations where the baseline 
hazards are varied to illustrate the impact this can have on the cumulative 
incidence, e.g. Putter et al. (2007). 
 Derivation of the cumulative incidence using cause-
specific hazard modelling 
Section 2.4.4 described Fine and Gray’s subdistribution proportional hazards 
model. In particular, it emphasised that the subdistribution hazard has a one-to-
one correspondence with the cumulative incidence function. However, there is 
some confusion in the literature as to whether the cause-specific hazard 
approach to modelling competing risks can also be used to calculate the 
cumulative incidence. The previous section highlighted that, when the cause-
specific hazard for a particular competing risk is considered in isolation, the 
effect of a covariate on that cause-specific hazard may not be reflected in the 
corresponding effect on the cumulative incidence for the same competing risk. 
However, as previously explained in sub-section 2.3.1, if the cause-specific 
hazards of each of the competing risks are considered, the cumulative incidence 
for a particular competing risk can be estimated. Even so, many of the 
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contributions fail to recognise that the cumulative incidence can be derived 
from cause-specific hazard modelling [e.g. Kim (2007), Latouche et al. (2013) 
and Austin et al. (2016)].  Kim (2007) stipulates that cause-specific hazards Cox 
modelling is not suitable for competing risks analysis due to the censoring of 
competing risks. It is implied that this is the case for the calculation of the 
cumulative incidence. However, the argument is not conveyed explicitly as 
relating to a “naïve” cause-specific hazard approach, i.e. when the cumulative 
incidence is inappropriately estimated using the cause-specific hazard of one 
event in isolation. The paper just categorically states that cause-specific hazard 
modelling is inadequate, rather than explaining how the cumulative incidence 
could be calculated using the modelling from each of the events. The article 
does not provide this information, even though it is illustrated earlier in the 
paper that the non-parametric estimation of the cumulative incidence involves 
the hazards of each of the competing risks. Other work (Latouche et al., 2013, 
Austin et al., 2016) does acknowledge that the “naïve” cause-specific approach 
is inappropriate for calculating the cumulative incidence. However the papers do 
not expand on this and outline how the cumulative incidence can be 
appropriately estimated from the cause-specific hazards. 
As part of their contributions, other authors do recognise that the cumulative 
incidence can be derived from cause-specific hazard modelling [e.g. Putter et 
al. (2007), Lau et al. (2009), Varadhan et al. (2010), Allignol et al. (2011) and 
Andersen et al. (2012)]. Putter et al. (2007) point out that the confusion has 
arisen because analysts have become accustomed to the one-to-one 
correspondence between the hazard and survival in standard survival analysis. 
While this may no longer hold with competing risks, the authors maintain there 
is nothing fundamentally wrong with using the cause-specific hazards approach. 
It is just that the interpretation of the results requires more care.  
Another contentious issue with cause-specific hazards modelling is whether it 
requires the competing risks to be independent of each other, in the sense that 
the occurrence of one does not affect the probability of others occurring. 
Pintilie (2007a) asserts that it does. However, Andersen et al. (2012) explain 
that the concept of independence in competing risks analysis is a throw-back to 
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the classical latent failure time approach which was discussed in sub-section 
2.4.2. This approach is now widely thought to be outdated and has been 
superseded with approaches based on observable quantities such as cause-
specific hazards and cumulative incidences.  
Several authors criticise aspects of Pintilie’s work, including that it is based 
around a latent failure time approach (Pintilie, 2007b, Pintilie, 2007c). In their 
letter to the editor Latouche et al. (Pintilie, 2007c) in particular object to 
Pintilie’s use of the term “cause specific hazard” with the latent failure time 
approach. They highlight that the article adds confusion because cause-specific 
hazard is terminology that is normally reserved for transition intensities in the 
more accepted approaches based on observable quantities. Related to this, they 
take issue with Pintilie’s statement that “When modelling the cause specific 
hazard, one performs the analysis under the assumption that competing risks do 
not exist”. This assumes independent latent failure times, which is untestable.  
On the contrary, Andersen et al. (2012) argue that inference in the conventional 
cause-specific hazard analysis makes no assumption about the independence of 
competing risks. Instead, the authors reiterate that the cumulative incidence 
can be estimated by taking into account the cause-specific hazard of each 
event. They then emphasise that the cause-specific hazard for a particular event 
can be calculated by censoring competing events. Furthermore, they stress that 
this censoring of competing events works because cause-specific hazards are 
time-local rates of occurrence of events that are mutually exclusive, and hence 
the likelihood factorises. 
 Variable selection strategies with competing risks 
While there are other variable selection strategies, likelihood-based approaches 
such as likelihood-ratio tests and information criteria, e.g. Akaike information 
criterion (AIC) and Bayesian information criterion (BIC), are popular due to being 
intuitive and easy to use. They are widely used in standard survival analysis, just 
as they are in other common modelling techniques in statistics. However, 
variable selection is less straightforward with competing risks survival analysis. 
This section discusses variable selection in the context of two common 
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approaches to modelling competing risks. Sub-section 2.7.1 focuses on Fine and 
Gray’s proportional subdistribution hazards model and sub-section 2.7.2 outlines 
considerations when using the cause-specific hazards approach. 
 Variable selection and Fine and Gray’s proportional 
subdistribution hazard approach  
Fine and Gray’s proportional subdistribution hazards model was previously 
described in sub-section 2.4.4. Motivated by the importance of parsimonious and 
accurate models to predict risk in medical research, and the lack of methods for 
covariate selection with Fine and Gray’s model, Kuk and Varadhan (2013) 
developed an approach to address this issue. The approach is that of an 
information criteria-based stepwise regression procedure for use with Fine and 
Gray’s model. The authors developed a version of their technique based on the 
well-recognised AIC and BIC and a new criteria that they propose called the 
BICcr. The BICcr is similar to the BIC, and differs only in the term used for 
penalisation. The penalisation term in the BIC is the familiar p + log n, where p 
is the number of parameters in the model and n is the number of observations. 
In contrast, the penalisation term in the newly proposed BICcr is p + log n* 
where p is as before and n* is the number with the event of interest. Therefore 
the penalty is more lenient with BICcr than it is with BIC.  
Kuk and Varadhan’s approach is used to decide which covariates to include in 
the Fine and Gray models presented later in this thesis in section 3.3. However, 
while their approach is one of stepwise variable selection it does not operate 
like a standard likelihood-ratio test. This is because it does not produce a 
statistic that follows a (asymptotic) chi-square distribution, or indeed that 
assumes any particular distribution. Therefore the standard likelihood-ratio test 
based approach for obtaining an overall p-value for a covariate with more than 
two levels is not applicable. Therefore, in the presentation in section 3.3, no 
overall p-values are shown for such covariates. 
 
 Chapter 2    Background to competing risks method    36                                                                                                                                                                                                  
 
 Methodological issues relating to variable selection with 
the cause-specific hazards approach 
Kuk and Varadhan’s approach outlined in the previous sub-section was made 
possible because of the one-to-one correspondence between the subdistribution 
hazard and the cumulative incidence. However, as mentioned previously in this 
thesis, such a correspondence may no longer exist between the hazard and 
probability/cumulative incidence in the presence of competing risks. Section 2.5 
described in detail a consequence of this, namely that the effect of a covariate 
on the cause-specific hazard may not necessarily translate into the same effect 
on the cumulative incidence. This is due to the cumulative incidence for an 
event of interest not only being affected by the cause-specific hazard of the 
event, but also by the cause-specific hazard of any competing events. 
Therefore, I would argue that considering the cause-specific hazard of one event 
in isolation from those of the competing events is not to be recommended. 
Consequently, likelihood-ratio tests and information criteria focused solely on 
one cause-specific hazard should be treated with caution in the presence of 
competing risks. The results are liable to mis-interpretation and misleading 
conclusions. Considering one cause-specific hazard in isolation is analogous to 
naïve Kaplan-Meier/Cox predictions. Such naïve predictions introduce inflated 
probabilities of the event of interest due to not taking into account the 
competing risks. Therefore for the cause-specific hazard modelling approach to 
competing risks presented in Chapter 3, no formal variable selection method is 
used to choose between the models for prediction. Instead, the variables 
selected are based upon those chosen for the two approaches involved in the 
comparison, namely the composite outcome and Fine and Gray’s proportional 
subdistribution hazards model.    
  Two schools of thought on the use of two common 
approaches to competing risks 
This section outlines the two schools of thought in the literature on the use of 
cause-specific hazard modelling and Fine and Gray’s proportional subdistribution 
hazard model. The first school of thought is that the research question should 
drive the modelling approach used. Alternative thinking is that the cause-
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specific hazard and cumulative incidence of each competing risk should be 
considered together in order to gain a full understanding of the competing risk 
process. The idea behind each is discussed in this section. 
 the research question should drive the modelling 
approach used 
Several contributions advocate that the research question should drive the 
approach to analysis, e.g. Dignam and Kocherginsky (2008), Lau et al. (2009), 
Dignam et al. (2012), Koller et al. (2012), Wolbers et al. (2014) and Austin et al. 
(2016). The premise of this argument is that the cause-specific hazard and 
subdistribution hazard/cumulative incidence estimate different quantities. The 
cause-specific hazard is the instantaneous rate of experiencing the event of 
interest among those who are still at risk of the event i.e. among those who 
have survived free of any of the events. However, as previously outlined in 
section 2.5 of this thesis, the effect of a covariate on the cause-specific hazard 
of a specific event may not translate into the same effect on its cumulative 
incidence. This is due to the one-to-one correspondence between the hazard and 
probability seen in standard survival analysis, not necessarily holding when 
competing risks are present. This problem with the cause-specific hazard 
motivated an approach that modelled subdistribution hazards, with such a 
quantity having a one-to-one link with the cumulative incidence. However, the 
subdistribution hazard for an event of interest involves a somewhat 
counterintuitive risk set. This is because those who experience a competing 
event are retained in the risk set, even though they cannot then possibly 
experience the event of interest as their first event. 
Because the cause-specific hazard and subdistribution hazard/cumulative 
incidence illustrate different aspects of a competing risks process, it naturally 
follows that the specific research question of interest can motivate the approach 
to analysis. In particular, due to the nature of the cause-specific hazard 
described above, etiology-based questions are most appropriately addressed by 
modelling cause-specific hazards. In other words, the cause-specific hazard 
approach can be useful if interest is in investigating whether there is a relative 
effect of a covariate on event rates (hazards) of a specific event of interest. In 
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contrast, modelling the cumulative incidence facilitates the estimation on the 
absolute scale of the effect of a covariate over time. An effect on the 
cumulative incidence for an event of interest could be due to a direct effect of 
that covariate on its cause-specific hazard, and/or due to an indirect effect that 
acts on the cause-specific hazard of a competing event. Therefore, as 
highlighted by Wolbers et al. (2014), modelling of the cumulative incidence 
seems the more pertinent approach for clinical decision making because it refers 
to absolute risks in the real-world where competing events do occur. 
Consequently, modelling of the subdistribution hazard/cumulative incidence is 
deemed the most appropriate approach to address questions of evaluating 
treatment policy in populations, for example risk/benefit trade-off in a health 
economics context, (Dignam and Kocherginsky, 2008) and for clinical predictions 
and risk-scoring systems (Austin et al., 2016). 
The contribution by Lau et al. (2009) provides a useful illustration with example 
research questions that can be posed, and suggestions of the most appropriate 
approach to take to address them. The authors’ example is that of the use of the 
antiretroviral drug abacavir which has been found to be associated with an 
increased risk of myocardial infarction (MI). They outline two competing 
research questions that can be posed: 
1) Is the use of abacavir directly associated with MI? 
2) Regardless of the direct association, are individuals taking abacavir more 
likely to experience an MI? 
The authors then continue by suggesting that the first question might be most 
appropriately answered by modelling the cause-specific hazards. They emphasise 
that the cause-specific hazard approach to modelling allows assessment of 
whether, at any given time, patients taking the drug have an increased 
instantaneous hazard rate for MI among all patients who have survived up to that 
point event-free. Conversely, for the second question, their article suggests that 
modelling subdistribution hazards would be more appropriate. They illustrate a 
related possible situation and emphasise that it may help decide policy. The 
situation is that when taking the drug has no effect on the cause-specific hazard 
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of an MI, but that the subdistribution hazard of MI for those taking the drug is 
increased. They go on to explain that this is due to a reduced hazard of the 
competing event death without MI in those taking the drug, which means more 
of such patients are available to experience an MI. 
 both the cause-specific hazard and subdistribution 
hazard/ cumulative incidence should be modelled for 
each competing risk   
Another school of thought is that both the cause-specific hazard and 
subdistribution hazard/cumulative incidence should be modelled for each 
competing risk [e.g., Andersen et al. (2012), and Bakoyannis and Touloumi 
(2012), Latouche et al. (2013) and Austin et al. (2016)]. This is advocated as a 
way of gaining a fuller understanding of the competing risks process. This is 
because, as mentioned previously, the cause-specific hazard is a key driving 
force in analysis that takes into account competing risks. The calculation of the 
cumulative incidence for a specific event involves the cause-specific hazard of 
each event (i.e. that of interest and any that compete). Considering both the 
cause-specific hazard and cumulative incidence together for every event can aid 
interpretation in competing risks analysis. It can provide a better appreciation of 
the results and the insights they give because the two outcomes complement 
each other. They each relay a related but different aspect of the competing 
risks process and together give a comprehensive picture of it. As mentioned 
previously in this section, an effect on the cumulative incidence of an event of 
interest could be due to a direct effect of that covariate on its cause-specific 
hazard, and/or due to an indirect effect that acts on the cause-specific hazard 
of a competing event. Furthermore, the effect of a covariate on the cause-
specific hazard of an event may not translate into the same effect on the 
corresponding cumulative incidence. This phenomenon was explored more fully 
in section 2.5 of this chapter. It will also be demonstrated empirically later in 
this thesis in chapter 3.   
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 Composite outcomes vs decomposition into competing 
risks 
Combining endpoints into composite outcomes is popular in randomised trials 
and other studies. This amalgamation of multiple events to maximise event rates 
has many advantages. These include the related concerns of greater precision in 
estimates of effects and increased statistical power, which both improve 
efficiency of the study. They can also be useful when it is unclear which specific 
outcome to focus on, and in particular when the combination of potentially 
important outcomes is thought to describe a disease process. However, as 
Allignol et al. (2011) emphasise, medical problems are typically too complex to 
be addressed by the analysis of one combined event. 
Furthermore, it is well-recognised in the literature that analysis of composite 
outcomes may only be advantageous when a covariate affects each of the 
individual components in the same direction (e.g. Varadhan et al. (2010)). When 
this is not the case, analysis that splits the outcome into its component 
competing risks is generally considered the most appropriate approach to take.  
Mell and Jeong (2010) explain how, in a competing risks scenario, using a 
composite outcome may actually reduce the efficiency of a trial. They highlight 
that patients at high risk of a competing event may be less likely to benefit from 
the treatment. Furthermore, they use the term “deadweight” in relation to such 
patients because including them in a trial may reduce efficiency of a trial and 
make it more costly, if the treatment being studied in the trial does not reduce 
the incidence of the competing outcome.  
Decomposing a composite outcome into its component parts may provide further 
insight into the effect of a covariate on the separate events. For instance, it 
may help identify which of the particular events a covariate affects and in which 
direction. Separating an outcome into several cause-specific ones may help to 
assess the effect of a covariate on each cause, and therefore not attribute an 
effect to the wrong cause as could be the case with a composite outcome. In a 
paper by Mell et al. (2012), the authors discuss the issue of decomposing all-
cause mortality into cancer- and non-cancer mortality. They highlight that it can 
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be beneficial to analyse each outcome specifically in order to ascertain the 
effectiveness of a treatment against cancer.  
Another potential insight of competing risks analysis becomes apparent when it 
is evident that an analysis of a composite outcome alone would mask the effects 
on its component parts. That is to say, a covariate might have opposing effects 
on two component parts of a composite outcome, and as a consequence there 
may be no effect on the composite outcome due to the opposing effects 
cancelling each other out. In other instances, using a composite outcome may 
mask an effect on a specific event of interest if it is in the opposite direction to 
the effect on the composite outcome. This is particularly likely to be the case 
when the incidence of a competing event is high and therefore dominates the 
composite outcome, but the effect on the competing outcome is in the opposite 
direction to the event of interest.  
The empirical analysis presented in chapter 3 will demonstrate the extra insight 
that can be gained by decomposing a composite outcome into its competing risks 
components. 
 
  Need for better recognition of competing risks in the 
clinical community 
This chapter so far has emphasised the need to use an analysis approach that 
takes into account competing risks, if such a scenario exists. It has also 
highlighted the key issues that need to be considered when faced with 
competing risks. Sub-section 2.10.1 will demonstrate that there has been an 
emergence of competing risks in the literature, particularly in the last 10-15 
years. Sub-sections 2.10.2 and 2.10.3 will then focus on a review of the 
contributions in the specific area of stroke epidemiology, and the competing 
risks of recurrence and death. The purpose of this is to identify gaps and issues 
in the literature that the empirical analysis in the next chapter will try to 
address.  
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 Review of recognition of the need for competing risks 
analyses, where appropriate 
A search was carried out to find literature that reviewed the extent of use of 
competing risks analyses (Appendix I). Two contributions were found (Mell et al. 
(2012) and Koller et al. (2012)). With their reviews, these authors have raised 
awareness of the need to recognise competing risks and analyse them 
appropriately. It was previously mentioned in section 2.9 that Mell et al. (2012) 
emphasised the need to decompose a composite outcome, when the treatment 
had differing effects on the component parts of the outcome. The authors’ 
review focused specifically on cancer trials, and whether effects on the 
component parts of cancer events and non-cancer related mortality were 
analysed separately. The authors found this only to be the case in 40% (47/118) 
of studies. 
The work by Koller et al. (2012) was a useful contribution that provided a more 
comprehensive review into the use of competing risks analyses. Their research 
began by emphasising that aging populations in particular necessitate 
considering competing risks analyses. The authors explained that an aging 
population is susceptible to competing risks due to a high level of comorbidities. 
As life expectancy continues to improve, this is only likely to increase further. 
Furthermore, the article included a literature search carried out to see how 
frequently competing risks were mentioned in biostatistical, core clinical and 
general high impact clinical journals. Their search strategy is detailed in 
Appendix II. I reproduced their search based on the criteria specified in 
Appendix II, and updated it by extending the dates of publication to 31 
December 2015. Figure 2.2(a), (b) and (c) summarise the findings by year for 
biostatistical, core clinical and general high impact clinical journals 
respectively.  It should be noted that the vertical axis of each of the Figures has 
a different scale. 
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Figure 2.2  original and updated search of competing risks literature based on the criteria of 
Koller et al. (2012)  
The original search found that, for the biostatistical and core clinical journals, 
there was generally a steady rise in the number of contributions over the decade 
starting 2000. In the updated search, this trend was continued in the core 
clinical journals while for the biostatistical journals there was a suggestion of 
levelling off. However, the appearance of competing risks in general high impact 
clinical journals was low. The original search only found between 0 and 3 
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articles published per year in such journals. The updated outlook also found 
small numbers, only achieving at most 10 articles per year.  
As part of their original research, Koller et al. (2012) also explored how 
competing risks issues were treated in high impact clinical journals. The authors 
searched for articles focusing on diseases that are prevalent or typical in aging 
or multimorbid patients, and that would have follow-up that could potentially 
raise competing risks issues. They then concentrated on critically appraising 50 
articles, paying particular attention to the following: 
 the use of the naïve Kaplan-Meier approach to estimate cumulative 
incidence when competing risks were actually present 
 neglecting competing risks either by not reporting competing events, or 
by reporting them but not analysing them 
They found that at least one of the issues was apparent in 70% (35/50) of the 
studied articles.   
 Review of competing risks analyses of stroke 
recurrence and death in the literature 
This sub-section describes a review of the literature that focused on the analysis 
of the competing risks recurrence and death in stroke. The purpose of this was 
to explore the existing use of, and in particular the approach used for, 
competing risks in this area. It provides the motivation for the empirical analysis 
of the stroke case study in the next chapter. A search strategy was developed to 
allow the review to take place. When this research began in 2011 an OvidSP 
search of titles, abstracts and keywords of contributions using relevant search 
terms was performed. However, this search has been an ongoing process. Email 
alerts of new articles were set up using Ovid and Web of Knowledge. A final 
OvidSP search was conducted to search contributions up to 31 August 2016. The 
entire search found 17 contributions and is summarised in Appendix III. Appendix 
IV contains an evidence table summarising what was found, which will be 
discussed in this sub-section.  
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In their study protocol, Wollenweber et al. (2014) state that they intend 
investigating post-stroke dementia as a primary endpoint. However stroke 
recurrence is also stipulated as a secondary endpoint. Unfortunately the paper 
does not provide any detail of a plan of analysis for stroke recurrence and only 
maintains that a very vague “competing risks analysis” will be carried out.  
Some of the contributions have studies with endpoints of all-cause mortality and 
stroke recurrence (Sun et al., 2013, Arntz et al., 2014, Dhamoon et al., 2016a, 
Dhamoon et al., 2016b). These authors use a standard Kaplan-Meier and/or Cox 
regression to analyse all-cause mortality and a Fine and Gray proportional 
subdistribution hazards model to analyse stroke recurrence. In the latter, death 
is treated as a competing risk when modelling the subdistribution hazards of 
recurrence. However, these papers do not present a corresponding Fine and 
Gray model for death without recurrence, with recurrence treated as a 
competing risk. Therefore, the contributions have missed the opportunity to 
convey the extra insight that may have been gained from the analysis of the 
other competing risk. For example, in the research by Dhamoon et al. (2016a), 
modelling the other competing risk may have clarified and provided further 
explanation for the result that South Asians had a higher cumulative incidence of 
recurrence than non-South Asians. Given that ethnicity had no effect on 
recurrence-free survival, modelling of death without recurrence (treating 
recurrence as a competing risk) is likely to have shown that South Asians had a 
lower cumulative incidence of death without recurrence. This is not explicitly 
evident from the modelling of all-cause mortality because this shows death 
overall. The modelling of death without recurrence as a competing risk could 
have helped explain the higher cumulative incidence of recurrence in that less 
patients were dying in such a manner and so more were alive to be at risk of 
recurrence.   
The analyses of all-cause mortality and those for just one competing risk in the 
four aforementioned contributions, fail to recognise that recurrence and death 
without recurrence act as competing risks and should be analysed separately and 
compared. Furthermore, the analysis of all-cause mortality does not distinguish 
between deaths with and without recurrence. Analysis involving the three events 
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recurrence, death after recurrence and death without recurrence simultaneously 
is the focus of Chapter 4. Instead of the analyses carried out, or ideally 
alongside them, it would have been preferable to also show the analysis of death 
without recurrence, with recurrence treated as a competing risk.  
Only three of the contributions used Fine and Gray’s model for both the 
outcomes recurrence treating death without recurrence as a competing risk and 
death without recurrence treating recurrence as a competing risk (Lewsey et al., 
2010, Andersen et al., 2011, He et al., 2015). The research by Lewsey et al. 
(2010) was the only contribution found from this literature search to explicitly 
acknowledge that results should be shown for each competing risk. 
Several of the contributions use a Cox (cause-specific hazards), rather than a 
Fine and Gray, model for their competing risks analysis (Ovbiagele, 2012, 
Stamplecoski et al., 2012, Ovbiagele, 2013, Castilloux et al., 2015, Choi et al., 
2016). Choi et al. (2016) use the test devised by Gray (1988) to compare 
competing risks cumulative incidence curves at a univariable level and take a 
Cox approach to multivariable modelling. The methods section of the paper 
states that deaths are treated as a competing risk. However, the paper also 
states that Fine and Gray’s proportional subdistribution hazards model was used, 
and then proceeds to show Cox regressions in the results. Therefore, this could 
cause confusion. 
Ovbiagele (2013) uses backwards stepwise variable selection to decide which 
covariates to include in the competing risks Cox regression. However, likelihood 
ratio tests need to be treated with caution in competing risks scenarios, as 
explained in section 2.7.2, especially when only considering the results from one 
competing risk in isolation. Furthermore, the paper appears to show “naïve” Cox 
predictions, because they are described as cumulative incidence curves derived 
using the Cox regression previously presented. 
The work by Rutten-Jacobs et al. (2013) uses the test devised by Gray (1988) to 
compare competing risks cumulative incidence curves for at most one covariate, 
and then Fine and Gray’s model at a multivariable level. The authors present 
separate results for recurrent strokes and for other arterial events alongside 
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those for the composite of the two. It would have been preferable to display 
results separately for recurrent strokes, for arterial events and for deaths. This 
is especially the case as death was a strong competing risk with 172 (23.8%) of 
the 724 patients dying. Furthermore, a more appropriate composite outcome 
would have combined all three events rather than excluding the deaths. 
 Review of the possibility of decomposing recurrence-
free survival after stroke in the literature that uses that 
outcome 
The previous sub-section reviewed the approach used for competing risks 
analysis of stroke recurrence and death in contributions that included such 
terminology. This sub-section will describe a review of the literature that 
included the outcome recurrence-free survival. In particular, for each 
contribution, the number of stroke recurrence and death events will be 
identified. Then a discussion will follow on whether decomposition of the 
composite outcome recurrence-free survival could have been an option, if it was 
not carried out. A search strategy was developed to allow the review to take 
place. In a similar manner to the search described in sub-section 2.10.2, the 
search was an ongoing process after an initial search when this research first 
began in 2011. A final OvidSP search of titles, abstracts and keywords of 
contributions to 31 August 2016 using the search terms  
(stroke AND recurrence-free survival).ab,ti,kw. 
was carried out. The entire search found 20 contributions and is summarised in 
Appendix V. Appendix VI contains an evidence table summarising what was 
found. 
 Contributions that may have benefited from decomposition of   
        the outcomes  
In the study by Elneihoum et al. (1998), the Kaplan-Meier and Cox regression 
approaches were used for all-cause mortality. Furthermore, a Cox regression was 
also presented for non-fatal recurrences, but it was not clear whether death was 
treated as a competing risk in the modelling. The 959 (43.4%) deaths would have 
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been a strong competing risk for the 137 (6%) of recurrences. In addition, a plot 
of the probability of recurrence is shown. However, the paper does not mention 
any appropriate competing risks approach and therefore it was probably based 
on the naïve Kaplan-Meier method. Finally the label RR, for relative risk, was 
used in the Cox results table. This is technically incorrect for recurrence because 
it was the hazard which was modelled, not the risk (i.e. not the probability). 
In the research by Ogasawara et al. (2002b), the authors use the Kaplan-Meier 
method for recurrence-free survival and a Cox regression for recurrence. 
However, in the latter the model included 10 covariates when there were only 
11 recurrences. There were too few events to warrant this number of covariates 
given the standard rule of thumb of 10 events per covariate (Peduzzi et al., 
1995). Furthermore, no details were provided of how deaths were treated in the 
Cox regression. The Kaplan-Meier plots presented suggest there were as many 
deaths as recurrences and therefore these would need to be treated as a 
competing risk. It is likely that the authors would have censored deaths when 
analysing recurrences. However clarification of this would have been beneficial 
due to the competing risks scenario. 
The contribution by Hillen et al. (2003a) used Kaplan-Meier analysis for 
recurrence-free survival. However, it also used a Kaplan-Meier approach for 
stroke recurrence, which is inappropriate with the paper failing to recognise 
that a more suitable method that takes into account competing risks should be 
used. This was particularly applicable to this study because death without 
recurrence was a strong competing risk, at 48.7% by 5 years, for the 153 (16.6%) 
of recurrences by 5 years. However, the authors do specify that deaths are 
censored in their parametric proportional hazards model for recurrence, which is 
the appropriate approach. That said, the paper also states that likelihoods were 
used to decide between parametric distributions and likelihood ratio tests to 
select covariates, both of which can be dubious in a competing risk scenario. 
The article by Hillen et al. (2003b) used a Cox regression for recurrence-free 
survival. However among the 561 patients in their study there were 66 
recurrences and 146 deaths. This number of events warrants decomposing the 
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composite outcome into the two competing risks recurrence and death without 
recurrence. It could provide more insight in the study, especially as stroke 
severity may have had opposing effects on recurrence and death, which might 
have been cancelling each other out.  
In their research Yokota et al. (2004) use Kaplan-Meier and Cox regression for 
recurrence-free survival. In a similar manner to Elneihoum et al. (1998) above, 
the label RR is used in the Cox results table, which is the wrong terminology in a 
competing risks context as previously explained. The patients in this study had 
198 recurrences and 286 deaths within 3 years. Therefore, there were enough of 
each event to consider decomposition of recurrence-free survival, which may 
have provided more insight. 
In the contribution by Lee et al. (2010), the methods section states that a 
Kaplan-Meier analysis and Cox regression was used for recurrence specifically. 
However, the Kaplan-Meier curve shown in the results is actually for recurrence-
free survival. If the article wished to present the cumulative incidence of 
recurrence specifically an appropriate method to take into account competing 
risks should have been used. Furthermore, it was not clear how deaths were 
treated in the Cox regression, and the number of deaths was not mentioned. 
However the Kaplan-Meier curve of recurrence-free survival appeared to be at 
around 80% by 5 years, and given that 14(7.7%) of the 181 patients had a 
recurrence, this left around 12% of the patients that died. Therefore, deaths 
were a strong competing risk for recurrence and the approach to analysis should 
reflect this. It would have been preferable to have clarification that this was the 
case. 
The work by Toschke et al. (2011) used a Cox regression for all-cause mortality 
and for recurrence. However, it was not clear whether death was treated as a 
competing risk in the modelling of the hazard of recurrence. The paper includes 
curves for the estimated probability of survival and for the estimated probability 
of stroke recurrence. It would appear from the survival curve, that among the 
3690 patients who survived 90 days, the probability of death within 5 years was 
around 15-30% depending on use of antihypertensive treatment. From the 
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recurrence curve, it would appear that the probability of recurrence within 6 
years was around 35-38% for the 3121 patients surviving 1 year. However, this 
recurrence curve presents naïve Cox predictions and as such is likely to have 
introduced inflation bias. It would have been more appropriate to also present 
Cox modelling of the hazards of the other competing risk, and then combine the 
hazards appropriately to create the predictions.  Alternatively, the Fine and 
Gray approach could have been used to present the cumulative incidence of 
recurrence taking into account competing risks. Even with the inflation bias, 
there was still likely to have been enough patients with recurrence and death 
without recurrence to analyse these two competing risks appropriately. A further 
limitation of this study was that only recurrences that occurred after 1-year post 
stroke were considered, ensuring it was a recurrence that was captured rather 
than just a repeat recording of the index stroke, but this wasted valuable 
information on recurrences in the intervening period. 
Chan et al. (2012)’s work used the Kaplan-Meier method for the two outcomes 
recurrence-free survival and major adverse cardiovascular events (MACE)-free 
survival. A Cox regression was used for the outcomes stroke recurrence and 
MACE. Among the patients in their study there were 10 recurrences, 12 MACEs 
and 8 deaths. Therefore deaths acted as a strong competing risk for recurrence 
and needed to be addressed appropriately. However, it was not clear whether 
competing risks were censored in their Cox models.  
 Contributions not likely to benefit from decomposition of the  
        outcomes  
Nadeau et al. (1992) used an unconventional way to present one of their 
outcomes. Overall survival was presented in the usual way by showing a Kaplan-
Meier curve. However for the other outcome the “percentage of patients free of 
non-stroke death who were free of stroke recurrence” is presented, which is 
somewhat confusing. This would appear to be a round-about way of expressing 
recurrence-free survival. However the paper also states “In the recurrence 
studies, non-stroke deaths were treated in the same-way as withdrawals.” This 
implies deaths were censored in the analysis of recurrence instead of included to 
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make a composite outcome. Regardless, there were too few events in the study 
to consider anything beyond a Kaplan-Meier analysis. 
In their contribution, Yokota et al. (1998) use a Kaplan-Meier analysis for 
recurrence-free survival and a Cox regression for recurrence specifically. 
However the authors were limited in the number of covariates they could 
consider due to only having 13 recurrences and 11 deaths in their study. 
The Kaplan-Meier and Cox regression approaches were used for recurrence-free 
survival in the research by Ogasawara et al. (2002a). Their study had 70 patients 
and 13 recurrences and 4 deaths. Given the small number of events, 
decomposition of recurrence-free survival was unlikely to provide any additional 
insight. 
In other research, Marnane et al. (2010) also used a Kaplan-Meier to analyse 
recurrence-free survival. Cox regression was again mentioned but it was unclear 
whether this was for recurrence alone or the composite outcome, because the 
abstract contained contradictory statements. With only 10 recurrences, there 
were not enough events to benefit from decomposition of the outcome. In 
addition, the use of 9 covariates in the Cox regression with such a small number 
of events was inappropriate.  
Kuwashiro et al. (2012) used a Kaplan-Meier approach for recurrence-free 
survival and logistic regression for the outcome recurrence by 12 months. The 
authors aimed to investigate factors associated with recurrence specifically. 
Their logistic regression approach was not unreasonable because there were not 
many deaths. Given the low number of deaths, obviously decomposition was not 
worth considering. However, the study only had 25 recurrences but 6 covariates 
in the model. The use of 6 covariates with 25 events was inappropriate given the 
standard rule of thumb of Peduzzi et al. (1996) that also applies to logistic 
regression. 
The contribution by Kim et al. (2014) used a Kaplan-Meier approach for 
recurrence-free survival and a Cox regression for stroke recurrence. The paper 
emphasises throughout the objective is to assess the risk of recurrence. In doing 
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so it fails to recognise that a Cox regression assesses the hazard which is 
different from the risk. In addition, the article does not mention whether there 
were any deaths in the study. If there were no or very few deaths then a logistic 
regression would have been a more sensible approach given that their outcome 
was at 90 days, a fixed point in time. That said, a Cox and logistic regression are 
unlikely to provide results with substantive differences, provided there are 
no/very few deaths and there is (near) complete follow-up of all patients. 
In another piece,  Fujimoto et al. (2015) used Kaplan-Meier and a Cox regression 
for recurrence-free survival. The authors were unlikely to gain any additional 
insight by decomposing this outcome due to relatively few deaths.  
 Summary of the review 
This section focused on an area where competing risks are not widely applied, 
specifically recurrence and death in stroke patients. The review in sub-section 
2.10.2 of contributions that involved competing risks analyses found that either 
Fine and Gray’s proportional subdistribution hazard model or cause-specific 
hazard Cox modelling was adopted. However, the presentation of analysis of 
both competing risks was very limited among the contributions using Fine and 
Gray’s model. Furthermore, none of the authors that used the cause-specific 
hazard Cox approach showed analysis for each competing risk, opting instead to 
just show modelling of recurrence. However, earlier in this chapter it was 
emphasised that the cause-specific hazard is a key driving force in the 
calculation of the cumulative incidence. Furthermore it was stressed that, to 
fully understand the effects on the outcomes of interest, the cause-specific 
hazard and cumulative incidence for each of the competing risks should be 
analysed. Therefore, Chapter 3 of this thesis will add to the existing research 
and present such a fully comprehensive analysis of the competing risks stroke 
recurrence and death. 
Sub-section 2.10.3 which focused on contributions that involved recurrence-free 
survival also found that, when authors used Cox regression for recurrence 
specifically, they neglected to present a corresponding analysis for death 
without recurrence. However, when modelling hazards of recurrence analysts 
 Chapter 2    Background to competing risks method    53                                                                                                                                                                                                  
 
are likely to be censoring deaths, and therefore inadvertently taking into 
account competing risks appropriately even if they are unaware that such a 
scenario exists. What could cause a problem however is when analysts try to 
derive cumulative incidences/probabilities from this and present naïve Cox 
predictions. Chapter 3 will also include a section highlighting the bias that can 
occur by inappropriately using a naïve Kaplan-Meier or naïve Cox approach. Sub-
section 2.10.3 also highlighted some instances when the opportunity was missed 
to decompose recurrence-free survival into the two competing risks recurrence 
and death without recurrence. Since some covariates are likely to have effects 
in opposite directions for the two competing risks, Chapter 3 will also compare 
analysis of the composite outcome with those of decomposition into the two 
competing risks. 
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 Competing risk analysis with the 
Edinburgh Stroke Study 
The previous chapter described the background to the competing risks approach, 
highlighted methodological issues that need to be considered and reviewed the 
literature into the extent of its use. In particular, the review focused on stroke 
recurrence and death, an area where the technique has not been used to its full 
potential. All of this motivated this current chapter which demonstrates 
empirical competing risks analyses with a stroke case study. This chapter 
presents various different aspects of competing risks analysis to illustrate the 
insights that can be gained over using standard survival analysis.   
The chapter begins by providing an overview of the case study, the Edinburgh 
Stroke Study, in section 3.1. Next, section 3.2 compares analyses of the 
composite outcome recurrence or death with those of the separate components 
recurrence and death without recurrence. The purpose of this is to illustrate the 
extra insight that can be gained by decomposing a composite outcome into its 
component competing risks. The focus of this section is Cox regression for the 
composite outcome and cause-specific hazards Cox regression for each of the 
two competing risks recurrence and death without recurrence. Then, section 3.3 
presents the Fine and Gray subdistribution hazards modelling approach to 
competing risks. The results are presented alongside those using the cause-
specific hazards approach demonstrated earlier in section 3.2. In particular, 
section 3.3 also includes cumulative hazard and cumulative incidence plots. The 
purpose of section 3.3 is to illustrate the greater understanding that can be 
gained of a competing risks process by considering both the hazard and 
cumulative incidence of each competing risk. Next, section 3.4 illustrates the 
consequences of not taking into account competing risks. Specifically, this 
section compares naïve Kaplan-Meier/Cox predictions to those that appropriately 
address that competing risks are present. Finally, section 3.5 summarises the 
analysis presented in this chapter and the extra insight gained over standard 
survival analysis.  
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 Overview of the Edinburgh Stroke Study 
All analysis in this chapter and chapter 5 was carried out using data from the 
Edinburgh Stroke Study (ESS), a case study used to demonstrate the potential in 
stroke epidemiology of the methods described in this thesis. ESS was a 
prospective, hospital-based cohort study of stroke patients followed-up with 
multiple overlapping methods for recurrent stroke, myocardial infarction, and 
death. The methods and process of data collection are described elsewhere 
(Jackson et al., 2009). 1237 patients who presented with a definite or probable 
stroke (excluding a subarachnoid haemorrhage) between the years 2002 and 
2005 were included in the analysis. These patients were followed-up for 
between 1 and 4 years, and details of any stroke recurrence and/or death were 
obtained. Table 3.1 on the next page shows the patient characteristics used in 
the analysis.  
The second column in Table 3.1 shows the distribution of covariates among the 
stroke patients. The remaining columns show, for each event of interest, the 
frequency of the event in patients with a particular covariate level, with the 
information with and without the characteristic shown for the binary covariates. 
While not the focus of this chapter, death after recurrence is considered in 
chapter 5 and is shown in Table 3.1 for completeness. To guide the reader, the 
third row shows that 621 of the patients were male. It also shows that 11.8% of 
males and 15.3% of females had recurrences, 18.7% of males and 23.4% of 
females died without recurrence and 42.5% of males and 34.0% of females died 
after a recurrence. Information on other rows of the table can be read similarly. 
The frequencies are shown as an indication of the (unadjusted) covariate effects 
on the events and should not be thought of as incidence in the usual sense due 
to censoring. However, they do show the effect of each of the covariates in 
absolute terms, ahead of the modelling of hazards later in the chapter which 
will be in relative terms. 
 
Previous cerebrovascular event was defined as previous stroke or transient 
ischaemic attack. Previous other occlusive vascular disease consisted of previous 
ischaemic heart disease or peripheral arterial disease. Previous hypertension was  
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Table 3.1  Patient characteristics involved in analyses of Edinburgh Stroke Study 
 
defined as a history of treated hypertension. High blood pressure was defined as 
a systolic blood pressure in excess of 160mmHg or a diastolic blood pressure in 
excess of 80mmHg at the time of initial assessment.  Symptomatic carotid 
disease was defined as the percentage stenosis in the internal carotid artery 
(ICA) on the same side as the brain lesion. If the lesion was not specific to one 
side, or the side was unknown, the largest stenosis was used. A patient was 
    n (%) 
% experiencing event amongst those with(without) 
characteristic2 
    
 
recurrence 
death without 
recurrence 
death after 
recurrence 
Total 1 1237 (100%) 167 (13.5%) 260 (21.0%) 63 (37.7%) 
age at stroke - mean(s.d.) 71 (12) 72 (10) 78 (10) 76 (9) 
male 621 (50.2%) 11.8% (15.3%) 18.7% (23.4%) 42.5% (34.0%) 
independent before stroke 1147 (92.7%) 13.9% (8.9%) 18.2% (56.7%) 36.5% (62.5%) 
previous cerebrovascular event 373 (30.2%) 16.4% (12.3%) 22.8% (20.3%) 37.7% (37.7%) 
previous other occlusive vascular 
disease 864 (69.8%) 16.4% (12.2%) 27.8% (18.0%) 53.2% (28.6%) 
previous hypertension  378 (30.6%) 15.1% (11.8%) 20.0% (22.1%) 37.8% (37.7%) 
diabetes  150 (12.1%) 15.3% (13.2%) 22.7% (20.8%) 47.8% (36.1%) 
non-smoker 436 (35.2%) 12.4% (14.1%) 25.0% (18.9%) 35.2% (38.9%) 
lift both arms off bed  1041 (84.2%) 15.0% (5.6%) 14.2% (57.1%) 35.9% (63.6%) 
walk independently 876 (70.8%) 14.4% (11.4%) 12.2% (42.4%) 29.4% (63.4%) 
orientated speech 1038 (83.9%) 14.0% (11.1%) 14.6% (54.3%) 33.1% (68.2%) 
stroke syndrome 
      Cortical 655 (53.0%) 14.0% 26.6% 44.6% 
  Lacunar 324 (26.2%) 12.7% 11.4% 34.1% 
  Other  258 (20.9%) 13.2% 19.0% 23.5% 
high blood pressure  444 (35.9%) 12.8% (13.9%) 21.4% (20.8%) 28.1% (42.7%) 
delay in assessment 
      0-1 days 282 (22.8%) 13.5% 34.4% 47.4% 
  2-6 days 300 (24.3%) 14.3% 25.3% 48.8% 
  7 days or more 655 (53.0%) 13.1% 13.3% 27.9% 
symptomatic carotid stenosis 
      <70% ICA 904 (73.1%) 12.7% 15.2% 31.3% 
  70-100% ICA 144 (11.6%) 22.2% 20.1% 50.0% 
  Unknown  189 (15.3%) 10.6% 49.7% 55.0% 
in atrial fibrillation 257 (20.8%) 16.7% (12.7%) 36.2% (17.0%) 53.5% (32.3%) 
visible infarct on scan 714 (57.7%) 13.7% (13.2%) 22.5% (18.9%) 43.9% (29.0%) 
haemorrhage on scan 88 (7.1%) 17.0% (13.2%) 35.2% (19.9%) 53.3% (36.2%) 
1 When symptomatic carotid disease was not recorded it was treated as a separate ‘Unknown’ category. This was because 
the information was not thought to be missing at random; instead the patients concerned were thought to be more likely to 
be too ill to have this assessed. When stroke syndrome was not recorded (55 patients) it was included in the category 
'Other', which also consisted of patients with posterior circulation syndrome (POCS). For all other variables, patients without 
a value recorded were included in the category of the variable that was most common. The latter was the case for 
independent before stroke (6), previous cerebrovascular event (3), previous other occlusive vascular disease (2), previous 
hypertension (1), smoking status (24), lift both arms off bed (4), walk (7), orientated speech (6), high blood pressure (11), in 
atrial fibrillation (74), visible infarct on scan (26) and haemorrhage on scan (26) . There were no unrecorded values for age, 
gender, diabetes and delay in assessment. 
2 with (without) characteristic shown for binary variables, and each level shown on separate rows for variables with 3 levels. 
mean (s.d.) are shown for the continuous variable age 
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considered to be in atrial fibrillation if they had a history of atrial fibrillation or 
it was present on ECG. Orientated speech was defined as able to talk and 
orientated in time, place and person.  The date of initial assessment was chosen 
as the starting date rather than the date of stroke onset to exclude recurrences 
before baseline information could be collected. If patients had more than one 
stroke before initial assessment the stroke immediately before initial assessment 
was selected as the index stroke. This was the case for two patients. The illness-
death modelling presented in Chapter 5 did not allow entry to different health 
states at the same time. Therefore patients with a recurrence on the same day 
as death were assumed to have died 0.5 days later than their recurrence. This 
was the case for four patients. 
 Analyses of the composite outcome versus 
decomposition of the outcome: cause-specific hazards 
approach to competing risks 
It could be seen in the previous section that there were 167 recurrences and 260 
deaths without recurrence among the 1237 patients. It is common in studies - 
and trials in particular - to study composite outcomes such as recurrence-free 
survival i.e. the composite event recurrence or death. However, decomposing a 
composite outcome into its component competing risks can often provide 
additional insight. This is particularly true when a covariate affects two 
different competing risks, but the effects are in opposing directions. In addition, 
it can be the case that one particular event is of interest but a competing event 
occurs more often. When this happens the analysis of the composite outcome 
may be dominated by factors associated with the competing event, and 
associations with the event of interest may become masked. In the Edinburgh 
Stroke Study, recurrences were of primary interest. Given that there were only 
167 recurrences but 260 deaths without recurrence, there was potential to gain 
insight from an analysis that decomposed the composite outcome into these two 
competing risks. In addition, it was thought that there may be some covariates 
that would affect each competing risk differently. This provided the motivation 
for the analysis in this section that compares analyses of the composite outcome 
recurrence or death with those of the separate components recurrence and 
death without recurrence. 
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Table 3.2 shows the effects of the covariates on the hazard of each of the events 
at the univariable (unadjusted) level.  
   
Cox regression of                                   
recurrence or death cause-specific hazard competing risks Cox modelling  
  
Baseline 
hazard ratio for 
recurrence or death 
without recurrence  
(95% CI) p-value  
hazard ratio for 
recurrence     
(95% CI) 
p-
value  
hazard ratio for 
death without 
recurrence 
      (95% CI) p-value  
age - centred 
on mean of 71 
 
1.05 (1.04, 1.06) <0.001 1.02 (1.00, 1.03) 0.012 1.08 (1.06, 1.09) <0.001 
male Female 0.74 (0.61, 0.90) 0.002 0.72 (0.53, 0.98) 0.038 0.76 (0.59, 0.97) 0.025 
independent 
before stroke No 0.36 (0.27, 0.48) <0.001 1.12 (0.55, 2.27) 0.763 0.24 (0.18, 0.33) <0.001 
previous 
cerebrovascular 
event  No 1.22 (1.00, 1.49) 0.055 1.34 (0.98, 1.84) 0.066 1.14 (0.88, 1.47) 0.329 
previous other 
occlusive 
vascular 
disease No 1.65 (1.36, 2.01) <0.001 1.53 (1.12, 2.09) 0.008 1.74 (1.36, 2.23) <0.001 
previous 
hypertension No 1.07 (0.88, 1.29) 0.504 1.33 (0.98, 1.81) 0.069 0.93 (0.73, 1.18) 0.543 
diabetes No 1.19 (0.90, 1.57) 0.223 1.23 (0.79, 1.91) 0.352 1.16 (0.81, 1.67) 0.417 
current smoker 
and ex-smoker 
<12 months 
Non-
smoker 0.85 (0.70, 1.03) 0.097 1.09 (0.79, 1.51) 0.602 0.73 (0.57, 0.93) 0.011 
lift both arms 
off bed  
No 
0.30 (0.24, 0.37) <0.001 1.70 (0.92, 3.14) 0.089 0.16 (0.13, 0.21) <0.001 
walk 
independently 
No 
0.37 (0.31, 0.45) <0.001 0.94 (0.66, 1.33) 0.714 0.22 (0.17, 0.28) <0.001 
orientated 
speech No 0.27 (0.22, 0.33) <0.001 0.77 (0.49, 1.20) 0.245 0.17 (0.13, 0.22) <0.001 
stroke 
syndrome 
  
<0.001 
 
0.448 
 
<0.001 
 
Lacunar Cortical 0.52 (0.40, 0.67) <0.001 0.79 (0.55, 1.15) 0.218 0.38 (0.26, 0.54) <0.001 
 
Other Cortical 0.75 (0.59, 0.96) 0.021 0.89 (0.60, 1.31) 0.551 0.68 (0.49, 0.93) 0.015 
high blood 
pressure  No 1.04 (0.85, 1.26) 0.728 0.98 (0.71, 1.34) 0.881 1.08 (0.84, 1.38) 0.573 
delay in 
assessment 
  
<0.001 
 
0.267 
 
<0.001 
 
2 - 6  d a y s 0-1 days 0.70 (0.55, 0.90) 0.005 0.90 (0.58, 1.39) 0.634 0.63 (0.46, 0.85) 0.002 
 
7 days or 
more 0-1 days 0.42 (0.34, 0.53) <0.001 0.74 (0.51, 1.09) 0.125 0.30 (0.22, 0.40) <0.001 
symptomatic 
carotid stenosis 
  
<0.001 
 
0.013 
 
<0.001 
 
70-100% ICA <70% ICA 1.63 (1.23, 2.15) 0.001 1.86 (1.26, 2.75) 0.002 1.43 (0.96, 2.13) 0.082 
 
Unknown <70% ICA 3.11 (2.49, 3.88) <0.001 1.21 (0.75, 1.94) 0.435 4.68 (3.59, 6.09) <0.001 
in atrial 
fibrillation No 2.20 (1.79, 2.70) <0.001 1.65 (1.17, 2.34) 0.005 2.60 (2.01, 3.35) <0.001 
visible infarct 
on scan No 1.20 (0.99, 1.46) 0.068 1.10 (0.81, 1.50) 0.527 1.26 (0.98, 1.62) 0.067 
haemorrhage 
on scan No 1.99 (1.46, 2.70) <0.001 1.64 (0.96, 2.78) 0.069 2.21 (1.52, 3.22) <0.001 
Table 3.2 Univariable Cox composite vs cause-specific hazard competing risks Cox modelling 
results 
 
The first section of Table 3.2 shows the results of Cox regression modelling of 
the composite outcome regression or death without recurrence. The rest of 
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Table 3.2 displays the results of the Cox cause-specific hazard approach to 
modelling the competing risks recurrence and death without recurrence. 
Covariates found to be statistically significant at the 5% level are shown in bold. 
Those covariates found to be statistically significant at the 10% level (marginally 
significant) are shown in italics. Alternate shading of the rows is used to help 
distinguish between the rows. The usual appropriate checks for violations of 
proportional hazards were carried out, although they are not shown for reasons 
of brevity. 
It can be seen in Table 3.2 that advancing age, being female, having other 
occlusive vascular disease, having high symptomatic carotid stenosis and having 
atrial fibrillation were each found to be associated with a higher hazard of the 
composite outcome recurrence or death and its components recurrence and 
death without recurrence. It can also be seen from Table 3.2 that there was a 
higher hazard of the composite outcome associated with not being independent 
before stroke, not being able to walk independently, not having orientated 
speech, having cortical syndrome, having the shortest delay in assessment and 
having a haemorrhage on scan. However, it could be seen from the competing 
risks analysis that these covariate levels were each all associated with a higher 
hazard of death without recurrence but were not found to have an association 
with recurrence (although having a haemorrhage on scan was associated with a 
higher hazard of recurrence at the 10% level). Therefore, these associations 
found with the composite outcome were primarily due to death without 
recurrence. There was also a higher hazard of the composite outcome associated 
with not being able to lift both arms off the bed and this too was primarily due 
to an increased hazard of death without recurrence. However, there was also a 
marginal association with the ability to lift both arms off the bed and recurrence 
but in the opposite direction. Importantly, this was only detectable from the 
competing risk analysis because associations with recurrence were masked in the 
composite outcome analysis, due to the dominance of death without recurrence. 
In terms of recurrence specifically, advancing age, being female, having other 
occlusive vascular disease, having high symptomatic carotid stenosis and having 
atrial fibrillation were each found to be associated with a higher hazard of the 
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event. However, as previously mentioned above, each of these covariate levels 
were also associated with an increased hazard of the competing risk death 
without recurrence. Therefore, this was something to bear in mind as this could 
influence the predictions of recurrence, particularly as in many instances the 
effect of the covariate was more strongly associated with death without 
recurrence than recurrence. 
Multivariable analysis was then carried out considering the variables together in 
a model, allowing the effect of each covariate to be adjusted by other relevant 
variables. Parsimony was used for ease of subsequent prediction. For the 
modelling of the composite outcome, likelihood-ratio tests using the 5% 
significance level were used to select variables. This was carried out using 
backward selection and then repeated using forward stepwise selection and 
then, for stability, the selections were checked to ensure they matched. A 
similar approach was not used for the competing risks cause-specific hazards 
modelling for the reasons raised in the section 2.7.2 of chapter 2. Instead, the 
cause-specific hazards modelling included the same variables that were included 
in the Fine and Gray subdistribution hazards approach presented in the following 
section of this chapter. The variable selection for the Fine and Gray model was 
based on the approach proposed by Kuk and Varadhan (2013). This provided a 
solution that was needed anyway to help aid the comparison of the two 
approaches in the next section. However, because the purpose of this section 
was to compare the effect of the covariates on each event, any covariate found 
to have a significant effect on any of the events was included in the models for 
each event. For each event, covariates found to be statistically significant at the 
5% and 10% level, are shown in bold and italics, respectively. Consequently, any 
covariate without such highlighting was only included for comparison purposes.  
This variable selection approach produced a sensible result in the sense that it 
included all those covariates found to be significant at the 10% level for either of 
the two events in the corresponding unparsimonious multivariable models. Table 
3.3 shows the final modelling results.  
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Cox regression of         
recurrence or death  cause-specific hazard competing risks Cox modelling 
  
Baseline 
hazard ratio for 
recurrence or 
death without 
recurrence 
(95% CI) 
p-
value  
hazard ratio for 
recurrence    
(95% CI) 
p-
value  
hazard ratio for 
death without 
recurrence    
(95% CI) 
p-
value  
age - centred on 
mean of 71 
 
1.04 (1.03, 1.05) <0.001 1.01 (0.99, 1.02) 0.240 1.06 (1.05, 1.07) <0.001 
male Female 0.90 (0.74, 1.09) 0.274 0.69 (0.50, 0.94) 0.021 1.01 (0.79, 1.30) 0.909 
independent 
before stroke No 0.70 (0.52, 0.94) 0.018 1.22 (0.59, 2.51) 0.589 0.66 (0.47, 0.91) 0.013 
previous other 
occlusive 
vascular disease No 1.30 (1.07, 1.59) 0.010 1.41 (1.02, 1.95) 0.037 1.21 (0.93, 1.56) 0.154 
lift both arms off 
bed  
No 
0.55 (0.43, 0.70) <0.001 2.37 (1.25, 4.49) 0.008 0.34 (0.26, 0.46) <0.001 
orientated 
speech No 0.52 (0.41, 0.66) <0.001 0.79 (0.48, 1.28) 0.340 0.43 (0.32, 0.58) <0.001 
symptomatic 
carotid stenosis 
  
<0.001 
 
0.004 
 
<0.001 
 
70-100% ICA <70% ICA 1.50 (1.13, 2.00) 0.005 2.06 (1.38, 3.07) <0.001 1.26 (0.84, 1.89) 0.271 
 
Unknown <70% ICA 2.15 (1.66, 2.79) <0.001 0.99 (0.57, 1.71) 0.970 2.85 (2.08, 3.89) <0.001 
in atrial 
fibrillation No 1.43 (1.15, 1.77) 0.001 1.67 (1.16, 2.40) 0.006 1.31 (1.00, 1.72) 0.052 
haemorrhage on 
scan No 0.91 (0.64, 1.29) 0.603 1.94 (1.05, 3.58) 0.036 0.68 (0.45, 1.04) 0.075 
 
Table 3.3  Multivariable Cox composite vs cause-specific hazard Cox modelling results 
 
It can be seen from Table 3.3 that the ability to lift both arms off the bed was 
associated with the composite outcome and each of the two competing risks. 
However, while being able to lift both arms off the bed was associated with a 
reduced hazard of the composite outcome and of death without recurrence, it 
was associated with an increased hazard of recurrence. Therefore, the increased 
hazard of recurrence was undetectable from the composite outcome analysis 
alone due to the dominance of deaths without recurrence. Hence, extra insight 
was gained from the analysis of the competing risks. It has helped to reveal that 
those who were able to lift both arms off the bed were more likely to have a 
recurrence rather than die before doing so. It has hence identified a group of 
patients who may benefit from prevention strategies for recurrence. 
Symptomatic carotid stenosis was also associated with the composite outcome 
and each of the two competing risks. Having 70-100% ICA stenosis, compared to 
<70% ICA, was associated with an increased hazard of the composite outcome 
and recurrence. Having unknown stenosis, compared to <70% ICA, was associated 
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with an increased hazard of the composite outcome and death without 
recurrence. Having atrial fibrillation was associated with an increased hazard of 
the composite outcome and recurrence, and such an association with death 
without recurrence only just failed to reach the 5% significance level. Advancing 
age, not being independent before stroke and not having orientated speech were 
found to be associated with an increased hazard of the composite outcome and 
death without recurrence. Having other occlusive vascular disease was also 
found to be associated with an increased hazard of the composite outcome and 
recurrence. Therefore, the decomposition of the composite outcome into the 
two competing risks highlighted which of the particular events had an 
association with the covariate. Consequently, the competing risks analyses 
provided added benefit over the analysis of the composite outcome alone. 
Being female was only found to be associated with an increased hazard of 
recurrence, with sex having a very negligible effect on death without 
recurrence. Therefore, this was something that was not evident from the 
analysis of the composite outcome alone. Having a haemorrhage on scan was 
found to have an association with an increased hazard of recurrence and a 
(marginally) reduced hazard of death without recurrence. This resulted in a lack 
of association with the composite outcome, with the opposing effects on each of 
the competing risks effectively cancelling each other out. Therefore, another 
added benefit of the analysis of each of the two competing risks was 
demonstrated. It unmasked associations not evident from the composite 
outcome analysis, highlighting information could be lost if a composite outcome 
is comprised of two events on which there are opposing effects. 
With regards to recurrence specifically, being female, having other occlusive 
vascular disease, being able to lift both arms off the bed, having high carotid 
stenosis, being in atrial fibrillation and having a haemorrhage on scan were 
associated with an increased hazard of recurrence. As mentioned above, the 
ability to lift both arms off the bed and symptomatic carotid stenosis were also 
associated with death without recurrence, although the effects were in the 
opposite direction. This emphasises again the analysis of recurrence, separate 
from that for death without recurrence and the composite outcome, provided 
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insights that were not evident from the other two analyses. It identified 
characteristics in patients that could help clinicians deciding on a strategy to 
improve the lives of the patients under their care. 
 Cause-specific hazards vs Fine and Gray 
subdistribution modelling approaches 
In section 2.5 of chapter 2, it was emphasised that a greater understanding of a 
competing risks scenario can be gained when the hazards and cumulative 
incidence functions for each of the competing risks are investigated. In 
particular, Latouche et al. (2013) recommend considering both cumulative 
hazard plots and cumulative incidence plots to assess the effects of covariates. 
This section aims to demonstrate the extra insight that such a comprehensive 
analysis can provide to help interpretation in the presence of competing risks. 
This would appear to be the first study to demonstrate the potential of such 
analysis of recurrence and death without recurrence in stroke patients.  
The section begins by showing, in Table 3.4 for each of the competing risks, the 
effects of the covariates on the cause-specific hazard alongside those on the 
subdistribution hazard. As indicated previously in chapter 2, the subdistribution 
hazard has a one-to-one correspondence with the cumulative incidence.  
Broadly speaking, for each event, the two approaches produced similar results in 
terms of the covariate effects being in the same direction. The rest of this 
section will discuss the effect of the covariates on the hazard of each event and 
how this translated into the corresponding effect on the subdistribution 
hazard/cumulative incidence of each event. Covariates that had similar effects 
on the hazard in terms of direction are discussed together.  
The section also includes Figures 3.1 – 3.5 that show, for each covariate in turn, 
cumulative hazard and cumulative incidence plots. Each of the Figures are based 
on the following reference patient: male, aged 71, who was independent before 
stroke, had previous other occlusive vascular disease, could lift both arms off  
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Baseline 
hazard ratio for 
recurrence        
(95% CI) 
p-
value  
subdistribution 
hazard ratio for 
recurrence 
 (95% CI) p-value  
age - centred on mean of 71 
 
1.01 (0.99, 1.02) 0.240 1.00 (0.99, 1.02) 0.600 
male Female 0.69 (0.50, 0.94) 0.021 0.68 (0.50, 0.93) 0.016 
independent before stroke No 1.22 (0.59, 2.51) 0.589 1.43 (0.69, 2.96) 0.340 
previous other occlusive vascular 
disease No 1.41 (1.02, 1.95) 0.037 1.35 (0.97, 1.89) 0.078 
lift both arms off bed  No 2.37 (1.25, 4.49) 0.008 3.55 (1.71, 7.37) 0.001 
orientated speech No 0.79 (0.48, 1.28) 0.340 0.94 (0.53, 1.65) 0.820 
symptomatic carotid stenosis 
  
0.004 
  
 
70-100% ICA <70% ICA 2.06 (1.38, 3.07) <0.001 2.10 (1.40, 3.15) <0.001 
 
Unknown <70% ICA 0.99 (0.57, 1.71) 0.970 0.81 (0.46, 1.42) 0.450 
in atrial fibrillation No 1.67 (1.16, 2.40) 0.006 1.62 (1.11, 2.36) 0.012 
haemorrhage on scan No 1.94 (1.05, 3.58) 0.036 2.13 (1.15, 3.95) 0.016 
       
  
Baseline 
hazard ratio for 
death without 
recurrence 
 (95% CI) 
p-
value  
subdistribution 
hazard ratio for 
death without 
recurrence  
(95% CI) p-value  
age - centred on mean of 71 
 
1.06 (1.05, 1.07) <0.001 1.06 (1.04, 1.07) <0.001 
male Female 1.01 (0.79, 1.30) 0.909 1.04 (0.80, 1.36) 0.750 
independent before stroke No 0.66 (0.47, 0.91) 0.013 0.67 (0.46, 0.98) 0.039 
previous other occlusive vascular 
disease No 1.21 (0.93, 1.56) 0.154 1.16 (0.89, 1.53) 0.270 
lift both arms off bed  No 0.34 (0.26, 0.46) <0.001 0.31 (0.23, 0.41) <0.001 
orientated speech No 0.43 (0.32, 0.58) <0.001 0.45 (0.33, 0.60) <0.001 
symptomatic carotid stenosis 
  
<0.001 
  
 
70-100% ICA <70% ICA 1.26 (0.84, 1.89) 0.271 1.10 (0.72, 1.67) 0.680 
 
Unknown <70% ICA 2.85 (2.08, 3.89) <0.001 2.81 (2.07, 3.81) <0.001 
in atrial fibrillation No 1.31 (1.00, 1.72) 0.052 1.19 (0.89, 1.59) 0.230 
haemorrhage on scan No 0.68 (0.45, 1.04) 0.075 0.62 (0.39, 1.00) 0.048 
 
 
Table 3.4  cause-specific hazards vs Fine and Gray’s subdistribution hazards multivariable 
modelling   
 
the bed, did not have orientated speech, had <70% ICA stenosis, did not have 
atrial fibrillation and did not have a haemorrhage on scan. For each covariate in 
turn, every level of that covariate is shown with the other covariates held at the 
reference level specified. 
The cumulative hazard plots are based on the Cox cause-specific hazard 
modelling. The cumulative incidence curves are based on Fine and Gray’s 
subdistribution hazard model. The latter were calculated using the default 
weighted equation approach in cmprsk from R.  
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A crucial point regarding the results presented in Table 3.4 is that the effects of 
the covariates are displayed as (subdistribution) hazard ratios, and as such are 
relative effects. In contrast, the results presented in Figures 3.1 – 3.5 show 
absolute difference in cumulative incidence between the levels of a given 
covariate. When the underlying prevalence of an event is low, then even a large 
relative effect will not impact greatly on the difference in cumulative incidences 
displayed on the absolute scale. This is particularly pertinent in this case study 
because the frequency of deaths without recurrence greatly exceeded the 
frequency of recurrences. 
 covariates that affect the hazard of each event but in 
opposite directions 
It can be seen that the ability to lift both arms off the bed, having a 
haemorrhage on scan and being independent before stroke were each associated 
with a higher hazard of recurrence and a reduced hazard of death without 
recurrence (Table 3.4). Alternatively, those without those characteristics were 
at a reduced hazard of recurrence and an increased hazard of death without 
recurrence. There were also corresponding effects on the cumulative incidences 
(Figure 3.1 and Figure 3.2).  
For each competing risk, the effect on the subdistribution hazard was more 
pronounced than the effect on the hazard (lift arms off bed and haemorrhage on 
scan). This would normally suggest that the hazard of the other event may be 
having an influence on the cumulative incidence of the event. However, when 
there are opposing effects on the hazards, as in this case, the influence of the 
competing hazard is not such an issue. This is because any influence of the 
competing hazard will not alter the conclusions from the effect from the hazard 
of the event of interest. For instance, being able to lift both arms off the bed 
was found to be associated with an increase in the hazard of recurrence and this 
contributed to a relative increase in the cumulative incidence of recurrence 
seen in Figure 3.1(b). That there was a decreased hazard of death without 
recurrence may mean there would be more available to be at risk of recurrence. 
However this would only result in an increase in the cumulative incidence of 
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recurrence and therefore not contrast with the conclusion from the effect on 
the hazard of recurrence. 
In Figure 3.1(a) and (b) it can be seen, as expected from Table 3.4, that the 
cumulative hazard and incidence of recurrence was higher for those who could 
lift both arms off the bed compared to those who could not, and that for death 
without recurrence the opposite was true. However, the relative effects found 
in Table 3.4 were not always apparent in Figure 3.1(b) and 3.1(d) due to the 
dominance of the absolute effect of death without recurrence over the absolute 
effect of recurrence. For example, Figure 3.1(b) did not reflect that the relative 
effect of lift arms was more pronounced for the subdistribution/incidence of 
recurrence than it was for the subdistribution/incidence of death without 
recurrence. Nor did it reflect that the effect on the subdistribution/incidence of 
recurrence was more pronounced than the effect on the hazard of recurrence in 
relative terms. Therefore it is imperative to consider both the relative effects 
(Table 3.4) and the absolute effects (Figure 3.1 and Figure 3.2) to fully 
appreciate the effects of the covariates on both the hazard and incidence of 
each of the competing events. This is also true of the effects of covariates that 
follow. 
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Figure 3.1 Cumulative hazard vs cumulative incidence: lift both arms and 
haemorrhage on scan 
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3.3.2   covariates that only affected the hazard of one event 
It could be seen that age had no effect on the hazard of recurrence but that 
advancing age increased the hazard of death without recurrence (Table 3.4). 
The corresponding effects on the cumulative incidences were consistent with 
this (Figure 3.2(d)). Therefore, in particular, the increased hazard of the 
competing event death without recurrence was not strong enough to materially 
affect the cumulative incidence of recurrence. Specifically, the heightened 
hazard of death before recurrence could occur, as age increased, did not have 
any discernible reduction on the risk of recurrence, as age increased, even 
though there would be less patients alive to experience it. 
It could also be seen that sex had no effect on the hazard of death without 
recurrence but being male decreased the hazard of recurrence (Table 3.4). 
Again, this was consistent with the corresponding effects on the cumulative 
incidences (Figure 3.3 (a) and (b)). This implies that the relative effect of being 
male on the cumulative incidence of recurrence was directly related to the 
hazard of recurrence without any indirect influence from the competing risk 
death without recurrence. Similarly, the cumulative incidence of death without 
recurrence was a direct effect which was not influenced by the effect of sex on 
recurrence.   
Analogous conclusions could be drawn for those with unknown carotid stenosis 
compared to those with 70-100% ICA, except it was unknown stenosis that had no 
effect on the hazard of recurrence while it was associated with an increase in 
the hazard of death without recurrence (Figure 3.3 (c) and (d)). 
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Figure 3.2 Cumulative hazard vs cumulative incidence: independence before stroke and age 
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Figure 3.3 Cumulative hazard vs cumulative incidence: sex and stenosis 
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3.3.3 covariates that affected the hazards of each event in 
the same direction 
It could be seen that having atrial fibrillation and other occlusive vascular 
disease each increased the hazard of both competing risks (Table 3.4 and Figure 
3.4(a) and (c)). These effects were also seen in the cumulative incidences 
although the effects were slightly attenuated. This suggests that there may have 
been a degree of influence of the competing risk on each of the events. 
Specifically, the attenuation in the effect on the cumulative incidence of 
recurrence may have been due to the increased hazard of death without 
recurrence, meaning there were less at risk to be susceptible to recurrence. A 
similar argument may explain the attenuation in the cumulative incidence of 
death without recurrence. 
Again, with reference to atrial fibrillation and other occlusive vascular disease, 
Table 3.4 shows that the relative effect in hazard/subdistribution hazard is 
actually higher for recurrence than for death without recurrence, but Figure 3.4 
seems to suggest the opposite. For instance, for those with other occlusive 
vascular disease, the increase in relative hazard of recurrence of 41% only 
equated to a difference in cumulative incidences at 3 years of 3.1%; specifically 
12.5% versus 9.4% respectively for those with and without other occlusive 
vascular disease. In contrast, the increase in relative hazard of death without 
recurrence of only 21% equated to a larger difference in cumulative incidence at 
3 years of 5.3%; specifically 54.4% versus 49.1% respectively for those with and 
without other occlusive vascular disease. Therefore, it helps to use both Table 
3.4 and the Figures to gauge the underlying prevalences that hazards are acting 
on to produce the cumulative incidences, especially when the occurrence of one 
event is so much higher than the other.  
There was a relative reduction in hazard of each competing risk for those with 
orientated speech, with a more pronounced effect for death without recurrence 
(Table 3.4). However on the absolute scale, there was no effect of orientated 
speech on the cumulative incidence of recurrence, even though there was a 
trend towards a reduced hazard (Figure 3.5).  
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Figure 3.4 Cumulative hazard vs cumulative incidence: atrial fibrillation and other occlusive 
vascular disease 
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Figure 3.5 Cumulative hazard vs cumulative incidence: orientated speech 
 
This may be explained by more of those with orientated speech having a 
recurrence than was perhaps expected, due to the decreased hazard of death 
without recurrence meaning there was more left to be at risk of recurrence. As 
such, the (non-significant) increase in the hazard of recurrence was masked from 
the cumulative incidence of recurrence, due to the more pronounced decrease 
in the hazard of death without recurrence.  
Finally, there was a relative increase in the hazard of each competing risk for 
those with 70-100% ICA symptomatic carotid stenosis compared to those for 
whom it was unknown/unassessable, with a more pronounced effect for 
recurrence (Table 3.4). Even though there was a (trend towards a) relative 
increase in the hazard of death without recurrence, on the absolute scale, there 
was no effect on the corresponding cumulative incidence (Figure 3.3 (d)). An 
inspection of the plots helps interpret this finding.  It can be seen in Figure 3.3 
(c) and (d), in those with 70-100% symptomatic carotid stenosis, that the 
cumulative hazard and incidence of recurrence was higher than for death 
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without recurrence. The stronger increase in the hazard of recurrence could 
explain why the cumulative incidence of death without recurrence for those 
with 70-100% ICA stenosis rose more gradually, and therefore was more in line 
with that for <70% ICA stenosis. 
 Consequences of not taking into account competing 
risks 
This section demonstrates some of the bias that can be introduced if an 
inappropriate approach that does not take into account competing risks is used. 
Two different illustrations are used. Firstly, the non-parametric naïve Kaplan-
Meier approach is compared to the competing risks cumulative incidence 
approach. Secondly, the estimates are based on modelling that considers the 
effects of covariates. The naïve cause-specific hazard Cox approach to modelling 
is compared to the more appropriate calculation of the cumulative incidence, 
which is based on combining the cause-specific hazard of each of the competing 
risks. The effects of selected covariates on death without recurrence are used 
for illustration. 
 Non-parametric naïve Kaplan-Meier versus competing 
risks cumulative incidence   
Figure 3.6 on the next page shows, for each of the competing risks, the non-
parametric naive Kaplan-Meier estimate of cumulative incidence, alongside that 
of the more appropriate estimate that takes into account competing risks.  
It can be seen in Figure 3.6 that, for death without recurrence (dashed lines), 
bias starts to be introduced from about 1 year onwards. The bias results in 
progressively more inflation of the cumulative incidence. By 3.5 years the biased 
cumulative incidence estimate is 29.2%, compared to the more appropriate 
estimate of 26.4%. Therefore, inflation of around 11% has resulted. With regards 
to recurrence (solid lines), the bias begins from as early as 6 months. By 4 years 
the biased estimate is 20.2%, compared to the more appropriate estimate of 
17.1%, an inflation of 18%. 
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Figure 3.6 non-parametric naïve KM vs competing risks cumulative incidence 
 
 Naïve cause-specific hazard-based cumulative  
incidence  versus that derived appropriately using the 
cause-specific hazards of each of the competing risks  
Figure 3.7 on the next page shows the effect of four different covariates in turn 
on the cumulative incidence of death without recurrence. Cumulative incidences 
based on the naïve cause-specific hazard approach and those based on the 
appropriate derivation using all cause-specific hazards are shown for each level 
of the covariate. Each plot shows the outcomes for the reference patient 
described in section 3.3 on page 63, alongside that when the level of the specific 
covariate is changed. 
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Figure 3.7 Cumulative incidences derived using the naïve cause-specific hazard approach 
versus those using the more appropriate cause-specific hazard approach. Abbreviations: 
CSH=cause-specific hazard, CIF=cumulative incidence function 
The reference patient had a biased 3.5 year cumulative incidence of 67.1% and a 
more appropriate cumulative incidence of 60.3%, an inflation bias of 11%. Each 
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of the changed covariate levels will now by commented on in turn. Figure 3.7(a) 
shows, that for not independent before stroke, the biased cumulative incidence 
was 81.6% by 3.5 years compared to the corresponding more appropriate 
estimate of 75.6%. Therefore not taking into account the competing risk inflated 
the estimate by 8%. The corresponding information for those with atrial 
fibrillation (Figure 3.7(b)) was a biased cumulative incidence of 76.7% and an 
appropriate cumulative incidence of 65.1% resulting in an inflation of 18%. 
Furthermore, the three corresponding percentages of interest were 53.1%, 42.7% 
and 24% for having a haemorrhage on scan (Figure 3.7(c)). Figure 3.7(d) 
demonstrates the effect of not using an appropriate competing risks method 
with regards to symptomatic carotid stenosis. It can be seen in Figure 3.7(d) that 
the most dramatic bias was introduced for 70-100% ICA stenosis. By 3.5 years, 
the biased and more appropriate cumulative incidences were 38.8% and 30.4% 
respectively, inflation of 28%. There was also prominent bias by 3.5 years with 
<70% ICA stenosis, with biased and more appropriate cumulative incidences of 
32.3% and 28.6% respectively, inflation of 13%.       
 Discussion/summary of results 
This chapter presented competing risks analyses of the Edinburgh Stroke Study 
(ESS), with ESS described in section 3.1. Each of the remaining sections 
presented various different aspects of competing risks analysis to illustrate the 
insights that can be gained over standard survival analysis. Section 3.2 
demonstrated the extra insight that can be gained from decomposing a 
composite outcome into its component competing risks. In particular, it was 
found that being able to lift both arms off the bed had opposing effects on the 
two competing risks. Those able to lift their arms off the bed were found to be 
at a reduced hazard of death without recurrence but at an increased hazard of 
recurrence. It may seem counterintuitive at first that the positive outlook of 
being able to lift arms could result in the negative outcome of recurrence. 
However, when considering this in the context of the competing risk death 
without recurrence, it becomes clear that recurrence, while still negative, is the 
least negative outcome. Those able to lift their arms off the bed were more 
susceptible to recurrence because they were more likely not to die before 
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having a recurrence. Not being able to lift both arms off the bed was found to be 
associated with the worse prognosis of death before even experiencing a 
recurrence. Importantly, the increased hazard of recurrence found to be 
associated with being able to lift both arms off the bed was undetectable from 
the analysis of the composite outcome alone, due to the dominance of death 
without recurrence. Therefore, the insightfulness of the competing risks analysis 
was demonstrated. It identified a group of patients who might benefit from 
targeted strategies to prevent recurrence. 
Having a haemorrhage was also found to have opposing effects on the two 
competing risks. Specifically, having a haemorrhage was associated with a higher 
hazard of recurrence, and not having one indicated a reduced hazard of death 
without recurrence, although the latter failed to reach significance at the 5% 
level. The analysis of the composite outcome did not find any evidence of an 
effect and therefore masked both of these effects on the competing risks. A lack 
of effect resulted because the opposing effects on each of the two competing 
risks were cancelling each other out. Therefore, this again demonstrated the 
added benefit of the competing risks analysis over that of the composite 
outcome alone. 
The effect of sex on the hazard of recurrence also highlighted the value of the 
competing risks analysis. The analysis of the composite outcome did not find any 
evidence of an effect of sex, and therefore masked that being female was 
associated with a higher hazard of recurrence. 
Section 3.3 demonstrated that a greater understanding of a competing risks 
scenario can be gained by considering both the hazard and cumulative incidence 
of each competing risk. In particular, it illustrated the effects of covariates on 
the (subdistribution) hazard ratios of each competing risk alongside presenting 
cumulative hazard and cumulative incidence plots. Furthermore, it emphasised 
how these aided interpretation of the effects found in the competing risks 
scenario. It showed that the effect of a covariate on the cause-specific hazard of 
an outcome may not necessarily translate into the same effect on the 
cumulative incidence. It would appear to be the first time such a comprehensive 
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competing risks analysis had been carried out for stroke recurrence and death 
without recurrence.  
For example, the cumulative hazard plot for orientated speech showed that the 
hazard of recurrence was lower for those with orientated speech, but the 
cumulative incidence plot showed no effect of orientated speech. This could be 
explained by the fact that those with orientated speech also had a lower hazard 
of death without recurrence, but that this reduced hazard was more pronounced 
than that for recurrence. This meant that there were more of those with 
orientated speech having a recurrence than was perhaps expected, due to there 
being more of them left to be at risk of recurrence owing to the decreased 
hazard of death without recurrence. Therefore, the cumulative incidence of 
recurrence for this group was in line with that for those without orientated 
speech, instead of being lower than it. 
In another example, the cumulative hazard plot for symptomatic carotid stenosis 
showed there to be no difference between the hazard of recurrence between 
those with <70% ICA and unknown/unassessable stenosis. However the 
corresponding cumulative incidence plot showed that the risk of recurrence was 
lower in those with unknown/unassessable stenosis. This could be explained by 
the increased hazard of death without recurrence for those with 
unknown/unassessable stenosis compared to <70% ICA. 
In another similar example, the cumulative hazard plot of symptomatic carotid 
stenosis showed that the hazard of death without recurrence was higher for 
those with 70-100% ICA than those with <70% ICA. However the corresponding 
cumulative incidence plot showed very little difference between the two groups. 
This could be explained by there being an even more pronounced effect of an 
increased hazard for recurrence than that for death without recurrence. This 
meant there were less of those with 70-100% ICA available to die without 
recurrence and therefore the corresponding cumulative incidence for this group 
was lower than expected and more in line with that for <70% ICA. 
In this research, none of the cumulative incidence curves for the two competing 
risks for a particular covariate level crossed as more time passed. This might 
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have been seen, however, in a study where the occurrence of the competing 
risks was more evenly balanced. It would also be more likely in such a situation 
if the competing risks had a stronger competing effect on each other or the 
study had a longer follow-up period. Furthermore, because the prevalence of 
death without recurrence was so much higher than that for recurrence, it was 
especially beneficial to consider both the relative effects (hazards) and absolute 
effects (cumulative incidences) for each competing risk. 
The chapter then proceeded to illustrate the consequences of not taking into 
account competing risks in section 3.4. To do this, naïve Kaplan-Meier/Cox 
predictions were compared to those that appropriately took competing risks into 
account. For instance, it was shown that inflation of 18% arose in the estimate of 
the 4-year cumulative incidence of recurrence when using the biased Kaplan-
Meier method compared to the more appropriate competing risks approach  
(sub-section 3.4.1). Furthermore, when the effects of covariates were taken into 
consideration, there was inflation in the estimate of the 3.5-year cumulative 
incidence of death without recurrence of 11% for the reference patient (sub-
section 3.4.2). In addition, inflation bias of 8%, 17% and 24% were evident when 
the values of independent before stroke, atrial fibrillation and haemorrhage on 
scan respectively were changed from that of the reference patient. Also, when 
the level of symptomatic carotid stenosis was changed to <70% and 70-100% ICA 
respectively, inflation biases of 27% and 13% were introduced. Therefore, it is 
imperative to use an approach that appropriately takes into account competing 
risks to avoid introducing such bias. 
The research in this study found that being female, having previous other 
occlusive vascular disease, being able to lift both arms off the bed, having 70-
100% ICA symptomatic carotid disease, having atrial fibrillation and having a 
haemorrhage on scan were each associated with a higher hazard of recurrence. 
It was also found that the above characteristics, with the exception of previous 
other occlusive vascular disease which was only significant at the 10% level, 
were associated with a higher cumulative incidence of recurrence.  
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However, the finding that females were more likely to have a recurrence is in 
contrast to the results from some of the studies summarised in Appendix III, the 
evidence table discussed in sub-section 2.10.2. While Rutten-Jacobs et al. (2013) 
(Netherlands) and Castilloux et al. (2015) (Canada) did not find any effect of 
gender on recurrence, Sun et al. (2013) (Singapore), Andersen et al. (2011) 
(Denmark) and Lewsey et al. (2010) (Scotland) did find being male to be 
associated with an increased risk of recurrence. This contrast with the study by 
Lewsey et al. (2010) in particular is worth exploring further because both studies 
used similar Scottish populations. In this current research, patients were 
followed-up from their index stroke and a limitation of this was that it was not 
possible to determine whether the stroke was a first-ever or a recurrent stroke. 
Therefore, for patients with recurrences, it was not known whether this was 
their first such event or a subsequent one. Time to recurrence and time to death 
are both likely to be very different between patients with a first-ever stroke and 
those who have already had a recurrence. However, the finding in the current 
research with regards to previous other occlusive vascular disease was similar to 
the results found by Castilloux et al. (2015) who found past medical conditions 
to be associated with a higher hazard of recurrence. In addition, the research in 
this chapter confirmed the results for stroke severity found by Andersen et al. 
(2011) and Rutten-Jacobs et al. (2013) and those for atrial fibrillation found by 
Lewsey et al. (2010). 
In the case study used in this chapter, the incidence of death without recurrence 
far exceeded that of recurrence. In situations such as this when the number of 
events are not well balanced, or the strength of competition between the events 
differs, it is imperative to consider both relative and absolute effects because 
otherwise inferences from competing risks analyses can be problematic. For 
example, this research showed that, compared to those with <70% ICA 
symptomatic carotid stenosis, those with 70-100% ICA symptomatic carotid 
stenosis were 26% more likely to die without recurrence. However, there was 
only a marginal difference between the two groups in terms of the absolute 
probabilities of death without recurrence, with 3-year probabilities of 26.4% 
versus 24.4%. Therefore, looking at either the relative or absolute effect in 
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isolation could be misleading because it does not give the whole picture of the 
competing risk process. 
On the other hand, it could be that the event that is not primarily of interest is 
so rare as to not affect the probability of an event of interest occurring. This 
would not constitute a competing risk process and therefore the rare event 
would not need to be included in the modelling. 
However, if the event of interest is rare then an alternative to the competing 
risk analysis in this chapter would need to be applied. This is because the 
competing risks analysis is based on studying the course of the disease by 
prospectively following up a cohort to see which subsequent outcomes they 
experience. In common with other investigations of rare outcomes, there are 
other study designs which are more efficient such as retrospective-based 
designs. 
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Chapter 4 Background to multi-state modelling 
4.1 Introduction 
The competing risks survival analysis framework was the focus of the previous 
two chapters. Chapter 2 provided the background to the approach, highlighted 
methodological issues that need to be considered and reviewed the literature 
into the extent of its use. Motivated by this, Chapter 3 presented empirical 
competing risks analyses with a stroke case study, an area where the technique 
has not been used to its full potential. Competing risks analyses are concerned 
with investigating which of two or more mutually exclusive events occur first 
and in that sense the risks are competing with one another. However, with the 
exception of when all the competing risks are specific causes of death, interest 
can be in the subsequent events experienced. Competing risks analysis is a 
simple form of modelling under the more general multi-state modelling survival 
analysis framework. This chapter focuses on multi-state modelling, which 
extends the competing risks approach to also consider events of interest that 
can happen after the first event.   
Multi-state modelling is of particular use when studying the course of a chronic 
and/or progressive disease. It allows each of the relevant stages (health states) 
across the disease pathway to be investigated. Therefore factors associated with 
an initial health state, a final health state (normally death) and all relevant 
states in between can be assessed. In particular, transitions involving different 
pathways can be compared. For example, in the stroke case study used in the 
previous chapter, the hazard of death in stroke patients could be compared 
between those who did and did not experience a recurrence. In addition, one of 
the main advantages of multi-state modelling over standard and competing risks 
survival analysis is the flexibility in predictions it can accommodate. Predictions 
of being in different health states over time can be estimated as patients enter 
the initial health state. Furthermore, dynamic predictions can be calculated, 
that is to say predictions as time progresses, especially as patients progress to 
other health states. Dynamic predictions have particular potential in an 
epidemiological/medical statistics context, but as yet that potential does not 
seem to be fully realised. In a health economics context, multi-state modelling 
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can be seen as an alternative form of state-transition modelling; a common 
approach in health economic modelling. Multi-state modelling has much to offer 
in that field, however as section 6.3 of chapter 6 will show it is not widely-
applied in that area. The continuous-time multi-state modelling framework is 
the specific focus of this current chapter. Discrete time decision-analytic state-
transition modelling is described in section 6.2 of chapter 6.  
This current chapter describes the multi-state modelling method, providing the 
background to the remaining empirical chapters of this thesis. Section 4.2 
introduces some important concepts relating to multi-state modelling, which is 
needed to fully understand the rest of the sections in this chapter. In particular, 
section 4.2 describes the illness-death model, a specific type of multi-state 
modelling that is later demonstrated empirically in Chapter 5 (stroke 
epidemiology) and Chapter 7 (health economics case study). Then, section 4.3 
provides an overview of Markov multi-state models. These models assume the 
Markov “memoryless” property. This is the condition that the next state to be 
visited, and the time that that occurs, only depends on the present state and not 
on any of the previous states visited or the time spent in previous states. Non-
parametric, semi-parametric and parametric approaches to fitting Markov multi-
state models are outlined separately. Next, section 4.4 describes semi-Markov 
multi-state models. These models relax the Markov property by assuming the 
process depends not only on the present state but also on the time since entry 
into the present state. The focus of section 4.5 is the flexibility in predictions 
that multi-state modelling can accommodate. Specifically, overviews are given 
of predictions at the start of the study for different health states and dynamic 
predictions that update prognosis as time progresses, and especially as patients 
progress to other health states.  
Contributions from the literature are used in the aforementioned sections of this 
chapter to help describe the multi-state modelling framework. Because these 
sections are discussing the methodological aspects of the approach, a robust 
search strategy was not developed to review all such contributions. However, for 
the final two sections of this chapter, section 4.6 and 4.7, search strategies 
were developed in order to review the extent of use of multi-state modelling. 
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Section 4.6 explores the use of multi-state modelling in a broad sense without 
concentrating on any particular area of medicine. Finally, section 4.7 discusses 
applied uses in the medical literature, with a particular focus on stroke 
epidemiology. This identifies gaps in existing research and motivates the 
empirical analysis of the stroke case study in the next chapter.  
4.2 Preliminary concepts 
The purpose of this section is to introduce important concepts related to multi-
state modelling necessary to fully understand the rest of the sections in the 
chapter. There has been a rapid emergence of literature in the medical 
statistics/general medical fields describing multi-state modelling in the last 10-
15 years. Contributions that provide succinct and useful introductions to multi-
state modelling include those by Putter et al. (2007) Commenges (1999), 
Hougaard (1999), Andersen et al. (2002), Andersen and Keiding (2002), Andersen 
and Perme (2008), Meira-Machado et al. (2009). Much of this chapter is largely 
based on these contributions. Multi-state modelling is also being increasingly 
recognised in the health economics field. Section 6.3 of chapter 6 provides a 
review in this area. 
Firstly, the illness-death model is introduced. The illness-death model, also 
known as the disability model, is one of the most straightforward and widely 
used models in multi-state modelling. The states and transitions involved in this 
model can be seen in Figure 4.1. 
Figure 4.1  State transition diagram for an illness-death model 
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There is an initial healthy state, an intermediate illness state and an absorbing 
death state. The death state is absorbing in the sense that once it is reached, it 
is not possible to move from it. (Generally, any state is said to be absorbing if 
there is no interest in what happens after it is reached).  The three transitions 
healthy  illness, healthy  death and illness  death are modelled. Therefore, 
patients in the healthy state can either move to the illness state, direct to the 
death state without entering the illness state or remain in the healthy state. 
Patients who reach the illness state can either move to the death state or 
remain in the illness state. One of the particular advantages of this modelling 
framework is that the risk of death with and without entering the intermediate 
state can be studied and compared.  
The model depicted in Figure 4.1 is said to be an “irreversible” or “uni-
directional” illness-death model. This is because once a patient reaches a new 
state, they cannot later revert to a previous one.  However, it is also possible for 
an illness-death model to be “reversible” or “bi-directional” by adding a 
transition for illness  healthy. This is particularly applicable to conditions that 
have a cure/remission phase. This chapter will focus on irreversible illness-death 
models for ease of illustration. However all the concepts discussed can be 
generalised to more complex models with more states and transitions. It will 
also be assumed that the times of transition are known exactly. Considerations 
for interval-censored data (Commenges, 2002) with missing or misclassification 
of states (van den Hout et al., 2014) are described elsewhere. Topics closely 
related to multi-state modelling including frailty (Putter and van Houwelingen, 
2015) and modelling of recurrences (Amorim and Cai, 2015) may also be of 
interest.  
As described in Andersen and Perme (2008), the formal definition of a multi-
state process is “a (continuous-time) stochastic process (X(t), t ∈  𝒯 ) with a 
finite state space 𝒮= { 0, 1, …, p} with right-continuous sample paths: X(t+) = 
X(t).” In the process, time is defined on 𝒯=[0, τ] or [0, τ) with τ ≤ + ∞. A multi-
state process X(.) also generates a history 𝒳𝑡 (an σ – algebra) which contains the 
history of the process in the interval [0, t]. This history consists of information 
relating to the previous states visited, and the time spent in previous states. 
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A fundamental concept in multi-state modelling is the transition probability.  For 
a state h and a state j the probability of h  j, the transition from h to j, is 
defined as: 
Phj (s,t) = Prob (X(t) = j | X(s) = h, 𝒳𝑠−) for h, j ∈ 𝒮,   s, t ∈ 𝒯,  s≤ t . 
Transition probabilities can also be represented in a matrix. The transition 
probability matrix for the illness-death model is 
𝑷(𝑠, 𝑡) = (
𝑝11(𝑠, 𝑡) 𝑝12(𝑠, 𝑡)   𝑝13(𝑠, 𝑡)
0 𝑝22(𝑠, 𝑡)   𝑝23(𝑠, 𝑡)
0                 0         𝑝33(𝑠, 𝑡) = 1
) 
Because the entries are probabilities, each row of 𝑷(𝑠, 𝑡) must sum to 1. 𝑝33(𝑠, 𝑡) 
is always one because the third state death is absorbing. 
Another related important concept is the transition intensity. This is defined as  
𝑞ℎ𝑗 (𝑡) =  lim
∆𝑡→0
𝑃ℎ𝑗(𝑡 ,𝑡+ ∆𝑡)
∆𝑡
  and as such is a derivative. 
It is usually known as the instantaneous hazard (rate) of moving from state h to j 
in the small time interval (t, t + ∆t). 
The transition intensities are often expressed in a transition intensity (hazard) 
matrix. All relevant transitions in a model are represented by non-zero entries, 
with zero entries otherwise. For example, for the illness-death model described 
previously, the transition intensity matrix would be: 
 
𝑸(𝑡) = (
𝑞11(𝑡) 𝑞12(𝑡)   𝑞13(𝑡)
0 𝑞22(𝑡)   𝑞23(𝑡)
0 0            0
) 
The matrix has as many rows and columns as there are states i.e. three. The 
intensities (hazard rates) for transitions 1  2 (healthy  illness),  1  3 
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(healthy  death) and   2  3 (illness  death) are represented by 
𝑞12(𝑡),    𝑞13(𝑡) and 𝑞23(𝑡) respectively. Each of the rows in 𝑸(𝑡) must add up to 
zero.  Therefore, 𝑞11(𝑡) =  −(𝑞12(𝑡) + 𝑞13(𝑡)) and 𝑞22(𝑡) =  −𝑞23(𝑡).  𝑞33(𝑡)  = 0 
because the third state death is absorbing. All other entries in 𝑸(𝑡) are zero 
because they do not represent a transition of interest in the model. 
A further important and related quantity is the cumulative hazard for the 
transition h  j, which is defined as: 
Hℎ𝑗(𝑡) = ∫ 𝑞ℎ𝑗(𝑠)
𝑡
0
 𝑑𝑠 
These all lead to the state occupation probability which is the quantity most of 
interest in multi-state modelling. It involves combining the hazards and 
probabilities of relevant transitions and its estimation will be described in 
subsequent sections of this chapter. It is defined as  
𝜋h(t) = Prob (X(t) = h) for h ∈ 𝒮 . The initial distribution, 𝜋h(0), is defined as  
𝜋h(0) = Prob (X(0) = h) for h ∈ 𝒮 leading to 𝜋h(t) = ∑  𝑗∈𝒮 𝜋j(0) Pjh(0,t). 
Another important consideration in multi-state modelling is the scale used to 
measure time. Two common approaches are “clock-forward” and “clock-reset”. 
With the clock-forward approach, time is measured from entry into the initial 
state, regardless of the state in the multi-state model. In contrast, with the 
clock-reset approach each time a patient enters a new state their clock is set 
back to zero. More details are available in the tutorial by Putter et al. (2007). 
A related concept is the Markov property.  The Markov property is the condition 
that the next state to be visited, and the time that that occurs, only depends on 
the present state, and not on any of the previous states visited or the time spent 
in previous states. Only clock-forward models can be Markov. The Markov 
property does not hold in clock-reset models because in that approach it is 
intrinsic that the time scale depends on the time spent in the previous state. 
However, if with the clock-reset approach, the sojourn time only depends on the 
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present state and the time since entry into that state, then the process is said to 
be semi-Markov. Markov and semi-Markov multi-state models are described in 
sections 4.3 and 4.4 respectively. 
4.3 Markov multi-state models 
This section describes estimation and prediction in Markov models. In Markov 
models, the Markov property described previously holds. Mathematically this is: 
Phj (s,t) = Prob (X(t) = j | X(s) = h, 𝒳𝑠−) 
            = Prob (X(t) = j | X(s) = h, X (tn-1)=in-1, …, X(t1)=i1) 
            = Prob (X(t) = j | X(s) = h) 
where 0 ≤ t1 ≤ … ≤ tn-1 ≤ s ≤ t ∈ 𝒯 is any non-decreasing sequence of n + 1 state 
occupation times and i1, …, in-1, i, j ∈ 𝒮.  
In other words, the state of the process at time t depends only on the most 
recent state occupied prior to time t. 
Non – parametric, semi – parametric and parametric methods will now be 
described separately. 
4.3.1 Non-parametric Markov multi-state models 
This section describes estimation for non-parametric Markov multi-state models. 
The models are non-parametric in the sense there are no covariates to be 
modelled. The standard non-parametric estimator of the cumulative transition 
intensity (hazard) is the Nelson-Aalen estimator. This is defined, for the 
transition h  j, as  
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?̂?ℎ𝑗(𝑡) =  ∑
𝑑𝑁ℎ𝑗(𝑡𝑖)
𝑌ℎ(𝑡𝑖)
𝑡𝑖 ≤𝑡
 
where   𝑡𝑖 indicates the event times,  𝑑𝑁ℎ𝑗(𝑡𝑖)  is the observed number of 
transitions from state h to state j at time 𝑡𝑖 and 𝑌ℎ(𝑡𝑖) is the number of subjects 
at risk of the h  j transition at time 𝑡𝑖 . 
At event times 𝑡𝑖 , the Nelson-Aalen estimator, ?̂?ℎ𝑗(𝑡)  , makes jumps of 
magnitude ∆?̂?ℎ𝑗(𝑡𝑖). 
The cumulative hazards can be expressed in a matrix 𝑨(𝑡) with dimensions S × S, 
where S is the number of states.  The Nelson-Aalen estimator can be used to 
estimate the off-diagonal entries of the matrix 𝐴ℎ𝑗(𝑡𝑖)  (h ≠ j). The diagonal 
entries  𝐴ℎℎ(𝑡𝑖) =  − ∑ ?̂?ℎ𝑗(𝑡)𝑗≠ℎ  . Therefore, each row of the cumulative hazard 
matrix 𝑨(𝑡) sums to 0.  
The transition probability matrix can also be estimated using the  
Aalen– Johansen estimator, which is a product integral approach. 
The Aalen – Johansen estimator of the transition probabilities is defined as  
?̂?(𝑠, 𝑡) = ∏ 𝐈
𝑢 ∈(𝑠,𝑡]
+ ∆ ?̂?(𝑢) 
where u indicates the event time, 𝐈 is the identity matrix and ∆ ?̂?(𝑢)can be 
estimated using the Nelson-Aalen estimator. 
Alternative approaches for estimating transition probabilities include those that 
solve the Komogorov forward equation using either matrix exponentials or by 
calculating eigenvalues [Appendix A of  Aalen et al. (2008)]. 
4.3.2  Semi-parametric Markov multi-state models 
In the previous section, non-parametric estimators were described in the sense 
no covariates were involved. This section describes semi-parametric estimation 
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that allows for covariates to be included. The standard semi-parametric 
approach is Cox proportional hazard regression modelling for each transition. It 
is essentially the same as the cause-specific hazard approach to competing risks, 
with causes now replaced with the more broad transitions. The transition 
intensity (hazard) for transition h → j under a Cox model is defined as: 
αhj (t) = αhj,0 (t) exp (𝛽T Zhj ) 
where Z is the vector of covariates at baseline 
αh,j0 (t) is the baseline hazard for transition h → j 
Zhj is a vector of transition-specific covariates 
and 𝛽 is the vector of coefficients for the covariates. 
 
It is semi-parametric in that the covariates introduce parameters but the 
distribution of the baseline hazard is unspecified. 
The model specified above is the most general “full” model in that every 
transition has its own baseline hazard and each different transition has its own 
covariate effects. It is also possible for baseline hazards for relevant transitions 
to be related. For example, the baseline hazard for a transition that involves 
movement into the absorbing state death may have a proportional effect on the 
baseline hazard of another transition, that also involves movement into that 
state. 
Just as in the previous sub-section, estimation of transition probabilities can be 
carried out using the Aalen-Johansen estimator. Strictly speaking, however, the 
Aalen-Johansen estimator does not involve any covariates, and therefore 
estimation in the semi-parametric approach is said to be by the Aalen-Johansen 
type estimator. However, in practice, estimation is for a particular patient with 
covariates evaluated for a specific combination of values. The cumulative hazard 
of each transition for the covariate combination of interest is all that is needed 
to calculate the transition probabilities. Estimation of a cumulative hazard for a 
particular covariate combination under Cox models is available in standard 
software packages. This can then be used as input in the Aalen-Johansen 
estimator.   
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4.3.3 Parametric Markov multi-state models 
So far in this section, estimators have either been non-parametric or semi-
parametric and as such no distributions have been specified for the (baseline) 
hazards. This part introduces parametric estimators whereby hazards follow a 
specified distribution. First, the time-homogeneous Markov model is outlined 
that uses constant hazards over time. Next, the piecewise constant model with 
hazards that are constant over fixed timed intervals is described. Finally, the 
concept of more general time-inhomogeneous models is introduced, where 
distributions are used that allow hazards to vary over time. Parametric models in 
particular facilitate extrapolation of survival, and other relevant outcomes, 
beyond the observation period of a study. Therefore, parametric models are also 
a particular focus of the extrapolation of survival section 6.5 of Chapter 6. 
4.3.3.1 Time-homogeneous Markov model/constant hazard 
It has just been mentioned that it can be beneficial to assume a specific 
parametric distribution for a transition hazard. The simplest and most 
commonly-applied parametric approach is the time-homogeneous Markov model 
where the hazard is assumed to be constant over time. 
Mathematically, the transition intensity (hazard) for transition h → j is defined 
as: 
αhj (t) =λ     ∀ t, t=[0, τ] 
where λ is a constant and  τ is the end of the observation period.   
The time-homogeneous Markov process follows an exponential distribution with 
the hazard = λ, hazard rate= λt, and the transition probability phj (t) =1-exp(-λt). 
4.3.3.2 Markov piecewise constant hazard model 
It may not always be appropriate to assume that the hazard is constant 
(homogeneous) throughout the whole time-frame of interest. A widely-used 
approach that is used when the homogeneity assumption is not satisfied is the 
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piecewise constant hazard method. This is the simplest non-homogeneous 
approach. With this approach transition intensities (hazards) are defined by: 
αhj (t) = αhjl  , θl-1 < t ≤ θl,        l = 1,2,3, …., q 
where θ =( θ1, … , θq-1) is a vector of cut-points for time intervals with 
0 = θ0 < θ1 < θ2 < … < θq-1 < θq =∞  . 
In other words, hazards are constant within fixed time intervals. It therefore 
offers the flexibility for hazards to be different across different time intervals. 
4.3.3.3 More general Markov time-inhomogeneous parametric models 
The assumption of constant hazards over the whole time period, or over time 
intervals, may be too stringent in practice. An alternative approach is to model 
the hazards with a parametric distribution that allows hazards to vary over time. 
For example, the Weibull and Gompertz distributions both have an additional 
parameter, compared to the exponential distribution, called a “shape” 
parameter. This parameter shapes the rate of change of the hazard over time. A 
Weibull distribution with a shape parameter of 1 and a Gompertz distribution 
with a shape parameter of 0 will each be equivalent to the exponential 
distribution. However, Weibull and Gompertz shape parameters >1 (<1) and >0 
(<0) respectively indicate hazards that increase (decrease) over time. 
Distributions with the flexibility for varying hazards over time are detailed in the 
extrapolation of survival section, section 6.5, of Chapter 6. 
4.3.3.4 Test of Markov property 
There are several ways of overcoming violations, or relaxing, the Markov 
property. For example, extra states can be added to reflect the possible order of 
transitions (Putter et al., 2007). Another option is to use the state arrival 
extended (semi-) Markov approach. This involves including a covariate that 
depends on the time since entry into a previous state in a Markov model. As 
such, the state arrival extended approach could act as a useful tool in which to 
test the appropriateness of the Markov property. The significance, both 
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statistically and clinically, of the covariate could help aid the decision as to 
whether the Markov assumption was reasonable. However, as with any covariate 
included in a model, any relevant assumptions such as linearity or proportional 
hazards must be met. Alternative tests that are more appropriate when 
violations of such assumptions are evident have also been proposed e.g. 
Rodríguez-Girondo and Uña-Álvarez (2016). 
4.4 Semi-Markov multi-state models 
The Markov assumption can be relaxed by fitting a semi-Markov model, also 
known as embedded Markov or Markov renewal models. With the semi-Markov 
approach, the process depends not only on the present state but also the time 
since entry into the present state. However, the Aalen- Johansen estimator (and 
eigenvector/matrix exponential equivalent) presented in section 4.3 relies on 
the Markov property holding.  This section describes a simulation-based 
approach to estimation of predictions that can be used with a semi-Markov 
model. It is the approach used in the mssample function in the mstate R 
package (de Wreede et al., 2010).  
Given a cumulative hazard for each transition evaluated for a specified set of 
covariate values, i.e. for a specific patient, state occupancy probabilities can be 
estimated by simulation by repeatedly sampling complete paths through the 
multi-state model.  
An algorithm to generate such paths is described in Fiocco et al. (2008) and 
repeated here. It is based on the ideas of Dabrowska (1995) for simulation in 
competing risks blocks. The algorithm makes use of the fact that a multi-state 
model can be separated into a series of (linked) competing risks blocks. It 
involves simulating transition times and states for each block. The algorithm is 
as follows: 
Let i be the starting state and ti = s the starting time. Repeat the following 
steps: 
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1. Let I be the set of states that can be reached from i. If I =∅, stop. 
Otherwise, let, for j ∈ I, Λ𝑖𝑗(𝑡) be the cumulative hazard function for transition 
i → j . 
2. Compute Λ𝑖(𝑡) = ∑ Λ𝑖𝑗(𝑡)𝑗 ∈ 𝓙  
3. Sample t∗(>ti) from Λ𝑖(𝑡) −  Λ𝑖(𝑡𝑖). If Λ𝑖(∞)is finite, t∗=∞ may be sampled with 
positive probability. 
4. If t∗=∞, stop. Otherwise, select state j as the next state with probability 
dΛ𝑖𝑗(𝑡
∗)/ dΛ𝑖(𝑡
∗). 
5. Set i = j and ti =t∗. 
This process should then be replicated M times, where M is a large number, to 
generate complete paths through the multi-state model. The probability of a 
future event E given the patient’s history Hs, P(E|Hs), can then be estimated 
with Hs as specified by the starting state and starting time in the algorithm. An 
estimate of P(E|Hs) is given by the proportion of the M paths in which the event 
of interest E occurred. 
Alternative kernel-based and landmark approaches are detailed in Spitoni et al. 
(2012) and Putter and Spitoni (2016) respectively.  
As with Markov models, semi-Markov models can also be non-parametric, semi-
parametric or parametric. 
4.5 Flexibility of predictions at different times over the 
course of the disease 
This section highlights one of the main advantages of multi-state modelling, that 
of the flexibility in predictions the approach can accommodate. Like standard 
survival analysis, multi-state modelling allows the calculation of predictions, at 
the start of a study, of having an event (health state) of interest at any given 
time over the period of observation of the study. Furthermore, because multi-
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state modelling considers several different health states of interest 
simultaneously, it allows predictions of being in any given state at any given 
time, i.e. state occupancy probabilities. Just as above, the approach facilitates 
such predictions at the start of a study. 
However, one of the additional benefits of multi-state modelling involving 
several health states of interest is that dynamic predictions can be carried out. 
That is to say, predictions can be updated as time elapses and especially as 
patients progress to other health states. This then allows, for example, 
predictions at the start of a study to be compared with those starting further 
along a disease process. In particular, predictions starting from a given health 
state at a specific time can be compared with those starting from a different 
health state at the same time. 
In the multi-state modelling framework, the procedure used to calculate the 
state occupancy probabilities is depend on whether a Markov or semi-Markov 
model is built. In particular, obtaining dynamic predictions is more 
straightforward with a Markov than a semi-Markov model. In a paper by de 
Wreede et al. (2011) the authors explain that, as a patient moves to different 
states, the state occupancy probabilities obtained from a Markov model can be 
used to reflect these transitions. There are as many sets of state occupancy 
probabilities as there are states in the model, with each set corresponding to a 
different starting state. All these probabilities can be obtained automatically 
from just a single Markov model. An appropriate dynamic prediction can be 
obtained for a patient by changing the set of predictions that are used when 
entering a new state, with the prediction time updating to the time of 
transition. For example, say, an objective is to predict the probability of being 
in a health state representing the composite outcome relapse or death. 
Specifically, the prediction is for patient A who is in the initial state in the time 
interval [0, a), intermediate state from [a,b) and the relapse/death state from 
time b. Up until time a, the set of predictions with the initial state as a starting 
state would be used. However in [a,b) the predictions used would change to 
those with the intermediate state as the starting state.  
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The approach to (dynamic) prediction with Markov modelling relies heavily on 
the properties of the Aalen-Johansen estimator, which was outlined previously in 
section 4.3 on page 90. However this is not applicable to semi-Markov modelling, 
and therefore for such models an alternative approach to dynamic prediction is 
required. One such approach involves subsetting the data such that, for each 
starting state/time of prediction combination of interest, a dataset of patients 
who were in the given state at the given time is created. Modelling is then 
carried out with each different dataset to obtain the required dynamic 
predictions. 
4.6 Broad review of multi-state models in the medical 
literature 
Section 4.2 began by emphasising that there has been a rapid emergence of 
literature in medical journals providing a review of the multi-state modelling 
framework. This section investigates the extent to which the term multi-state 
modelling or related items has appeared in selected biostatistical, core clinical 
and general high impact clinical journals in a broad sense i.e. any mention of the 
terms from a methodology aspect or an application of the technique that is not 
specific to any particular area of medicine. The search strategy is detailed in 
Appendix VII. Figure 4.2(a) and (b) summarise the findings by year for the 
selected biostatistical and core clinical journals, respectively. 
 
 
 
 Chapter 4    Background to multi-state modelling    98                                                                                                                                                                                                  
 
 
Figure 4.2  Broad search of multi-state modelling in the medical literature 
 
The search found that, in the biostatistical journals, there was a steady 
emergence of between 11 and 21 articles in each year from 2007 onwards. 
However, the appearance of multi-state modelling in the core clinical journals 
was not as pronounced, only reaching 7 articles at most in any one year. In the 
general high impact clinical journals, there was only 3 articles in total over the 
16-year period (one each in 2004, 2007 and 2015). 
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4.7 Review of illness-death modelling of stroke, 
recurrence and death in the literature 
This section describes a review of the literature that focuses on illness-death 
modelling of stroke, recurrence and death. The purpose of this is to identify 
gaps in the research and provide the context for the empirical illness-death 
modelling of stroke, recurrence and death in the next chapter. An illness-death 
model is also known as a disability model and is a commonly-used multi-state 
model. A search strategy was developed to allow the review to take place. An 
OvidSP search of titles, abstracts and keywords of contributions to 29/09/2016 
was performed using the following search terms: 
("multi-state model" OR "multistate model" OR "multi state model" OR "illness-
death model" OR "illness death model" OR "multi-state models" OR "multistate 
models" OR "multi state models" OR "illness-death models" OR "illness death 
models" OR "multi-state modelling" OR "multistate modelling" OR "multi state 
modelling" OR "illness-death modelling" OR "illness death modelling" OR "multi-
state modeling" OR "multistate modeling" OR "multi state modeling" OR "illness-
death modeling" OR "illness death modeling" OR "disability model*"  OR ("multi-
state" AND "Markov") OR ("multistate" AND "Markov") OR ("multi state" AND 
"Markov") OR ("illness-death" AND "Markov") OR ("illness death" AND "Markov") OR 
("disability AND "Markov") OR ("multi-state" AND "semi-Markov") OR ("multistate" 
AND "semi-Markov") OR ("multi state" AND "semi-Markov") OR ("illness-death" AND 
"semi-Markov") OR ("illness death" AND "semi-Markov") OR ("disability AND "semi-
Markov") OR ("multi-state" AND "model") OR ("multistate" AND "model") OR ("multi 
state" AND "model") OR ("illness-death" AND "model") OR ("illness death" AND 
"model") OR ("multi-state" AND "models") OR ("multistate" AND "models") OR 
("multi state" AND "models") OR ("illness-death" AND "models") OR ("illness death" 
AND "models") OR ("multi-state" AND "modelling") OR ("multistate" AND 
"modelling") OR ("multi state" AND "modelling") OR ("illness-death" AND 
"modelling") OR ("illness death" AND "modelling") OR ("multi-state" AND 
"modeling") OR ("multistate" AND "modeling") OR ("multi state" AND "modeling") 
OR ("illness-death" AND "modeling") OR ("illness death" AND "modeling") AND 
(stroke OR ischemic OR ischaemic OR "intracerebral hemorrhage" OR 
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"intracerebral haemorrhage" OR "subarachnoid hemorrhage" OR "subarachnoid 
haemorrhage" OR ICH OR SAH) AND (recur* OR multiple)).ab,ti,kw.  
The entire search found 15 contributions. After disregarding 8 duplicates, 3 that 
did not involve stroke patients, 1 that did not involve recurrence of stroke and 1 
which did not involve multi-state modelling, this left only 2 contributions. Each 
of these contributions were published very recently. The first contribution was 
an abstract by Penn et al. (2016) for a conference held in February 2016. The 
second was a journal article by Wetmore et al. (2016) published in September 
2016. The work by Penn et al. (2016) aimed to investigate whether referral to a 
transient ischaemic attack (TIA) unit reduced the risk of recurrent stroke. To do 
this, the authors used a multi-state model with the states symptom onset, 
referral, arrival at the unit, recurrent stroke and death. They found associations 
between age, ABCDD, gender and unit intervention and the transitions in the 
model. The main finding stated in the abstract was that referrals to TIA units 
reduced the risk of recurrent stroke within 90 days. The information was 
somewhat limited because only the abstract was available. However, this 
contribution did highlight, as well as being useful to study the clinical pathway 
of a disease (especially chronic or progressive), multi-state models can be used 
to see how patients flow through the health care system, what factors influence 
the transitions and possible critical points for intervention. 
The article by Wetmore et al. (2016) reported on a study of hemodialysis 
patients who had experienced an ischemic stroke. The authors used a classic 
“illness-death” multi-state model to explore factors associated with stroke  
recurrence, stroke  death and recurrence  death, with Cox regressions used 
to model each transition. However there was no clarification of whether a 
Markov or semi-Markov approach was used. The paper stated that age was 
treated as a time-dependent variable by assessing it at first stroke and then 
again at the recurrent stroke. This treatment of age suggests a “clock-reset” 
approach to time was adopted and a semi-Markov approach was used. However, 
the probability plots presented appear to be those that can be created after 
using the probtrans function in mstate, which is only applicable to Markov 
models. Updating the value of age on entering a new state does not seem 
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appropriate with a Markov model. This is because a Markov model measures time 
using the “clock-forward” approach which means time is measured from the 
initial state, even in states that are further along the clinical pathway of the 
disease.  
Furthermore, on a number of occasions throughout the article, a parsimonious 
model is mentioned. However, while an AIC-based method has been devised by 
Kuk and Varadhan (2013) for the Fine and Gray proportional subdistribution 
hazards modelling approach to competing risks, no equivalent has yet been 
suggested for the cause-specific hazards modelling approach to competing risks 
used in multi-state modelling. Using AICs/likelihoods for variable selection could 
be inappropriate and needs to be treated with caution. This was discussed 
further in section 2.7.2 of chapter 2.  
In addition, the  explanation of transition probabilities is misguided (Wetmore et 
al. (2016)). The paper appears to be confusing state occupancy probabilities 
with transition probabilities. For instance, it uses the example of the transition 
probability for stroke  death but then outlines that this involves patients who 
could die directly after their first stroke, or die after experiencing a recurrent 
stroke. This latter explanation in fact relates to the state occupancy probability 
for the death state. In the multi-state modelling framework, the only 
probabilities it is appropriate to estimate is state occupancy probabilities. 
Because of the presence of competing risks, probabilities for a particular 
transition are not an appropriate quantity to estimate. This is analogous to 
estimating survival in a competing risks scenario, the inappropriateness of which 
is detailed in 2.3 of chapter 2.  
In another statement that relates to the confusion between state occupancy and 
transition probabilities the paper states “the Cox proportional hazards 
framework facilitates calculates [sic] probabilities of transition from the current 
state to the next state within a given time interval” (Wetmore et al. (2016)). 
This is misleading because by using the term transition probability, rather than 
state occupancy probability, a naïve Cox approach to prediction is being 
advocated. 
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Wetmore et al. (2016) then proceed to show plots of predicted probabilities. The 
first plot shows the stacked predictions of being in a given state over time, i.e. 
the state occupancy probabilities. Nonetheless, the paper continues to cause 
confusion by describing the plot as a “stacked transition probability graph”. The 
predictions in this first plot were predictions from time zero and do not update 
to reflect any states patients may progress to as time elapses. In the second 
plot, the paper does attempt to plot such dynamic predictions. However, the 
approach to this is unconventional and misguided. The article aims to 
demonstrate “the impact on survival of a subsequent stroke”. It does this by 
showing what survival drops to should a patient experience a recurrent stroke at 
1, 2 or 3 years. At the time of the recurrent stroke however, survival 
immediately drops 10-20% depending on when the recurrence occurred. This 
approach is not suitable because it fails to recognise that patients who have a 
recurrence are still alive at that point and so their survival is 100% at the time of 
recurrence. The article appears to have misinterpreted how to calculate 
dynamic predictions. 
The review in this section has shown that there was very little in the way of 
literature that focused on illness-death modelling of stroke, recurrence and 
death. The two contributions that emerged were only published in 2016. One of 
these pieces was a conference abstract and as such was limited in the 
information it provided about the multi-state model. The other contribution was 
a journal article but misled readers on some aspects of multi-state modelling. 
Therefore, while it is encouraging to see the start of multi-state modelling 
involving stroke, recurrence and death in the clinical literature, there is much 
scope to raise awareness of the technique in this disease area. This illness-death 
model will be the focus of the next chapter of this thesis. The chapter will 
include Cox cause-specific hazard modelling of each transition to assess the 
effects of covariates. It will also present predictions both at the time of the 
index stroke and dynamically as patients enter new states. Furthermore, it will 
highlight the extra insight gained from the multi-state modelling approach over 
and above that of competing risks analysis. 
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Chapter 5 Multi-state modelling with the 
Edinburgh Stroke Study data 
Chapter 3 presented competing risks analyses of the Edinburgh Stroke Study. 
These involved following patients to determine which one of the two events 
recurrence or death without recurrence they experienced first, if any. It did not 
consider any subsequent events experienced by those who had a recurrence. 
However, as explained in the previous chapter, the multi-state modelling 
approach can be used as an extension to competing risks to also consider events 
of interest that can happen after the first event. This chapter builds on the 
competing risks analysis of chapter 3 and presents a multi-state modelling 
approach.  
Section 5.1 begins by describing the illness-death model used, a particular type 
of multi-state model,  with the transitions stroke  recurrence, stroke  death 
and recurrence  death. The covariate effects on each of the transitions, at a 
univariable (unadjusted) and multivariable level are then presented. Predictions 
are then the focus of section 5.2, with both predictions at the time of index 
stroke and dynamic predictions illustrated. The dynamic predictions update the 
patient’s prognosis taking into account the time elapsed and any subsequent 
events since the initial stroke. Next, section 5.3 highlights the extra insight 
gained from the multi-state modelling approach over and above the competing 
risk analysis in Chapter 3. Finally, section 5.4 summarises the analysis presented 
in this chapter. 
5.1 Description of the multi-state model and results for 
covariate effects 
This section begins by describing the specific multi-state model used in terms of 
the health states, and transitions between them, that were considered. The 
section then continues by demonstrating the effect of the covariates on each of 
the transitions. 
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Figure 5.1 displays the state-transition diagram for the illness-death model used 
throughout this chapter. The purpose of showing Figure 5.1 is to provide the 
context for all the analysis that follows. When introducing the model, particular 
emphasis is given to how it builds on from the previous competing risks analysis. 
Figure 5.1  State-transition diagram for the illness-death model 
 
It can be seen in Figure 5.1 that the three health states stroke, recurrence and 
death are of interest, together with the three transitions stroke  recurrence, 
stroke  death and recurrence  death. 
While the competing risks analysis in chapter 3 also considered  
stroke  recurrence and stroke  death, the addition of recurrence  death in 
the multi-state modelling allows for different predictions. Now, recurrence acts 
as an intermediate state between the initial stroke state and final death stroke. 
Therefore, the multi-state modelling demonstrated in this chapter will build on 
the competing risks analysis and, in particular, allows comparison of the risk of 
death with and without recurrence. 
The patient characteristics used in the Edinburgh Stroke Study were previously 
described, overall and by state in the model, in Table 3.1 within section 3.1 on 
page 56.   
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The effects of the characteristics, or covariates, on each transition were then 
assessed more formally using Cox proportional hazard regression models. All the 
modelling in this chapter was Cox proportional hazards regression. As such, the 
usual appropriate checks for violations of proportional hazards were carried out, 
although they are not shown for reasons of brevity. 
Table 5.1 shows the effects of the covariates on the hazard of each of the 
transitions at the univariable (unadjusted) level.  
The results for stroke  recurrence and stroke  death were previously 
presented in the competing risk analysis in section 3.2 of chapter 3. They are 
repeated in this chapter to allow comparison of the results between all three 
transitions in the multi-state model. However focus will be primarily on the 
effects of the covariates on recurrence  death, as the addition of this 
transition is what distinguishes the multi-state modelling from the previous 
competing risks analysis. Covariates found to be statistically significant at the 5% 
level are shown in bold and those found to be statistically significant at the 10% 
level are shown in italics. 
Before carrying out the analysis for the recurrence  death transition, a Markov 
model was built to investigate the effect of time in the stroke state on post-
recurrence death. The covariate for time in the stroke state was found to have a 
statistically significant effect on post-recurrence death (p-value <0.001). In 
addition, its coefficient (s.e) of 1.709 (0.314) was likely to be of a size of 
practical importance. That positive coefficient indicated that the longer patients 
spent in the recurrence-free state before reaching recurrence, the more likely 
they were to die following recurrence. It is unclear why this was the case. 
Because the stroke state was a previous state, its statistical and practical 
significance indicates that the future did depend on patient history and 
therefore that the Markov property did not hold. Therefore a semi-Markov, 
rather than Markov, approach was taken for the modelling of the recurrence  
death transition. 
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stroke -> recurrence stroke -> death recurrence-> death 
  
Baseline 
hazard ratio 
 (95% CI) 
p-
value  
hazard ratio 
 (95% CI) p-value  
hazard ratio  
(95% CI) p-value  
age - centred 
on mean of 71  
1.02 (1.00, 1.03) 0.012 1.08 (1.06, 1.09) <0.001 1.06 (1.03, 1.09) <0.001 
male Female 0.72 (0.53, 0.98) 0.038 0.76 (0.59, 0.97) 0.025 1.26 (0.77, 2.06) 0.360 
independent 
before stroke 
No 1.12 (0.55, 2.27) 0.763 0.24 (0.18, 0.33) <0.001 0.59 (0.24, 1.49) 0.267 
previous 
cerebrovascular 
event  
No 1.34 (0.98, 1.84) 0.066 1.14 (0.88, 1.47) 0.329 1.09 (0.65, 1.82) 0.754 
previous other 
occlusive 
vascular 
disease 
No 1.53 (1.12, 2.09) 0.008 1.74 (1.36, 2.23) <0.001 2.03 (1.24, 3.34) 0.005 
previous 
hypertension 
No 1.33 (0.98, 1.81) 0.069 0.93 (0.73, 1.18) 0.543 0.99 (0.60, 1.64) 0.972 
diabetes No 1.23 (0.79, 1.91) 0.352 1.16 (0.81, 1.67) 0.417 1.53 (0.80, 2.93) 0.202 
current smoker 
and ex-smoker 
<12 months 
Non-
smoker 
1.09 (0.79, 1.51) 0.602 0.73 (0.57, 0.93) 0.011 1.16 (0.68, 1.99) 0.588 
lift both arms 
off bed  
No 1.70 (0.92, 3.14) 0.089 0.16 (0.13, 0.21) <0.001 0.44 (0.20, 0.97) 0.043 
walk 
independently 
No 0.94 (0.66, 1.33) 0.714 0.22 (0.17, 0.28) <0.001 0.40 (0.24, 0.66) <0.001 
orientated 
speech 
No 0.77 (0.49, 1.20) 0.245 0.17 (0.13, 0.22) <0.001 0.36 (0.20, 0.64) 0.001 
stroke 
syndrome   
0.448 
 
<0.001 
 
0.042 
 
Lacunar Cortical 0.79 (0.55, 1.15) 0.218 0.38 (0.26, 0.54) <0.001 0.64 (0.35, 1.18) 0.151 
 
Other Cortical 0.89 (0.60, 1.31) 0.551 0.68 (0.49, 0.93) 0.015 0.43 (0.20, 0.92) 0.030 
high blood 
pressure  
No 0.98 (0.71, 1.34) 0.881 1.08 (0.84, 1.38) 0.573 0.57 (0.32, 1.00) 0.051 
delay in 
assessment   
0.267 
 
<0.001 
 
0.018 
 
2-6 days 0-1 days 0.90 (0.58, 1.39) 0.634 0.63 (0.46, 0.85) 0.002 1.00 (0.53, 1.88) 1.000 
 
7 days or 
more 
0-1 days 0.74 (0.51, 1.09) 0.125 0.30 (0.22, 0.40) <0.001 0.49 (0.26, 0.90) 0.021 
symptomatic 
carotid stenosis   
0.013 
 
<0.001 
 
0.026 
 
70-100% 
ICA 
<70% ICA 1.86 (1.26, 2.75) 0.002 1.43 (0.96, 2.13) 0.082 1.79 (0.99, 3.23) 0.053 
 
Unknown <70% ICA 1.21 (0.75, 1.94) 0.435 4.68 (3.59, 6.09) <0.001 2.35 (1.20, 4.64) 0.013 
in atrial 
fibrillation 
No 1.65 (1.17, 2.34) 0.005 2.60 (2.01, 3.35) <0.001 1.99 (1.19, 3.33) 0.008 
visible infarct 
on scan 
No 1.10 (0.81, 1.50) 0.527 1.26 (0.98, 1.62) 0.067 1.58 (0.93, 2.70) 0.090 
haemorrhage on 
scan 
No 1.64 (0.96, 2.78) 0.069 2.21 (1.52, 3.22) <0.001 1.83 (0.87, 3.85) 0.110 
Table 5.1 Univariable Cox Regression for each of the transitions in the ESS multi-state model 
 
It can be seen in Table 5.1 that aging, having previous other occlusive vascular 
disease, not being able to walk independently, not having orientated speech, 
having a cortical stroke, having the shortest delay in assessment, having high 
symptomatic carotid stenosis and having atrial fibrillation were each associated 
with a higher hazard of death after recurrence. For each of these effects, there 
were corresponding effects in the same direction for stroke  recurrence and 
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stroke  death.  Not being able to lift both arms off the bed was also associated 
with a higher hazard of death after recurrence. However, it was associated with 
a reduced hazard of recurrence, albeit at the 10% significance level, with such 
patients having a higher hazard of death without recurrence. Furthermore, there 
was a reduced hazard of death after recurrence, albeit at the 10% significance 
level, for those with high blood pressure. This probably reflects that those with 
known high blood pressure were more likely to be receiving anti-hypertensive 
treatment. In addition, there was a higher hazard of death after recurrence, 
albeit at the 10% significance level, for those with a visible infarct on scanning.  
An unparsimonious multivariable analysis was then carried out considering the 
variables together in a model, allowing the effect of each covariate to be 
adjusted by other relevant variables (confounders). Table 5.2 on the next page 
shows the resultant model. 
It can be seen in Table 5.2 that aging, having previous other occlusive vascular 
disease, having the shortest delay in assessment and having high symptomatic 
carotid stenosis were still associated with a higher hazard of death after 
recurrence.  In addition, having a visible infarct on scan was also now found to 
be associated with a higher hazard of death after recurrence. 
A parsimonious multivariable model was then built for ease of subsequent 
prediction (Table 5.3). For the recurrence → death transition, backward 
selection using likelihood ratio tests were used to select variables for inclusion, 
with significance at the 5% level used as the criteria. The resultant model 
contained age, previous other occlusive vascular disease, symptomatic carotid 
stenosis and visible infarct on scan. The directions of the associations of each of 
these covariates with death after recurrence were as previously described for 
Table 5.2.  
 
 
 
 Chapter 5    Multi-state modelling with the Edinburgh Stroke Study data    108                                                                                                                                                                                                  
 
   
stroke -> recurrence stroke -> death recurrence-> death 
  
Baseline 
hazard ratio 
(95% CI) 
p-
value  
hazard ratio (95% 
CI) p-value  
hazard ratio 
(95% CI) 
p-
value  
age - centred 
on mean of 71  
1.01 (0.99, 1.02) 0.233 1.06 (1.05, 1.07) <0.001 1.07 (1.03, 1.11) 0.001 
male Female 0.67 (0.49, 0.92) 0.014 1.01 (0.78, 1.30) 0.950 1.71 (0.95, 3.07) 0.071 
independent 
before stroke 
No 1.19 (0.57, 2.46) 0.648 0.66 (0.47, 0.93) 0.019 2.58 (0.73, 9.18) 0.143 
previous 
cerebrovascular 
event  
No 1.17 (0.84, 1.63) 0.344 0.93 (0.71, 1.23) 0.624 1.44 (0.80, 2.61) 0.225 
previous other 
occlusive 
vascular 
disease 
No 1.33 (0.95, 1.85) 0.094 1.19 (0.91, 1.54) 0.203 2.66 (1.50, 4.72) 0.001 
previous 
hypertension 
No 1.12 (0.81, 1.56) 0.480 0.86 (0.66, 1.12) 0.263 0.95 (0.54, 1.68) 0.859 
diabetes No 1.16 (0.74, 1.82) 0.525 1.20 (0.82, 1.74) 0.353 1.83 (0.85, 3.93) 0.121 
current smoker 
and ex-smoker 
<12 months 
Non-
smoker 
1.14 (0.82, 1.60) 0.434 1.09 (0.84, 1.42) 0.506 0.90 (0.48, 1.68) 0.742 
lift both arms off 
bed  
No 2.56 (1.27, 5.13) 0.008 0.37 (0.26, 0.53) <0.001 0.79 (0.28, 2.19) 0.647 
walk 
independently 
No 1.03 (0.66, 1.62) 0.887 0.80 (0.55, 1.15) 0.232 0.92 (0.41, 2.06) 0.833 
orientated 
speech 
No 0.88 (0.53, 1.46) 0.616 0.46 (0.33, 0.64) <0.001 0.58 (0.25, 1.33) 0.197 
stroke 
syndrome   
0.981 
 
0.240 
 
0.074 
 
Lacunar Cortical 0.98 (0.66, 1.45) 0.925 0.73 (0.49, 1.07) 0.104 0.99 (0.48, 2.03) 0.973 
 
Other Cortical 1.03 (0.68, 1.56) 0.897 0.97 (0.69, 1.37) 0.868 0.39 (0.16, 0.95) 0.037 
high blood 
pressure  
No 1.06 (0.76, 1.48) 0.726 0.81 (0.61, 1.07) 0.137 0.73 (0.39, 1.36) 0.323 
delay in 
assessment   
0.307 
 
0.718 
 
0.016 
 
2-6 days 0-1 days 0.80 (0.51, 1.26) 0.342 0.88 (0.64, 1.21) 0.424 2.00 (0.89, 4.49) 0.092 
 
7 days or 
more 
0-1 days 0.70 (0.45, 1.09) 0.118 0.95 (0.66, 1.37) 0.773 0.68 (0.29, 1.61) 0.381 
symptomatic 
carotid stenosis   
0.012 
 
<0.001 
 
0.107 
 
70-100% 
ICA 
<70% ICA 1.94 (1.28, 2.96) 0.002 1.15 (0.76, 1.75) 0.499 1.43 (0.72, 2.85) 0.303 
 
Unknown <70% ICA 0.96 (0.55, 1.67) 0.887 2.67 (1.93, 3.70) <0.001 2.82 (1.06, 7.45) 0.037 
in atrial 
fibrillation 
No 1.60 (1.10, 2.33) 0.014 1.27 (0.96, 1.68) 0.093 1.11 (0.58, 2.13) 0.752 
visible infarct 
on scan 
No 1.13 (0.81, 1.57) 0.484 0.98 (0.74, 1.32) 0.915 3.01 (1.48, 6.12) 0.002 
haemorrhage 
on scan 
No 2.06 (1.09, 3.91) 0.027 0.69 (0.43, 1.11) 0.130 1.94 (0.64, 5.85) 0.239 
 
Table 5.2  Unparsimonious multivariable Cox regression for each of the transitions in the ESS 
multi-state model 
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stroke -> recurrence stroke -> death recurrence-> death 
  
Baseline 
hazard ratio 
(95% CI) 
p-
value  
hazard ratio 
(95% CI) 
p-
value  
hazard ratio 
(95% CI) 
p-
value  
age - centred on 
mean of 71  
1.01 (0.99, 1.02) 0.240 1.06 (1.05, 1.07) <0.001 1.08 (1.05, 1.11) <0.001 
male Female 0.69 (0.50, 0.94) 0.021 1.01 (0.79, 1.30) 0.909 
  
independent 
before stroke 
No 1.22 (0.59, 2.51) 0.589 0.66 (0.47, 0.91) 0.013 
  
previous other 
occlusive vascular 
disease 
No 1.41 (1.02, 1.95) 0.037 1.21 (0.93, 1.56) 0.154 2.42 (1.46, 4.03) 0.001 
lift both arms off 
bed  
No 2.37 (1.25, 4.49) 0.008 0.34 (0.26, 0.46) <0.001 
  
orientated speech No 0.79 (0.48, 1.28) 0.340 0.43 (0.32, 0.58) <0.001 
  
symptomatic 
carotid stenosis   
0.004 
 
<0.001 
 
0.003 
 
70-100% ICA <70% ICA 2.06 (1.38, 3.07) <0.001 1.26 (0.84, 1.89) 0.271 1.91 (1.06, 3.47) 0.032 
 
Unknown <70% ICA 0.99 (0.57, 1.71) 0.970 2.85 (2.08, 3.89) <0.001 3.33 (1.65, 6.71) 0.001 
in atrial fibrillation No 1.67 (1.16, 2.40) 0.006 1.31 (1.00, 1.72) 0.052 
  
visible infarct on 
scan 
No 
    
2.11 (1.21, 3.66) 0.008 
haemorrhage on 
scan 
No 1.94 (1.05, 3.58) 0.036 0.68 (0.45, 1.04) 0.075 
  
 
Table 5.3  Parsimonious multivariable Cox Regression for each of the transitions in the ESS 
multi-state model 
 
The modelling shown in Table 5.3 for each of the three transitions formed the 
basis of the predictions at the time of the index stroke displayed in the next 
section. Modelling was also carried out in preparation for dynamic predictions. 
 
Such predictions took place after a specified time point and accounted for the 
time that had elapsed and any transitions experienced by the patients up to that 
time point. Time points of 6 months and 1 year on from the index stroke were 
used. Therefore modelling was undertaken using just those patients who had 
managed to survive for 6 months after their stroke, and then again with those 
who were still alive 1 year on from their stroke.  Separate modelling was carried 
out for those who managed to stay in the initial stroke state to the specified 
time and for those who had experienced a recurrence by that time. For the 
modelling for those still in the initial stroke state, multi-state modelling of the 
three transitions was carried out. A similar approach was used for variable 
selection as for the predictions at the time of the index stroke. For those who 
experienced a recurrence, modelling of death after recurrence was carried out.  
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Table 5.4 shows the results of modelling for those who were still in the initial 
stroke state 6 months on from their stroke. This involved 1037 patients amongst 
whom there were subsequently 92 recurrences, 135 deaths without recurrence 
and 32 deaths after recurrence. Due to the modelling using a different cohort of 
patients – smaller in number but having survived 6 months free of recurrence – 
than at the time of the index stroke, the covariates included were slightly 
different. However, the effects of the covariates that were included were 
generally similar and in the same direction as in the previous modelling. 
 
Table 5.4  Parsimonious multivariable Cox Regression for each of the transitions in the ESS 
multi-state model: in initial stroke state 6 months on from stroke 
 
Table 5.5 shows the corresponding results for those who were still in the initial 
stroke state 1 year on from their stroke. This involved 960 patients amongst 
whom there were subsequently 64 recurrences, 88 deaths without recurrence 
and 23 deaths after recurrence. 
   
stroke -> recurrence stroke -> death recurrence-> death 
  
Baseline 
hazard ratio 
(95% CI) 
p-
value  
hazard ratio  
(95% CI) 
p-
value  
hazard ratio 
 (95% CI) 
p-value  
age - centred 
on mean of 71  
1.02 (1.00, 1.04) 0.029 1.07 (1.05, 1.09) <0.001 
  
male Female 0.68 (0.44, 1.04) 0.073 0.95 (0.67, 1.35) 0.785 
  
independent 
before stroke 
No 1.29 (0.47, 3.55) 0.624 0.51 (0.31, 0.84) 0.008 
  
previous other 
occlusive 
vascular 
disease 
No 
    
4.09 (1.91, 8.79) <0.001 
lift both arms 
off bed  
No 1.76 (0.79, 3.90) 0.167 0.66 (0.42, 1.05) 0.081 
  
orientated 
speech 
No 0.73 (0.38, 1.41) 0.353 0.55 (0.35, 0.87) 0.010 
  
symptomatic 
carotid 
stenosis 
  
0.059 
 
0.004 
 
0.008 
 
70-100% 
ICA 
<70% ICA 2.03 (1.18, 3.50) 0.011 1.55 (0.94, 2.56) 0.086 2.85 (1.20, 6.78) 0.018 
 
Unknown <70% ICA 1.07 (0.52, 2.19) 0.851 2.24 (1.39, 3.61) 0.001 3.87 (1.48, 10.17) 0.006 
in atrial 
fibrillation 
No 1.28 (0.76, 2.16) 0.361 1.56 (1.06, 2.29) 0.024 3.53 (1.58, 7.89) 0.002 
haemorrhage 
on scan 
No 2.12 (0.98, 4.57) 0.055 0.51 (0.23, 1.11) 0.088 
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stroke -> recurrence stroke -> death recurrence-> death 
  
Baseline 
hazard ratio 
(95% CI) 
p-
value  
hazard ratio (95% 
CI) 
p-
value  
hazard ratio (95% 
CI) p-value  
age  
 
1.03 (1.00, 1.05) 0.031 1.06 (1.03, 1.08) <0.001 
  
independent 
before stroke 
No 1.61 (0.39, 6.64) 0.511 0.43 (0.23, 0.78) 0.006 
  
previous other 
occlusive 
vascular 
disease 
No 1.04 (0.61, 1.79) 0.873 1.44 (0.94, 2.23) 0.097 4.01 (1.59, 10.10) 0.003 
lift both arms 
off bed  
No 1.49 (0.59, 3.78) 0.400 0.52 (0.30, 0.91) 0.021 
  
stroke 
syndrome   
0.346 
 
0.111 
  
 
Lacunar Cortical 0.74 (0.40, 1.36) 0.325 0.56 (0.32, 0.99) 0.047 
  
 
Other Cortical 0.63 (0.30, 1.29) 0.205 0.77 (0.43, 1.39) 0.388 
  
symptomatic 
carotid 
stenosis 
  
0.041 
 
0.230 
 
0.010 
 
70-100% 
ICA 
<70% ICA 2.24 (1.20, 4.17) 0.011 1.37 (0.74, 2.54) 0.311 3.66 (1.38, 9.69) 0.009 
 
Unknown <70% ICA 1.62 (0.74, 3.53) 0.225 1.64 (0.90, 3.01) 0.108 5.09 (1.39, 18.66) 0.014 
in atrial 
fibrillation 
No 0.94 (0.47, 1.87) 0.853 1.68 (1.05, 2.70) 0.031 
  
 
Table 5.5 Parsimonious multivariable Cox Regression for each of the transitions in the ESS 
multi-state model: in initial stroke state 1 year on from stroke 
 
Age was the only predictor included in the modelling of death after recurrence 
for the 56 patients (with 12 subsequent deaths) who were in the recurrence 
state 6 months on from their stroke. Age, centred on the mean of 71, had a 
coefficient (s.e) of 0.0533 (0.0265) and p-value of 0.044 in the resultant Cox 
model. The null model was used to model death after recurrence in the 70 
patients who were in the recurrence state 1 year on from their stroke, 7 of 
whom experienced death. 
5.2 Results of multi-state modelling: predictions 
This section highlights some of the possibilities in prediction with multi-state 
modelling. Two different prediction procedures are illustrated: prediction from 
the start of the study and dynamic prediction. The dynamic aspect of the latter 
is two-fold, taking into account changes in prediction as time elapses and also as 
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patients move to different health states. For each type of prediction, four 
patient profiles of differing risk are used for illustration. The patient profiles 
used can be seen in Table 5.6. 
 
(a) high 
risk 
(b) low risk (c) mid 
risk 1 
(d) mid 
risk 2 
age at stroke 61 61 71 71 
sex female male male male 
independent before stroke    
previous cardiovascular or peripheral 
vascular disease    
lift both arms off bed     
orientated speech    
symptomatic carotid stenosis Unknown <70% ICA 
70-100% 
ICA 
70-100% 
ICA 
in atrial fibrillation    
visible infarct on scan    
haemorrhage on scan    
stroke syndrome cortical lacunar cortical cortical 
 
Table 5.6 Risk profiles used for prediction 
 
5.2.1 Predictions from the start of the study 
Figure 5.2 on the next page shows, for each of the different risk profiles, 
predictions of being in each of the health states in the model with death divided 
into pre- and post- recurrence deaths. Predictions were at the time of the index 
stroke. 
It can be seen in Figure 5.2(a) that the probability of high-risk patients 
remaining in the initial stroke state (Alive, no recurrence) was essentially zero 
by the end of the 4 years of observation. This was primarily due to the very high 
risk of death without recurrence at 97% by 4 years. It could also be seen that the 
risk of death without recurrence was particularly severe within the first year 
post stroke. The risk of such a death was already 50% by 0.1 years post-stroke, 
rising to 88% by 1 year. In addition, the percentage of patients with recurrence 
at any one time did not exceed 1.1%. However this risk was only prevented from 
increasing by the risk of post-recurrence deaths, which was 3.2% by 4 years. 
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Figure 5.2  Predictions, at the time of the index stroke, of being in each health state over 
time 
 
In contrast, 73% of those with the specified low-risk profile were predicted to 
still be in the initial stroke state 4 years post stroke (Figure 5.2(b)). Patients 
who did move from the stroke state were most likely to be alive with a 
recurrence. The percentage of patients with a recurrence had generally rose 
over the 4 years to 20% by 4 years. This was because there was a minimal risk of 
post-recurrence deaths. The risk of such deaths was only at 1% by 4 years. Even 
the risk of pre-recurrence deaths, prominent in the other risk groups, was only 
5% by 4 years.  
 Chapter 5    Multi-state modelling with the Edinburgh Stroke Study data    114                                                                                                                                                                                                  
 
For those with the mid-risk1 profile (Figure 5.2(c)), the probability of remaining 
alive without a recurrence, i.e. in the initial stroke state, was 46% 4 years post 
stroke. By far the most likely reason to move from the initial stroke state was 
pre-recurrence death with the percentage of patients doing so having reached 
45% by 4 years. The risk of being in recurrence at any one time and of post-
recurrence death was minimal at 7% and 2% respectively at 4 years. 
Figure 5.2(d), (mid-risk2 profile), is shown to demonstrate the effect of being 
able to lift both arms off the bed. The only difference between patients with 
mid-risk1 (Figure 5.2(c)) and mid-risk2 (Figure 5.2(d)) was that the latter were 
able to lift both arms off the bed and the former were not. Comparing Figure 
5.2(c) and Figure 5.2(d) it can be seen that those who were able to lift both 
arms off the bed were more likely to be alive with no recurrence, 16% versus 7% 
of patients, respectively, 4 years post stroke. In addition, the risk of death 
without recurrence was much lower in those who could lift both arms off the 
bed, compared to those who could not, at 17% versus 45% 4 years post stroke.  A 
higher percentage of those who could lift both arms off the bed were predicted 
to die after recurrence at 5% versus 2% in those who could not lift both arms off 
the bed. This is expected as there was a higher percentage of recurrences 
amongst those who could lift both arms off the bed compared to those who 
could not do so. 
5.2.2 Dynamic predictions 
The remainder of this section now focuses on dynamic predictions. These 
predictions provide an update to the predictions from the start of the study, 
that takes into account the time that has elapsed and whether any states of 
interest in the model have been experienced.  
Figure 5.3 shows, for patients who were still in the stroke state at the time of 
prediction, dynamic predictions of being in each of the health states in the 
model with death divided into pre- and post-recurrence deaths. Each of the four 
plots represent a different risk profile. Different health states are distinguished 
by colour and different starting times of prediction are distinguished by line 
style. 
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Figure 5.3 Dynamic predictions of each event 
 
Figure 5.3(a) demonstrates, for those at high risk, the predictions of being alive 
with no recurrence from the later starting times showed substantial 
improvement, albeit with convergence resulting in similar predictions by 4 years. 
For instance, the 1-year prediction of being alive with no recurrence at the time 
of stroke of 9% improved to 61% for those who managed to stay in that state 6 
months on from the index stroke. In addition, the corresponding 2-year 
prediction improved from the 3% at the time of the stroke to 34% and 55%, 
respectively, 6 months and 1 year on from the stroke. However, there was a lot 
less discrepancy in the 4-year predictions of 0%, 2% and 3% at the time of stroke, 
6 months on and 1 year on respectively. It can also be seen in Figure 5.3(a) that, 
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for predictions from each of the starting points, the probability of being in 
recurrence was virtually zero over time. This was due to the post-recurrence 
deaths which prevented this probability from increasing. The percentage of post-
recurrence deaths was also relatively low, and therefore the dramatic drops 
seen in the percentage of being alive with no recurrence were predominately 
due to the sharp increases in the percentage of pre-recurrence deaths.  
For those at low risk, the 4-year predictions of being alive with no recurrence 
improved from the 73% at the time of the index stroke to 80% starting 6 months 
on, and improved further still to 88% when the prediction started 1 year on 
(Figure 5.3(b)). Figure 5.3(b) also exhibits a reduction in the 4-year probability 
of being in recurrence, at 0.20, 0.14 and 0.06 for the predictions starting at the 
index stroke, 6 months on and 1 year on respectively.  
It can be seen in Figure 5.3(c) that, for those at mid-risk, the 4-year prediction 
of staying alive with no recurrence 6 months on from the index stroke was 60%. 
This was a marked improvement on the corresponding prediction at the time of 
the index stroke of 46%. It can be clearly seen that this was due to a 
corresponding reduction in pre-recurrence deaths. It can also be seen in Figure 
5.3(c) that the probability of being alive with no recurrence at 4 years was lower 
when the prediction started 1 year on, compared to 6 months on, from the index 
stroke. It was evident that this was due to a higher percentage of post-
recurrence deaths by 4 years when prediction started 1 year on, compared to 6 
months on, from the index stroke.  
The most marked difference between those at mid-risk who could not lift both 
arms off the bed (Figure 5.3(c)) and those who could (Figure 5.3(d)) was in the 
percentage of pre-recurrence deaths. In the latter, the percentage of pre-
recurrence deaths at 4 years was only 17% when predicting from the time of the 
index stroke, with similar predictions when starting 6 months on and 1 year on 
from the index stroke. Consequently, Figure 5.3(d) did not demonstrate the 
improvement in the prediction of being alive with no recurrence seen in Figure 
5.3(c) between the predictions that started at the index stroke and 6 months on 
from then. Instead, in Figure 5.3(d), the predictions of being alive with no 
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recurrence starting from progressively later times showed initial improvement 
before converging to a similar point by 4 years. The convergence of the 
predictions at the time of the index stroke and 6 months on was due to a 
combination of, in the predictions starting 6 months on, a steady relatively 
smaller frequency of recurrences over time together with the percentage of pre-
recurrence deaths rising more sharply. In addition to this, a rise in the 
percentage of post-recurrence deaths also contributed to the convergence of the 
predictions that started at 1 year. 
5.3 Comparison with competing risks analysis 
This section demonstrates the differences in predictions that can occur when 
using multi-state modelling compared to competing risks analysis. The risk 
profile mid-risk 1 previously outlined in Table 5.6 on page 112 is used for 
illustration.  
Figure 5.4 shows the competing risks cumulative incidence of recurrence 
alongside the probability of being in recurrence from the multi-state model. The 
probability of death after recurrence from the multi-state model is also shown 
because it aids interpretation of the difference in predictions as explained 
below. 
 
Figure 5.4  comparison of predictions of recurrence: multi-state modelling vs competing risks 
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It can be seen in Figure 5.4 that there was a marked discrepancy between the 
competing risks cumulative incidence of recurrence (dashed line) and the 
probability of being in recurrence from the multi-state model (solid line). Due to 
the estimate from the competing risks analysis being a cumulative incidence, it 
increased monotonically. It reflected the proportion of patients who had 
experienced a recurrence by a certain point in time. However, it did not take 
into account that patients will not be in the recurrence state indefinitely; 
patients will all inevitably die and therefore leave the recurrence state and 
enter the death state. The inclusion on the plot of the probability of death after 
recurrence from the multi-state model (dotted line) helps emphasise this. The 
competing risks analysis considered the flow from the stroke state into the 
recurrence state. However the predictions from the multi-state modelling gave a 
fuller picture by reflecting the flow both in and out of the recurrence state.  
5.4 Discussion 
This chapter presented analysis demonstrating the effects of covariates on each 
of the hazards for each relevant transition in a multi-state model of stroke, 
recurrence and death. Furthermore, it illustrated how these effects translated 
into state occupancy probabilities, with predictions at the time of the index 
stroke, and dynamically as time elapsed with any transitions experienced taken 
into account. In addition, it demonstrated the extra insight that can be gained 
from predictions from a multi-state model over and above that from a competing 
risks analysis. In particular, it emphasised that because cumulative incidences 
are the way predictions are presented from a competing risk analysis, the effect 
is one of monotonic increases. However, predictions in multi-state modelling 
consider the flow in and out of a health state and therefore provide additional 
insight to inform clinical decision making. That is to say, for a patient with a 
given set of risk factors, the modelling can give a prediction of being alive with 
recurrence over time, rather than just a prediction of the time that a recurrence 
is likely to happen. In doing so, it can help in identifying those likely to benefit 
from interventions to prolong their life after recurrence, or perhaps a group for 
inclusion in a trial investigating strategies to prevent subsequent recurrences. 
From another perspective, it may help with resource allocation by 
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differentiating those patients unlikely to benefit from such strategies because 
they have been severely debilitated and show no sign of improvement, and it 
may be more appropriate not to prolong their suffering.  
Multi-state modelling could provide a useful tool for clinicians to predict 
outcomes for their patients and to aid discussions with them. In particular, 
dynamic predictions could be used to communicate any improvements in 
prognosis as time has elapsed. For example, the concept of overcoming a 
“critical risk period” could be emphasised as positive news for a patient. That is 
to say, explaining that now they have survived through a particular period when 
the risk of death (or recurrence) is high, highlight the improvement in prognosis 
compared to earlier. Another use for the predictions that multi-state modelling 
can accommodate could be to encourage patients to change an aspect of an 
unhealthy lifestyle to improve their health. This is discussed further in  
Chapter 8. 
A consideration with dynamic prediction can be whether the values for 
covariates, where appropriate, should be updated to reflect the transitions 
experienced. This is particularly applicable to models involving recurrence, as 
often updated information on covariates is available at the time of recurrence, 
such as severity of disease. Even when predicting at the time of the initial state, 
it can be tempting to use covariates measured at the time of recurrence in the 
modelling of the recurrence  death transition. However, this would not be of 
any practical use for prediction for those in the initial state, at time 0 or 
dynamically, because this information would not be known at the time of 
prediction. Furthermore, in particular, all covariates included in any transition 
in a Markov model would need to start at the initial state value, as this is the 
way time is measured in Markov modelling.  
However, the landmarking approach does offer more flexibility when the 
predictions are for patients in the recurrence state at the time of prediction. 
Therefore, covariates measured at the time of recurrence can be considered. 
The data used for the analysis in this chapter was originally extracted for a 
competing risks analysis and did not contain covariate information at the time of 
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recurrence. However, because the study formed a register of stroke patients, all 
covariate information collected at the time of stroke would have also been 
available at the time of recurrence of strokes, because recurrences would have 
been included as separate strokes. That the analysis did not include covariates 
measured at the time of recurrence was also a limitation due to the omission of 
potential confounders. It is quite possible/likely that age at recurrence and 
severity of recurrence account for some of the association found between having 
a recurrence and subsequent mortality after recurrence. Furthermore, the 
recording of such information at post-stroke assessments could help to inform 
dynamic predictions, for both those still in the initial stroke state and those who 
had experienced a recurrence by the time of prediction. Therefore, it is worth 
bearing in mind the flexibility offered by the approach to accommodate updated 
covariate information and to exploit this in future research.  Doing so would 
enhance the insights such as those outlined at the end of the first paragraph of 
this discussion section. 
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Chapter 6 Health economic modelling: 
two common approaches, review of the use of multi-state 
modelling, the assessment of model fit and extrapolation 
This chapter begins by summarising two common approaches in health economic 
modelling: partitioned survival (section 6.1) and Markov decision-analytic 
modelling (section 6.2). The purpose of this is to provide background and 
context for the next chapter which presents empirical analysis that compares 
these two methods with multi-state modelling. In order to put into context the 
use of multi-state modelling for health economic modelling, section 6.3 contains 
a review of multi-state modelling in the health economics literature. The 
chapter then discusses the assessment of fit of models over the observed period 
of a study in section 6.4. Finally, section 6.5 focuses on extrapolation of 
outcomes beyond the observed period, which is a particularly important issue 
and has been a prominent topic in the health economics literature in recent 
years. After some initial background to the need for extrapolation, section 6.5 
describes the conventional approach to extrapolation of parametric regression 
and some alternative approaches. The topic of extrapolation is then revisited at 
the end of this thesis in Chapter 8, where further developments in contributions 
to the literature in this fast-moving area are discussed.  
This thesis does not describe the following standard concepts in health economic 
modelling for which references are provided for the interested reader: 
calculating cost-effectiveness (Drummond et al., 2005), assessing robustness of 
results with one-way and probabilistic sensitivity analyses [Drummond et al. 
(2005) and Briggs et al. (2006)] and discounting of costs and benefits (Drummond 
et al., 2005). 
These concepts are not specific to any one approach to modelling. In particular, 
they are applicable when using the two approaches described in this chapter and 
the multi-state modelling described in chapter 4. 
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6.1 Partitioned survival 
 
One common approach in health economic modelling is partitioned survival. 
Partitioned survival involves splitting overall survival into partitions that 
represent different health states experienced while alive. Typically, each health 
state differs in terms of the quality of life it provides. The method was proposed 
by Glasziou et al. (1990) and is often called the Q-TWiST (Quality-adjusted Time 
Without Symptoms of disease and Toxicity of treatment) method. It is also 
described in Gelber et al. (1991) and Gelber et al. (1995), with the latter 
forming the basis for the description presented in this section.  
There are three steps to the partitioned survival method: 
1. define relevant outcomes that will determine the health states of 
interest 
2. partition the overall survival 
3. compare the treatments 
 
Step 1: Define the relevant outcomes/health states of interest 
 
Illustration of The Q-TWiST method normally involves the outcomes toxicity, 
disease-free survival and overall survival. It gets its name because time without 
either symptoms of disease or toxicity of treatment is one of the health states of 
interest. This description of the method, however, uses the outcomes 
progression-free survival and overall survival. This is a common approach in the 
oncology setting and chapter 7 of this thesis, the empirical chapter that includes 
an application of this method, is based on a clinical trial with these outcomes. 
Given that the relevant outcomes are progression-free survival and overall 
survival, the health states while alive that can be considered are progression-
free and progression. Figure 6.1 illustrates these different health states across 
time to eventual death for an individual patient. Utility weights are often 
assigned to health states to represent the quality of life experienced while in 
them. For illustration, Figure 6.1 assumes utilities of 0.8 and 0.6 for the 
progression-free and progression states respectively. 
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Figure 6.1 Illustration of quality-adjusted survival  
 
The two extremes for utility weights are 1 representing perfect health and 0 for 
death or states as bad as death. The utilities of 0.6 for progression and 0.8 for 
progression-free reflect the quality of life experienced relative to these two 
extremes. An estimate of quality-adjusted survival can then be obtained, for an 
individual patient, from: 
Q-SURV = UPROGFREE × PROGFREE + UPROG × PROG  
where PROGFREE = time spent progression-free, 
          PROG = time spent in the progression state, 
          UPROGFREE = utility while progression free, 
          UPROG = utility while in the progression state. 
 
However, interest is in comparing treatment groups rather than individual 
patients. For this, PROGFREE and PROG need to represent the mean time spent 
in these states in a particular treatment group. Their derivation is explained in 
Steps 2 and 3 below. 
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Step 2: Partition overall survival 
The next step is to partition the overall survival Kaplan-Meier curve into the 
health states defined in Step 1. Partitioning overall survival into progression-free 
and progression requires the progression-free survival Kaplan-Meier curve. Each  
treatment group should be considered separately.  
Figure 6.2 shows an example of the partitioning of overall survival (OS) using 
progression-free survival (PFS).  
 
Figure 6.2  Illustration of partitioned survival  
 
 
The area between the curves provide estimates of the mean duration in the 
relevant health state. Therefore, the mean duration in the progression state can 
be estimated from the area between the overall survival (OS) and progression-
free survival (PFS) curves. Similarly, an estimate of the mean duration 
progression-free can be obtained from the area under the progression-free 
survival curve. 
However, not every patient in the study in this illustration was observed long 
enough to reach progression and/or die. Therefore the progression-free survival 
and overall survival curves did not represent the entire lifetime of patients. 
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When the follow-up in a study stops before every patient has experienced the 
relevant outcomes, the estimates of mean duration in relevant states are said to 
be restricted means. In order to obtain estimates of the mean time in relevant 
states, instead of restricted means, parametric survival regression is one 
approach that can be used to extrapolate survival curves until the whole lifetime 
is represented. This is described later in this chapter in section 6.5. 
Step 3: Comparison of treatments 
 
The final step in the partitioned survival approach is to compare treatments in 
terms of the Q-SURV outcome described at the end of Step 1. Estimates of Q-
SURV are obtained for each treatment separately. The mean durations in the 
relevant states required for Q-SURV are calculated from the areas under the 
curves as detailed in Step 2. The treatment effect is then estimated from the 
difference between Q-SURV in the treatment group and that in the control 
group. 
6.2 Markov decision-analytic modelling 
Another common approach in health economic modelling is Markov decision-
analytic modelling. Instead of deriving mean times in relevant states from 
survival outcomes, as in partitioned survival, Markov decision-analytic modelling 
models the transitions between states directly [Sonnenberg and Beck (1993), 
Briggs and Sculpher (1998), Briggs et al. (2006) and Sun and Faunce (2008)]. It 
being a form of state transition modelling means it shares many similarities with 
the multi-state modelling which was the focus of the previous two chapters. 
Alongside describing the Markov decision-analytic approach this section will 
emphasis key differences between it and multi-state modelling. 
6.2.1 Define the relevant health states  
As with partitioned survival, the first step in Markov decision-analytic modelling 
is to define the health states of interest. Continuing with the illustrative 
example, Figure 6.3 shows the transition diagram for the Markov decision-
analytic model. 
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Figure 6.3 Markov decision-analytic model transition diagram 
 
 
The three states of interest are progression-free, progression and death. 
Initially, all patients are in the progression-free state. The three transitions 
progression-free  progression, progression-free  death and progression  
death are modelled. Therefore the composite event outcome progression or 
death, from the progression-free survival outcome used in the partitioned 
survival approach, is split into the two transitions of progression-free  
progression and progression-free  death. There are now two routes to death – 
either directly or via progression. 
In general, there is a decision to be made about which transitions are to be 
included in the model. This is also the case for multi-state modelling. However, 
all the transitions that are possible mathematically may not be of interest or 
make practical sense. For example, as already mentioned in section 4.2 for 
multi-state models, it is possible for models to have reversible transitions. That 
is to say once a patient reaches a state it is possible to revert to a previous one. 
This could be particularly useful for illnesses with a cure/remission phase. 
However, for instance, it would not make sense for a model to include a 
transition that involved movement from the death state.  
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The time horizon, i.e. the finite time frame over which to model, is split into 
discrete cycles. These cycles need to be sufficiently short to capture changes in 
clinical outcomes and costs. In practice, models typically use monthly or annual 
cycles. The circular arrows in Figure 6.3 next to the progression-free and 
progression states represent patients that stayed within that state for the length 
of a cycle.  
Therefore patients in the progression-free state could either move to the 
progression state, move direct to the death state without entering the 
progression state or remain in the progression-free state. Patients in the 
progression state could either move to the death state or remain in the 
progression state. Obviously patients who reach the death state cannot move 
from that state once there, hence the name “absorbing state” given to death. 
Patients must be in only one of the states at the end of each cycle. 
However, the notion of cycles is specific to Markov decision-analytic modelling 
because it measures time discretely. The use of cycles is not an issue for multi-
state modelling because it measures time continuously. That is to say, it uses 
the individual patient level data and therefore the exact time of transition is 
known, rather than the typical cohort simulation of Markov decision-analytic 
modelling over a series of cycles. Therefore, the circular arrows in Figure 6.3 
that represent staying in a state within a cycle are only a feature of transition 
diagrams for Markov-decision analytic modelling and not multi-state modelling. 
6.2.2 (Relaxation of) the Markov property 
The Markov property – often called the “memoryless property” - is assumed to 
hold in Markov models. This is the condition that movement from the present 
state is not dependent on the previous states visited or the length of the visits. 
Therefore Markov models are said to have no memory of the previous history of 
patients. (This was previously mentioned in chapter 4 because multi-state 
models can also be Markov).  
However, the Markov property can be relaxed by including tunnel states in the 
modelling. Figure 6.4 illustrates the use of tunnel states. 
 Chapter 6    Health economic modelling:     128                                                                                                                                                                                                  
 
 
Figure 6.4 Illustration of tunnel states in Markov decision-analytic modelling 
 
A tunnel state is a temporary state that is only occupied for one cycle. The 
“tunnel” the patients pass through indicates both the state occupied and the 
number of previous cycles spent in that state. Modelling incorporating tunnel 
states is known as “semi-Markov”, reflecting the relaxation of the Markov 
property. 
In contrast, tunnels states are not needed to build semi-Markov multi-state 
models. Semi-Markov models in multi-state modelling were described in section 
4.4 of chapter 4. 
6.2.3 Assignment of transition probabilities/obtaining results 
Probabilities of occurrence are assigned to each of the transitions before 
modelling commences. These can be obtained from several sources including 
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published literature, empirical modelling and expert opinion. Published 
literature could include clinical trials, meta-analyses or observational studies. 
The transition probabilities are stored in an n × n matrix, with n being the 
number of states. However, only the entries of the matrix representing 
transitions will be non-zero because, as previously mentioned in sub-section 
6.2.1, not all transitions between states will be relevant. In contrast, with multi-
state modelling as previously mentioned in chapter 4, transition probabilities are 
calculated by appropriately combining hazards of individual transitions. 
Typically, this is after fitting survival regression models for the transition 
hazards using individual patient level data.  
Transition probabilities (Markov decision-analytic modelling) /transition hazards 
(multi-state modelling) can be constant over time (time homogeneous) or be 
time-dependent (time inhomogeneous).  
Standard approaches for obtaining results from Markov decision-analytic 
modelling are covered extensively elsewhere and are not described in this 
thesis. For example, the contribution by Sonnenberg and Beck (1993) provides a 
succinct summary of the matrix algebra solution, cohort simulation and Monte 
Carlo simulation. 
6.3 Review of multi-state models for health economic 
modelling in the literature 
In recent years, there has been an increase in contributions involving the 
continuous-time multi-state modelling framework in the health economics 
literature, and in a health economics context in the more general medical 
literature. This section summarises and critiques such contributions. The purpose 
of this review was to explore to what extent the methodology and applications 
were illustrated and to identify any barriers to adoption of the approach. It also 
sought to identify areas where multi-state modelling had not been used to its 
full potential. Due to it being a form of state-transition modelling, multi-state 
modelling has huge potential as an alternative to conventional spreadsheet-
based approaches for cost-effectiveness modelling but it is not widely applied. It 
is syntax-based providing a transparent record of the analysis and it makes errors 
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easier to spot. Furthermore, it explicitly allows testing of the Markov property 
by simply adding a relevant covariate and semi-Markov modelling does not 
require tunnel states. Of particular note, Markov models can be built in seconds 
and therefore their creation is a lot less cumbersome and time-consuming. 
A search strategy was developed to allow the review to take place. An initial 
search took place when this research began in 2011. OvidSP was searched for 
titles, abstracts and keywords with the terms:  
(("multi-state" AND "?Markov" AND cost*) OR ("multistate" AND "?Markov" AND 
cost*) OR ("multi state" AND "?Markov" AND cost*) OR ("illness-death" AND 
"?Markov" AND cost*) OR ("illness death" AND "?Markov" AND cost*) OR 
("disability model*" AND "?Markov" AND cost*) OR (continuous-time AND 
?Markov AND cost*) OR (continuous AND time AND ?Markov AND cost*) OR 
("multi-state model*" AND cost*) OR ("multistate model*" AND cost*) OR ("multi 
state model*" AND cost*) OR ("illness-death model*" AND cost*) OR ("illness 
death model*" AND cost*) OR ("disability model*" AND cost*)).ti,ab,kw.  
However, this search has been an ongoing process. Email alerts of new articles 
were set up using OvidSP and Web of Knowledge. A final OvidSP search using the 
strategy above was then conducted to search for contributions up to 
05/10/2016. Three health economic journals known to have relevant 
contributions were also specifically targeted – Medical Decision Making, Value in 
Health and Health Economics.  These journals were searched again for “multi-
state model*” OR “multistate model*” OR “multi state model*” OR “continuous-
time” OR "continuous time" 
in titles/abstracts/keywords to capture those contributions that were not found 
from the other searches.  
In addition, email notifications of new content alerts were also set up for these 
three journals at the beginning of my research period and any relevant 
contributions were included. I also checked the reference lists of articles I had 
already reviewed and articles that cited papers that I already knew had 
contributed to this area of research.  
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In addition the NICE website (www.nice.org.uk) was searched on 05/10/2016 
using the terms:  
"multi-state" OR "multi-state Markov" OR "multi-state semi-Markov” OR 
"multistate" OR "multistate Markov" OR "multistate semi-Markov” OR 
"multi state" OR "multi state Markov" OR "multi state semi-Markov” OR 
multi-state OR multistate OR "continuous-time" OR "continuous time" 
 
and found 6 technology appraisals (TAs). However, each of these 6 TAs did not 
involve continuous-time multi-state modelling, and were excluded for that 
reason. Furthermore, a search was performed on the National Institute for 
Health Research (NIHR) Journals Library website www.journalslibrary.nihr.ac.uk 
on 05/10/2016 within the journal Health Technology Assessment specifically, 
and using the NICE website’s NICE Evidence Search facility with source set to   
NIHR Journals Library, using the search terms: 
multi-state OR multistate OR “multi state” OR “multi-state” OR “multistate” OR 
"continuous-time" OR "continuous time" 
and found 7 NIHR Health Technology Assessment Reports. However, 4 of these 
did not involve multi-state modelling. The other 3 were found in the main 
OvidSP search but did not involve the continuous-time multi-state modelling 
framework and were excluded for that reason. 
Each of the above search strategies collectively found 27 contributions relevant 
to continuous-time multi-state modelling (Appendix VIII), which will be discussed 
in the commentary in the rest of this section.  Of note though, the rejection of 
the contributions from the two sources of health technology assessments 
highlights there seems to be some inconsistences in terminology with regards to 
multi-state modelling between the fields of medical statistics/epidemiology and 
health economics. In the former, the term appears to be used exclusively in the 
context of continuous-time, unless otherwise explicitly stated, whereas there is 
a lot more ambiguity in the latter where it appears to be used both in a 
continuous-time and discrete-time context. 
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6.3.1 Methodological issues: continuous-time multi-state 
modelling contrasted with Markov decision-analytic models 
It is recognised that, in health economics, the vast majority of state-transition 
modelling is carried out using Markov decision-analytic models within a discrete-
time framework, instead of a continuous-time multi-state modelling approach 
[e.g. van Rosmalen et al. (2013)]. Section 6.2 described Markov decision-analytic 
modelling. Briefly, it typically involves following a cohort of patients from an 
initial health state over a series of discrete cycles, with movement between 
states based on pre-assigned transition probabilities. van Rosmalen et al. (2013) 
and Cao et al. (2016) highlight that a half-cycle correction is often undertaken 
to reduce measurement bias due to the assumption that transitions only occur at 
discrete times. van Rosmalen et al. (2013) stress that bias can be particularly 
apparent with long cycles but that the shorter cycle lengths required to 
overcome the bias can be computationally intensive. However, the continuous-
time multi-state modelling framework uses the exact time of transitions and 
therefore, as stated by Cao et al. (2016), there is no such bias and therefore no 
need for a half-cycle correction.  
Begun et al. (2013) discuss the point that continuous-time models are preferable 
to discrete-time models, because the former allow for transitions that may have 
a small probability and therefore cannot be observed during a small time unit. 
They also emphasise that continuous-time models are more realistic as they 
allow for state transitions to occur at any moment.  A conference proceeding by 
Tichy (2014) also highlights that a continuous-time framework can be preferable 
due to overcoming the need for cycles.  
In Markov modelling, the Markov “memoryless” property is assumed to hold. This 
is the condition that movement from the current state does not depend on the 
previous states visited or the time spent in any previous states. In the discrete- 
time framework, one way of relaxing the Markov assumption is to incorporate 
tunnel states, that represent previous cycles spent in a state, into the model. 
Hawkins et al. (2005) developed an alternative way of representing tunnel states 
using multi-dimensional transition matrices to incorporate dependency on the 
previous cycles spent in states. While it was still in the discrete-time framework, 
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it was however an important contribution demonstrating how to conduct the 
analysis in the open-source language R, and hence a departure from the reliance 
on spreadsheet-based packages.  
For the calculation of transition probabilities, many of the contributions have 
commented that, transition probabilities are used as inputs in the discrete-time 
framework, whilst in the continuous-time framework transition hazards (rates) 
are used (Welton and Ades (2005), Begun et al. (2013) and van Rosmalen et al. 
(2013)).  Welton and Ades (2005) emphasise that transition rates are commonly 
used for combining information from different studies. Therefore, the use of 
transition rates, rather than transition probabilities, provides a natural 
mechanism to conduct evidence synthesis. Price et al. (2011) stress the need to 
synthesize evidence from all available trials to assess which is the most effective 
treatment. In their article, Price et al. (2011) describe how to conduct a meta-
analysis to compare different treatments across several trials in a multi-state 
modelling context. They show how to estimate the treatment effects needed for 
each of the transitions in the modelling. 
6.3.2 Approaches to calculating transition probabilities in 
continuous-time multi-state modelling 
The research describing the methodology of the continuous-time multi-state 
modelling approach mainly focuses on calculating transition probabilities by 
solving Kolmogorov’s forward differential equations using matrix algebra based 
around matrix exponentials [Welton and Ades (2005), Begun et al. (2013) and 
van Rosmalen et al. (2013)]. Welton and Ades (2005) and Begun et al. (2013) 
each provide worthwhile contributions that demonstrate how the continuous-
time multi-state modelling framework can be used with both fully and partially-
observable data. Begun et al. (2013) illustrate an approach based on Cox semi-
parametric regression. The contribution provides a useful introduction to the 
concept. However, it does not include code or details of a software package to 
allow others to adopt the approach. Extending the Cox regression to fully 
parametric regression would have allowed for extrapolation of survival outcomes 
that were not observed in all patients. Welton and Ades (2005) present a 
Bayesian approach to solving the forward equations which has the benefit of 
 Chapter 6    Health economic modelling:     134                                                                                                                                                                                                  
 
being able to propagate uncertainty through the model, and include WinBUGs 
code in an appendix. When proposing the continuous-time approach, van 
Rosmalen et al. (2013) also provide code as an appendix that is based around 
matrix exponentials. They distinguish multi-state modelling from discrete-event 
simulation in that, whilst both use a continuous-time framework, the former is 
deterministic (exact) and the latter is stochastic and therefore subject to 
simulation errors. Furthermore, van Rosmalen et al. (2013) offer multi-state 
modelling as an alternative to discrete-event simulation or microsimulation. In 
particular, they emphasise its advantages over simulation approaches of not 
requiring dedicated software, needing less computation time and not being 
subject to simulation error. However, they also acknowledge that the required 
programming of matrix exponentials for their proposed approach is a drawback 
compared to the more user-friendly spreadsheets used in the discrete-time 
Markov decision-analytic modelling.  
6.3.3 Some applied uses of multi-state modelling in the  
health economics literature 
The applied use of multi-state modelling for lung cancer by Bongers et al. (2016) 
adds value to the existing contributions in that it helps to highlight multi-state 
modelling as an alternative to microsimulation models, albeit in a roundabout 
way.  The article makes use of the mstate package in R to undertake multi-
state modelling.  However, rather than using the facility in mstate to calculate 
transition probabilities, it only goes so far as to calculate transition hazards 
which are then used to inform assumptions in a microsimulation model. Another 
very recent contribution also carried out multi-state modelling in R, but then 
proceeded to build a conventional Markov decision-analytic model informed in 
part from the transition probabilities of the multi-state model (Scotland et al. 
(2016)). Therefore, the implementation in these two contributions fell short of 
showcasing the full capabilities of mstate for carrying out multi-state 
modelling.  Anything that can be built in Excel can be coded in statistics 
software. Therefore, there is scope to avoid the two-step process and perform 
all the health economic modelling using the same software.  
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Another contribution that made partial use of mstate was the piece by Egger et 
al. (2016). They created a multi-state model to investigate the effect of 
adherence to clinical guidelines on outcomes for elderly patients admitted to 
hospital with community-acquired pneumonia. The model had 14 cycles. 
However, since each cycle represented a day, it could be considered to be using 
a continuous-time framework. The authors used mstate to derive transition 
probabilities, for a given covariate profile, from Cox cause-specific hazard 
modelling. These transition probabilities were then transformed into beta 
distributions in the model using the estimates and standard errors from the Cox 
modelling. However, it was not clear how this transformation occurred. An 
alternative approach could have been to carry out regressions assuming the 
hazards followed parametric distributions, and using the hazards from these in 
conjunction with mstate to calculate state occupancy probabilities. The 
research in this thesis will involve an adaption of mstate to allow such 
parametric regressions instead of Cox modelling. 
Other applied uses of continuous-time multi-state modelling have also emerged 
in the literature in the areas of heart failure (Cao et al., 2013), coronary artery 
disease (Asaria et al., 2016), diabetes (Jensen et al., 2014), kidney disease 
(Begun et al., 2013), mRSA (De Angelis et al., 2011), HIV (Le Pen et al. (2001)) 
and colorectal cancer (Castelli et al., 2007). 
Cao et al. (2013) provide a useful illustration of how continuous-time multi-state 
modelling can be used for cost-effectiveness analysis. Their contribution is from 
the perspective of producers of health technology as decision makers, rather 
than a societal perspective. As such, instead of focusing on Cost per quality-
adjusted life year, their analysis concentrated on “commerical headroom”. This 
is identical to the net monetary benefit which is a standard concept described in 
(Drummond et al., 2005). They use the msm package in R alongside 
bootstrapping. Furthermore, their contribution also includes probability 
sensitivity analysis. 
Asaria et al. (2016) illustrate an applied use of a state-transition model which is 
more akin to the continuous-time multi-state modelling framework, than a 
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discrete-time Markov decision-analytical approach. However, the paper did not 
model the transitions simultaneously using the individual patient level data in 
the usual manner of multi-state modelling. Instead, they developed risk 
equations for each of the transitions separately and then later incorporated 
them into a competing risks framework. Therefore, it was not clear whether 
their post-equation competing risk adjustment appropriately took account of the 
competing risks scenario which was present. 
The demonstration of an applied use of multi-state modelling by Jensen et al. 
(2014) was a quite complex illustration. The authors built a multi-state model of 
adherence to long term medication in those with Type 2 diabetes. The 
assignment of states and transitions between states involved an algorithm which 
was not easy to follow. While the authors state they used SAS for their analysis, 
they did not provide any code in an appendix to allow others to adopt a similar 
approach. This was unfortunate especially considering its complexity. 
6.3.4  Multi-state modelling applied to infections 
Several authors provide helpful demonstrations that showcase how multi-state 
modelling can be used to estimate the mean length of stay in various health 
states, which could then be used in the calculation of costs for hospital-acquired 
infections in particular [De Angelis et al. (2011), Stewardson et al. (2012) 
Stewardson et al. (2013), Stewardson et al. (2015), Stevens et al. (2015), Ndir et 
al. (2016a) and Ndir et al. (2016b)]. This is in contrast to the more typical use of 
calculating mean (quality-adjusted) life years in relevant health states, which is 
particularly relevant for chronic and/or progressive diseases. They are a useful 
addition to the literature, because as De Angelis et al. (2011) highlight, the 
mean length of stay approach has potential for acute, non-recurrable diseases.  
In a follow-up to the work of De Angelis et al. (2011), some of the same authors 
[Macedo-Vinas et al. (2011) and Macedo-Vinas et al. (2013)] use the excess 
length of stay calculated to derive excess bed-days which were then used to 
estimate attributable costs.  The work by De Angelis et al. (2011) and Macedo-
Vinas et al. (2013) studied MRSA. In other research, which included De Angelis as 
an author, a similar approach was used to investigate excess length of stay with 
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bloodstream infections in adults in a Swiss hospital by Stewardson et al. (2012) 
and Stewardson et al. (2013) and in wider Europe by Stewardson et al. (2015). A 
different group of authors also used the approach to investigate bloodstream 
infections, but in a paediatric setting in Senegal (Ndir et al. (2016a)). 
Furthermore, Ndir et al. (2016b) used the approach to investigate infections 
caused by extended-spectrum beta-lactamases producing Enterobacteriaceae. 
In other research, Stevens et al. (2015) used the approach to investigate excess 
length of stay attributable to Clostridium difficile infection and Arefian et al. 
(2016) used it to investigate excess length of stay and costs due to health care-
associated infections in general. All of the contributions in this section have 
advocated the use of multi-state modelling because it explicitly takes into 
account the time of infection by including infection as a state. Furthermore, 
Mitchell and Gardner (2012) carried out a review of methods used to investigate 
length of stay for Clostridium difficile infection. However, the methods used 
were prior to the uptake of multi-state modelling and therefore introduced bias 
due to not taking into account the timing of the infection. The authors 
concluded that multi-state modelling was a more appropriate method, and 
encouraged collection of the timing of the events that would constitute states in 
the model. In a related review, Nelson et al. (2015) investigated the magnitude 
of bias introduced by failing to take into account the timing of the infection. 
Again these authors recommended using an appropriate method such as multi-
state modelling or matching. In another related piece, Barnett et al. ((2016) 
demonstrated the time-dependency bias when not using multi-state modelling by 
comparing such a model to a generalised linear model. Shi et al. (2014) 
investigated the time-dependency bias still further. The authors took into 
account patient heterogeneity using an approach based on centred residuals 
from a generalised linear model which were incorporated into a multi-state 
model. These contributions have been useful in that they have highlighted an 
aspect of bias that can occur and demonstrated how multi-state modelling can 
provide a solution. 
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6.3.5 Multi-state modelling applied to HIV 
Le Pen et al. ((2001) ‘s research is concerned with the effect of highly active 
antiretroviral therapy in HIV patients. It is an interesting contribution because it 
raises awareness of the inclusion of irreversible states in multi-state modelling 
i.e. that patients can revert back to states they have been in previously. 
Therefore it highlights an alternative approach to the more standard model that 
normally follows the natural progression of a disease. The states are based on all 
possible combinations of CD4 cell count and viral load, each of which are 
grouped into three categories, plus a death state. Therefore there are ten states 
in the model. The paper makes a valiant attempt to model both progression of 
disease and improvement in prognosis by modelling transitions between these 
nine + one health states. However the model is arguably too complex because 
the model starts with the nine states as initial states. There are too few patients 
in many of the states even at the initial stage, never mind to follow through to 
the end of their study. Several other papers used a similar model for HIV based 
on CD4 cell count and HIV RNA levels (Chaudhary et al. (2010) and Erdesz et al. 
(2010)) and CD4 cell count and HIV-I viral load (Athanasakis et al., 2014) and 
therefore also have the same complexity issues. 
6.3.6 Multi-state modelling contrasted with partitioned survival 
During a conference, Rael et al. ((2016) raised awareness of the advantages of 
multi-state modelling/state-transition modelling over partitioned survival. They 
emphasised that modelling the transitions between the states progression-free, 
post-progression and death can answer more research questions than separate 
analyses of progression-free survival and overall survival. In particular, they 
highlighted that treatment effects on pre- and post-progression survival, and 
whether the observed overall survival benefit is driven solely by the progression-
free survival can both by investigated with such models. However, the 
contribution advocated using patient-level simulations to calculate state 
occupancy probabilities alongside the multi-state modelling. It failed to 
recognise that all analysis can be incorporated under the one multi-state 
modelling framework without the need for a separate simulation model. In 
addition, it states that a limitation of multi-state modelling is that the data 
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must be mature enough to estimate the transitions. They could have also noted 
that maturity is also a requirement of analysis using separate modelling of 
progression-free survival and overall survival. Lastly, it maintains that software 
for multi-state modelling is less well developed. A major component of the 
research carried out during this PhD will address this final point. 
6.3.7 Misunderstandings in the literature 
van Rosmalen et al. (2013) mention that multi-state modelling is Markov when 
an exponential distribution is used to model the transition hazards and semi-
Markov otherwise. This is a different interpretation to Putter et al. (2007), as 
explained in section 4.2 of chapter 4, which differentiate Markov from semi-
Markov by using the way time is measured: from first entering the initial state 
for the Markov approach and by resetting the clock back to zero when patients 
enter a new state with the semi-Markov approach. The contribution by van 
Rosmalen et al. (2013) fails to recognise that it is possible for the process in 
both a Markov and semi-Markov model to be time-homogeneous or time-
inhomogeneous. Time homogeneous processes involve the use of the exponential 
distribution with a hazard that is constant over time. In contrast, in a time-
inhomogeneous process the hazard varies over time. Parametric distributions 
other than exponential can be used in these situations. However this does not 
appear to be well known in the literature, and some incorrect use of terminology 
has resulted. There are instances where papers describe time-homogeneous 
processes but then proceed to use distributions other than the exponential; for 
example, Cao et al. (2016) and Castelli et al. (2007) using log-normal and 
Weibull distributions respectively.    
Another issue that is not always recognised relates to competing risks which 
often occur in state-transition models. When faced with competing risks and the 
modelling of hazards, it is not always appropriate to use AICs for model 
selection. This was discussed previously in section 2.7.2 of chapter 2. However 
some of the research has used AICs to decide between parametric distributions 
for the hazard (Cao et al. (2016) and Asaria et al. (2016)). Another important 
point related to competing risks is apparent in the work by Clarke et al. (2014). 
The article uses Kaplan-Meier curves as a basis for the transition probabilities 
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used in their model. It acknowledges that this is likely to introduce bias although 
it does not specifically attribute it to the censoring of competing risks. Instead, 
the article acknowledges they may be informative censoring resulting in inflated 
survival, and therefore it would appear that it states the bias in the wrong 
direction. 
6.3.8 Alternative approaches 
Cao et al. (2016) propose an alternative approach to continuous-time multi-state 
modelling called vertical modelling. However, it does appear to be overly 
complex. The simulation is difficult to understand and follow, for which no code 
is provided. It requires separate models to be built for the sojourn times and the 
future state probabilities. In addition, possible nonlinearity between the two 
needs to be checked, with fractional polynomials used for that purpose in the 
illustration given in the paper. The article argues that the vertical modelling 
approach has advantages over the pattern mixture formulation and cause-
specific hazards approaches. From the description of the pattern mixture 
formulation, the approach suffers from interpretation problems and seems to be 
unrealistic as it involves conditioning on the future. The paper also argues that 
the cause-specific hazards approach has interpretation problems as it cannot be 
directly expressed as probabilities, and therefore would make discussions with 
clinicians difficult. However I counter this argument as the complexity of the 
vertical modelling approach would make the communication of results with 
clinicians problematic. The perceived difficulty with the cause-specific approach 
can be easily overcome. The facility to calculate state occupancy probabilities 
using that approach exists in procedures such as those in the mstate package 
in R. 
Kim and Thompson (2011) ‘s contribution focuses on competing risks specifically 
rather than multi-state modelling in general. The method proposed in the paper 
is a continuous-time type approach as the calculations were restricted to 6-
month intervals, rather than measuring time continuously. The justification 
given for this is that it makes it compatible with methods for costs and 
discounting. However, these methods seem to be just as compatible in a 
continuous sense. The method involves estimating Life Years gained and cost-
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effectiveness using cause-specific, rather than all-cause, mortality. The 
motivation for this is that it is not always useful to use all-cause mortality for 
Life Years gained, because only a few causes of death may affect the 
interventions studied. The paper illustrates, perhaps counter-intuitively, that 
greater power can be achieved to detect differences in cause-specific mortality 
than in all-cause mortality. It also finds greater precision, in terms of smaller 
standard errors, with its estimator compared to using all-cause mortality. 
However, upon extrapolating the results over a life-time horizon it is found that 
results using cause-specific and all-cause mortality are similar. In addition, the  
loss of precision over the period of the study for all-cause mortality is not 
evident upon extrapolation. The paper concludes that a long-term all-cause 
mortality outcome can be used, but only when it is appropriate to assume that 
rates of other-cause mortality are the same across groups. Otherwise, it 
stipulates a cause-specific approach should be used. It cautions against using the 
usual competing risks cumulative incidence approach when it is calculated 
separately for each group. The proposed approach is interesting but it is not 
likely to be widely-applied in practice. This is because it involves naïve Kaplan-
Meier estimates, which is in contrast to all the established competing risks 
literature that caution against this due to the bias it can introduce.   
6.3.9 Summary of the review  
This review of the literature has shown limited, but growing, awareness of the 
continuous-time multi-state modelling framework in the literature for health 
economics where it has huge potential. However it has highlighted that 
applications of the approach are scarce, with the field acknowledging that use of 
the continuous-time framework greatly lags behind its discrete-time 
counterpart. To my knowledge, there has been no articles illustrating 
continuous-time multi-state modelling as an alternative by comparing it to 
commonly-used approaches in cost-effectiveness analysis. Therefore, Chapter 7 
of this thesis, and its accompanying publication (Williams et al., 2017b), 
presents an empirical analysis comparing multi-state modelling to the two more 
widely-used approaches of partitioned survival and Markov decision-analytic 
modelling.  
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6.3.9.1 Code to encourage adoption of the approach 
Some of the research has provided code and/or references to software packages 
(Cao et al. (2013), Welton and Ades (2005), van Rosmalen et al. (2013), Bongers 
et al. (2016) and Asaria et al. (2016)), overcoming a barrier that previously 
prevented modellers easily adopting similar approaches. This should help 
encourage the consideration of the continuous-time multi-state modelling 
approach, where individual patient level data is available. Such data was 
available to Clarke et al. (2014) and Hettle et al. (2012), but they opted for a 
discrete-time approach instead.  
However, it was also apparent from the literature that one of the main 
perceived barriers to adopting the continuous-time multi-state modelling 
approach was the implementation of the algebra involved together with a lack of 
readily available software. In order to fill this gap, I created a webpage with 
customisable R functions to allow users to carry out full cost-effectiveness 
analyses. I also published an accompanying tutorial paper in the Medical Decision 
Making journal, a journal popular in the health economics field (Williams et al., 
2017a). This paper guides the users through the steps involved in a cost-
effectiveness analysis using multi-state modelling and encourages adoption of 
the approach.  It demonstrates how to use multi-state modelling to calculate 
mean (quality-adjusted) life years gained and incremental cost-effectiveness 
ratios. It also illustrates how the approach can be used in deterministic and 
probabilistic sensitivity analyses. In using a syntax-based approach, it benefits 
from the transparency of the code used and analysis that is all contained in one 
file. Therefore, errors are arguably easier to spot than in spreadsheet packages, 
where cells can be accidentally changed without the analyst’s knowledge. The 
calculation of the transition probabilities for Markov multi-state modelling was 
not implemented using matrix exponentials. Instead, an equivalent 
representation using product integrals, described in more detail in section 4.3 of 
chapter 4 was used which is less computationally intensive and more intuitive 
than matrix exponentials. The simulation approach used for semi-Markov multi-
state modelling was covered in section 4.4. 
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6.4 Assessment of fit over the observed period of a study 
This section discusses issues worth consideration when assessing the fit to the 
data observed in a trial or other study. The need to test the proportional hazards 
(PH) assumption, when considering fitting such models is emphasised [Grieve et 
al. (2013), Latimer (2013), Bagust and Beale (2014), Latimer (2014)]. One 
method recommended for this purpose by Latimer (2013) is to plot the log-
cumulative hazards versus log time, also known as a log-log plot, for each 
treatment group. If the lines are reasonably parallel there is no suggestion of a 
violation of the proportional hazards assumption. Data that follows an 
exponential distribution will produce a plot that has a straight line with slope 1, 
whereas data from a Weibull distribution will be represented as a straight line 
with a slope other than 1. The plot is useful for assessing the hazards at the 
earlier times rather than the later times when there are fewer events anyway 
(Latimer, 2014).  
Bagust and Beale (2014) prefer a plot of the cumulative hazards versus time to 
assess whether the proportional hazard assumption holds or not. It is useful for 
visualising the hazards long-term, rather than in the initial time period during 
which there can often be a higher hazard which takes this initial period to settle 
down. Bagust and Beale (2014) argue it is easier to distinguish an exponential 
distribution from a Weibull distribution with this plot because, rather than both 
being represented as straight lines as they are in the log-log plot, the cumulative 
hazard plot can show non-linear trends indicating hazards that either increase or 
decrease. This can also be seen as a weakness of this plot however because, as 
Latimer (2014) points out, they are more difficult to assess visually because 
proportional hazards are represented by lines that diverge at a constant rate 
rather than parallel lines.  
When considering fitting models in the accelerated failure time (AFT) framework 
(described later in section 6.5), it is recommended to test whether AFT is an 
appropriate fit by plotting Q-Q plots (Bradburn et al. (2003)). This plots the 
percentiles/quantiles of the survival times in one treatment group versus the 
corresponding information in the other treatment group. They should show as a 
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straight line that passes through the origin with slope equal to the acceleration 
factor of the model. An alternative approach for assessing whether AFT and/or 
PH models provide appropriate fits are Cox-Snell residual plots. These check that 
the survival times follow an exponential distribution with hazard equal to 1, 
which is indicative of a good-fitting model. The plots show the observed and 
fitted cumulative hazard and should show a straight line through the origin with 
a slope equal to one. Cox-Snell residual plots can be used for both AFT and PH 
models, allowing a direct comparison of such models.  
If there is evidence from the plots described above to suggest a violation of the 
PH or AFT assumption, as appropriate, for the treatment covariate, or indeed 
any covariate, then such models should not be fitted. Instead, separate fits can 
be used for each treatment (Bagust and Beale, 2014), although this no longer 
allows direct estimation of a treatment effect. When the PH/AFT assumption is 
assumed to hold, separate fits for each treatment can also be carried out as a 
sensitivity analysis – to check there are no major discrepancies in results 
between them and the PH/AFT model with treatment as a covariate. It is worth 
noting however that (Cox) PH models are reasonably robust to minor deviations 
from the PH assumption. If an inspection of the Kaplan-Meier curves does not 
show evidence of obvious divergence, convergence or crossing of the curves, 
then one could assume that hazards are proportional. The hazard ratio can be 
thought of as the “average” effect across the period of observation. 
Visual assessments of the fit to the observed data, such as comparing the 
predicted survival with the Kaplan-Meier survival estimate and the plots 
described above, are useful for comparing fits with different distributional 
assumptions, such as those described later in section 6.5. It can also be 
worthwhile calculating AICs (Akaike, 1974) or BICs  (Schwarz, 1978) because they 
do not have the subjectivity of the visual inspection of plots. However, 
assessment of fit should not be based solely on one of these but rather they 
should both be considered. In addition, the fit to the observed data is only one 
consideration if extrapolation beyond the observed period is required 
(extrapolation will be discussed in the next section). In that situation, AICs/BICs 
can be of limited value because they are only concerned with the fit over the 
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observed period and not on how reasonable the extrapolation looks. 
Furthermore, caution is advised when using AICs/BICs with a competing risks 
scenario (common in state-transition modelling) and the modelling of hazards, as 
previously discussed in section 2.7.2.  
6.5 Extrapolation of outcomes for use in economic 
evaluations  
6.5.1 Motivation for extrapolation 
It is often the case that a study does not have sufficient follow-up to observe the 
outcomes in every patient, e.g. in the example illustrated in  
Figure 6.2  not every patient was observed long enough to reach progression 
and/or die. However, in health economics, a lifetime perspective is often 
needed because an estimate of the mean time in relevant states is needed, to 
be used with the mean costs, in the calculation of cost-effectiveness measures. 
Therefore extrapolation of survival beyond the observed period is often 
necessary. This has received much attention in the literature recently, e.g. 
Tappenden et al. (2006), Connock et al. (2011) ,Grieve et al. (2013), Latimer 
(2013), Stevens and Longson (2013), Bagust and Beale (2014) and Latimer (2014). 
Several of these papers have commented on the need to achieve a balance of 
both a good fit to the observed data and a sensible and clinically plausible 
extrapolation.  
A useful first step is to use a parametric fit to the observed (Kaplan-Meier) 
survival curve and extrapolate it until it reaches the desired time horizon. There 
is a general consensus to consider all the “standard” distributions – i.e. 
exponential, Weibull, Gompertz, log normal, log-logistic and generalised 
gamma. Focus should be on trying to achieve sensible extrapolation, in the sense 
that it should be clinically plausible and/or compatible with external data. If the 
extended predictions do not adequately represent zero, i.e a lifetime 
perspective, at the end of the time horizon, then an alternative is to start the 
extrapolation from the tail of the observed Kaplan-Meier curve. Tappenden et 
al. (2006) outline an approach based on fitting a linear regression to the Kaplan-
Meier curve and then back-transforming to the equivalent using parametric 
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regression. It involves rearranging the survival function (or function thereof) into 
a linear function of time that can be used to fit a linear regression. The 
resultant coefficients are that used in the original parametric survival function 
after transformation into that scale. This approach could be used to start 
extrapolation from the tail of the observed curve. However the choice of 
suitable points will be somewhat arbitrary and therefore sensitivity analysis for 
this choice should be undertaken. In addition, the tail of the observed curve is 
where estimates will be least precise. The fact that the confidence interval 
around the Kaplan-Meier survival estimates demonstrate their precision can be 
used as an aid to help decide when to start extrapolation. Another sensitivity 
analysis that is recommended by Grieve et al. (2013) is considering different 
treatment effects long-term. Specifically, the authors advocate considering no 
treatment effect in the unobserved period, a reduction in the treatment effect 
over time and a treatment effect from the observed period that persists over the 
unobserved period. 
6.5.2 Conventional approach: parametric regression 
This section summarises some considerations with regards to parametric survival 
regression as it pertains to extrapolation. The conventional approach for 
extrapolation of survival is to use parametric survival regression – either fitting a 
model to all the observed data, or starting the fit from some point on the tail of 
the Kaplan-Meier curve. Two common ways to fit such models are proportional 
hazards and accelerated failure time models. In a proportional hazards model, 
the hazard function can be written as 
  
h(t) = h0(t) exp(βx) 
 
where x is the vector of covariates and β is the vector of regression coefficients. 
h0(t) is the baseline hazard and is assumed to be parametric. Common 
parametric distributions used for proportional hazards models are Weibull, 
exponential and Gompertz. 
In an accelerated failure time model, the natural logarithm of the survival time 
is modelled as a linear function of the covariates i.e. 
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 log(t)= βx +ε 
where ε is the error term and β and x are as for the proportional hazards model. 
The distribution used for the error term determines the type of model. Common 
accelerated failure time models are log normal, log-logistic and generalised 
gamma. The Weibull can also be expressed as an accelerated failure time model. 
Table 6.1 shows the survival and hazard functions for six standard distributions 
used in health economic modelling. An exponential model is time homogeneous, 
(i.e. the hazard rate is constant), whereas the other distributions are time 
inhomogeneous.    
For each distribution there is an equation for the survival and hazard functions, 
allowing survival to be extended to the desired time horizon. 
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Table 6.1 Common parametric distributions 
Distribution Survival Hazard ℎ(𝑡) or density 𝑓(𝑡), where appropriate 
Weibull 𝑆(𝑡) = exp(−𝜆𝑡𝛾) ℎ(𝑡) = 𝛾𝜆𝑡𝛾−1 
where λj = 𝑒𝑥𝑝(𝑥𝑗  𝛽) and 𝛾 is estimated from the data 
exponential 𝑆(𝑡) = 𝑒𝑥𝑝(−𝜆𝑡) ℎ(𝑡) = 𝜆 
where λj = 𝑒𝑥𝑝(𝑥𝑗  𝛽) 
Gompertz 𝑆(𝑡) = 𝑒𝑥𝑝{−𝜆𝛾−1(𝑒λ𝑡 − 1)} ℎ(𝑡) = 𝜆 𝑒𝑥𝑝(𝛾𝑡) 
where λj = 𝑒𝑥𝑝(𝑥𝑗  𝛽) and 𝛾 is estimated from the data 
log normal 
𝑆(𝑡) = 1 − 𝜙 {
𝑙𝑜𝑔( 𝑡) −  µ
𝜎
}  𝑓(𝑡) =
1
𝑡𝜎√2𝜋
𝑒𝑥𝑝 [
−1
2𝜎2
 {𝑙𝑜𝑔(𝑡) − µ}2] 
Where 𝜙(𝑧)  is the standard normal cumulative distribution function, µ𝑗 = 𝑥𝑗𝛽 
and 𝜎 is estimated from the data 
log-logistic 
𝑆(𝑡) =
1
1 + (𝜆𝑡1 𝛾⁄ )
 𝑓(𝑡) =
𝜆1⁄𝛾𝑡1 𝛾−1⁄
𝛾 {1 + (𝜆𝑡)1 𝛾⁄ }2
  
where λj = 𝑒𝑥𝑝(−𝑥𝑗  𝛽) and 𝛾 is estimated from the data 
generalised 
gamma 
𝑆(𝑡) = 1 − 𝐼(𝛾, 𝑢) if к > 0 
𝑆(𝑡) = 1 − 𝜙(𝑧) if к = 0 
𝑆(𝑡) = 𝐼(𝛾, 𝑢) if к < 0 
𝑓(𝑡) =
𝛾𝛾
𝜎𝑡√𝛾 𝛤(𝛾)
   𝑒𝑥𝑝(𝑧√𝛾 − 𝑢) if к ≠ 0 
𝑓(𝑡) =
1
𝜎𝑡√2𝜋
𝑒𝑥𝑝 [
−𝑧2
2
 ] if к = 0 
 
where 𝐼(𝛾, 𝑢)  is the incomplete gamma function, 𝛾 = |к|−2 , 𝑢 =  𝛾 𝑒𝑥𝑝(|к|𝑧), 
z = sign(к){log(t)-  µ }/  𝜎 , µj = 𝑥𝑗  𝛽 , 𝜙(𝑧)  is the standard normal cumulative 
distribution function and к and 𝜎 are estimated from the data 
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6.5.3 Alternative approaches to extrapolation  
As previously mentioned, it is recommended to consider a range of different 
distributions. Several alternative, more complex, approaches can also be 
explored; particularly if the standard distributions do not provide an adequate 
fit, either to the complete observed data or starting from a point on the tail of 
the Kaplan-Meier curve. Examples include flexible parametric methods involving 
splines (Andersson et al., 2013), using less standard distributions such as the 
generalised F (Jackson et al., 2010) or poly-Weibull (Demiris et al., 2015) and 
using a Bayesian semi-parametric approach with piecewise-constant hazards 
(Jackson et al., 2010). 
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Chapter 7 Comparing Markov decision-analytic 
modelling, partitioned survival and multi-state 
modelling 
 
7.1 Introduction 
This chapter presents an analysis comparing three different approaches to 
estimating benefit (survival) in a health economics context. It was motivated by 
an existing Markov decision-analytic model which was created for a 
manufacturer’s submission to NICE for a technology appraisal. However the 
Evidence Review Group (ERG), working on behalf of NICE, had some concerns 
about the model and initiated their own sensitivity analysis. Both the original 
model and the additional analysis to address the ERG’s concerns highlighted that 
there was scope to consider other approaches. Therefore, this chapter uses the 
manufacturer’s economic model as a basis for a case study that compared it to 
two alternative approaches. These used the individual patient level trial data 
that was the main source underlying the model. Specifically, the two approaches 
compared to the existing Markov-decision analytic model were partitioned 
survival and multi-state modelling. As such, this chapter provides an empirical 
analysis that complements earlier parts of this thesis that provided a more 
methodology background to Markov decision-analytic modelling (section 6.2), 
partitioned survival (section 6.1) and multi-state modelling (chapter 4). 
The extrapolations and choice of time horizon used in the comparison of the 
approaches did not benefit substantially from being informed by external data. 
This was primarily because the approaches were contrasted with a 
manufacturer’s existing decision-analytic model, and used the same time 
horizon as that model for comparison purposes. There was no attempt to vary 
the time horizon, or the extrapolation to this target horizon, and assess their 
clinical plausibility. This limitation was due to the model building process being 
carried out by another party, and therefore having no access to the resources 
and clinical expertise that team would have had. The extrapolations were 
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instead carried out by making use of parametric survival regressions using six 
standard distributions. Using external data to strengthen the clinical plausibility 
of extrapolations, particularly combining randomised clinical trial data with 
longer-term follow-up in observational routine data, is discussed in chapter 8.  
Section 7.2 introduces the decision problem the manufacturer’s economic model 
was designed to address alongside summarising the structure of the model itself. 
It then continues with outlining some concerns the Evidence Review Group had 
with the model. This highlighted that there was scope to consider alternative 
approaches and hence provided the motivation for the rest of this chapter. Since 
the alternative approaches considered used the individual patient level data 
from a trial, section 7.3 briefly describes this trial data to put the analysis that 
follows into context. Next, section 7.4 demonstrates the partitioned survival 
approach. The chapter then continues with section 7.5 that presents an analysis 
of the trial data using the multi-state modelling approach. The results of the 
three approaches are then compared in section 7.6. Sensitivity analyses, for the 
multi-state modelling specifically, are presented in section 7.7. Then, section 
7.8 provides a direct comparison of the Markov decision-analytic modelling with 
the multi-state modelling. The purpose of this is to demonstrate that multi-state 
modelling can provide an alternative way of implementing a decision-analytic 
model, because when the same assumptions are made with each, the results 
compare well.  Finally, the chapter ends with a summary of the results and a 
discussion in section 7.9. 
7.2 Description of the decision problem and the 
existing Markov decision-analytic model  
This chapter presents an empirical analysis using a case study in a health 
economics context. The case study was based around the economic model 
created by a manufacturer (Roche, 2008) in their submission to NICE for the 
specific technology appraisal TA174 (NICE, 2009). This section briefly describes 
the decision problem that model was designed to address, the structure of the 
model and the assumptions made by the manufacturer with regards to the 
transition probabilities. 
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7.2.1 The decision problem 
The decision problem focused on evaluating the clinical and cost-effectiveness 
of rituximab in combination with chemotherapy for the first-line treatment of 
chronic lymphocytic leukaemia. As such, the population under consideration was 
patients with previously untreated chronic lymphocytic leukaemia. Furthermore, 
the intervention studied was rituximab combined with fludarabine and 
cyclophosphamide and the comparator was fludarabine and cyclophosphamide 
alone. In addition, the main outcome to be evaluated by the economic model 
was the incremental cost per quality-adjusted life year, a standard approach in 
health economic modelling. Costs and benefits were discounted at a rate of 3.5% 
annually. Finally, the model took a lifetime perspective with a time horizon of 
15 years. The manufacturer’s justification for this length of horizon was that 
only 1.3% of the cohort were estimated to survive beyond 15 years 
[Roche (2008): p109]. Also, the report by the Evidence Review Group stated that 
advice given to them thought this to be an appropriate time frame (PenTAG, 
2009). 
7.2.2 Structure of the model   
The main source of data for the model was the CLL-8 trial (Hallek et al., 2010). 
This trial reported on the outcomes progression-free survival and overall survival 
for each patient. Data on post-progression survival was also available. This 
allowed focus to be on the three states progression-free, progression and death 
& the transitions between them. Specifically, the three transitions that were 
modelled were progression-free  progression, progression-free  death and 
progression  death.  A state transition diagram for this model was previously 
presented in Figure 6.3 on page 126. Furthermore, time was measured in 
monthly cycles.  
The manufacturers took the usual approach in Markov decision-analytic 
modelling of assigning probabilities of occurrence to each of the transitions 
before modelling started. The assumptions made by the manufacturer for each 
of the transitions were as follows: 
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 progression  death 
A monthly probability of 0.0405 was used, the same for each arm. It was based 
on an assumption of a constant death rate that was derived from the inverse of 
the mean of 24.1791 months from the Kaplan-Meier estimate of post-progression 
survival. 
 progression-free  death 
the observed rate of death whilst progression-free, or an age-specific 
background mortality rate, whichever was largest. The observed monthly 
probability of death whilst progression-free was 0.0012 and 0.00139 in the RFC 
and FC arms respectively. 
 progression-free  progression 
This was calculated by adding together the probability for progression-free  
death and the probability of staying in the progression-free state, and then 
subtracting the result from one. The probability of staying in the progression-
free state was based on a Weibull regression fitted to the observed progression-
free survival data that was then extrapolated to 15 years.  
Of particular note was the assumption for the probability of progression  death  
  ̶  specifically because it was the same for each treatment arm.  
7.2.3 Sensitivity analysis initiated by the Evidence Review 
Group 
The three leftmost columns of numbers in Table 7.1 [adapted from PenTAG 
(2009)] show the original Mean Life Years and QALY results submitted by the 
manufacturer. However the Evidence Review Group (ERG), working on behalf of 
NICE, had some concerns about the model presented by the manufacturer 
(PenTAG, 2009). In particular, the ERG were concerned about the overall 
survival gain that resulted from the model because this was not demonstrated 
empirically. Consequently, the ERG asked the manufacturer to carry out two 
sensitivity analyses to remove the benefit in overall survival. Table 7.1 also 
shows these two sensitivity analyses initiated by the ERG. The first sensitivity 
analysis removed the overall survival benefit by increasing the probability of 
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death in the progressed state in the RFC arm only by 315%. The second 
sensitivity analysis removed the benefit by decreasing the probability of death in 
the progressed state in the FC arm only to 57.4% of what it was originally. 
With both sensitivity analyses, the mean QALYs gained reduced to 0.24 from the 
0.88 in the manufacturer’s original submission. 
 
Manufacturer's 
Original Submission 
Sensitivity Analysis 1 Sensitivity Analysis 2 
  RFC FC  
Incre-
mental RFC FC  
Incre-
mental RFC FC  
Incre-
mental 
Mean Life Years 5.73 4.65 1.07 4.66 4.65 0.00 5.73 5.72 0.00 
Mean Life Years in PFS 4.11 2.93 1.18 4.11 2.93 1.18 4.11 2.93 1.18 
Mean Life Years in 
Progression 1.62 1.73 -0.11 0.55 1.73 -1.18 1.62 2.80 -1.18 
          Mean QALYs 4.26 3.38 0.88 3.62 3.38 0.24 4.26 4.02 0.24
Mean QALY in PFS 3.29 2.34 0.95 3.29 2.34 0.95 3.29 2.34 0.95 
Mean QALY in 
Progression 0.97 1.04 -0.07 0.33 1.04 -0.71 0.97 1.68 -0.71 
 
Table 7.1   Mean Life Years/QALYs for time horizon of 15 years:  
                  Sensitivity analyses initiated by the ERG to remove the benefit in overall    
                  survival [adapted from PenTAG (2009)] 
 
Table 7.2 shows the Costs per Life Years/QALYs gained from the manufacturer’s 
submission and the two sensitivity analyses initiated by the ERG (PenTAG, 2009). 
It can be seen that, due to the reductions in QALY gained in the sensitivity 
analyses, the cost per QALYs had increased to just above the £30,000 per QALY 
gained willingness-to-pay threshold. 
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Manufacturer's Original 
Submission 
Sensitivity Analysis 1 Sensitivity Analysis 2 
  RFC FC  
Incre-
mental RFC FC  
Incre-
mental RFC FC  
Incre-
mental 
Mean Life 
Years 5.73 4.65 1.07 4.66 4.65 0.00 5.73 5.72 0.00 
Mean 
QALYs 4.26 3.38 0.88 
           
3.62 3.38 0.24 4.26 
 
4.02 0.24 
Mean 
Total Cost 
 
£25,595  
 
£13,978  
 
£11,617  
 
£21,204  
 
£13,978   £7,226  
 
£25,595  
 
£18,367   £ 7,228  
Cost per 
Life Year 
Gained 
 
£10,825  
 
£ 3,473,529  
 
£2,756,887  
Cost per 
QALY 
Gained   £13,189    £30,336    £30,304  
 
Table 7.2   Cost per Life Year gained & Cost per QALY gained: manufacturers submission    
                  and ERG sensitivity analyses [adapted from PenTAG (2009)] 
 
Table 7.3 shows what the changes in the probability of death after progression in 
the two sensitivity analyses initiated by the ERG equate to in terms of hazard 
ratios (before discounting). 
  
Sensitivity 
analysis 1 
Sensitivity 
analysis 2 
Change to probability of death in progression in RFC arm 315% increase no change 
Change to probability of death in progression in FC arm 
no change 
57.4% of 
original 
   Probability of death in progression in RFC arm 0.168 0.041 
Probability of death in progression in FC arm 0.041 0.023 
   Probability of death in progression in RFC arm expressed as a rate 0.184 0.041 
Probability of death in progression in FC arm expressed as a rate 0.041 0.024 
   Hazard ratio  4.451 1.758 
 
Table 7.3  ERG sensitivity analyses expressed as hazard ratios 
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However, fitting a Cox regression to the observed data resulted in a hazard ratio 
of 1.364. Therefore, the assumptions made in the sensitivity analyses initiated 
by the ERG resulted in larger effects than were observed in the data, especially 
so in sensitivity analysis 2. It was the sensitivity analyses initiated by the ERG 
that motivated the exploration of the alternative approaches presented in the 
rest of this chapter.  
 
7.3 Description of Rituximab clinical trial dataset 
So far in this chapter, the analyses discussed were carried out by the 
manufacturer or the ERG (with the exception of those presented in Table 7.3). 
The rest of this chapter will focus on modelling approaches, wholly carried out 
by myself as part of the research conducted for this PhD, that used the 
individual patient level data. Consequently, this section summarises this trial 
data to provide background.  
As mentioned earlier in this chapter, the basis for the case study used for 
illustration was an economic model in a manufacturer’s submission 
(Roche, 2008) to NICE for the specific technology appraisal TA174 (NICE, 2009). 
The CLL-8 trial (Hallek et al., 2010) was the main source of data used to 
populate the model. For comparison, the partitioned survival approach (section 
7.4) and multi-state modelling (section 7.5) presented later in this chapter used 
the data from this trial directly. 
Table 7.4 summarises the number of events of relevance for the 408 patients in 
the RFC arm and the 409 patients in the FC arm. 
Patients were in the trial for up to 4 years and not all of them were observed to 
the end of their life. This meant extrapolation of survival was necessary to gain 
a lifetime perspective. As already explained in section 7.2, a time horizon of 15 
years was used in the manufacturer’s economic model. To help with the 
comparison with the two approaches wholly using the individual patient level 
data from the trial, a time horizon of 15 years was also used with each of them.  
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 RFC  FC  
 (n=408) (n=409) 
progression 106 148 
death after progression 23 27 
death without progression 21 26 
 
Table 7.4   Summary of number of events in the CLL-8 trial  
 
7.4 Partitioned survival 
This section presents analysis using the partitioned survival method, the first 
approach considered as an alternative to the manufacturer’s economic model. It 
can be thought of as simpler to implement than the state-transition approaches 
it will be compared to in this chapter, as it only involves Kaplan-Meier curves of 
the survival outcomes of interest. A background to the approach was given in 
section 6.1 of the previous chapter. For this illustration of it using the case 
study, it involved the trial outcomes progression-free survival and overall 
survival, which are considered in turn in sections 7.4.1 and 7.4.2.  For all the 
approaches compared in this chapter, an objective was to achieve a balance of a 
good fit to the data over the observed period of the trial and a suitable 
extrapolation to the time horizon of 15 years. For each of the survival outcomes 
involved in the partitioned survival, the fit over the observed period of the trial 
and that over the extrapolated period were initially considered separately.  
7.4.1 Progression-free survival 
7.4.1.1 Assessment of fit over the observation period of the trial 
This section assesses the fit (of survival regressions) over the observed period of 
the trial for progression-free survival. Some methodological background to this 
was given in section 6.4 of the previous chapter. Before carrying out survival 
regression, a standard first step is to check for violations of the proportional 
hazards assumption. Therefore, initially plots were created to visualise the data 
and to check for such violations. Figure 7.1 shows the Kaplan-Meier estimates of 
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progression-free survival, together with 95% confidence intervals, for the 
treatment groups RFC and FC. 
 
Figure 7.1  Kaplan-Meier estimates of progression-free survival for RFC and FC 
 
While progression-free survival did drop slightly quicker in the initial 1 year 
period, it settled down after this and the lines were still roughly parallel 
throughout with no severe convergence or divergence or crossing of the lines. 
A log-log plot, including a dashed reference line with slope 1, can be seen in 
Figure 7.2. 
The lines were roughly parallel and appeared to have a slope greater than 1. 
This indicated the underlying data followed a distribution with hazards that 
increased with time, suggesting that a Weibull or Gompertz fit (rather than an 
exponential) was worth consideration.   
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Figure 7.2 log-log plot of progression-free survival 
 
Figure 7.3 shows a cumulative hazard plot. 
Figure 7.3  Cumulative hazard plot of progression-free survival 
  
The lines appeared to diverge at a constant rate – indicative of hazards that 
increase over time - suggesting again that a Weibull or Gompertz fit (rather than 
an exponential) was worth consideration.  
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Since there was nothing to suggest any severe violations of the proportional 
hazards assumption for treatment from Figures 7.1 – 7.3, it was worthwhile 
considering such models. (The appropriateness of accelerated failure time 
models was assessed at a later stage using the Cox-Snell residuals plot on page 
161, thereby allowing a comparison of all accelerated failure time and 
proportional hazards models at the same time).  
Parametric regression models were then fitted to the data over the whole 
observation period of the trial using each of the standard distributions. Due to 
no evidence of severe violations of the proportional hazards assumption, models 
with treatment as a covariate were fitted rather than fitting a separate model 
for each treatment. Figure 7.4 (a) and (b) show, for RFC and FC respectively, the 
Kaplan-Meier estimates of progression-free survival and that predicted from 
each of the models. 
 
Figure 7.4  Kaplan-Meier and prediction estimates of progression-free survival:  
                  (a) RFC (b) FC 
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Figure 7.4(a) shows the exponential and log normal fitted the RFC data least 
well. The other distributions all provided a reasonable (similar) fit up to 3 years 
after which they started to diverge. The Weibull, generalised gamma and 
Gompertz distributions appeared to provide relatively good fits from year 3 to 4. 
However it was difficult to choose between distributions over this period due to 
the greater uncertainty in the Kaplan-Meier estimates. It can be seen in Figure 
7.4(b) that again the Weibull, generalised gamma and Gompertz distributions 
provided the better fits to the FC data, although there was little to choose 
between them. 
Figure 7.5 displays the Cox-Snell residuals following each of the model fits. 
Figure 7.5    Cox-Snell residuals following the parametric regression of progression-free 
                    survival  
 
Again, it indicated the fits from Weibull, generalised gamma and Gompertz were 
more suitable.  
 
Table 7.5 shows the AICs for each of the model fits.  
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Distribution AIC 
exponential 1575.9 
Weibull 1545.7 
Gompertz 1548.9 
log-logistic 1551.5 
log normal 1572.6 
generalised gamma 1547.4 
 
Table 7.5  AICs from parametric regressions models for progression-free survival 
 
It suggested that the Weibull provided the best fit of all the distributions 
considered as it had the lowest AIC. 
 
7.4.1.2 Extrapolation of progression-free survival 
The assessment of fit then moved on to considering the unobserved 
extrapolation period from 4 years to the time horizon of 15 years. The 
conventional approach to extrapolation of fitting parametric regressions using 
standard distributions to the whole Kaplan-Meier curve, and then extending the 
fit out to the desired time horizon was used. Extrapolations that represented 
zero by 15 years were considered reasonable. As with the assessment of the 
observed fit presently previously, the models had treatment as a covariate 
rather than fitting separate models for each treatment.  
In Figure 7.6(a) and (b) the extrapolation of progression-free survival to 15 years 
can be seen, for RFC and FC respectively, based on the model fits using each 
distribution.  
It is evident that the Weibull, generalised gamma and Gompertz extrapolations 
most adequately represented the time horizon of 15 years, although the 
Gompertz survival reaches zero somewhat earlier than that time point. 
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Figure 7.6  Extrapolated progression-free survival to 15 years: (a) RFC  (b) FC  
  
 
7.4.1.3 Choice of base-case model 
This part takes into consideration all the results presented in this section so far 
to decide on a base-case model for progression-free survival. The Weibull, 
generalised gamma and Gompertz models with treatment as a covariate all 
seemed to provide a reasonable fit over the observed period of the trial. The AIC 
indicated the Weibull provided the best fit. Taking into account both these 
assessments of fit, the Weibull model was considered the best fit to the 
observed data. 
The Weibull also provided a sensible extrapolation in terms of representing a 
lifetime of 15 years. Sensitivity analysis considering separate Weibull fits for 
each treatment showed there was very little difference between them and the 
Weibull model with treatment as a covariate (see below). Therefore the Weibull 
fit with treatment as a covariate, and then extrapolated to 15 years, was chosen 
as the base case model for progression-free survival. A summary of the model is 
shown in Table 7.6. 
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  coefficient s.e.  HR (95% CI) p-value 
treatment (RFC vs FC)  -0.519 0.117 0.595 (0.473, 0.748) <0.001 
log(scale) 1.237 0.060   
log(shape) 0.310 0.051   
 
Table 7.6  Weibull model for progression-free survival 
 
7.4.1.4 Selected sensitivity analyses 
Sensitivity analyses were carried out to check there were no substantive 
differences between the model fits with treatment as a covariate and separate 
fits for each of the treatments. The fit over the observed period of the trial and 
that over the extrapolated period were considered separately. 
Sensitivity analysis with fit for each treatment – observed period 
The black solid line in Figure 7.7 and Figure 7.8 show the Kaplan-Meier estimate 
of progression-free survival for RFC and FC respectively. All other solid lines in 
Figure 7.7 and Figure 7.8 show, for RFC and FC respectively, the progression-
free survival predicted by models fitted with treatment as a covariate, with 
colour used to distinguish between different distributions. For each colour, the 
corresponding dashed line shows the prediction when only the data from the 
specified treatment were fitted with the same distribution.  
Figure 7.7 and Figure 7.8 show there was very little difference between the 
model types for a given distribution for either of the treatments, with some of 
the lines being indistinguishable. Please note, the y-axis of Figure 7.7 starts at 
0.4, rather than 0, for clarity. 
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Figure 7.7    Predicted progression-free survival: treatment as a covariate vs separate fit for  
                  RFC. 
 
Figure 7.8   Predicted progression-free survival: treatment as a covariate vs separate fit for  
                  FC. 
Table 7.7 and Table 7.8 show, for RFC and FC respectively, the area under the 
predicted progression-free survival curve for each of the two types of fits for 
each distribution. There was very little difference between the two types of fit, 
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with the exception of log normal for FC which was found to be one of the least 
reasonable fits anyway.  
 
  
with treatment as a covariate in the 
model 
 
separate fit for each 
treatment 
exponential 3.120 
 
3.120 
Weibull 3.109 
 
3.107 
Gompertz 3.084 
 
3.079 
log-logistic 3.134 
 
3.134 
log normal 3.143 
 
3.156 
generalised gamma 3.102 
 
3.088 
 
Table 7.7  Progression-free survival (years) AUCs from model with treatment as a covariate 
vs separate fit for RFC 
 
 
  
with treatment as a covariate in the 
model 
 
separate fit for each 
treatment 
exponential 2.586 
 
2.586 
Weibull 2.567 
 
2.568 
Gompertz 2.543 
 
2.548 
log-logistic 2.607 
 
2.607 
log normal 2.635 
 
2.621 
generalised gamma 2.562 
 
2.567 
 
Table 7.8   Progression-free survival (years) AUCs from model with treatment as a covariate 
vs separate fit for FC 
 
 
Sensitivity analysis with fit for each treatment – extrapolation period 
Figure 7.9 and Figure 7.10 show, for RFC and FC respectively, the results of a 
sensitivity analysis carried out to assess whether there were any substantive 
differences between the extrapolation based on the models with treatment as a 
covariate and those with separate fits for each of the treatments.  
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Figure 7.9  Extrapolated progression-free survival: treatment as a covariate vs separate fit 
for RFC. 
 
Only one red curve is shown in Figure 7.9 for the exponential distribution 
because both types of model produced identical fits. The curves from the two 
types of log-logistic model were indistinguishable by eye, and therefore again 
only one orange curve is evident.  The two types of model for the log normal, 
Weibull and Gompertz produced very similar fits. The generalised gamma was 
the only distribution for which there was a more marked difference: its separate 
fit for RFC was indistinguishable from the fit for the Gompertz with treatment as 
a covariate. 
Figure 7.10 displays only one curve for the exponential and log-logistic for the 
same reason as in Figure 7.9. 
The two fits for the Weibull and the separate generalised gamma fit for FC were 
indistinguishable. Furthermore, the two fits for the log-normal and Gompertz 
were very similar.  
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Figure 7.10  Extrapolated progression-free survival: treatment as a covariate vs separate fit 
for FC. 
 
Table 7.9 and Table 7.10 show, for RFC and FC respectively, the area under 
progression-free survival curves extrapolated to 15 years for each of the two 
types of fit for a given distribution.  
There was very little difference between the two types of fit for a given 
distribution, with the exception of log normal - which did not adequately 
represent the time horizon of 15 years anyway – and generalised gamma.  
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with treatment as a 
covariate in the model 
 
separate fit for RFC 
exponential 5.939 
 
5.939 
Weibull 4.590 
 
4.473 
Gompertz 3.701 
 
3.598 
log-logistic 5.706 
 
5.703 
log normal 6.322 
 
6.535 
generalised gamma 4.363 
 
3.689 
 
Table 7.9  Extrapolated progression-free survival AUCs from model with treatment as a 
covariate vs separate fit for RFC 
 
 
  
with treatment as a 
covariate in the model 
 
separate fit for FC 
exponential 3.978 
 
3.978 
Weibull 3.154 
 
3.196 
Gompertz 2.796 
 
2.845 
log-logistic 4.210 
 
4.214 
log normal 4.704 
 
4.560 
generalised gamma 3.023 
 
3.175 
 
Table 7.10   Extrapolated progression-free survival AUCs from model with treatment as a 
covariate vs separate fit for FC 
 
7.4.2 Overall survival 
The focus of the analysis then changed to overall survival, the other survival 
outcome involved in this illustration of partitioned survival. 
7.4.2.1 Assessment of fit over the observation period of the trial 
In a similar manner to the beginning of the previous sub-section that focused on 
progression-free survival, this sub-section focuses on a corresponding assessment 
of fit over the observed period of the trial for overall survival. As such, initially 
plots were created to visualise the data and to check for violations of the 
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proportional hazards assumption. Figure 7.11 shows the Kaplan-Meier estimates 
of overall survival, together with 95% confidence intervals, for the treatment 
groups RFC and FC.  
Figure 7.11  Kaplan-Meier estimates of overall survival for RFC and FC 
 
The lines were roughly parallel in the first three years indicating no obvious 
violation of the proportional hazards assumption over this period. After three 
years there was more divergence as there was a greater drop in survival in the 
FC group. However there was a greater degree of uncertainty in the data over 
this period. 
A log-log plot including a dashed reference line with slope 1 can be seen in 
Figure 7.12. 
The lines were roughly parallel and appeared to have a slope of 1. This would 
suggest the underlying data follow an exponential distribution.  The lines did 
cross over for a short period – however this was not unexpected given the 
closeness of the lines. 
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Figure 7.12  Log-log plot of all-cause mortality (1-overall survival) 
 
Figure 7.13 shows a cumulative hazard plot. 
 
Figure 7.13  Cumulative hazard plot of all-cause mortality (1-overall survival) 
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The lines appeared roughly parallel (up until 3 years anyway, after which there 
was greater uncertainty in the estimates) suggestive of a constant hazard of 
dying.  Therefore the exponential was an appropriate distribution for initial 
consideration. Since there was nothing to suggest any severe violations of the 
proportional hazards assumption for treatment from Figures 7.11 - 7.13, it was 
worthwhile considering such models, and in particular the exponential. Again, 
assessment of the accelerated failure time models was carried out using the 
Cox-Snell residuals plot (page 173). 
Parametric regression models were then fitted over the whole observation 
period of the trial for each treatment using each of the standard distributions. 
As with the analysis presented previously for progression-free survival, models 
were fitted with treatment as a covariate, rather than fitting a separate model 
for each treatment. Figure 7.14(a) and (b) show, for RFC and FC respectively, 
the Kaplan-Meier estimate of survival with the 95% confidence interval and the 
predicted survival from each of the models. Please note, the y-axes of both 
Figures do not reach zero for clarity. 
Figure 7.14  Kaplan-Meier and prediction estimates of overall survival: (a) RFC (b) FC  
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Figure 7.14(a) and (b) show that the fits from each of the six distributions were 
very similar up to 2.5 years, after which there was some divergence. However, 
In this latter period there was greater uncertainty in the data over this period, 
especially for FC. 
The Cox-Snell residuals following each of the model fits are presented in Figure 
7.15. 
 
Figure 7.15 Cox-Snell residuals following the parametric regression of overall survival 
 
 
Again, it demonstrated the fits were, until divergence in the later period, all 
reasonable as well as being very similar. 
Table 7.11 shows the AICs from each of the model fits.  
It suggested that the exponential provided the best fit of the distributions 
considered as it had the lowest AIC value. 
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Distribution AIC 
exponential 756.940 
Weibull  758.936 
Gompertz 758.939 
log-logistic 758.978 
log normal 759.930 
generalised gamma 760.812 
 
Table 7.11  AICs from parametric regressions models for overall survival 
   
7.4.2.2 Extrapolation of overall survival 
The assessment of fit then moved on to considering the unobserved 
extrapolation period from 4 years to the time horizon of 15 years. The 
conventional approach to extrapolation of fitting parametric regressions using 
standard distributions to the whole Kaplan-Meier curve, and then extending the 
fit out to the desired time horizon was considered initially. Extrapolations that 
represented zero by 15 years were considered reasonable. As with the 
assessment of the observed fit presently previously, the models had treatment 
as a covariate rather than fitting separate models for each treatment.  
Figure 7.16 (a) and (b) show, for RFC and FC respectively, the predicted overall 
survival from each of the models, together with the corresponding observed 
Kaplan-Meier estimate. It can be seen that each of the models were far from 
producing overall survival of zero at 15 years. 
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Figure 7.16   Extrapolated overall survival to 15 years: (a) RFC (b) FC 
 
 
Therefore focus changed to starting the extrapolation from the tail of the 
Kaplan-Meier curve. Each of the observed time points were considered in turn as 
the starting point for extrapolation. Weibull models were fitted following the 
approach of Tappenden et al. (2006) mentioned previously in section 6.5.  
Each of the treatment groups were considered separately.  
Exponential models were considered but were not fitted. This was due to the 
intercept in the linear regression acting as a nuisance parameter that caused 
problems in transforming the fitted line to an exponential survival function. 
Gompertz models were also considered using the approach of Tappenden et al. 
(2006) but an assumption of these models, namely that the logarithm of the 
hazard was linear with time, was not met and therefore they were not fitted to 
the data. Tappenden et al. (2006)’s article did not include corresponding details 
for the accelerated failure time framework and were not derived for this thesis. 
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Extrapolation from the tail of the overall survival Kaplan-Meier curve: FC 
Table 7.12 and Figure 7.17 summarise the results of fitting Weibull extrapolation 
models for FC, showing the results based on a wide range of starting points for 
extrapolation – those closest to 0, 0.5, 1, 1.5, 2, 2.5, 3 and 3.5 years & the one 
that best represented a time horizon of 15 years, namely a starting point of 
3.663 years.  
Starting point of 
extrapolation (years) 
n at risk at starting 
point of extrapolation 
survival at 15 years 
0 409 36.9% 
0.498 372 42.4% 
0.999 351 40.2% 
1.487 319 39.2% 
1.996 201 32.5% 
2.489 120 10.6% 
2.773 95 4.7% 
2.995 73 11.0% 
3.491 32 2.0% 
3.663 23 0.3% 
Table 7.12   Extrapolation of overall survival for FC using Weibull models 
                     - Summary using a selection of starting points 
 
Figure 7.17    Extrapolation of overall survival for FC using Weibull models 
                   - Summary using a selection of starting points 
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Starting time points in the ranges 2.727 – 2.828 and 3.455 - 3.762 years achieved 
survival of less than 5% upon extrapolation to 15 years. While there was less 
uncertainty in the Kaplan-Meier estimate in the time points over the range 
2.727 – 2.828, the survival they achieved was as high as 4.7% at best upon 
extrapolation to 15 years.  
However, time points over the range 3.455 - 3.762 provided better 
representation of the time horizon, with the smallest survival estimate at 15 
years being 0.3% when the extrapolation started at 3.663 years. Therefore, a 
Weibull fit to the Kaplan-Meier tail beginning at 3.663 years was the basis for 
the extrapolated section of the base case model of overall survival for FC. 
Extrapolation from the tail of the overall survival Kaplan-Meier curve: RFC 
Table 7.13 and Figure 7.18 summarise the results of fitting Weibull models for 
RFC.  
Starting point of 
extrapolation 
(years) 
n at risk at 
starting point of 
extrapolation survival at 15 years  
0 408 52.2% 
0.479 389 56.6% 
0.983 375 61.3% 
1.495 356 63.9% 
1.993 240 66.7% 
2.486 147 70.0% 
2.998 85 70.2% 
3.493 44 85.4% 
3.973 10 85.4% 
 
Table 7.13   Extrapolation of overall survival for RFC using Weibull  
                  models - Summary using a selection of starting points 
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Figure 7.18  Extrapolation of overall survival for RFC using Weibull models  
                  - Summary using a selection of starting points 
 
It can be seen that none of the models provided any fits that came anywhere 
close to reaching zero at 15 years, and that there was no improvement on the 
original fit to the whole Kaplan curve (i.e. the red line representing the 
extrapolation that started at 0 years) with any of the distributions. 
Since neither a parametric fit to the whole – or a tail of any length of the – 
Kaplan-Meier curve adequately represented survival of zero upon extrapolation 
to 15 years, it was decided to derive the extrapolated survival probabilities for 
RFC by applying a hazard ratio to the survival probabilities already predicted for 
FC. 
As a starting point, the hazard ratio of 0.753 from the exponential model over 
the observed period (the model found to be the most reasonable fit to the 
observed data) was applied to the extrapolated survival probabilities already 
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predicted for FC. Figure 7.19 shows the predicted overall survival for both RFC 
and FC. Using a hazard ratio of 0.753 resulted in a reasonable representation of 
the time horizon with survival of 1.4% at 15 years for RFC.   
 
Figure 7.19 Overall survival to 15 years for RFC and FC 
 
7.4.2.3 Base-case models used for overall survival 
Table 7.14 shows a summary of the models used for overall survival. 
  parameter  
exponential fit over observed period (0 - 3.663 years) 
lambdaFC 0.064 
lambdaRFC 0.048 
  Weibull fit used for extrapolation (3.663 - 15 years) 
gamma 2.257 
lambdaFC 0.013 
 
Table 7.14   Base case models for overall survival 
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An exponential regression with treatment as a covariate was used for predictions 
over the observed period of 0-3.663 years. Therefore, the predictions for both 
treatment arms were derived using the same model. 
Over the extrapolated period, a Weibull fit was derived for the FC arm, using the 
aforementioned approach of Tappenden et al. (2006) based on linear regression. 
The extrapolation for the RFC arm was derived by applying a hazard ratio of 
0.753 to the extrapolated survival probabilities for the FC arm. 
7.4.2.4 Selected sensitivity analyses 
Sensitivity analyses were carried out to check there were no substantive 
differences between the model fits with treatment as a covariate and separate 
fits for each of the treatments. Only the fit over the observed period of the trial 
was considered. Such a sensitivity analysis over the extrapolated period was not 
required because the base-case extrapolation was already based on separate fits 
for each treatment.  
The results of the aforementioned sensitivity analyses are shown in Figure 7.20 
(RFC) and  Figure 7.21 (FC). Please note, the y-axes of both Figures do not reach 
zero for clarity. 
Figure 7.20  Predicted overall survival: treatment as a covariate vs separate fit for RFC. 
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The exponential, log-logistic, Weibull, generalised gamma and Gompertz curves 
in Figure 7.20 from the two types of model were very similar to the extent they 
were difficult to distinguish by eye.  The two types of model using the log 
normal distribution also produced very similar fits. 
Figure 7.21   Predicted overall survival: treatment as a covariate vs separate fit for FC. 
 
As in Figure 7.20, it was difficult to distinguish between the exponential, log-
logistic, Weibull, generalised gamma and Gompertz curves from the two types of 
model (Figure 7.21). The two fits using the log-normal distribution were again 
very similar. 
 
Table 7.15 and Table 7.16 show, for RFC and FC respectively, the area under the 
overall survival curves for each of the two types of fits for each distribution. 
There was very little difference between the two types of fit. 
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Table 7.15   Overall survival AUCs from model with treatment as a covariate vs separate fit 
for RFC 
  
with treatment as a 
covariate in the model 
 
separate fit for 
each treatment 
exponential 3.631 
 
3.631 
Weibull 3.634 
 
3.625 
Gompertz 3.633 
 
3.618 
log-logistic 3.617 
 
3.607 
log normal 3.550 
 
3.541 
generalised gamma 3.607 
 
3.607 
 
 
 
Table 7.16  Overall survival AUCs from model with treatment as a covariate vs separate fit 
for FC 
 
  
with treatment as a 
covariate in the model 
 
separate fit for 
each treatment 
exponential 3.037 
 
3.037 
Weibull 3.041 
 
3.052 
Gompertz 3.039 
 
3.056 
log-logistic 3.007 
 
3.019 
log normal 2.912 
 
2.926 
generalised gamma 2.995 
 
2.985 
 
 
 
7.4.3 Compatibility of fits for progression-free and overall 
survival 
While carrying out the partitioned survival approach, each of the health states 
that overall survival was partitioned into were modelled separately. Figure 
7.22(a) and (b) show the resulting base case progression-free survival curve and 
overall survival curve (section 7.4.1 and 7.4.2) for FC and RFC respectively.  
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Figure 7.22  Base case partitioned survival for (a) FC  and (b) RFC   
 
They provide a visual check that each of the fits were compatible, which may 
not always be the case because they were modelled separately. It can be seen 
that the fits were compatible for each of the treatment arms, in the sense that 
overall survival was greater than or equal to progression-free survival throughout 
the 15 years.   
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7.4.3.1 Sensitivity analysis for treatment effect in extrapolated period 
A sensitivity analysis was then carried out, reducing the treatment effect upon 
extrapolation (Table 7.17). There was a slight improvement in the 
representation of the whole lifetime upon reduction of the treatment effect, in 
the sense of overall survival reaching zero. However, none of the reductions 
provided a sensible extrapolation to 15 years, with regards to the compatibility 
specified above, as they all resulted in survival at 15 years which was less than 
the 1.2% survival for progression-free survival.   
hazard ratio overall survival at 15 years 
0.753 1.4% 
0.8 1.1% 
0.85 0.8% 
0.9 0.6% 
0.95 0.5% 
 
Table 7.17  Effect of reducing the treatment effect on extrapolated overall survival to 15 
years for RFC. 
 
It was not thought appropriate to consider increasing the treatment effect upon 
extrapolation.  
7.5 Multi-state modelling 
7.5.1 Introduction 
This section presents analysis of the health economics case study using the 
multi-state modelling approach. It was the second approach considered as an 
alternative to the manufacturer’s economic model, and the main focus of the 
research in this thesis. It shares many similarities with the original 
manufacturer’s economic modelling due to them both being state-transition 
modelling approaches. The structure of the model is the same in the sense the 
health states and the transitions between them that are modelled are identical. 
However, there are also some important differences. In particular, in this 
illustration of multi-state modelling each of the transitions between states were 
based on regression modelling using the individual patient level trial data. This 
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use of multi-state modelling as an alternative approach was motivated by the 
ERG’s concern with the original manufacturer’s model that the overall survival 
gain it demonstrated was not seen empirically.  
This section, and those that follow, will demonstrate that anything that can be 
produced using conventional Markov-decision analytic modelling can just as 
easily be performed using multi-state modelling. The implementation of multi-
state modelling for cost-effectiveness in R is described elsewhere in one of my 
accompanying publications to this chapter (Williams et al., 2017a). This paper 
also outlines the advantages of using a syntax-based approach with statistical 
software instead of the spreadsheet-based approaches that are more commonly 
employed for state-transition modelling.  
In sub-section 7.5.2, just as with the partitioned survival demonstrated in the 
previous section, the appropriateness of the proportional hazards assumption 
was considered before building any models. Then, whether the Markov property 
held was investigated in sub-section 7.5.3. Next, the distribution to use for each 
of the transitions was explored in sub-section 7.5.4. Following on from this, in 
sub-section 7.5.5, the model used for the base-case analysis is summarised.  
7.5.2 Consideration of the appropriateness of the 
proportional hazards assumption 
This section assesses, prior to carrying out any modelling, the suitability of the 
proportional hazards assumption. In Figure 7.23(a), (b) and (c) a log-log plot for 
treatment is shown for each of the respective transitions. A log-log plot is also 
shown for time in previous state for the progression  death transition (Figure 
7.23(d)). This was because this covariate was to be included in this transition in 
the modelling carried out in the next section, section 7.5.3. For Figure 7.23(d), 
the median time progression-free in those who experienced death after 
progression was used as a cut-off to provide two groups that were balanced in 
terms of the number of events. 
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Figure 7.23  Log-log plots for the transitions in the multi-state model 
 
It can be seen from Figure 7.23 (a), (b) and (c) that the lines in the treatment 
plots for each transition were roughly parallel, with any crossing of the lines due 
to the lack of a treatment effect rather than any major violation of the 
proportional hazards assumption. Figure 7.23(d) showed lines that were again 
roughly parallel for time in the previous state for progression  death, with no 
suggestion of any major violation of the proportional hazards assumption.   
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Figure 7.24 shows cumulative hazard versus time plots for treatment for each of 
the transitions. Again, a corresponding plot is also shown for time in the previous 
state for the progression  death transition. 
 
Figure 7.24  Cumulative hazard versus time plots for the transitions in the multi-state model 
 
In Figure 7.24 (a), (b) and (d) the lines diverged suggesting that it would be 
worthwhile considering a distribution that allows increasing hazards over time.  
Figure 7.24 (c) was indicative of the lack of a treatment effect rather than any 
major violation of the proportional hazards assumption.  
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7.5.3 Deciding on the appropriateness of the Markov 
property 
To help decide whether the Markov property held, a Cox Markov state-arrival 
extended model for progression  death was initially fitted. Table 7.18 shows 
the results of fitting this model.  
 
 hazard ratio (95% CI) p-value 
treatment (RFC vs FC) 1.555 (0.874, 2.766) 0.133 
time spent progression-free 0.413 (0.215, 0.794) 0.008 
 
Table 7.18  Results of a Cox Markov state-arrival extended model for  
progression  death 
 
As previously mentioned in Williams et al. (2017a), the time spent progression-
free was found to have a statistically significant association with death after 
progression (p-value = 0.008). The hazard ratio point estimate and 95% 
confidence interval were below one, indicating that the longer the time spent 
progression-free, the lower the risk of death after reaching the progression 
state. For each increase of one year in the progression-free state the hazard of 
death reduced by 58.7%. The point estimate of 58.7% equates to, for those in 
the FC treatment arm who spent one year in the progression-free state, an 
absolute risk of death of 72.9% 4 years after reaching the progression state. The 
corresponding figure for those in the FC arm who spend two years in the 
progression-free state was 41.7%. The equivalent figures for the RFC arm were 
86.9% and 56.8%. The effect of time in the previous state was of a size likely to 
be of practical importance, both in relative and absolute terms. Therefore there 
was evidence to suggest the Markov property did not hold, indicating that a 
semi-Markov model was more appropriate than a Markov approach.  
7.5.4 Choice of distribution for each transition 
This section assesses the fit to each of the states and relevant transitions using 
six standard distributions with a semi-Markov multi-state modelling approach. In 
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a similar manner to the partitioned survival approach presented earlier in this 
chapter, fits were assessed over both the observed period of the trial and the 
period of extrapolation.  Also, similar to the previous analyses, models with 
treatment as a covariate were used rather than models for each treatment 
separately. This was thought appropriate due to the lack of any severe violation 
of the proportional hazards assumption presenting in section 7.5.2. 
For each of the transitions in the multi-state model, the fit over the observed 
period of the trial and that over the extrapolated period were considered 
separately. 
7.5.4.1 Progression   death 
The fit to the progression  death transition was considered initially as this was 
the simplest transition to assess in the sense that the observed data could be 
expressed as a (standard) Kaplan-Meier survival curve.  
Assessment of fit over the observed period 
Figure 7.25 (a) and (b) show, for RFC and FC respectively over the observed 
period of the trial, the cumulative incidence (1-Kaplan-Meier) estimate of death 
after progression, its 95% confidence interval (CI) and estimates predicted by 
parametric survival regressions using standard distributions. 
It can be seen from Figure 7.25 (a) and (b) that there was little to choose 
between the distributions for either RFC or FC, especially as they only started to 
diverge at the tail of the cumulative incidence curve where there was the most 
uncertainty. 
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Figure 7.25  Progression  death for over trial observation period: (a) RFC and (b) FC  
 
Figure 7.26 on the next page displays the Cox-Snell residuals following each of 
the model fits. 
There was very little to choose between the distributions in terms of the Cox-
Snell residuals. 
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Figure 7.26  Progression  death : Cox-Snell residuals 
 
Table 7.19 shows the AICs from each of the model fits.  
 
 
  AIC 
Weibull 240.2 
exponential 239.0 
Gompertz 240.5 
log-logistic 240.8 
log normal 243.1 
generalised gamma 242.2 
 
Table 7.19  AICs from parametric regression models for progression -> death 
 
It suggests the exponential provided the best fit over the observed period of the 
trial as it had the lowest AIC value, although there was little to choose between 
the distributions. 
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Assessment of fit over the period of extrapolation 
The assessment of fit then moved on to considering the unobserved 
extrapolation period from 4 years to the time horizon of 15 years. The 
conventional approach to extrapolation of fitting parametric regressions using 
standard distributions and then extending the fit out to the desired time horizon 
was used. Extrapolations that represented zero by 15 years were considered 
reasonable. As with the assessment of the observed fit presently previously, the 
models had treatment as a covariate rather than fitting separate models for 
each treatment.  
Figure 7.27 (a) and (b) show, for RFC and FC respectively, the cumulative 
incidence (1-Kaplan-Meier) estimate of death after progression and that 
predicted by parametric survival regressions using standard distributions with 
extrapolation to 15 years.  
  
Figure 7.27  Progression death extrapolated to 15 years: (a) RFC and (b) FC 
 
The Gompertz, generalised gamma and Weibull distributions each provided the 
required extrapolation by 15 years for both treatment arms. The exponential 
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distribution also provided a sensible extrapolation for the RFC arm. Given that 
this plot was based on death since progression, rather than from the start of the 
study, the Gompertz fits were probably most plausible. That was because 
everyone seemed to have died by 10 years, rather than taking the whole time 
horizon of 15 years to do so, thereby still leaving some time to be attributed to 
the time they would spent progression-free before reaching progression. 
Choice of base-case model 
Consequently, for the base-case analysis of the progression  death transition, 
the Gompertz distribution was chosen as it seemed to provide the best balance 
between the observed data and extrapolation to 15 years. 
7.5.4.2 Progression-free   progression 
The second transition for which the fit was assessed was progression-free  
progression. This was carried out by examining the fit for the probability of 
being in the progression state at any given time. However this state was an 
intermediate state and as such had flow in (progression-free  progression) and 
out (progression  death) of it. To focus on comparing distributions for the 
transition progression-free  progression specifically, a Gompertz fit was used 
for progression  death throughout. Other parametric distributions for 
progression  death were considered in the sensitivity analyses in section 7.7.1.  
The fit over the observed period of the trial and that over the extrapolated 
period were considered separately.  
Assessment of fit over the observation period of the trial 
In Figure 7.28 (a) and (b) the probability of being in progression at any given 
time over the observed period of the trial can be seen for RFC and FC 
respectively. The coloured lines each show a different distribution fitted to the 
progression-free  progression transition. Furthermore, each of the different 
shades of a colour show when a different distribution was used for progression-
free  death. Therefore, given that 6 distributions were used for each 
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transition, each line in a particular shade of a particular colour represents one 
of the 36 possible ways of using the distributions for modelling the transitions. 
 
Figure 7.28  Probability of progression over trial observation period for (a) RFC and (b) FC    
    Different distributions for progression-free progression are distinguished by colour    
    Shades of each colour represent a different distribution used for progression-free  death 
 
Each of the different shades of a particular colour gave similar fits. Therefore 
the fit to progression-free  progression did not seem to be affected by the 
distribution used for progression-free  death.  
Figure 7.28(a) indicates that, over the observed period of the trial, the 
Gompertz fit for progression-free  progression provided the best fit for the 
probability of progression for the RFC treatment arm. It can be seen in Figure 
7.28(b) that a reasonable fit for the probability of progression for the FC arm 
was achieved when the Gompertz, generalised gamma and Weibull distributions 
were used for progression-free  progression. 
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Assessment of fit over the extrapolated period 
 
Figure 7.29  Probability of progression extrapolated to 15 years: (a) RFC and (b) FC          
    Different distributions for progression-free progression are distinguished by colour    
    Shades of each colour represent a different distribution used for progression-free  death 
 
Figure 7.29 (a) and (b) indicate the Gompertz fit for progression-free  
progression provided the most reasonable extrapolation for each treatment arm. 
It can be seen in Figure 7.29 (b) that the fit for FC was also reasonable upon 
extrapolation with the Weibull and generalised gamma models. 
Choice of base-case model 
For the base-case analysis of the progression-free  progression transition, the 
Gompertz distribution was chosen as it seemed to provide the best balance 
between the fit to the observed data and the extrapolation to 15 years. 
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7.5.4.3 Progression-free  death (without progression) 
The third and final transition that was assessed was progression-free  death. 
To focus on comparing the fits of different distributions for this transition 
specifically, the progression  death and progression-free  progression 
transitions were fitted using a Gompertz distribution throughout. Alternative fits 
for each of the transitions are considered in the sensitivity analysis presented in 
section 7.7.1. 
Figure 7.30 (a) and (b) show, for RFC and FC respectively over the observed 
period of the trial, the competing risks (CR) cumulative incidence estimate of 
progression-free  death and that predicted by parametric survival regressions 
using standard distributions. It can be seen in Figure 7.30 (a) the generalised 
gamma fit probably provided the best fit over the observed period for RFC, 
although the Gompertz provided a very similar fit over the first 2 years. Figure 
7.30 (b) shows the Gompertz and log normal fits seemed to be the most suitable 
over the observed period for FC. 
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Figure 7.30  Progression-free  death without progression over the trial observation period: 
                  Gompertz used for progression  death and progression-free  progression 
                  abbreviation used: CR=competing risks 
 
Figure 7.31 shows the same information as Figure 7.30, only this time the 
estimates have been extrapolated to 15 years.  
Figure 7.31 (a) and (b) show that the fits over the extrapolated period all 
seemed to be flat. Whilst this does not seem very realistic, indicating that the 
vast majority of patients had reached progression and possibly died after 
progression over the period, the generalised gamma and Gompertz were 
probably the best fit of all the distributions considered for RFC as they also 
provided the best fits over the observed period. Similarly, the Gompertz and log 
normal fits probably provided the best extrapolations for FC. Taking all this into 
account, the Gompertz was chosen for the base-case analysis for progression-
free  death with progression, with alternative distributions considered in the 
sensitivity analysis in section 7.7.1. 
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Figure 7.31   Progression-free  death without progression extrapolated to 15 years 
(a) RFC (b) FC 
Gompertz used for progression  death and progression-free  progression 
abbreviation used: CR=competing risks 
 
 
7.5.5 Summary of base-case model for each transition 
Table 7.20 shows, for each transition, a summary of the Gompertz models used 
for the base case analysis. 
Alternative distributions for each transition are considered in the sensitivity 
analysis presented in section 7.7.1. 
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  coefficient s.e.  HR (95% CI) p-value 
progression-free  
progression 
  
 
 treatment (RFC vs FC) -0.558 0.128 0.572 (0.446, 0.735) <0.001 
constant -2.187 0.130  
 
gamma 0.474 0.068  
 
   
 
 
progression-free   death 
  
 
 
treatment (RFC vs FC) -0.343 0.294 0.710 (0.399, 1.262) 0.243 
constant -2.825 0.265  
 
gamma -0.487 0.207  
 
   
 
 
progression   death 
  
 
 
treatment (RFC vs FC) 0.342 0.285 1.408 (0.806, 2.461) 0.229 
constant -1.627 0.267  
 
gamma 0.174 0.244  
 
 
Table 7.20  Base case models (all Gompertz) for the three transitions using the multi-state   
                  modelling approach 
 
7.6 Comparison of the three approaches 
In this section the results using the Markov decision-analytic model, partitioned 
survival and multi-state modelling are compared. It is based largely on a 
previous version of a similar comparison that was presented in Williams et al. 
(2017b).  
Firstly, sub-section 7.6.1 visually assesses the fits using each of the approaches.  
Secondly, the survival estimates in terms of mean Life Years and QALYs are 
compared (sub-section 7.6.2). Thirdly, the costs used in each approach are 
described in sub-section 7.6.3. Finally, sub-section 7.6.4 summarises and 
compares the incremental cost-effectiveness ratios.  
7.6.1 Visual assessment of the fits 
In this sub-section each of the modelling approaches are compared by informally 
visually assessing the fits. The assessment was based on a balance of achieving a 
good fit to the observed data and extrapolation that represented a lifetime since 
entry into the trial of 15 years.  
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7.6.1.1 progression-free state 
Figure 7.32 shows the predictions of being in the progression-free state using 
each of the approaches.   
 
Figure 7.32 Probability of being in the progression-free state using each approach 
 
The partitioned survival approach and the Markov decision-analytic modelling 
were based on the same fit to progression-free survival. For both treatment 
arms, each of the three approaches appeared to be well-fitting to the Kaplan-
Meier estimate. However, the extrapolation using the multi-state modelling 
approach reached zero somewhat earlier than the other approaches. This seems 
plausible as it allows those patients who reach the progression state to spend 
some time there before reaching the end of their lives. 
7.6.1.2 progression state 
Figure 7.33 (a) and (b) show, for the RFC and FC arm respectively, the 
predictions of being in the progression state with each of the approaches. 
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Figure 7.33  Probability of being in the progression state using each approach 
                 (a) RFC (b) FC 
 
The vertical solid lines on Figure 7.33 (a) and (b) are positioned where there 
were less than 20 patients at risk of death after progression, an indication of 
more uncertainty in the observed proportion estimates. They therefore provide a 
dividing line between the periods of observation and extrapolation. To further 
emphasise the uncertainty, the shaded areas show the 95% confidence intervals 
for the observed proportions. They were created using 5000 bootstrapped 
samples. 
For the RFC arm, the fit to the observed data was good from all approaches up 
until the vertical line (Figure 7.33 (a)). Subsequently however, there was a 
marked difference between the approaches in where and when the predictions 
of being in progression peaked. Furthermore, the partitioned survival approach 
and the multi-state modelling were the only methods to reach zero by 15 years. 
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For the FC arm, the fit to the observed data from the partitioned survival 
approach and multi-state modelling was good fit up until the vertical line (Figure 
7.33 (b)). However, this could only be said of the Markov decision-analytic 
modelling up to 2.3 years. Again, there was a marked difference between the 
approaches in the peaks. Furthermore, all approaches reached zero by 15 years 
as required. 
7.6.1.3 death state 
 
Figure 7.34 (a) and (b) show the Kaplan-Meier estimates of being in the death 
state, together with the predictions from each of the modelling approaches, for 
the RFC and FC arms respectively.   
 
Figure 7.34   Probability of being in the death state using each approach 
                     (a) RFC (b) FC 
 
The multi-state modelling and partitioned survival approach fitted the observed 
data over the first 4 years reasonably well. However, the Markov decision-
analytic modelling underestimated death over the first 2 years. All approaches 
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reached a probability of one by 15 years for FC (Figure 7.34 (b)). However the 
multi-state modelling was the only approach to do so for RFC (Figure 7.34 (a)). 
7.6.1.4 death without progression 
Figure 7.35 shows, for each treatment arm, the competing risk cumulative 
incidence estimate of death without progression together with the predictions 
from the multi-state modelling.  
 
Figure 7.35   death without progression 
 
It can be seen that the multi-state modelling fitted the observed data fairly 
well. These predictions were possible because the multi-state modelling allowed 
the state occupancy probabilities of death to be split into death without 
progression and death after progression. An equivalent Figure from the Markov 
decision-analytic model was not available.  
Furthermore, the partitioned survival approach did not model death without 
progression. 
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7.6.1.5 death after progression 
Figure 7.36 shows, for each treatment arm, the Kaplan-Meier estimate of  
death once in the progression state, together with the predictions from the 
multi-state modelling and the manufacturer’s assumption. 
 
Figure 7.36  post-progression death 
 
Each of the predictions from the multi-state modelling were close to their 
corresponding Kaplan-Meier estimate. It can be seen that the extrapolation for 
both methods was fairly good at reaching one by 15 years. However, the 
manufacturer’s assumption was less well-fitting to each of the treatment arms.  
The partitioned survival approach did not model death after reaching the 
progression state. 
7.6.2 Mean Life Years/QALYs 
Table 7.21 shows the mean Life Years and QALYs results for each relevant health 
state using each of the three approaches.  Mean QALYs were calculated by 
assuming a utility of 0.8 for the time spent progression-free and 0.6 for the time 
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spent in progression, the approach used by the manufacturer in the Markov 
decision-analytic model. All of the information in the table was discounted at 
3.5%.   
 
Markov decision –
analytic modelling Partitioned survival Multi-state modelling 
  RFC FC  
Incre-
mental RFC FC  
Incre-
mental RFC FC  
Incre-
mental 
Mean Life Years 5.73 4.65 1.07 5.96 5.31 0.65 5.24 4.96 0.28 
Mean Life Years 
Progression-free 
4.11 2.93 1.18 4.10 2.92 1.18 3.35 2.55 0.81 
Mean Life Years in 
Progression 
1.62 1.73 -0.11 1.86 2.39 -0.53 1.89 2.42 -0.53 
          
Mean QALYs 4.26 3.38 0.88 4.40 3.77 0.63 3.82 3.49 0.33 
Mean QALYs Progression-
free 
3.29 2.34 0.94 3.28 2.34 0.95 2.68 2.04 0.65 
Mean QALYs in Progression 0.97 1.04 -0.07 1.11 1.43 -0.32 1.13 1.45 -0.32 
 
Table 7.21  Mean Life Years and QALYs results: all three approaches 
 
It can be seen in Table 7.21 that the mean Life Years/QALYs Progression-free 
results were similar for the partitioned survival and Markov decision-analytic 
modelling approaches, with the multi-state modelling having a smaller benefit.   
 
Furthermore, each approach found a decrement in mean Life Years/QALYs in 
Progression. The decrements were largest with the partitioned survival and 
multi-state modelling approaches with mean Life Years (QALYs) of -0.53 (-0.32). 
The corresponding decrement in mean Life Years (QALYs) of -0.11 (-0.07) with 
the Markov decision-analytic modelling was somewhat smaller. This was due to 
the assumption of no treatment effect used for the progression  death 
transition in that model.  
In terms of mean Life Years/QALYs overall, the largest benefit was seen with the 
Markov decision-analytic modelling due to the smallest decrement in time in 
progression with that approach. In contrast, the benefits were far smaller with 
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the multi-state modelling approach due to the combination of having the 
smallest benefit Progression-free and the largest decrement whilst in 
Progression. 
7.6.3  Description of the costs 
Table 7.22 shows a breakdown of the mean costs used with each of the three 
approaches.  Most of the mean costs were not related to the time spent in 
relevant health states. However, cost of supportive care whilst in PFS, cost of 
supportive care whilst in progression and cost of 2nd line and subsequent 
therapy whilst in progression were all associated with time spent in relevant 
states. Therefore, the mean life years in the appropriate states were used in the 
calculation of these costs.  All other costs were taken from the original 
manufacturer’s submission [Roche (2008), pp127-131]. 
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Markov decision-analytic 
modelling Partitioned survival Multi-state modelling 
 
RFC  FC Incremental RFC  FC Incremental RFC  FC Incremental 
Mean cost of PFS  18965 6891 12074 18963 6890 12074 18711 6764 11947 
Costs of Rituximab  10113 0 10113 10113 0 10113 10113 0 10113 
Administration costs of Rituximab  1224 0 1224 1224 0 1224 1224 0 1224 
Cost of Fludarabine  2776 2790 -14 2776 2790 -14 2776 2790 -14 
Administration costs of Fludarabine  1109 1115 -6 1109 1115 -6 1109 1115 -6 
Costs of Cyclophosphamide  21 22 0 21 22 0 21 22 0 
Administration costs of Cyclophosphamide  1109 1115 -6 1109 1115 -6 1109 1115 -6 
Cost of supportive care in PFS  1381 983 398 1379 982 397 1127 855 272 
Cost of Bone Marrow Transplantation  592 360 231 592 360 231 592 360 231 
Cost of Blood Transfusions  640 507 133 640 507 133 640 507 133 
Mean cost of Progression  6630 7088 -458 6406 8233 -1827 6450 8248 -1798 
Cost of supportive care in progression 1630 1742 -111 1873 2407 -534 1905 2436 -531 
Cost of 2nd line and subsequent therapy 5001 5344 -340 4533 5825 -1293 4546 5812 -1267 
Mean Total Cost 25595 13978 11617 25369 15122 10247 25161 15012 10149 
 
 
Table 7.22  Costs breakdown: all three approaches
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7.6.4 Incremental cost-effectiveness ratios with each 
approach 
Table 7.23 shows the incremental cost-effectiveness ratio that resulted with 
each approach. It can be seen in Table 7.23 that the partitioned survival and 
Markov decision-analytic modelling deemed the RFC treatment cost-effective. 
However when the multi-state modelling approach was used, the Cost per QALY 
gained was £30,702, in excess of the commonly used willingness to pay threshold 
of £20,000 - £30,000 per QALY gained. 
  
Markov decision-analytic 
modelling 
Partitioned survival Multi-state modelling 
 
RFC  FC 
Incre-
mental RFC  FC 
Incre-
mental RFC  FC 
Incre-
mental 
Mean Life 
Years 
5.73 4.65 1.07 5.96 5.31 0.65 5.24 4.96 0.28 
Mean QALYs 4.26 3.38 0.88 4.40 3.77 0.63 3.82 3.49 0.33 
Mean Total 
Cost 
£25,595 £13,978 £11,617 £25,369 £15,122 £10,247 £25,161 £15,012 £10,149 
Cost per Life 
Year Gained   
£10,825 
  
£15,696 
  
£36,049 
Cost per 
QALY gained 
    £13,189     £16,310     £30,702 
 
Table 7.23  Incremental cost effectiveness ratios: all three approaches 
 
To provide more insight into how the approaches compared, the mean Life 
Years/QALYs results in Table 7.23 were split into those over the observed period 
(Table 7.24) and those over the unobserved extrapolation period (Table 7.25). 
It can be seen in Table 7.24 that the approaches were reasonably comparable 
over the observed period of the trial. However, in the unobserved extrapolation 
period (Table 7.25) there was an increment in mean Life Years/QALYs gained 
while in progression with the Markov decision-analytic modelling. This was in 
contrast to the rest of the approaches which found decrements. 
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Markov decision –
analytic modelling Partitioned survival Multi-state modelling 
  
RFC FC 
Incre-
mental 
RFC FC 
Incre-
mental 
RFC FC 
Incre-
mental 
Mean Life Years 3.42 3.27 0.16 3.42 3.32 0.10 3.40 3.28 0.12 
Mean Life Years 
Progression-free 
2.85 2.44 0.41 2.85 2.42 0.43 2.86 2.37 0.49 
Mean Life Years in 
Progression 
0.57 0.82 -0.25 0.57 0.90 -0.33 0.53 0.91 -0.37 
          
Mean QALYs 2.62 2.45 0.18 2.62 2.48 0.15 2.61 2.44 0.17 
Mean QALYs Progression-
free 
2.28 1.95 0.33 2.28 1.94 0.34 2.29 1.90 0.39 
Mean QALYs in Progression 0.34 0.49 -0.15 0.34 0.54 -0.20 0.32 0.54 -0.22 
 
Table 7.24  Mean Life Years and QALYs: trial observation period of 0-4 years 
 
 
 
Markov decision–
analytic modelling Partitioned survival Multi-state modelling 
  
RFC FC 
Incre-
mental 
RFC FC 
Incre-
mental 
RFC FC 
Incre-
mental 
Mean Life Years 2.30 1.39 0.92 2.54 1.99 0.55 1.85 1.68 0.16 
Mean Life Years 
Progression-free 
1.26 0.48 0.78 1.26 0.50 0.75 0.49 0.17 0.32 
Mean Life Years in 
Progression 
1.05 0.90 0.14 1.29 1.49 -0.20 1.36 1.51 -0.15 
          
Mean QALYs 1.63 0.93 0.71 1.78 1.29 0.48 1.21 1.04 0.16 
Mean QALYs Progression-
free 
1.01 0.39 0.62 1.00 0.40 0.60 0.39 0.14 0.25 
Mean QALYs in Progression 0.63 0.54 0.08 0.77 0.89 -0.12 0.81 0.91 -0.09 
 
Table 7.25   Mean Life Years and QALYs: extrapolation over 4-15 years 
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7.7 Sensitivity analyses for the multi-state modelling  
approach 
In this section, results of sensitivity analyses are presented to check the 
robustness of the multi-state model from deviations from the base-case 
assumptions. Only sensitivity analyses for the multi-state modelling are 
considered, it being the main focus of this thesis. The section is based largely on 
the sensitivity analyses presented in Williams et al. (2017a). However, the data 
underlying the analyses were different. This was because the published tutorial 
paper was not based on the actual trial data but on data digitised from 
published curves.  
Three sub-sections of sensitivity analyses are shown. In sub-section 7.7.1 
alternative distributions for each of the transitions are considered. Sub-section 
7.7.2 explores other one-way sensitivity analyses and sub-section 7.7.3 presents 
the results of probabilistic sensitivity analyses. 
7.7.1 Using alternative distributions for each of the 
transitions in the multi-state modelling 
When building the multi-state models, six parametric distributions were 
considered for each of the three transitions resulting in 63 = 216 combinations of 
distributional fits to assess. Table A1 in the Appendix IX shows the results – in 
terms of incremental QALYs, incremental costs and Cost per QALYs gained – for 
each of these combinations. The results are shown sorted by Cost per QALYs 
gained, with the exception of the base case model which is shown first. 
It can be seen in Table A1 that the Cost per QALYs gained ranged from £11,393 
to £344,585. However, many of the combinations did not provide a reasonable 
fit to at least one transition for at least one treatment arm. When this was the 
case, the Cost per QALYs were shaded in grey. The scenario each particular 
shade represents are described in the remaining part of this section. In common 
with earlier sections of this chapter, fits were evaluated by considering both the 
observed fit to the data and whether a reasonable extrapolation of survival was 
achieved in terms of reaching zero by 15 years.  
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Figure 7.25 (a) and (b) on page 190 showed, for the RFC and FC treatment arms 
respectively, that there was little to choose between the distributions for 
progression  death over the observed period of the trial. However Figure 7.27 
(a) and (b) on page 192 showed that the log-logistic and log normal fits did not 
provide sensible extrapolations for either arm. Therefore the Costs per QALYs 
gained in Table A1 for each combination that used either a log-logistic or log 
normal distribution for progression  death were shaded in grey. 
Only the remaining four distributions were considered any further for 
progression  death. Figure 7.37, focusing on the RFC arm, shows the 
probability of being in the progression state at any given time, with  
progression   death fitted using (a) Gompertz, (b) exponential, (c) Weibull and 
(d) generalised gamma. 
Figure 7.38 shows the equivalent information for the FC arm. 
 
 
Figure 7.37 and Figure 7.38 show that fitting progression-free  progression 
using the Gompertz distribution provided the best fit for the probability of 
progression upon extrapolation, for the RFC and FC arm respectively, regardless 
of the distribution used for progression  death. Furthermore, the Gompertz 
was the only distribution that, when fitted to progression  death, resulted in 
an extrapolation to zero by 15 years for the probability of being in the 
progression state. When a Gompertz was used for progression  death, the 
Weibull and generalised gamma also provided sensible extrapolations for the 
probability of being in the progression state, but only for the FC arm. In 
addition, the distribution used for progression-free  death had very little 
influence on the fits, as indicated by the very similar curves for the different 
shades of a particular colour. 
Consequently, the Cost per QALYs gained in Table A1 for each combination that 
did not use a Gompertz for progression-free  progression or a Gompertz for 
progression  death - that was not already highlighted in grey – was highlighted 
in light grey. 
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Figure 7.37       Probability of progression for RFC: extrapolation to 15 years 
                   Progression  death fitted using: (a) Gompertz, (b) exponential (c) Weibull   
                   and (d) generalised gamma           
Different distributions for progression-free progression are distinguished by colour 
Shades of each colour represent a different distribution used for progression-free  death  
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Figure 7.38      Probability of progression for FC: extrapolation to 15 years 
                  Progression  death fitted using: (a) Gompertz, (b) exponential (c)      
                  Weibull and (d) generalised gamma                    
Different distributions for progression-free progression are distinguished by colour 
Shades of each colour represent a different distribution used for progression-free  death  
   
The only Costs per QALYs gained in Table A1 that were not highlighted either in 
grey or light grey were those that involved a Gompertz fit for progression-free  
progression and progression  death. For this scenario, the effect of the 
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distribution used to fit progression-free  death on the probability of being in 
the progression-free and progression states – the two states relevant for the 
calculation of the Cost per QALYs gained - was considered.       
Figure 7.39 shows the aforementioned effect on the probability of remaining in 
the progression-free state (a) over the observed period of the trial and (b) upon 
extrapolation to 15 years. Figure 7.39 (c) and (d) show the corresponding 
information for the effect on the probability of being in the progression state. 
Each of the coloured lines in the plots represent a different parametric 
distribution used to fit progression-free  death. 
It can be seen from each of the four plots in Figure 7.39 that reasonable 
(similar) fits for the probability of being in the aforementioned states were 
achieved regardless of the distribution used for progression-free  death. 
Because the non-highlighted Cost per QALYs gained in Table A1 could not be 
disregarded, in the sense they did not result from unreasonable fits for the 
transitions/states, the robustness of the fit for progression-free  death was 
considered as part of the one-way sensitivity analyses in the following sub-
section.  
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Figure 7.39    Effect of fit to progression-free  death on probability of being in the:  
(a) progression-free state over the observed period of the trial 
(b) progression-free state extrapolated to 15 years 
(c) progression state over the observed period of the trial 
(d) progression state extrapolated to 15 years 
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7.7.2 One-way sensitivity analyses in multi-state modelling 
In this sub-section results of one-way sensitivity analyses are presented in a 
tornado plot. The sensitivity analyses carried out are described below: 
1) To allow computation of the Gompertz cumulative hazards, the time points 
used in the base-case calculation (measured in years) were in 1/12 
increments until 7.5 years, followed by 1/144 increments until 12 years and 
then 1/600 to 15 years. The one-way sensitivity analyses included varying the 
number of time points. An increase, equivalent to using a shorter cycle 
length, was considered by using 1/144 increments between 7.5 and 11 years 
and then 1/600 to 15 years. Less time points were also considered by using 
1/12 increments up to 118/12 (9.83 years) followed by the same increments 
as the base-case analysis. 
2) In the base-case analysis it was assumed that the treatment effect observed 
during the trial persisted to the time horizon. Two sensitivity analyses are 
presented where the treatment effect no longer persists in the extrapolation 
period. Firstly, the probability in the extrapolation period for one treatment 
was calculated by applying a hazard ratio of 1 to the probability for the other 
treatment. Alternatively, the model used in the extrapolation period did not 
include treatment as a covariate. 
3) The previous sub-section found there were combinations of distributions that 
could not be disregarded due to a poor fit for a state or a transition. This was 
the case when Gompertz distributions were used for the progression-free  
progression and progression  death transitions. Therefore, the sensitivity 
analyses include varying the distribution used for progression-free  death 
when the other two transitions were fitted using Gompertz distributions.  
4) The base-case analysis had a 15-year time horizon. An analysis was carried 
out with a 20-year time horizon. 
5) The remaining sensitivity analyses were based on the one-way sensitivity 
analyses carried out by the manufacturer as part of their economic modelling          
[Roche (2008),p145] 
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Figure 7.40   Tornado plot: one-way sensitivity analyses 
 
Figure 7.40 shows that varying the utility conveyed the most uncertainty with an 
incremental cost-effectiveness ratio (ICER) £7768 higher and £8832 lower than 
the base-case, when the gap between the utilities for the health states 
narrowed and widened respectively. Furthermore, only seven of the eighteen 
one-way sensitivity analyses lead to decreases from the base-case ICER. In 
particular, only four of those led to ICERs that did not exceed the commonly 
used threshold of £30,000 per QALY gained.   
7.7.3 Probabilistic sensitivity analysis for multi-state 
modelling 
A probabilistic sensitivity analysis was carried out for clinical effectiveness 
resulting in state occupancy probabilities for each draw. In addition, each of the 
cost parameters were assumed to follow Beta Pert distribution in line with the 
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economic modelling carried out by the manufacturer. Table 7.26 shows the 
mean base-case estimates together with the ranges used to generate the 
distributions. The particular Beta Pert distribution chosen for the cost of 
monthly supportive care and 2nd line and subsequent therapy whilst in 
progression was dependent on the mean life years in progression. All other 
distribution parameters values were as presented by the manufacturer [Roche 
(2008), pp137-138]. 
Costs Base case Minimum Maximum 
Monthly supportive care cost whilst in PFS  £28 £14 £42 
Monthly supportive care and 2nd line and 
subsequent therapy cost whilst in 
progression  
£259.89 £129.94 £389.83  
Administration - Deliver exclusively Oral 
Chemotherapy  
£280 £174 £482 
Administration - Deliver complex 
Chemotherapy, including prolonged 
infusional treatment at first attendance  
£430 £210 £795 
Bone marrow transplant  £47,565.05 £34,318.25 £54,646.47 
Blood transfusion  £289.73 £173.84 £405.62 
1 Unit of blood  £161.11 £96.67 £225.26 
 
Table 7.26   Beta Pert distributions used in probabilistic sensitivity analysis for cost   
                    parameters 
In Figure 7.41 the cost-effectiveness plane can be seen. The probabilistic 
sensitivity analysis involved 1000 draws with 10% excluded due to computational 
difficulties. All draws resulted in the RFC treatment being more costly than FC, 
therefore only the NW and NE quadrants are shown.  
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Figure 7.41   Cost-effectiveness plane 
 
A cost-effectiveness acceptability curve is shown in Figure 7.42. 
Figure 7.42   Cost-effectiveness acceptability curve 
 
It can be seen in Figure 7.42 that, given the common range in the UK of a 
willingness to pay of £20,000 - £30,000 per QALY gained, RFC only had a 
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probability of 0.27-0.40 of being cost-effective. Even at a willingness to pay of 
£100,000 the probability that RFC was cost-effective compared to FC was only 
0.65. 
7.8 Direct comparison of the manufacturer’s Markov 
decision-analytic model with multi-state modelling 
In the analysis in this chapter up to now, different assumptions were used with 
regards to transition probabilities/hazards with each of the approaches. The 
purpose of this section is to show that multi-state modelling can produce 
equivalent results to Markov decision-analytic modelling, if the same 
assumptions are used for each approach. Much of this section is based on an 
appendix in one of my accompanying publications to this chapter (Williams et 
al., 2017b).  
In order to facilitate the direct comparison, the assumptions used for the 
transition probabilities in the manufacturer’s Markov decision-analytic modelling 
were converted to transition hazards for use with the multi-state modelling. For 
comparison purposes transition probabilities, rather than the transition hazards 
on which multi-state modelling is based, were also used.  However, the Markov 
decision-analytic modelling did not assign probabilities to the progression–free  
progression transition/progression state directly. Instead the probability for the 
progression state was derived from the probabilities for progression  death, 
progression-free  death and the probability of staying in the progression-free 
state. The transition hazards and probabilities for use with the multi-state 
modelling were obtained in a similar manner. 
Figure 7.43 shows the predictions of staying in the progression-free state for 
each of the treatment arms.  
It can be seen in Figure 7.43 that the predictions from each approach were very 
similar for both treatments.  
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Figure 7.43   Probability of staying in the progression-free state: equivalent assumptions 
 
Figure 7.44 (a) and (b) show the predictions of being in the progression state for 
RFC and FC respectively. 
 
It can be seen in Figure 7.44 (a) and (b) that the predictions from the 
manufacturer’s Markov decision-analytic modelling and the multi-state 
modelling using transition probabilities were similar. They had a higher peak 
than with the multi-state modelling using transition hazards. 
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Figure 7.44   Probability of being in the progression state: equivalent assumptions 
                  (a) RFC (b) FC 
 
In Figure 7.45 the predictions of being in the death state can be seen for RFC 
and FC.  
Figure 7.45 shows that the predictions from the manufacturer’s Markov decision-
analytic modelling and multi-state modelling using transition probabilities were 
reasonably comparable, with slightly higher predictions with the multi-state 
modelling using transition hazards. 
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Figure 7.45   Probability of being in the death state: equivalent assumptions 
 
 
Table 7.27 shows the incremental mean Life Years in each of the relevant health 
states using each of the approaches. Two methods of calculating the mean Life 
Years are shown. Firstly, the trapezoidal rule is used to calculate the area under 
the curve, the approach used throughout in this chapter for the multi-state 
modelling. Secondly, the probabilities at each time point were summed 
together, the approach used by the manufacturer in their Markov decision –
analytic model. The actual results presented by the manufacturer are shown in 
bold. 
It can be seen in Table 7.27 that the results for the incremental mean Life Years 
in Progression were not overly sensitive to the method used to calculate the 
means for any of the approaches. Furthermore, it can be seen that the results 
for the individual treatments from the multi-state modelling with transition 
probabilities were closer to that for the Markov decision-analytic model than the 
corresponding results using transition hazards. However, in terms of incremental  
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mean Life Years calculated using: 
  
area under the curve with 
trapezoidal rule 
sum of transition 
probabilities over time 
  RFC FC Incremental 
 
RFC FC Incremental 
Mean Life Years Progression-free        
multi-state modelling using transition 
hazards 
4.07 2.89 1.18 
 
4.11 2.93 1.18 
multi-state modelling using transition 
probabilities 
4.11 2.87 1.24 
 
4.15 2.92 1.24 
Markov decision modelling without a 
half-cycle correction 
4.10 2.92 1.18 
 
4.15 2.96 1.18 
Markov decision modelling with a half-
cycle correction 
4.07 2.88 1.18 
 
4.11 2.93 1.18 
 
       
 
       
Mean Life Years in Progression        
multi-state modelling using transition 
hazards 
1.45 1.58 -0.13 
 
1.45 1.58 -0.13 
multi-state modelling using transition 
probabilities 
1.58 1.73 -0.15 
 
1.59 1.73 -0.15 
Markov decision modelling without a 
half-cycle correction 
1.61 1.73 -0.11 
 
1.62 1.73 -0.11 
Markov decision modelling with a half-
cycle correction 
1.62 1.73 -0.11 
 
1.62 1.73 -0.11 
 
  
Table 7.27  Incremental mean Life Years in each health state: equivalent assumptions 
 
results, the transition hazards approach produced means that were nearer the 
Markov decision-analytic modelling results. This was because, whilst there was 
more discrepancy between the individual treatment means, the differences were 
comparable for each treatment resulting in a similar incremental effect. 
 
Table 7.27 also shows that the results for the incremental mean Life Years 
Progression-free were sensitive to the method used to calculate the means. 
Regardless of the method used, the multi-state modelling approach using 
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transition probabilities produced incremental results which were higher than any 
of the (similar) corresponding results from the other approaches. Furthermore, it 
can be seen that the transition hazards approach was most comparable to the 
actual Markov decision-analytic modelling when the summing of probabilities 
method was used. When the trapezoidal rule was used, the results using the 
multi-state modelling with transition hazards and the Markov decision-analytic 
modelling were similar. However it was the Markov decision-analytic modelling 
without the half-cycle correction that most represented the actual Markov 
decision-analytic modelling when the trapezoidal rule was used.  This suggests 
that using the trapezoidal rule for calculating the means (based on probabilities 
without a half-cycle correction) may be equivalent to the summing of 
probabilities for which there was a half-cycle correction.  
7.9 Summary of the results and Discussion 
This chapter demonstrated and compared three different approaches to 
estimating benefit (survival) for use in economic evaluations – Markov decision-
analytic modelling, partitioned survival and multi-state modelling. An existing 
Markov decision-analytic model created by a manufacturer in a submission to 
NICE for a technology appraisal acted as motivation for the comparison. The 
model, and the trial data that was the main source underlying it, acted as a case 
study with a health economics context for this thesis.  
The manufacturer’s Markov decision-analytic model found the treatment to be 
cost-effective with a Cost per QALY gained of £13,189. The mean Life Years 
(QALYs) gained in the model was 1.07 (0.88) for the treatment RFC compared to 
FC. However, the Evidence Review Group (ERG) who reviewed the submission 
thought that an overall survival benefit of such a magnitude was inappropriate 
(PenTAG, 2009). This was mainly because the manufacturer assumed no 
treatment effect while in progression, which meant most of the benefit was 
found whilst progression-free. The ERG initiated two sensitivity analyses that 
completely removed the overall survival benefit. These resulted in Costs per 
QALY gained of £30,336 and £30,304, just above a willingness-to-pay threshold 
of £30,000 per QALY gained. After further investigation as part of the research in 
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this thesis, these analyses were equivalent to hazard ratios of death after 
progression of 4.451 and 1.758. However when a Cox regression was fitted to the 
observed data the hazard ratio was 1.364, and therefore a discrepancy was 
apparent. This motivated the exploration of alternative approaches to analysis – 
namely partitioned survival and multi-state modelling. 
Unlike the Markov decision-analytic modelling and multi-state modelling that 
modelled transitions between all relevant health states, the partitioned survival 
approach was based on calculating area under the curves of survival outcomes in 
the trial. As such, progression  death was not modelled directly. It was instead 
derived from the area under the overall survival and progression-free survival 
curves, the outcomes in the trial. Parametric regressions were fitted to these 
curves to allow extrapolation. A Weibull regression fitted to progression-free 
survival observed over the trial period was extrapolated to 15 years. However 
this approach was not adequate for overall survival as there was no parametric 
fit that led to survival of zero upon extrapolation to 15 years. Therefore the 
predictions for overall survival were based on different fits during the observed 
and extrapolation periods. The partitioned survival approach resulted in a Cost 
per QALY gained of £16,308, and therefore deemed the treatment of interest 
cost-effective. 
With the multi-state modelling approach, the Markov property was formally 
tested by using a state arrival-extended model. This involved including a 
covariate for the time in the previous state when modelling progression  
death. Evidence of a violation of the Markov property was found and this led to 
modelling using a semi-Markov approach. It resulted in a Cost per QALY gained of 
£30,702. This exceeded the willingness-to-pay threshold of £30,000 per QALY 
gained and therefore the treatment was found not to be cost-effective. 
Therefore, a discrepancy in results was evident between the three approaches. 
An analysis was carried out using identical assumptions with the Markov decision-
analytic modelling and the multi-state modelling. This produced very similar 
results demonstrating that multi-state modelling can be used as an alternative to 
conventional Markov decision-analytic modelling. Furthermore, an accompanying 
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publication to this chapter provided a tutorial to encourage others to adopt the 
approach, with elegant implementation using the statistical software R rather 
than having to rely on spreadsheets (Williams et al., 2017a). The analysis with 
the identical assumptions confirmed that the disparity seen in the main analysis 
was due to the different assumptions used with the different approaches. 
Furthermore, the main analysis, where each approach used different 
assumptions, demonstrated that the approaches compared well over the 
observed period of the trial, with most of the discrepancy apparent in the 
extrapolated period. Consequently, the comparison highlighted that it is 
imperative to rigorously check any assumptions used to ensure they are realistic. 
It is these in particular that can influence clinical and cost-effectiveness results, 
much more than the approach used for the modelling itself.  
Liaising with clinicians and/or using external data sources such as registry data 
are recommended ways of gathering evidence to help ensure assumptions are 
realistic. In the comparison illustrated in this chapter, the main discrepancy in 
mean benefits gained overall stemmed from the differences between the 
approaches in mean Life Years gained whilst in progression. It could be seen in 
Figure 7.33 that this was primarily due to differences in the magnitude, and 
timing, of the peak for the probability of being in the progression state. 
Therefore, it would be worthwhile for any modellers faced with a similar 
situation to gather information to reduce uncertainty surrounding this peak and 
the predictions over time generally. 
With the Markov decision-analytic modelling, the probability for the progression-
free  death transition was based on the maximum of the observed death rate 
and an age-related background mortality rate in the general population. 
However, the progression-free  death transition had the competing risk of the 
progression-free  progression transition. Therefore, the observed death rate 
used to inform the transition may have been inflated if the competing risk was 
not taken into account, analogous to naïve Kaplan-Meier estimates. Hence, it 
would also be worthwhile checking that any inflation of the observed death rate 
while progression-free did not bias the predicted probability of  
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progression-free  progression and the related prediction over time of being in 
the progression  state.  
The extrapolation for progression-free  death appeared to be unrealistically 
flat as mortality would be expected to increase as patients aged. While it was 
not the case in this illustration, it may be worth investigating whether the 
extrapolations are sensitive to the order in which transitions are considered 
when choosing distributions. In this research, the plateau over the extrapolation 
period was most likely due to the relatively few pre-progression deaths, with the 
vast majority of patients having a progression and then having a post-progression 
death sometime before the end of the time horizon.  
In addition, it would be beneficial to verify that any assumption used for a 
treatment effect post-progression is clinically plausible. It would also be 
advantageous, for each transition, to use appropriate available information to 
help inform assumptions with regards to continuation of treatment effects in the 
extrapolation period. Finally, it is worth taking a common sense approach, in 
conjunction with clinical opinion and external data such as registry data, to 
decide on a time horizon and extrapolation to that point that is realistic in a 
clinical sense.  
The visual assessment of fits from each of the approaches suggested the 
partitioned survival approach provided the most reasonable fit. At first, this 
might appear a surprising result as one might expect an approach that models 
each of the transitions between health states of interest to provide the most 
sensible predictions. However in this example, partitioned survival was the only 
approach in which the regressions were fitted directly to the observed (Kaplan-
Meier) curves for the initial and absorbing states. In addition, the predictions for 
the intermediate state – the only other one that required prediction – were 
derived from the predictions for these two other (directly fitted) states. 
Therefore, partitioned survival would provide the best fit to the observed data. 
Furthermore, it was the only approach that had observed data (Kaplan-Meier 
curves) to check the fit to every transition/state.  
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It may be that a state-transition approach, such as Markov decision-analytic 
modelling or multi-state modelling, is only advantageous in more complicated 
models where more states/transitions are of interest. However, more complex 
models have the drawback of being more difficult to check against observed 
data. This is because more intermediate states will mean more states with flow 
in and out of them. A model with several of such states will be more difficult to 
check against observed data because this will not just involve Kaplan-Meier 
curves, but will have to take account of the fact that patients can enter such 
states but also subsequently leave them. That said, prior knowledge of, or 
relevant external data to inform, the expected shape of such curves should help. 
It is also worth noting that in the illustration in this research, when the situation 
arose that a survival outcome over the observed period did not reach zero upon 
extrapolation, it was reasonably straightforward to use separate fits for the 
observed and extrapolated periods with the partitioned survival approach. It 
would be more complicated to use a similar technique with a state-transition 
approach. This is because some of the transitions would be interlinked and 
therefore it would not just be survival outcomes in isolation that would need to 
be considered.  
An important consideration should be the number of covariates used in the 
modelling. In this illustration, treatment was the only covariate used in the 
modelling for each of the transitions. When data for other possible predictors 
and confounders are available from the trial/study, it would be worthwhile 
considering them in the modelling as they should result in more accurate 
predictions of the states/transitions of interest. However there can no longer be  
the same reliance on visual assessment of fits, by comparing observed data with 
model predictions, as they become impractical. That said, a  workaround might 
be comparing predictions from parametric regressions with those from a Cox 
regression as a surrogate for the observed data.  
Multi-state modelling has huge potential as an alternative elegant way of 
estimating transition probabilities in health economic modelling.  The multi-
state modelling approach uses the individual patient data directly to model the 
transitions and negates deciding on transition probabilities a priori. It uses the 
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exact times of transition and as such does not require modelling over (arbitrary) 
discrete cycles, nor does it require the use of tunnel states. Additionally, this 
particular multi-state modelling approach incorporates parametric distributions 
for hazards, which as well as allowing extrapolation of survival, can permit 
hazards that vary over time if required. Given the modelling at the individual 
patient level, multi-state modelling also provides an alternative to 
microsimulation (Davis et al., 2014). 
Using a statistical package to build multi-state models is less time consuming 
than building a model using a series of spreadsheets, the approach frequently 
used in Markov decision-analytic modelling.  The creation of a model in R, the 
calculation of the associated transition probabilities, the areas under the curves 
to obtain the mean life years/ QALYs and the discounting each only require one 
line of R code. The syntax-based approach of statistical software also means 
that it is easily reproducible. It is somewhat easier to understand and perform 
all the required modelling and other calculations when the syntax is all 
contained in one document rather than in a series of spreadsheets. The functions 
available in my published tutorial paper (Williams et al., 2017a) contain 
modifiable arguments that can be changed to suit the requirements of the user. 
This provides a valuable resource to health economic modellers as it overcomes 
the lack of available software that was a barrier to adopting the approach.  
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Chapter 8 Main insights, limitations and potential 
areas of future research 
8.1 Introduction 
The overall aim of this thesis was to explore the potential of competing risks 
analysis and multi-state modelling in an epidemiological and health economics 
context, in areas where they were not widely used. The thesis described the 
background to each of the methods. This included emphasising the importance 
of recognising a competing risks scenario when it exists, methodological issues 
that might need to be considered and the extra insight that can be gained from 
using each of the methods over standard survival analysis. The research was 
centred around two different case studies – one in epidemiology and one in 
health economics. The epidemiological one focused on stroke and the specific 
outcomes recurrence and death. The health economics case study was motivated 
by the economic model included in a technical appraisal submitted to NICE. This 
evaluated the cost-effectiveness of a chemotherapy regime for the first-line 
treatment of chronic lymphocytic leukaemia.  
The background chapters also included reviews of the extent of use of 
competing risks (section 2.10.2) and multi-state modelling (section 4.7) in stroke 
epidemiology, thereby achieving the first of the stated objectives on page 3 of 
this thesis. These reviews found this was an area where the full potential of the 
methods was not demonstrated and motivated the empirical chapters in stroke 
epidemiology. This thesis appears to include the first study to demonstrate the 
greater understanding that can be achieved by examining both the cause-
specific hazards and the subdistribution hazards/cumulative incidences of each 
of the two competing risks recurrence and death without recurrence in stroke 
patients. Furthermore, it appears to be the first research to showcase the 
potential of dynamic predictions in a multi-state model of stroke, recurrence 
and death. 
Multi-state modelling was the focus for the health economics context. In 
particular, this thesis aimed to illustrate that multi-state modelling can provide 
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an alternative to common approaches in health economic modelling. The review 
of the use of multi-state modelling in health economics found that a barrier to 
implementation was a lack of readily available software. This motivated a 
tutorial paper I have subsequently published with accompanying R code and 
customisable functions to allow analysts to adopt the approach with their own 
data (Williams et al., 2017a).  
Importantly throughout the chapters that described the methods, including the 
reviews of the literature into the extent of their use specific to the two case 
studies, misconceptions and misunderstandings related to some of the 
methodological issues were highlighted. The purpose of this was to alleviate the 
confusion that could arise from some of the conflicting messages in the 
literature.  
Section 8.2 of this final chapter summarises the main insights from the empirical 
chapters of this thesis, demonstrating where appropriate some of the issues and 
considerations emphasised in the background chapters. Specifically, sub-section 
8.2.1 focuses on how an aspect of the second objective for the stroke study was 
met, namely demonstrating the extra insight gained from competing risks 
analysis over standard survival analysis. Next, sub-section 8.2.2 provides an 
overview of how the last aspect of that objective, that of demonstrating the 
insight from multi-state modelling in a stroke epidemiology context, was 
achieved. Then, sub-section 8.2.3 outlines how meeting the two objectives in 
the health economics context provided extra insight.  In section 8.3 limitations 
of the analysis in this thesis are discussed alongside solutions to overcoming 
them. Finally, the thesis concludes with section 8.4 that discusses future 
potential directions for the research that would help encourage adoption of the 
multi-state modelling framework beyond the illustrated case studies. 
8.2 Main insights  
8.2.1   Insights gained from the competing risks analysis over 
and above standard survival analysis 
Chapter 3 met the objective of demonstrating the extra insight gained from 
competing risks analysis of the stroke case study, with particular emphasis on  
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three different comparisons involving its use.  These were: 
(i) composite outcome versus decomposition of the outcome into the competing 
risks 
(ii) cause-specific hazard and Fine and Gray subdistribution hazard modelling 
approaches 
(iii) naïve Kaplan-Meier/Cox estimates versus the competing risks cumulative 
incidence. 
The insights found from each of these will be summarised in turn. 
8.2.1.1 Composite outcome versus decomposition of the outcome 
into the competing risks 
Decomposing a composite outcome into its component competing risks can 
provide useful insight. This is especially the case when a covariate affects two 
competing risks but in opposite directions. The decomposition of a non-fatal 
outcome from death can be particularly useful because it could help distinguish 
those patients that are likely to die from those that may still benefit from a 
targeted intervention. In the analysis presented in section 3.2 of this thesis, 
extra insights were gained from the decomposition for the effects of the ability 
to lift both arms off the bed, haemorrhage on scan and gender. It was found that 
being able to lift both arms off the bed was associated with a higher hazard of 
recurrence and a reduced hazard of death without recurrence. However, this 
association with recurrence was undetectable from the analysis of the composite 
outcome. This was due to it being in a different direction from that for death 
without recurrence, together with the composite outcome being dominated with 
death without recurrence. Therefore the competing risks analysis was crucial in 
identifying the association between the ability to lift both arms and recurrence. 
Another covariate that had opposing effects on each of the two competing risks 
was haemorrhage on scan. Similar to the ability to lift both arms, having a 
haemorrhage was associated with an increased hazard of recurrence and a 
marginally reduced hazard of death without recurrence. However, no evidence 
was found of an association with haemorrhage and the composite outcome, and 
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therefore the composite analysis masked both of the effects found for the 
competing risks. The opposing effects on the competing risks were effectively 
cancelling each other out in the analysis of the composite outcome. Therefore, 
this again demonstrated the extra insight gained from the competing risks 
analysis over that of the standard composite outcome survival analysis. In 
particular, it revealed that haemorrhage was in fact a risk factor for recurrence 
and therefore identified a subset of patients likely to benefit from strategies to 
prevent recurrence. 
The analysis of the composite outcome also did not find any evidence of an 
effect of sex. However the competing risks analysis found that being female was 
associated with a higher hazard of recurrence. Therefore this illustrated another 
effect that was masked from the analysis of the composite outcome, again 
highlighting the value of the competing risks analyses. 
8.2.1.2 Cause-specific hazard and Fine and Gray subdistribution 
hazard modelling 
In section 2.5 of this thesis, it was emphasised that a greater understanding of a 
competing risks scenario can be gained when both the hazards and cumulative 
incidence functions for each of the competing risks are considered. In particular, 
Latouche et al. (2013) recommended displaying both cumulative hazard plots 
and cumulative incidence plots to assess the effects of covariates. With this in 
mind, section 3.3 of this thesis showed such plots for each covariate. This 
appeared to be the first research to consider both cumulative hazards and 
cumulative incidences for the outcomes recurrence and death without 
recurrence in stroke patients. These helped to demonstrate the methodological 
issue emphasised in section 2.5 that the effects of a covariate on the cause-
specific hazard and cumulative incidence of an outcome may differ. For 
instance, the cumulative hazard plot for orientated speech in section 3.3 showed 
that the hazard of recurrence was lower for those with orientated speech than 
those without it. However the cumulative incidence plot demonstrated that 
orientated speech had no effect on the cumulative incidence of recurrence. 
While this might seem surprising at first, this could be explained by knowing that 
those with orientated speech also had a lower hazard of death without 
recurrence, but that importantly this reduced hazard was more pronounced than 
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that for recurrence. This meant that there was more of those with orientated 
speech having a recurrence than was perhaps expected, due to there being more 
of them left to be at risk of recurrence owing to the decreased hazard of death 
without recurrence. Consequently, the cumulative incidence of recurrence for 
this group was in line with that for those without orientated speech, instead of 
being lower than it. Many similar examples were also illustrated in section 3.5 of 
this thesis. They demonstrated that exploring both the hazards and cumulative 
incidences of each of the two competing risks can help in the interpretation of 
such outcomes, which would not be possible if considering only the hazard or 
cumulative incidence in isolation.     
8.2.1.3 naïve Kaplan-Meier/Cox estimates versus the competing risks 
cumulative incidences 
Section 2.3 of this thesis emphasised that the naïve Kaplan/Cox approach is 
inappropriate in the presence of competing risks. Estimates using this approach 
introduce bias in the form of inflated cumulative incidences, with the extent of 
the bias relating to the strength of the effect of the competing outcome. Section 
3.4 of this thesis illustrated the bias that can be introduced by not appropriately 
taking into account the competing risks in the stroke epidemiology case study. 
For example, it was found that inflation of 18% resulted in the estimate of the 4-
year cumulative incidence of recurrence when using the biased Kaplan-Meier 
method instead of the more appropriate competing risks cumulative incidence 
approach. Furthermore, when the effects of covariates were taken into account, 
the naïve Cox prediction introduced 11% inflation in the 3.5-year cumulative 
incidence of death without recurrence for the reference patient. Therefore, the 
illustration in section 3.4 demonstrated it is imperative to use an approach that 
appropriately takes into account competing risks to avoid introducing such 
inflation bias. Over-estimating the incidence of an event could lead to misguided 
clinical decisions.     
This piece of empirical analysis has reiterated the bias that can be introduced by 
using a naïve Kaplan-Meier approach when competing risks are present. Before 
conducting any of the analysis in this thesis, a literature search was conducted 
to find reviews that raised awareness of the need to recognise competing risks 
and analyse them appropriately (section 2.10.1). Two such reviews were found. 
Chapter 8     Main insights, limitations and potential areas of future research 236                  236Main insights, limitations and potential areas of future research                                                                                                                                                                                                    
Mell et al. (2012) found that only 40% of the cancer studies they reviewed 
analysed cancer events and non-cancer mortality separately. Koller et al. (2012) 
found that 70% of studies they reviewed in high impact clinical journals either 
used a naïve Kaplan-Meier approach, neglected to report competing risks or 
failed to analyse them.  
More recent contributions have also found that the naïve Kaplan-Meier approach 
has continued to be used [van Walraven and McAlister (2016) and Schumacher et 
al. (2016)]. In the studies reviewed in each contribution, 46% (van Walraven and 
McAlister, 2016) and 49% (Schumacher et al., 2016) were found to be susceptible 
to such competing risks bias. It is apparent that there is some delay in 
recognising the message regarding the need to analyse competing risks 
appropriately. However, the suggestion by van Walraven and McAlister (2016) to 
explicitly include the number of competing outcomes in the CONSORT/STROBE 
guidelines is a step in the right direction. In addition, as van Walraven and 
McAlister (2016) point out, there has quite recently been a move towards the 
base packages of popular software packages including the facility to create 
cumulative incidence curves for competing risks, rather than just Kaplan-Meier 
analyses. SAS, Stata and R all now have readily available procedures to create 
these and therefore there is some cause for optimism that more appropriate 
analysis will be more widely adopted. 
8.2.2  Insights gained from the multi-state modelling of stroke, 
recurrence and death  
Section 4.5 of this thesis highlighted that one of the main advantages of multi-
state modelling is the flexibility of predictions it can offer. The usual predictions 
at time zero of being in a health state by some future time point can be 
accommodated. However, dynamic predictions are also possible with multi-state 
modelling. These dynamic predictions update a patient’s prognosis taking into 
account the time elapsed and any subsequent events experienced.  
Chapter 5 illustrated both types of prediction from a model of stroke, 
recurrence and death. In particular, it demonstrated dynamic predictions that 
could be used by clinicians as a communication tool to update their patients on 
their risk of relevant outcomes given their current stage in their illness. 
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The illustration of the flexibility of predictions offered by multi-state modelling 
in section 5.2 met the second objective in a stroke epidemiology context on 
page 3 of this thesis, that is to say to demonstrate the added insight of multi-
state modelling over standard survival analysis. In addition, section 5.3 
demonstrated that predictions from multi-state modelling reflect that 
intermediate states have flow in and out of them, in contrast to the competing 
risks cumulative incidence predictions that are monotonic. In doing so, it 
highlighted the extra insight gained from multi-state modelling compared to 
competing risks analysis.   
8.2.3 Insights gained from exploring multi-state modelling in a 
health economics context 
8.2.3.1  Publishing a tutorial paper to help encourage adoption of    
             multi-state modelling for cost-effectiveness analysis in R  
Section 6.3 of this thesis met the objective of exploring the extent of use of 
multi-state modelling in the health economics literature. It identified that a 
barrier to its use was the lack of readily available software. Motivated by this, a 
large component of this PhD research involved creating a series of customisable 
R functions for use by others to perform multi-state modelling for the purposes 
of cost-effectiveness analysis. All the coding now accompanies a tutorial paper I 
published providing a step-by-step guide to using the approach (Williams et al., 
2017a). The paper demonstrates how to use multi-state modelling to calculate 
mean (quality-adjusted) life years gained and incremental cost-effectiveness 
ratios. It also illustrates how to carry out deterministic and probabilistic 
sensitivity analyses with the approach. It is based on adaptions to the existing R 
package mstate to accommodate parametric multi-state modelling, thereby 
facilitating extrapolation of survival curves. All functions have arguments that 
can be changed to suit the data and context of the user e.g. the number of 
transitions, covariates included, the discount rate and the time horizon. 
Furthermore, in using a syntax-based approach, it benefits from the 
transparency of the code used and analysis that is all contained in one file.  
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8.2.3.2 Illustration of multi-state modelling as an alternative to 
partitioned survival and Markov decision-analytic modelling 
Chapter 7 achieved the objective of demonstrating, with the help of the 
aforementioned tutorial paper, a comparison of multi-state modelling with two 
common approaches in health economic modelling. An existing Markov decision-
analytic model developed by a manufacturer in a submission to NICE for a 
technology appraisal was used as a basis for the comparison. That economic 
model sought to evaluate the clinical and cost-effectiveness of rituximab in 
combination with fludarabine and cyclophosphamide compared to fludarabine 
and cyclophosphamide alone for the first-line treatment of chronic lymphocytic 
leukaemia. The model had the three health states progression-free, progression 
and death & the transitions progression-free → progression, progression-free → 
death and progression → death. The manufacturers took the usual approach in 
state-transition decision-analytic modelling of making a prior assumptions about 
the transition probabilities before the modelling commenced.  
By way of comparison, Chapter 7 used the trial data on which that economic 
model was based to carry out analyses using the partitioned survival and multi-
state modelling approaches. The partitioned survival approach involved fitting 
parametric regression to the overall survival and progression-free survival curves 
to allow extrapolation to the desired time horizon. The mean time spent in 
progression was then derived from the area between the two survival curves. 
The multi-state modelling used the individual patient level data directly to build 
parametric regression models for the hazard of each of the transitions in the 
model. These hazards for each transition were then appropriately combined to 
calculate the state occupancy probabilities.  
For each of the three approaches, the (incremental) mean (quality-adjusted) 
time in each state was presented along with the incremental cost-effectiveness 
ratio. Furthermore, for the multi-state modelling that was the main focus of this 
thesis, sensitivity analyses were presented. A tornado diagram was shown to 
summarise the results of one-way sensitivity analyses and a cost-effectiveness 
plane and cost-effectiveness acceptability curve were presented to summarise 
the extent of the uncertainty from the probabilistic sensitivity analyses. The 
chapter helped to demonstrate that any output required from a conventional 
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decision-analytic model can just as easily be produced using the multi-state 
modelling framework. 
Chapter 7 showed that the conventional state-transition decision-analytic 
modelling approach and multi-state modelling produced equivalent results when 
they made the same assumptions with regards to the transition 
probabilities/hazards. Furthermore, when the comparison of the approaches 
each using different assumptions were split into the results in the observed and 
extrapolated period, it was found that the approaches mainly differed over the 
period of extrapolation. Therefore, the research demonstrated that it is 
imperative to check whether the assumptions used are realistic. It is the choice 
of assumptions that can influence the clinical and cost-effectiveness results, 
much more than the approach to the modelling itself. 
8.3 Limitations 
The purpose of this thesis was to showcase multi-state modelling in an 
epidemiological and health economics context, in areas where their potential 
had not been fully realised. However the research did have some limitations. 
This section highlights some of the limitations and outlines, where possible, 
some solutions that could overcome them in future. 
8.3.1 Limited follow-up with covariates versus extended 
follow-up with limited covariates 
As is often the case with studies/trials of health outcomes, the case studies used 
as examples in this thesis had relatively short follow-up. However the studies did 
have a wealth of covariate information to help explain which factors were 
associated with the outcomes of interest. This was particularly the case for the 
stroke epidemiology study. This would have also been the case in the trial data 
used for the health economics example. However this was less evident because 
only the covariate treatment was used in the analysis, for comparison purposes 
with the existing economic model. On the other hand, external data that could 
help inform extrapolation of the outcomes to the time horizon, e.g. life tables 
or hospital episode data, tend to be limited in terms of covariate information. 
Therefore, some trade-off is necessary between study data with limited follow-
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up but covariates, and routine administrative data with longer follow-up but a 
lack of covariates. However, the lack of covariates in the longer term data may 
be mitigated if the datasets are linked at individual patient level, and longer 
follow-up is only required to identify occurrence of outcomes. Furthermore, the 
use of longitudinal cohort studies may alleviate some of the limitations. In 
addition, such studies offer the opportunity to benefit from the emergence of 
joint modelling of longitudinal and competing risks/multi-state modelling 
survival data [e.g. Williamson et al. (2008) and Ferrer et al. (2016)]. 
8.3.2 Variable selection with competing risks and multi-
state modelling 
Prognostic models are used to predict outcomes for individual patients with a 
given set of risk factors. When developing such models, careful consideration 
should be given to the predictor variables (i.e. risk factors) selected for inclusion 
in the model. Parsimonious models are deemed to be the most practical because 
they are easier to use for predicting outcomes for new patients and more likely 
to generalise to different populations. Recognised strategies for curtailing the 
number of variables include choosing only those that are clinically relevant, 
removing obvious collinearity and ignoring those with data quality issues. 
Examples of the latter include measurement error or a high level of missing 
data. However, even after following such strategies to disregard variables of 
obvious limited value, the number of variables can still exceed Peduzzi et al. 
(1995)’s standard rule of thumb of 10 events per variable. Therefore, modelling-
based variable selection procedures are often required. This section outlines 
some of the challenges and limitations of variable selection in the context of 
competing risks and multi-state modelling and describes very recent advances 
that could help overcome them. 
8.3.2.1 Variable selection with Fine and Gray’s proportional 
subdistribution hazard modelling 
It was previously highlighted in section 2.7.1 of this thesis that Kuk and 
Varadhan (2013) have developed an information criterion-based test to help 
select variables for Fine and Gray’s proportional subdistribution hazards 
modelling. The approach incorporated stepwise regression techniques. Such 
techniques are popular due to being easy to use. However, they have also been 
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heavily criticised for stability problems and their automation process, the latter 
meaning that analysts unaccustomed to prognostic modelling may not make 
appropriate considerations such as ensuring all variables are clinically relevant. 
Fu et al. (2017) have proposed an alternative approach using penalised 
regression with Fine and Gray’s model. As well as providing an alternative to 
stepwise techniques, penalised regression is a shrinkage method and as such can 
overcome difficulties due to overfitting. In particular, many penalised regression 
techniques can be used for variable selection as they facilitate removal of 
variables, with lasso-based regression being perhaps the most well-known 
example of this. 
Kuk and Varadhan (2013)’s aforementioned stepwise information-criteria based 
approach appears to be the first article to address variable selection using Fine 
and Gray’s model. Consequently, it was a useful contribution in that it 
highlighted the issue and provided a starting point to build on. Furthermore, Fu 
et al. (2017)’s development to a penalised regression approach is a valuable 
addition to the literature on variable selection for competing risks model for the 
reasons described above. 
8.3.2.2 Variable selection with cause-specific hazard modelling 
It was previously mentioned in section 2.6 of this thesis that prediction is 
possible with the cause-specific hazard approach to competing risks modelling. 
However, variable selection is much more challenging with this approach. This is 
because of the phenomenon that the effect of a covariate on the cause-specific 
hazard will not necessarily translate into the same effect on the corresponding 
cumulative incidence. The cumulative incidence may also be affected by the 
cause-specific hazards of any competing events (section 2.5). Consequently, 
when selecting covariates to include in modelling, it is not recommended to 
focus on the cause-specific hazard for one event in isolation. While the two 
aforementioned methods with Fine and Gray’s model can result in models for 
each event that differ in the covariates they contain, a different approach is 
required for cause-specific hazard modelling. 
Instead, each of the events could be considered simultaneously and the effects 
of a given covariate on each event taken together as a group when deciding on 
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selection of that covariate. As Most et al. (2016) point out, in multiple response 
models such as competing risks, a distinction can be made between variable 
selection and parameter selection. This is because in multiple response models 
the effect of one covariate can be represented by several parameters e.g. a 
parameter for the effect on each event. 
When aiming for parsimonious modelling using the cause-specific hazard 
approach with a view to using it for prediction, Most et al. (2016) emphasis on 
selecting variables instead of selecting individual parameters is a very useful 
recommendation. It means that all coefficients that correspond to the same 
covariate can enter or leave the model jointly (Tutz et al., 2015) i.e. even if a 
covariate only has an association with one event, that covariate will be kept in 
the models for the competing events. However, the work by Most et al. (2016) is 
from the perspective of the discrete-time, rather than the continuous-time, 
competing risks framework. There does not appear to be any contributions in the 
literature detailing an equivalent for the latter as yet, and unfortunately Most et 
al. (2016)’s piece does not include any code that could be adapted for 
continuous-time. 
Some may question why prediction using cause-specific hazard modelling is 
considered, when variable selection is a more challenging process than it is with 
Fine and Gray’s subdistribution hazard modelling. While there is the option of 
Fine and Gray’s approach for modelling competing risks, this is not the case in 
multi-state modelling. In addition, Fine and Gray’s model and cause-specific 
hazard modelling may not both simultaneously meet the proportional hazards 
(PH) assumption for the covariates. Therefore, in instances when the PH 
assumption is met with the cause-specific hazard modelling approach but not 
with Fine and Gray’s model, analysts may favour the former for calculating 
predictions. 
Therefore, in the (continuous-time) cause-specific hazard modelling approach to 
competing risks and multi-state modelling, a notable limitation is the lack of a 
recognised appropriate variable selection method in preparation for calculating 
predictions. This is also true in general for any state transition model, including 
the commonly used Markov decision-analytic model in health economics, 
because the presence of competing risks means the transition-specific covariate 
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effects may not necessarily translate into the same effect on the state 
occupancy probability that is ultimately of interest. 
However, it may be possible to overcome the lack of a suitable variable 
selection method. Adapting the aforementioned work by Most et al. (2016) from 
a discrete-time to a continuous-time framework may solve the problem for 
competing risks. With regards to multi-state modelling, Reulen and Kneib (2016) 
proposes a boosting  method using penalisation of the (partial) likelihood as a 
way of selecting a parsimonious model. However, this is a variable selection 
approach tailored to modelling for etiological reasons, rather than for 
subsequent prognostic modelling, because it results in models for transition-
specific hazards that do not all contain the same variables. On the other hand, 
Turlach et al. (2005), Simon et al. (2013) and Tutz et al. (2015) have developed 
variable selection methods using lasso-based penalisation for multinomial logit 
models. While not formulated for a survival analysis framework, their 
contributions may provide some insight into a solution for competing risks/multi-
state modelling because multinomial logit models share with them the feature of 
being multi-response. In particular, the approaches use grouped penalisation 
with groups that contain all the coefficients belonging to the same variable in 
the context previously mentioned in the piece by Most et al. (2016). Of 
particular note, the original lasso (Tibshirani, 1996) is adapted to accommodate 
grouping so that all coefficients that correspond to the same covariate enter or 
level the model jointly.  
It is encouraging that variable selection methods have already been developed 
for multivariate modelling, and therefore it is hoped that an adaption to cause-
specific hazard modelling will appear in the literature in the near feature. The 
resultant parsimonious modelling for each cause-specific hazard could then be 
used to calculate predictions as detailed previously in section 2.6. 
8.3.2.3 Limitation for analysis in the wider health economics context   
Some health economic modellers may be reluctant to adopt a multi-state 
modelling approach using syntax with statistical software. They may see R, and 
other software packages that allow users to write their own code, as less user-
friendly than spreadsheet packages such as Excel. However this might be due to 
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fear of the unknown rather than a barrier that cannot be overcome. The next 
section of this thesis includes details of anticipated developments of the R code, 
including incorporating a more user-friendly interface. 
8.4  Areas of future research 
This section gives an overview of some potential directions this research could 
take in future. 
8.4.1 Enhancing health economic multi-state modelling by 
combining trial data with longer-term routine 
administrative data 
8.4.1.1 Reform of the Cancer Drugs Fund 
The Cancer Drugs Fund was introduced in 2010/2011 to fund cancer treatments 
not recommended by NICE for routine use in the NHS. In a news piece in the 
British Medical Journal, Mayor (2016) explains that reasons for such non-approval 
include that the drug was new and not yet assessed, or that it was for a rare 
cancer not being appraised by NICE. Mayor (2016) also emphasises that another 
reason why drugs have not been recommended for routine use is the uncertainty 
regarding their clinical-effectiveness and cost-effectiveness. It was envisaged 
that the Cancer Drugs Fund would address this. However it has been 
acknowledged that the fund needs reform, because as the Mayor (2016) piece 
highlights, it did not collect data on outcomes of use of the drugs it funded even 
though it had spent £1.27 billion. 
A reform of the Cancer Drugs Fund was implemented in July 2016 that entails 
that drugs be funded for up to 2 years in order for further evidence to be 
collected. After this a short NICE appraisal will take place that considers this 
additional evidence. If approved, the drug will be licenced for routine use in the 
NHS. If it is rejected, it will only be considered for use on a case-by-case basis. 
That a reform of the Cancer Drugs Fund was required, highlights that more 
attention needs to be given to evaluating the clinical-effectiveness and cost-
effectiveness of such drugs and the uncertainty in the results. Indeed a recent 
article by Aggarwal A. (2017) found that only 38% (18/47) of drugs funded by the 
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Cancer Drugs Fund in 2015 were found to be effective. This need for more 
evidence means that there will be a greater demand for modelling in health 
economic evaluations. 
However, because the reform does not stipulate exactly how the evidence 
should be collected, there is some debate over whether this reform will address 
the uncertainty in effectiveness. Grieve et al. (2016) have concerns that, while 
the reform encourages early access to drugs, it is at a high cost and still does not 
address uncertainty surrounding the clinical benefits. The article argues that the 
reform does not encourage manufacturers to conduct randomised clinical trials 
(RCTs), and does not advocate the sole use of observational data due to the 
biased estimates of effectiveness that can result. The authors point out that, 
once the drugs are widely used, if real world data is used alone to assess 
treatments randomisation will be impossible weakening the evidence base. A 
solution is proposed by Grieve et al. (2016) involving assessing treatment 
effectiveness using timely and pragmatic low-cost RCTs in conjunction with 
follow-up from routine collected data. Furthermore, if there is an ongoing trial 
it may be more efficient to wait and make decisions based on assessing the long-
term outcomes from that trial, because a new trial may not provide sufficient 
evidence to justify the expense. The authors also argue that when RCTs are 
deemed unethical or impractical, then the non-randomised studies that are 
conducted should minimise confounding. These studies should collect 
longitudinal data on all relevant prognostic characteristics for those with and 
without the drug. Recent developments in strategies to minimise the selection 
bias from confounding include flexible regression incorporating machine learning 
for model selection Kreif et al. (2015), propensity score matching (PSM) with 
regression adjustment Kreif et al. (2013) and an extension of PSM called Genetic 
Matching Radice et al. (2012). Incorporating such methods into state-transition 
approaches, such as multi-state modelling, is an area of further research worth 
exploring. 
In a rapid reply to Grieve et al. (2016)’s article, Hatswell (2016) stresses that the 
current Cancer Drugs Fund reform does not address the most pertinent issue in 
terms of uncertainty, that of effectiveness in the long-term. He agrees with  
Grieve et al. (2016) that collection of evidence on long-term outcomes would be 
more effective in studies that complement and extend the original clinical trials.  
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In a rapid reply from Longson et al. (2016) of NICE to Grieve et al. (2016)’s 
article, the authors refute the implication that the reform will rely heavily on 
observational data. The authors emphasise that the reform will include a data 
collection plan that will outline the key areas of uncertainty and how these will 
be addressed. On an optimistic note, they highlight that there is scope to use 
RCTs alongside observational data. Furthermore, they mention that ongoing 
RCTs can be used to help evaluate long-term effects and reduce uncertainty in 
extrapolated estimates. This renewed focus on addressing uncertainty, and not 
just relying on trials or observational data alone but instead combining them to 
obtain evidence long-term, should mean that the use of modelling that can 
facilitate this will increase. In particular, it could provide a window of 
opportunity for increasing adoption of multi-state modelling. 
8.4.1.2 GetReal project on methods for real word evidence collection 
and synthesis 
Combining trial data with the real world evidence from observational data is also 
being investigated by the GetReal consortium (www.imi-getreal.eu), with a 
specific aim of improving estimates of real word effectiveness. In particular, 
Workpackage 4 of the GetReal project is concerned with identifying and sharing 
best practice in synthesis and prediction modelling to estimate the real world 
effectiveness of treatments, beyond the efficacy estimated in the controlled 
environment of an RCT. An article by this group concerned with mathematical 
modelling to predict drug effectiveness from trials has already identified multi-
state modelling as a method that has potential, but that has scope to be more 
widely-applied (Panayidou et al., 2016). However, the multi-state models found 
in the review described in that paper were under the discrete-time  framework, 
i.e. they were typically what this thesis has termed conventional (Markov) 
decision-analytic models. The authors acknowledge that building such models 
can be cumbersome and time-consuming. However, the continuous-time multi-
state modelling approach that has been the focus of this thesis overcomes such 
problems. In particular, continuous-time Markov multi-state models can be build 
in seconds (Williams et al., 2017a) and are therefore much less time-consuming 
than their discrete-time counterparts. This is mainly due to the modelling not 
requiring any form of simulation, such as cohort simulation. It is hoped that this 
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will help encourage the adoption of continuous-time multi-state modelling for 
cost-effectiveness analysis.  
8.4.1.3 Extrapolation 
Increasingly in the literature, more importance is being placed on assessing the 
suitability of extrapolations in terms of being clinically plausible, and in 
particular using external data to help inform the extrapolation. In the UK, NICE 
(2013) recommend that any extrapolation is assessed for “both clinical and 
biological plausibility of the inferred outcome as well as its coherence with 
external data sources”.  
Bayesian evidence synthesis that incorporates external information is 
demonstrated in the work by Demiris and Sharples (2006). In another article, 
Nelson et al. (2008) show how internal and external data could be used to inform 
the extrapolation in conjunction with time-metric and age-metric survival 
analysis. That is to say, in particular, the time to event was measured using time 
since initiation of treatment in the initial period when there was a high risk of 
death. Then, when the hazard of death could be assumed to be more stable, 
time was measured using age to facilitate extrapolation. Hwang and Wang (1999) 
proposed a method that utilises general population life table estimates to 
simulate a reference population to help inform the extrapolation. Specifically, 
their method involved a linear extrapolation of a logit-transformation of the 
survival ratio between the reference and specific population of interest, 
assuming a constant excess hazard. This approach has been applied by many 
authors including Chu et al. (2008a), Chu et al. (2008b), Lee et al. (2012), Yang 
et al. (2012), Chen et al. (2013) and Ho et al. (2006).  
A very recent special issue of the journal Medical Decision Making specifically 
focused on methods for extrapolation in cost-effectiveness analyses was 
published in 2017. The contributions outlined how analysts could incorporate 
external data into their models [e.g. Jackson et al. (2017), Guyot et al. (2017), 
Negrín et al. (2017) and Meacock et al. (2017)]. 
The contribution by Jackson et al. (2017) is a valuable addition to the literature 
that starts by stating that the conventional approach to extrapolation is 
Chapter 8     Main insights, limitations and potential areas of future research 248                  248Main insights, limitations and potential areas of future research                                                                                                                                                                                                    
parametric regression. However, the authors include the caveat that the 
observed follow-up should represent a large enough proportion of the whole 
lifetime when using this approach. In addition, they emphasise that this assumes 
that the observed hazards and trends will continue long term, but that this 
becomes more implausible as the proportion of the unobserved lifetime 
increases. They also stress that the extent of uncertainty in the extrapolation 
needs quantified, which can be difficult if observed data is immature. Jackson et 
al. (2017) reiterate the NICE recommendation that extrapolation be evaluated as 
to its clinical and biological plausibility and also coherence with external data. 
The article then proceeds to review methods of extrapolation involving external 
data, discuss the required assumptions and the circumstances under which 
method can be appropriate. In particular, the paper provides guidance on what 
to do when the disease and external (or treatment and control) populations have 
the same mortality all the time, the same mortality after some time and 
different mortalities in the short and long term. For the latter, the authors give 
an overview of how the external data could be adjusted to represent the 
population of interest. This included making assumptions about the 
proportionality of the all-cause or cause-specific hazards or about the additive 
excess hazard. The authors then discuss possible forms the survival function 
could take.  
Guyot et al. (2017) detail how Bayesian multi-parameter evidence synthesis 
incorporating splines can be used to combine the observed trial data with 
external data sources to inform the extrapolation. In doing so, the authors 
demonstrate a useful approach encouraging analysts to explicitly use all 
available information outwith the trial to obtain extrapolations that are sensible 
and clinically plausible.  
The work by Negrín et al. (2017) adds value in that it raises awareness of the 
need to consider the uncertainty in the estimates of extrapolated outcomes. The 
authors caution against the use of relying on “best-fit” models based on 
information criteria because they fail to address two areas of model uncertainty. 
Specifically, the two areas are uncertainty surrounding the true distribution and 
that related to the stability over time of the model parameters. Instead, their 
article demonstrates the use of Bayesian model averaging which can take into 
account both. The authors use two different approaches to this: one based on 
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selection using Bayesian information criterion (BIC), and an alternative 
incorporating optimistic and pessimistic scenarios. Negrín et al. (2017) include 
the alternative because they acknowledge that information criteria can only 
assess the goodness of fit of observed data, and cannot help decide how 
reasonable the extrapolation looks.  
The premise of the paper by Meacock et al. (2017) is the authors’ position that 
the usual binary outcome of 30-day mortality used to evaluate policy evaluations 
has room for improvement. The authors explain that this dichotomy assumes 
that those that die do so instantly, and therefore any time spent alive is ignored. 
In addition, those that do remain alive beyond 30 days are given a life 
expectancy based on that of the general population. However, those that the 
policy or program has an influence on are likely to be different from the general 
population. Furthermore, it is often possible to observe patients for more than 
30 days but this longer term follow-up is not always utilised. The authors point 
out that trials often use all the follow-up data available and use parametric 
survival analysis to extrapolate the desired outcome over the lifetime. The aim 
of Meacock et al. (2017)’s article was to illustrate how this approach could be of 
use as a method of extrapolation in the evaluation of health policies. They did 
this by comparing the crude 30-day mortality outcome with parametric survival 
regression, both of which were coupled with general population life expectancy 
estimates to assess differences in remaining life years in the short term i.e. over 
1 year. Furthermore, they also utilised the observed survival data over 1 year to 
carry out parametric survival regression, therefore basing the estimates on the 
population of interest rather than the general population. They performed 
extrapolation to a lifetime horizon and external validation using 3-year observed 
survival data they had available. Because of the initial very high risk of survival 
they fitted two separate models. The first was for short-term survival and was 
based on the observed 1-year data. The second was for long-term extrapolation, 
but excluded the high risk period, instead of being based on the data from 30 
days onwards. After demonstrating the improved estimation with parametric 
survival regression, they then proceeded to use a difference-in-differences 
design to evaluate the effect on life expectancy of a policy. 
Meacock et al. (2017) demonstrate the added value of using the observed data 
to estimate remaining life expectancy over the 30-day mortality estimates, 
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especially when with the latter the life expectancy estimates were from the 
general population rather than the population of interest. This was to be 
expected because in their example the life expectancy estimates for their 
population of interest differed quite considerably from that of the general 
population. However, the external validity of the extrapolation demonstrated in 
the paper was somewhat limited because it was only based on 3-years follow-up 
of mortality. Given their population had a mean age of 72 it would have been 
preferable if at least 10-years follow-up of mortality was obtained for a more 
comprehensive external validation to the lifetime horizon. Estimates of 
mortality at more points over the lifecourse would ideally have been available to 
check that the extrapolation was sensible and clinically plausible, especially as 
their population were aged from 18 years onwards. 
In the analysis presented in Chapter 7 of this thesis the extrapolation and choice 
of time horizon did not benefit substantially from being informed by external 
data. This was primarily because the approaches were contrasted with an 
existing decision-analytic model already created by a manufacturer, and used 
the same time horizon as that model for comparison purposes. This constraint on 
the time horizon is likely only to be specific to this illustration due to it being 
based on a comparison with an existing model. It is not a limitation to the future 
use of multi-state modelling. Indeed, the R functions already created as part of 
this research (Williams et al., 2017a) facilitate choosing a different fit in the 
observed period from that in the period that requires extrapolation. Their scope 
could be easily widened to incorporate external data. 
Another point worthy of consideration related to extrapolation in health 
economic modelling, but true of the whole time-frame of interest, is the impact 
of discounting on the predictions of being in relevant states. Given that after 
discounting the corresponding prediction curves will be lower and possibly 
somewhat different in shape, raises the issue as to whether it should be the fit 
to the curves after discounting that are evaluated instead. 
While it is encouraging that guidance on extrapolation is increasing in the 
literature, its primary focus has been on the extrapolation of individual 
outcomes in isolation. Research into adaptions to existing methods of 
extrapolation for state-transition modelling would be a welcome addition. The 
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next section outlines how extrapolation can be more complex when multiple 
outcomes are considered simultaneously. 
8.4.1.4 Implications for the choice of modelling approach 
The previous sub-sections on the Cancer Drug Funds reform, the GetReal project 
and the use of external data for extrapolation have highlighted that there is 
huge scope to improve the evaluation of effectiveness and cost-effectiveness; 
specifically, by making use of the mechanisms that are available to combine 
study data with routine administrative data for longer-term follow-up. Within 
medical research there is an increasing ethos of data sharing. Indeed, public-
funded research grant bodies are stipulating that data generated from research 
is shared with the wider research community, where possible. Furthermore, 
initiatives are emerging that allow trial data to be assessed by researchers e.g.   
https://clinicalstudydatarequest.com/. In addition, linkages with data from 
studies and routine administrative data are become more readily available, 
especially as the latter matures and new linkages become increasingly possible. 
Data such as hospital episode statistics and disease-specific (e.g. cancer) and 
death registries are among the sources of information that are likely to be 
useful. 
With health economic modelling, interest is often on modelling several health 
states relevant to a (disease) process simultaneously. This allows for each of the 
different health states to be assigned a utility value representing quality of life, 
facilitating the calculation of cost-effectiveness measures such as cost per 
quality of life year gained. Multi-state modelling is a natural choice for this, 
especially when all the different data sources are linked at individual patient 
level. It also has the flexibility to incorporate aggregated data as sources of 
information to inform assumptions about transitions. However, analysts should 
consider carefully where to source the information required before embarking on 
any modelling to ensure that sensible and clinically relevant results emerge. This 
is particularly true of any extrapolation required as this is often the aspect with 
the greatest uncertainty.  
While external data on death is likely to be available from death registries, 
information for other outcomes/health states in an intended model may be more 
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difficult to access. Furthermore, because with state-transition modelling the 
transitions can be interlinked, it can be problematic to achieve sensible results 
for each of the health states simultaneously. A less complex model may provide 
a solution when there is difficulty obtaining data to inform/check the plausibility 
of the results for the transitions and states. This could involve combining states 
so that a state-transition model consists of less transitions. In a competing risks 
scenario, it could involve combining the competing risks into composite 
outcomes and conducting standard survival analysis or taking the partitioned 
survival approach instead. The use of less complex models may also overcome 
problems that may arise when there is sparse information on covariates for an 
outcome. Combining events into composite health states may support allowing 
more covariates to be assessed. 
8.4.2 Consideration of multiple comparators 
In the health economics case study illustrated in this thesis, there was one 
comparator for the treatment and the two treatments were compared head-to-
head in a single trial. However a full economic evaluation can involve multiple 
comparator treatments, the data for which can come from several different 
sources, particularly if multiple clinical trials and/or manufacturers are 
involved. The multi-state modelling approach can still be used in this context if 
an estimate of effect, either direct or indirect, between the different 
comparators can be found. Further research in this area would be worthwhile. 
8.4.3  Simulation exercise to dissect the differences in the 
approaches compared 
While multi-state modelling and decision-analytic modelling – the two state-
transition modelling approaches – were compared when the assumptions used 
differed and when they were equivalent, this was not extended to the 
partitioned survival approach. A worthwhile area of future research would be a 
simulation exercise to fully understand the mechanisms that differ between each 
of the three approaches. This could focus on varying specific aspects to help 
dissect what was driving the discrepancies between the approaches e.g. hazard 
ratios used including assumed distributions, effects of treatment across 
transitions/events, level of censoring, extrapolation and time horizon. 
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8.4.4 Validation of models  
The stroke epidemiology case study used in this thesis is part of a wider Stroke 
Complications and Outcomes Prediction Engine (SCOPE) study. SCOPE is a 
collaboration that brings together individual patient level data from various 
studies and trials for the purpose of developing and validating prognostic 
models. Therefore this is a valuable resource in which to internally and 
externally validate the competing risks and multi-state models for stroke 
developed in Chapter 3 and Chapter 5 of this thesis. In particular, both the 
calibration and discrimination of the models could be evaluated. However, an 
important consideration for external validation in particular, of competing risks 
analyses and multi-state modelling, is that the proportion of events due to a 
specific competing risk/health state is comparable to that in the data used to 
develop the model.  It would also be worthwhile to validate the modelling in the 
health economics context.  
8.4.5 Predictions and modifiable lifestyle factors 
Chapter 5 illustrated survival predictions both from the start of the study and 
dynamically. These predictions could provide a useful communication tool for 
clinicians to discuss prognosis with their patients. However mortality may be a 
difficult subject for patients to engage with, especially if they feel they do not 
have control over their future. In the models demonstrated in this thesis, no 
modifiable lifestyle factors were included as covariates. However there are 
many areas where modifiable lifestyle factors are predictors, such as diabetes 
and heart disease. The flexibility of predictions that multi-state modelling 
facilitates has huge potential in chronic disease where changes in lifestyle could 
result in improvements in outcomes for patients. The predictions from multi-
state modelling could aid clinicians when trying to encourage patients to take 
control of aspects of their lifestyle that could improve their health. For 
example, tobacco and alcohol consumption, body mass index, diet, exercise, 
cholesterol and blood pressure. Clinicians could discuss with patients the 
predictions of being in each of the relevant health states applicable to their 
disease if they continue with their current lifestyle. They then could try and 
motivate their patients to change by discussing how the predictions could 
improve with a change in lifestyle. The dynamic predictions in particular could 
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help the discussions in routine follow-up clinics because they would reflect the 
time that has elapsed since diagnosis and any health states experienced by the 
patient.  
8.4.6  Widening the functionality of the coding for cost-
effectiveness analysis in R using multi-state modelling   
The R functions and accompanying code in the tutorial paper developed as part 
of this research has provided health economic modellers with the tools to start 
adopting multi-state modelling with their own data. It acts as a strong 
foundation to build on, with there being much scope to develop it further. A few 
examples of intended developments will now be outlined.  
 It is anticipated that the existing facility within mstate to produce 
standard errors for predictions will be extended to the parametric 
approach. In particular, the current bootstrapping procedure in mstate 
for the semi-Markov model would benefit from adaption.  
 Another area that could be developed within this multi-state modelling 
framework is Value of Information analysis. This would be a worthwhile 
extension to the existing functionality that carries out probabilistic 
sensitivity analysis. It would allow evaluation of whether future research, 
and what aspects in particular, would be value for money and worthwhile 
doing. Specifically, aspects where more information would be of benefit 
to help reduce uncertainty could be investigated, while at the same time 
considering the cost of a proposed study to assess whether the outlay 
would be justified.  
 One barrier that may make analysts reluctant to adopt multi-state 
modelling is that conventionally it requires data at individual patient level 
data. However, health economists do not always have access to this and 
anyway economic evaluations are often strengthened by synthesising 
evidence from various different sources to inform the assumptions with 
regards to transitions. Consequently, the functions developed as part of 
this research include those that can be used when individual patient level 
data are not available or when several different sources are used. 
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However there is scope to widen the contexts in which they could be 
used. 
 In the case studies used in this research missing covariate information was 
not such an issue. However missing information is very common in medical 
research. Therefore, it is intended that the coding will incorporate the 
option to perform multiple imputation for those users who require it. 
To widen the exposure and accessibility of the existing code and intended 
developments above, it is envisaged that I will bring them all together into a 
comprehensive R package available through CRAN (https://cran.r-project.org/) 
This would be the ideal platform for those interested in using the code to keep 
abreast of any developments in this ongoing work. The package would also 
include vignettes with step-by-step guides on various aspects of the multi-state 
modelling framework in a cost-effectiveness analysis context. It may also 
encourage users to suggest developments and improvements of their own to help 
widen the adoption of the approach among health economic modellers.  
Alongside the R package it is also my intention to use the shiny application 
(http://shiny.rstudio.com/) within R studio (https://www.rstudio.com/) to 
create a more user-friendly web-based front-end to the package of functions and 
related code. Finally, to raise awareness of the approach and engage with those 
that could benefit from using it, I intend running courses on using R for cost-
effectiveness analysis at conferences aimed at health economic modellers.  
The research conducted as part of this thesis has demonstrated the usefulness of 
competing risks and multi-state modelling, in areas where they are not widely 
applied. It has also provided motivation for the future directions detailed above. 
It is hoped this will encourage further adoption of the multi-state modelling 
framework, in the many areas where it has not yet reached its full potential.  
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Appendix I Literature search of reviews of extent 
of use of competing risks 
 
A search was conducted using OvidSP (All Resources – including MEDLINE and 
Embase) of titles, abstracts and keywords to 31/08/2016 using the following 
search terms: 
("competing risks" and review and (liter* or stud* or systematic)).ab,ti,kw. 
 
The following diagram summaries the search leading to 2 contributions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified  
(n = 250) 
Records after duplicates removed 
(n = 129) 
Records included 
(n = 2) 
Records excluded due to 
not reviewing the extent 
of use of competing risks  
(n = 127) 
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Appendix II Koller et al. (2012)’s search strategy  
 
Pubmed search for studies on competing risks that used the following search 
terms: 
 
(a)  involving selected biostatistical journals 
 
(“competing cause” OR “competing causes” OR “competing risk” OR “competing risks” OR 
“competing outcome” OR “competing outcomes” OR “competing endpoints”) AND (Biom J[Jour] 
OR Biometrics[Jour] OR Biostatistics[Jour] OR Lifetime Data Anal[Jour] OR Stat Methods Med 
Res[Jour] OR Stat Med[Jour])  
 
Limits activated: English, Field: Title/Abstract 
Searched time period: 1 January 2000 until 28 October 2010 
 
(b)  involving high-impact medical journals 
 
(“competing cause” OR “competing causes” OR “competing risk” OR “competing risks” OR 
“competing outcome” OR “competing outcomes” OR “competing endpoints”) AND (N Engl J 
Med[Jour] OR JAMA[Jour] OR bmj[Jour] OR Ann Intern Med[Jour] OR Lancet[Jour] OR PLoS 
Med[Jour]) 
 
Limits activated: English, Field: Title/Abstract 
Searched time period: 1 January 2000 until 28 October 2010 
 
and (c) involving core clinical journals 
 
 
(“competing cause” OR “competing causes” OR “competing risk” OR “competing risks” OR 
“competing outcome” OR “competing outcomes” OR “competing endpoints”) 
 
Limits activated: English, Field: Title/Abstract, core clinical journals 
Searched time period: 1 January 2000 until 28 October 2010 
 
 
I replicated each of these searches and then also updated them by revising the 
searched time period to 1 January 2000 until 31 December 2015. 
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Appendix III Literature search of competing risks 
analyses of stroke recurrence and death 
 
A search was conducted using OvidSP of titles, abstracts and keywords to 
31/08/2016 using the following search terms: 
competing cause OR competing causes OR competing risk OR competing risks OR 
competing outcome OR competing outcomes OR competing endpoints AND stroke 
AND recur* 
The following diagram summaries the search leading to 17 contributions. 
 
 
 
 
 
 
 
Records included 
(n = 17) 
Records excluded due to: 
not stroke patients at start of study (n=3) 
not adults (n=1) 
pregnancy-specific intervention (n=1) 
not competing risks analysis of recurrence 
and death (n=4) 
  
Records identified  
(n = 52) 
Records after duplicates removed 
(n = 26) 
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Abbreviations used in Table: CAD=coronary artery disease, CKD=chronic kidney disease, ICH= intracerebral hemorrhage, eGRF=estimated Glomerular Filtration Rate, F&G model=Fine and 
Gray's proportional subdistribution hazards model, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MI=myocardial infarction, PVD=peripheral vascular disease, SAH=subarachnoid 
hemorrhage, TIA=transient ischemic attack 
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Appendix IV Evidence from the literature of competing risks analyses of stroke 
recurrence and death 
Author/                                        
Country 
Cohort/                               
age range 
Time period/                                  
length of follow-up/                     
sample size 
Approaches to 
analysis 
covariates used 
Primary 
outcome 
Main findings 
Wollenweber et al. 
(2014) 
 
 
 
 
ischemic infarct 
or ICH within 3 
days and no 
prior dementia 
Study time period not 
specified 
vague mention of 
competing risks 
analysis 
n/a - protocol, no 
modelling presented 
post-stroke 
dementia but 
stroke 
recurrence 
included as a 
secondary end 
point 
n/a - protocol only 
Germany 
 
proposed follow-up of 5 
years    
 ≥ 18 years 
plan to include n=600 
 
      
Sun et al. (2013) 
index ischemic 
stroke, ICH or 
SAH 
2000 - 2004 
standard Cox for 
death and F&G 
model for 
recurrence (but not 
death without 
recurrence) 
admitting year, age, 
gender, ethnicity, 
stroke subtype 
all-cause 
mortality 
(41.7%) and 
stroke 
recurrence 
(15.7%) 
recurrence more likely 
with haemorrhages and 
with aging 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 year follow-up 
ethnicity, gender and 
admitting year had no 
effect on recurrence 
after haemorrhagic (ICH 
or SAH) strokes 
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Abbreviations used in Table: CAD=coronary artery disease, CKD=chronic kidney disease, ICH= intracerebral hemorrhage, eGRF=estimated Glomerular Filtration Rate, F&G model=Fine and 
Gray's proportional subdistribution hazards model, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MI=myocardial infarction, PVD=peripheral vascular disease, SAH=subarachnoid 
hemorrhage, TIA=transient ischemic attack 
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Author/                                        
Country 
Cohort/                               
age range 
Time period/                                  
length of follow-up/                     
sample size 
Approaches to 
analysis 
covariates used 
Primary 
outcome 
Main findings 
Singapore 
age-range not 
specified 
n=12,559   
earlier year, male and 
being Malay or other 
was associated with a 
high risk of recurrence 
after ischemic stroke 
Arntz et al (2014)   
first-ever TIA, 
ischemic stroke 
or intracerebral 
hamorrhage 
Study time period not 
specified 
intention to use KM 
primariliy, F&G 
model only as 
secondary 
n/a - protocol, no 
modelling presented 
all-cause 
mortality and 
risk of 
recurrent 
vascular events 
n/a - protocol only 
 
 
 
 
 
 
 
 
 
 
proposed follow-up of 3 
years     
Netherlands aged 18-49 
plan to recruit 1500 
patients over 3-4 years 
      
 
Dhamoon et al. 
(2016a) + 
Conference 
abstract by 
Dhamoon et al. 
(2016b)  
 
 
diabetics with 
first ischemic 
stroke 
1 Apr 2002 - 31 Mar 
2012 
F&G model for 
recurrence with 
death as competing 
risk, but no 
corresponding model 
for death with 
recurrence as 
competing risk 
ethnicity, age, sex, 
income, hypertension, 
atrial fibrillation, 
stroke or TIA, MI, CAD, 
PVD and Charlson 
score 
death, all-cause 
readmission. 
Readmission for 
stroke/TIA, 
readmission for 
CAD, composite 
endpoint of all 
of the above 
combined  
South Asian diabetic 
stroke patients aged 
65+ have a higher 
recurrent stroke rate 
than their non- South 
Asian counterparts 
 
maximum follow-up to 
31 Mar 2013 with 
median follow-up of 
3.18 years 
 
 
 
 
 
Canada ≥ 18 years n= 25,495 
Instead, KM and Cox 
are used for death 
Also medication use in 
those aged ≥ 65 years 
 
  
           
                    261   
 
Abbreviations used in Table: CAD=coronary artery disease, CKD=chronic kidney disease, ICH= intracerebral hemorrhage, eGRF=estimated Glomerular Filtration Rate, F&G model=Fine and 
Gray's proportional subdistribution hazards model, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MI=myocardial infarction, PVD=peripheral vascular disease, SAH=subarachnoid 
hemorrhage, TIA=transient ischemic attack 
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Author/                                        
Country 
Cohort/                               
age range 
Time period/                                  
length of follow-up/                     
sample size 
Approaches to 
analysis 
covariates used 
Primary 
outcome 
Main findings 
Lewsey et al. 
(2010) + 
Conference 
abstract by Inglis et 
al. (2009) 
strokes based 
on ICD9/10 
codes 
1986 - 2001 
acknowledge should 
show results for 
each competing risk 
age, sex, 
socioeconomic status 
and comorbidity 
recurrent 
stroke within 5 
years (10.8%) 
Adjusted risk of 
recurrent stroke 
decreased by 27% 
between 1986 and 
2001. Adjusted risk of 
death being first event 
decreased by 28% 
between 1986 and 
2001.  
  
5 year follow-up 
F&G model for 
recurrence with 
death as competing 
risk 
 
death without 
recurrence 
within 5 years 
(57.8%) 
recurrences more likely 
in males, the most 
deprived and those with 
depression, 
hypertension, diabetes 
and atrial fibrillation 
 
 
Scotland 
 
n=128, 511 
F&G model for death 
with recurrence as 
competing risk 
  
 
death without 
recurrence was 
associated with aging, 
being female, and 
having heart failure, 
cancer, renal failure, 
Parkinsonism, dementia 
and falls and fractures. 
Having hypertension 
was associated with a 
reduced risk of death 
without recurrence 
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Abbreviations used in Table: CAD=coronary artery disease, CKD=chronic kidney disease, ICH= intracerebral hemorrhage, eGRF=estimated Glomerular Filtration Rate, F&G model=Fine and 
Gray's proportional subdistribution hazards model, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MI=myocardial infarction, PVD=peripheral vascular disease, SAH=subarachnoid 
hemorrhage, TIA=transient ischemic attack 
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Author/                                        
Country 
Cohort/                               
age range 
Time period/                                  
length of follow-up/                     
sample size 
Approaches to 
analysis 
covariates used 
Primary 
outcome 
Main findings 
Andersen et al. 
(2011) 
hospitalized 
stroke patients 
2002-2010 
F&G model with 
recurrent stroke and 
death treated as 
competing risks 
age, stroke severity 
score, gender, 
cardiovascular risk 
factors 
recurrent 
stroke (10%), 
death (26%) 
men at higher risk of 
dying after stroke 
(probable typo) 
Conference 
abstract  
median follow-up of 2.6 
years  
stroke recurrence not 
found to be related to 
age 
Denmark   n=29, 599   
higher risk of stroke 
recurrence in males and 
with an initial mild 
stroke 
He et al (2015) 
First-ever  
hamorrhagic, 
ischemic or 
other strokes: 
based on 
ICD9/10 codes 
1996 - 2011 
F&G model for 
recurrence with 
death as competing 
risk 
indigenous status, 
age, gender, stroke 
subtype, year of 
diagnosis, remoteness 
of residence, atrial 
fibrillation, 
hypercholesterolemia, 
modified Charlson 
Comorbidity Index and 
age*indigenous 
interaction 
recurrent 
stroke (13.5%),  
 
long-term 
death, 
 
 case fatality 
comorbidities did not 
explain the disparity in 
stroke recurrence 
between the indigenous 
and non-indigenous 
populations, whereas 
comorbidities did partly 
explain the disparity in 
case fatality and long-
term survival 
  
follow-up to 30 Jun 
2013 
F&G model for death 
with recurrence as 
competing risk 
 
Australia 
age range not 
specified but 
 ≤ 44, 45-64 and 
≥ 65 used in 
analysis 
n=2,105 
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Abbreviations used in Table: CAD=coronary artery disease, CKD=chronic kidney disease, ICH= intracerebral hemorrhage, eGRF=estimated Glomerular Filtration Rate, F&G model=Fine and 
Gray's proportional subdistribution hazards model, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MI=myocardial infarction, PVD=peripheral vascular disease, SAH=subarachnoid 
hemorrhage, TIA=transient ischemic attack 
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Author/                                        
Country 
Cohort/                               
age range 
Time period/                                  
length of follow-up/                     
sample size 
Approaches to 
analysis 
covariates used 
Primary 
outcome 
Main findings 
Ovbiagele (2012) 
index ischemic 
stroke 
Sep 1996 - May 2003 
Cox models with 
competing risks 
low eGFR + others not 
specified 
primary -time 
to first 
(recurrent) 
stroke, MI or 
vascular death 
low eGFR (CKD) found 
to be associated with 
primary outcome in 
adjusted model 
Conference 
abstract  
2 year follow-up 
  
secondary - 
time to first 
(recurrent) 
stroke 
no evidence of 
significant association 
of CKD with first 
(recurrent) stroke alone 
Country not 
specified  
n=3,673 
 
  
  
Stamplecoski et al. 
(2012) 
ischemic stroke, 
TIA or ICH 
July 1 2003 -Mar 31 2008 
competing risks Cox 
modelling with 
death and 
readmission as 
competing risks 
age, sex, initial stroke 
severity, 
comorbidities, type of 
stroke, discharge 
medications 
readmission 
(any reason) 
within 30d, 1yr 
and 2yr 
respectively: 
9.6%, 31.4%, 
42.3% 
no association results 
given in abstract for 
recurrent stroke 
readmission specifically 
Conference 
abstract  
30day, 1year and 2year 
follow-up   
death: 2.9%, 
13.2% and 
19.6% 
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Abbreviations used in Table: CAD=coronary artery disease, CKD=chronic kidney disease, ICH= intracerebral hemorrhage, eGRF=estimated Glomerular Filtration Rate, F&G model=Fine and 
Gray's proportional subdistribution hazards model, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MI=myocardial infarction, PVD=peripheral vascular disease, SAH=subarachnoid 
hemorrhage, TIA=transient ischemic attack 
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Author/                                        
Country 
Cohort/                               
age range 
Time period/                                  
length of follow-up/                     
sample size 
Approaches to 
analysis 
covariates used 
Primary 
outcome 
Main findings 
Ovbiagele (2013) 
non-disabling 
cerebral 
infarction 
Sep 1996 - May 2003 
competing risk Cox 
regression but used 
LRTs 
age, sex , race, 
history of previous 
stroke, severity of 
stroke, history of 
congestive heart 
failure, history of 
CAD, history of 
diabetes, history of 
carotid 
endarterectomy 
, body mass index, 
alcohol use in the 
previous 
year, current smoking, 
lipid modifier drug 
use, baseline 
antithrombotic use, 
total cholesterol, and 
low density 
lipoproteincholesterol 
primary - 
recurrence of 
stroke 
U-shape for association 
with systolic blood 
pressure for both 
primary and secondary 
outcomes. Low-normal 
and high have greater 
hazard of recurrence 
than normal-high 
  
2 year follow-up 
appear to show 
"naïve" Cox 
predictions 
secondary - 
composite 
outcome of 
stroke, MI or 
vascular death 
 
≥ 35 years n=3,680     
Castilloux et al. 
(2015) 
acute ischemic 
stroke (AIS) 
2011-2012 
competing risk 
model due to high 
death rate 
age, gender, past 
medical conditions, 
patient's region 
AIS recurrence , 
death 
aging and past medical 
conditions associated 
with higher hazard of 
death 
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Abbreviations used in Table: CAD=coronary artery disease, CKD=chronic kidney disease, ICH= intracerebral hemorrhage, eGRF=estimated Glomerular Filtration Rate, F&G model=Fine and 
Gray's proportional subdistribution hazards model, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MI=myocardial infarction, PVD=peripheral vascular disease, SAH=subarachnoid 
hemorrhage, TIA=transient ischemic attack 
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Author/                                        
Country 
Cohort/                               
age range 
Time period/                                  
length of follow-up/                     
sample size 
Approaches to 
analysis 
covariates used 
Primary 
outcome 
Main findings 
Conference 
abstract  
1 year follow-up Cox model specified 
  
past medical conditions 
associated with higher 
hazard of recurrence 
Canada 
age range not 
specified but 
85% are 65+ 
n=6,609 
 
  
 
Age not predictor of AIS 
recurrence. Gender and 
patient's region not 
predictive of death or 
AIS recurrence 
Choi et al. (2016) 
First-ever stroke 
patients with 
atrial 
fibrillation (AF) 
2008 -2012 
competing risk Cox 
model free-fatty acid, fasting 
blood sugar, diabetes, 
previous coronary 
artery disease, high-
density lipoprotein 
cholesterol, CHADS2 
score, CHA2DS2 - VASC 
score 
(1) any 
recurrent 
stroke after 3 
years (14.8%) 
i.e. ischemic or 
hemorrhagic  
free-fatty acid is a 
predictor for recurrent 
stroke in AF patients, 
even after adjusting for 
covariates in 
established models. It is 
associated with a higher 
hazard 
  
median follow-up of 
17.5 months  
(2) ischemic 
stroke or 
systemic 
embolism (ISSE) 
and 
Korea 
age-range not 
specified 
n=279 
Gray's test to 
compare cumulative 
incidence curves  
(3) ischemic 
stroke 
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Abbreviations used in Table: CAD=coronary artery disease, CKD=chronic kidney disease, ICH= intracerebral hemorrhage, eGRF=estimated Glomerular Filtration Rate, F&G model=Fine and 
Gray's proportional subdistribution hazards model, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MI=myocardial infarction, PVD=peripheral vascular disease, SAH=subarachnoid 
hemorrhage, TIA=transient ischemic attack 
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Author/                                        
Country 
Cohort/                               
age range 
Time period/                                  
length of follow-up/                     
sample size 
Approaches to 
analysis 
covariates used 
Primary 
outcome 
Main findings 
Rutten-Jacobs et 
al. (2013) 
first-ever TIA, 
ischemic stroke 
or intracerebral 
hamorrhage 
1 Jan 1980 - 1 Nov 2010 
Gray's test to 
compare cumulative 
incidence curves and 
F&G model  
age, sex and decade 
which index event 
occurred 
any vascular 
event with 
separate 
analyses for 
fatal or non-
fatal stroke and 
other arterial 
events 
no effect of age or sex 
on recurrent stroke 
  
follow-up mean (range):                    
9.1 (0-31) years     
Netherlands aged 18-50 n=724     
 
type of stroke and 
stroke severity found to 
be associated with 
recurrent stroke 
Wolinsky et al. 
(2009) 
≥ 70 years 1993 - 2005 
didn't have stroke recurrence specifically as an outcome, it was combined with first-ever 
strokes 
USA 
 
n=5,511     
 
  
Zhan et al. (2015) 
first incidence 
of stroke 
Time period of study 
and follow-up not 
specified 
F&G model as SHRs 
specified 
smoking + others that 
are not specified 
ischemic stroke 
recurrence 
(108/594) 
trend association was 
found between smoking 
and stroke recurrence 
but did not reach 
significance 
  
English abstract for 
article that is not 
written in English 
 
n=594 
recurrence as 
outcome, competing 
events are 
unspecified but 
frequency of 
occurrence is 
provided 
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Appendix V PRISMA diagram for literature search 
for use of recurrence-free survival as an 
outcome in stroke 
 
 The following diagram summaries the search leading to 20 contributions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified  
(n = 115) 
Records after duplicates removed 
(n = 71) 
Records excluded due to: 
not stroke patients at start of study (n=50) 
not adults (n=1) 
 
Records included 
(n = 20) 
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Abbreviations used in Tables: IQR=interquartile range, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MACE=major adverse cardiovascular event, 
PH=proportional hazards, WHO=World Health Organisation 
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Appendix VI Evidence of contributions to the literature using recurrence-free survival 
after stroke 
 
Contributions that may have benefited from decomposition of the outcomes  
Author/                                        
Country 
Cohort/                                     
age range 
Time period/                                 
length of follow-
up/                     
sample size 
Primary outcome + 
decomposition (n) 
Comments on approaches to analysis 
Elneihoum et al. 
(1998) 
WHO definition used for 
stroke 
1989 - 1992 
all-cause mortality and 
recurrence 
KM for survival, Cox for all-cause mortality, Cox for 
non-fatal recurrences 
  3 year follow-up 137 (6%) recurrences 
show probability of recurrence figure by age, can 
only assume it must be naïve KM as paper does not 
mention any appropriate competing risks approach 
Sweden  n=2,290 959 (43.4%) deaths 
not clear whether death was treated as a 
competing risk (i.e. censored) in the modelling of 
the hazard of recurrence 
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Abbreviations used in Tables: IQR=interquartile range, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MACE=major adverse cardiovascular event, 
PH=proportional hazards, WHO=World Health Organisation 
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Author/                                        
Country 
Cohort/                                     
age range 
Time period/                                 
length of follow-
up/                     
sample size 
Primary outcome + 
decomposition (n) 
Comments on approaches to analysis 
Ogasawara et al. 
(2002b) 
unilateral carotid artery 
or middle cerebral artery 
occlusion  
Jan 1993-Mar 1996 stroke recurrence or death KM for recurrence-free survival 
  
2 year follow-up 11 recurrences  Cox for recurrence 
Japan 
mean (range) age of  57 
(38-69) 
n=70 8/23 + 3/47 recurrences 
 
Hillen et al. (2003a) First-ever strokes Jan 1995-Aug 2000 
recurrence-free survival, 
recurrence 
Use KM for both recurrence-free survival and 
stroke recurrence 
  3 year follow-up 
153 (16.6%) recurrences by 5 
years 
Parametric PH model for recurrence or death. Also 
parametric PH for recurrence and specify that 
deaths are censored 
UK  n=1,626 recurrence or death, 65.3% 
Use likelihood to decide between parametric 
distributions. Use LRTs to select covariates 
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Abbreviations used in Tables: IQR=interquartile range, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MACE=major adverse cardiovascular event, 
PH=proportional hazards, WHO=World Health Organisation 
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Author/                                        
Country 
Cohort/                                     
age range 
Time period/                                 
length of follow-
up/                     
sample size 
Primary outcome + 
decomposition (n) 
Comments on approaches to analysis 
Hillen et al. (2003b) 
patients surviving 3 
months after first ever 
stroke 
1995-1998 
disability + recurrence-free 
survival over 5 years 
Cox for recurrence-free survival 
  3 year follow-up 212 recurrences or death  
UK  n=561 66 recurrences,    146 deaths  
Yokota et al. (2004) first-ever acute strokes 
1 Apr 1978 - 31 
Mar 1997 
recurrence-free survival but 
KM for recurrence-free survival,                                                           
Cox for recurrence-free survival   
min 3 year follow-
up,     
follow-up to 31 
Mar 2000 unless 
had an event 
198 recurrences and 286 deaths 
within 3 years 
Japan 
 
n=1,565 
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Abbreviations used in Tables: IQR=interquartile range, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MACE=major adverse cardiovascular event, 
PH=proportional hazards, WHO=World Health Organisation 
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Author/                                        
Country 
Cohort/                                     
age range 
Time period/                                 
length of follow-
up/                     
sample size 
Primary outcome + 
decomposition (n) 
Comments on approaches to analysis 
Lee et al. (2010) 
cryptogenic stroke with 
patent foramen ovale 
Jan 2000 - Apr 
2007 
recurrent ischemic stroke  KM for recurrence in methods 
+ conference 
abstract by Lee et al. 
(2009) 
 
median follow-up 
of                                        
3.5 years,                                 
follow-up to Aug 
2008 
14 (7.7%) recurrences Cox for recurrence 
South Korea  n=181  KM for recurrence-free survival 
Toschke et al. (2011) 
Diagnosed with index 
stroke between 1997-
2006 with no stroke for at 
least 2yrs prior 
1997-2006 
effects of antihypertensive use 
on: survival after 1yr, recurrence 
after 1yr 
Cox for all-cause mortality, Cox also for recurrence 
   
survival,                                
recurrence-free survival 
Not clear whether death was treated as a 
competing risk in modelling of hazard of recurrence 
UK   n=44,244 
 
~30% deaths by 5years among 
3690 patients surviving 90 days                
35-40% recurrences by 6 years 
among 3121 patients surviving 
1year 
A naïve Cox probability of recurrence is presented 
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Abbreviations used in Tables: IQR=interquartile range, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MACE=major adverse cardiovascular event, 
PH=proportional hazards, WHO=World Health Organisation 
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Author/                                        
Country 
Cohort/                                     
age range 
Time period/                                 
length of follow-
up/                     
sample size 
Primary outcome + 
decomposition (n) 
Comments on approaches to analysis 
Chan et al. (2012) 
prior history of 
atherothrombotic/            
hemorrhagic stroke 
  recurrence free survival KM for recurrence-free survival 
  
30 months follow-
up 
10 recurrences, 12 MACEs, 8 
deaths 
KM for MACE-free survival 
Hong Kong mean(sd) age of 67(11) n=127  Cox for stroke recurrence and MACE 
Abbreviations used: IQR=interquartile range, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MACE=major adverse cardiovascular event, 
PH=proportional hazards, WHO=World Health Organisation 
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Abbreviations used in Tables: IQR=interquartile range, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MACE=major adverse cardiovascular event, 
PH=proportional hazards, WHO=World Health Organisation 
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Contributions not likely to benefit from decomposition of the outcomes  
Author/                                        
Country 
Cohort/                                     
age range 
Time period/                                 
length of follow-
up/                     
sample size 
Primary outcome + 
decomposition (n) 
Comments on approaches to analysis 
Nadeau et al. 
(1992) 
vertebrobasilar 
stroke  
  30 day and 3 year survival KM used for survival and recurrences 
 
all male 3 year follow-up stroke recurrence 
KM curves shown for overall survival and recurrence-free 
survival 
 
mean age of 63 n=57 13 recurrences  
 
Yokota et al. 
(1998) 
ischemic stroke 1987-1995 stroke recurrence KM for recurrence-free survival 
  
median follow-up 
of  2.7 years,                                                                                              
range 2 days - 7.8 
years 
13 recurrences Cox for recurrence 
Japan 
mean (range) age 
of  63 (28-81) 
n=105 11 deaths 
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PH=proportional hazards, WHO=World Health Organisation 
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Author/                                        
Country 
Cohort/                                     
age range 
Time period/                                 
length of follow-
up/                     
sample size 
Primary outcome + 
decomposition (n) 
Comments on approaches to analysis 
Ogasawara et 
al. (2002a) 
symptomatic 
internal carotid 
artery or middle 
cerebral artery 
occlusion  
Jan 1993-Mar 
1996 
5 year risk of recurrent stroke KM and Cox for recurrence-free survival 
  
5 year follow-up stroke recurrence or death 
 
Japan 
mean (range) age 
of  57 (38-69) 
n=70 13 recurrences and 4 deaths 
 
Marnane et al. 
(2010) 
ischemic stroke   
stroke recurrence,          
functional outcome (modified 
Rankin score) 
KM and Cox for recurrence-free survival 
Conference 
abstract   
1 year follow-up 
6 and 10 recurrences by 7 and 
14 days respectively  
Ireland 
 
n=365 
  
          275 
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Author/                                        
Country 
Cohort/                                     
age range 
Time period/                                 
length of follow-
up/                     
sample size 
Primary outcome + 
decomposition (n) 
Comments on approaches to analysis 
Kuwashiro et 
al. (2012) 
ischemic stroke 
Jun 2007 - Apr 
2008 
recurrence-free survival KM for recurrence-free survival 
  
1year follow-up 25 (9.6%) recurrences 
mentions KM to compare recurrence vs non-recurrence groups 
in methods but not results 
Japan mean age 67 n=256 8 deaths used logistic regression with recurrence by 1year as outcome 
Kim et al. 
(2014) 
acute ishaemic 
strokes 
Mar 2003 - Apr 
2011 
recurrence-free survival KM for recurrence-free survival 
  
90 days follow-up 
recurrent ischemic stroke within 
90 days 
KM for recurrence 
USA 
median (IQR) age 
of  70 (58-80) 
n=2,378 
106 (5.9%) recurrences by 90 
days 
Cox for recurrence 
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Author/                                        
Country 
Cohort/                                     
age range 
Time period/                                 
length of follow-
up/                     
sample size 
Primary outcome + 
decomposition (n) 
Comments on approaches to analysis 
Fujimoto et al. 
(2015) 
acute ishaemic 
strokes 
  stroke recurrence and death KM for recurrence-free survival 
Conference 
abstract   
median follow-up 
of                                      
3.2 years 
recurrence 12%, 11.8%, 18.2% 
and 6.7% when split by embolic 
source 
Cox for recurrence and death 
+ another 
conference 
abstract by 
Mezuki et al 
(2013) 
 
n=542 
recurrence and death 14.4%, 
15.1%, 21.6% and 6.7% when 
split by embolic source 
 
Abbreviations used: IQR=interquartile range, KM=Kaplan-Meier estimate, LRTs= likelihood ratio tests, MACE=major adverse cardiovascular event, 
PH=proportional hazards, WHO=World Health Organisation 
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Appendix VII Literature search of broad use of 
multi-state modelling in medical literature 
 
Pubmed search for multi-state modelling that used the following search terms: 
 
(a)  involving selected biostatistical journals 
 
"multi-state model" OR "multistate model" OR "multi state model" OR "illness-
death model" OR "illness death model" OR "multi-state models" OR "multistate 
models" OR "multi state models" OR "illness-death models" OR "illness death 
models" OR "multi-state modelling" OR "multistate modelling" OR "multi state 
modelling" OR "illness-death modelling" OR "illness death modelling" OR "multi-
state modeling" OR "multistate modeling" OR "multi state modeling" OR "illness-
death modeling" OR "illness death modeling" OR "disability model*" OR ("multi-
state" AND "Markov") OR ("multistate" AND "Markov") OR ("multi state" AND 
"Markov") OR ("illness-death" AND "Markov") OR ("illness death" AND "Markov") OR 
("disability AND "Markov") OR ("multi-state" AND "semi-Markov") OR ("multistate" 
AND "semi-Markov") OR ("multi state" AND "semi-Markov") OR ("illness-death" AND 
"semi-Markov") OR ("illness death" AND "semi-Markov") OR ("disability AND "semi-
Markov") OR ("multi-state" AND "model") OR ("multistate" AND "model") OR ("multi 
state" AND "model") OR ("illness-death" AND "model") OR ("illness death" AND 
"model") OR ("multi-state" AND "models") OR ("multistate" AND "models") OR 
("multi state" AND "models") OR ("illness-death" AND "models") OR ("illness death" 
AND "models")OR ("multi-state" AND "modelling") OR ("multistate" AND 
"modelling") OR ("multi state" AND "modelling") OR ("illness-death" AND 
"modelling") OR ("illness death" AND "modelling") OR ("multi-state" AND 
"modeling") OR ("multistate" AND "modeling") OR ("multi state" AND "modeling") 
OR ("illness-death" AND "modeling") OR ("illness death" AND "modeling")  
AND (Biom J[Jour] OR Biometrics[Jour] OR Biostatistics[Jour] OR Lifetime Data 
Anal[Jour] OR Stat Methods Med Res[Jour] OR Stat Med[Jour])  
Limits activated: Title/Abstract 
Searched time period: 1 January 2000 until 31 December 2015 
 
(b)  involving high-impact medical journals 
 
"multi-state model" OR "multistate model" OR "multi state model" OR "illness-
death model" OR "illness death model" OR "multi-state models" OR "multistate 
models" OR "multi state models" OR "illness-death models" OR "illness death 
models" OR "multi-state modelling" OR "multistate modelling" OR "multi state 
modelling" OR "illness-death modelling" OR "illness death modelling" OR "multi-
state modeling" OR "multistate modeling" OR "multi state modeling" OR "illness-
death modeling" OR "illness death modeling" OR "disability model*" OR ("multi-
state" AND "Markov") OR ("multistate" AND "Markov") OR ("multi state" AND 
"Markov") OR ("illness-death" AND "Markov") OR ("illness death" AND "Markov") OR 
("disability AND "Markov") OR ("multi-state" AND "semi-Markov") OR ("multistate" 
AND "semi-Markov") OR ("multi state" AND "semi-Markov") OR ("illness-death" AND 
"semi-Markov") OR ("illness death" AND "semi-Markov") OR ("disability AND "semi-
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Markov") OR ("multi-state" AND "model") OR ("multistate" AND "model") OR ("multi 
state" AND "model") OR ("illness-death" AND "model") OR ("illness death" AND 
"model") OR ("multi-state" AND "models") OR ("multistate" AND "models") OR 
("multi state" AND "models") OR ("illness-death" AND "models") OR ("illness death" 
AND "models")OR ("multi-state" AND "modelling") OR ("multistate" AND 
"modelling") OR ("multi state" AND "modelling") OR ("illness-death" AND 
"modelling") OR ("illness death" AND "modelling") OR ("multi-state" AND 
"modeling") OR ("multistate" AND "modeling") OR ("multi state" AND "modeling") 
OR ("illness-death" AND "modeling") OR ("illness death" AND "modeling")  
 AND (N Engl J Med[Jour] OR JAMA[Jour] OR bmj[Jour] OR Ann Intern Med[Jour] 
OR Lancet[Jour] OR PLoS Med[Jour]) 
 
Limits activated: Title/Abstract 
Searched time period: 1 January 2000 until 31 December 2015 
 
and (c) involving core clinical journals 
 
 
"multi-state model" OR "multistate model" OR "multi state model" OR "illness-
death model" OR "illness death model" OR "multi-state models" OR "multistate 
models" OR "multi state models" OR "illness-death models" OR "illness death 
models" OR "multi-state modelling" OR "multistate modelling" OR "multi state 
modelling" OR "illness-death modelling" OR "illness death modelling" OR "multi-
state modeling" OR "multistate modeling" OR "multi state modeling" OR "illness-
death modeling" OR "illness death modeling" OR "disability model*" OR ("multi-
state" AND "Markov") OR ("multistate" AND "Markov") OR ("multi state" AND 
"Markov") OR ("illness-death" AND "Markov") OR ("illness death" AND "Markov") OR 
("disability AND "Markov") OR ("multi-state" AND "semi-Markov") OR ("multistate" 
AND "semi-Markov") OR ("multi state" AND "semi-Markov") OR ("illness-death" AND 
"semi-Markov") OR ("illness death" AND "semi-Markov") OR ("disability AND "semi-
Markov") OR ("multi-state" AND "model") OR ("multistate" AND "model") OR ("multi 
state" AND "model") OR ("illness-death" AND "model") OR ("illness death" AND 
"model") OR ("multi-state" AND "models") OR ("multistate" AND "models") OR 
("multi state" AND "models") OR ("illness-death" AND "models") OR ("illness death" 
AND "models")OR ("multi-state" AND "modelling") OR ("multistate" AND 
"modelling") OR ("multi state" AND "modelling") OR ("illness-death" AND 
"modelling") OR ("illness death" AND "modelling") OR ("multi-state" AND 
"modeling") OR ("multistate" AND "modeling") OR ("multi state" AND "modeling") 
OR ("illness-death" AND "modeling") OR ("illness death" AND "modeling")  
 
Limits activated: Title/Abstract, core clinical journals 
Searched time period: 1 January 2000 until 31 December 2015 
 
In addition, for each of the three searches above, the term “cost*” was added to 
help identify studies involving cost-effectiveness analysis. If found, these were 
removed. This was the case for 1, 1 and 4 articles in biostatistical, high-impact 
medical and core clinical journals respectively.
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Appendix VIII PRISMA diagram for literature search 
of use of multi-state modelling in health economics 
literature 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Records identified from  
OvidSP search 
 
(n = 403) 
Records after duplicates removed 
(n = 225) 
Additional records included through 
other sources: 
 
Medical Decision Making journal (n= 2) 
Value in Health journal (n= 3) 
Health Economics journal (n= 1) 
NICE TA submissions (n = 6) 
NIHR Health Technology Assessment 
journal (n=4) 
 
 
Records included 
(n = 21) 
Records excluded due to: 
not continuous-time multi-state modelling/not health 
economics context (n=167) 
not humans (n=11) 
conference abstract with limited information (n=18) 
not accessible (n=6) 
publications that accompany this thesis (n=2) 
Total contributions 
(n = 27) 
Records excluded due to  
not being continuous-time multi-
state modelling: 
NICE TA submissions (n = 6) 
NIHR Health Technology 
Assessment journal (n=4) 
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Appendix IX 
 
Table A1 Cost per QALYs results in all 216 combinations 
Distribution used for:         
progression-
free -> 
progression 
progression-
free -> 
death 
progression-> 
death 
incremental 
QALYs 
incremental 
Costs (£) 
Cost per 
QALY 
gained 
(£) 
Gompertz Gompertz Gompertz 0.331 10149 30702 
exponential Gompertz Gompertz 0.844 9620 11393 
exponential exponential Gompertz 0.841 9613 11424 
exponential Log-logistic Gompertz 0.829 9548 11515 
exponential Log normal Gompertz 0.829 9570 11543 
exponential Gompertz generalised 
gamma 
0.797 9324 11699 
exponential generalised 
gamma 
Gompertz 0.805 9534 11839 
exponential Weibull Gompertz 0.807 9557 11844 
exponential exponential generalised 
gamma 
0.791 9372 11848 
exponential Log-logistic generalised 
gamma 
0.782 9261 11849 
exponential Log normal generalised 
gamma 
0.783 9293 11867 
exponential Gompertz exponential 0.756 9160 12117 
exponential Weibull generalised 
gamma 
0.760 9275 12205 
exponential generalised 
gamma 
generalised 
gamma 
0.752 9215 12249 
exponential exponential Weibull 0.753 9241 12272 
exponential Log-logistic Weibull 0.750 9217 12294 
exponential Gompertz Log-logistic 0.777 9585 12343 
exponential Weibull Weibull 0.735 9215 12539 
exponential Gompertz Weibull 0.728 9221 12667 
exponential generalised 
gamma 
Log-logistic 0.729 9359 12841 
exponential Log normal Weibull 0.714 9175 12850 
exponential Log normal Log-logistic 0.713 9466 13279 
exponential generalised 
gamma 
exponential 0.676 9019 13336 
exponential generalised 
gamma 
Weibull 0.683 9138 13384 
exponential Log-logistic Log-logistic 0.705 9480 13450 
exponential exponential exponential 0.665 9048 13597 
exponential Log normal exponential 0.664 9044 13611 
exponential Weibull Log-logistic 0.697 9503 13643 
exponential Log-logistic exponential 0.654 9095 13907 
exponential Weibull Log normal 0.664 9239 13913 
exponential Log-logistic Log normal 0.659 9215 13993 
exponential Weibull exponential 0.651 9134 14040 
exponential Gompertz Log normal 0.650 9170 14096 
Log normal Gompertz Gompertz 0.691 9847 14245 
exponential exponential Log-logistic 0.659 9503 14427 
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Distribution used for:         
progression-
free -> 
progression 
progression-
free -> 
death 
progression-> 
death 
incremental 
QALYs 
incremental 
Costs (£) 
Cost per 
QALY 
gained 
(£) 
Log normal Log normal Gompertz 0.675 9780 14481 
Log-logistic Gompertz Gompertz 0.687 9992 14535 
Log normal Gompertz generalised 
gamma 
0.645 9518 14760 
exponential generalised 
gamma 
Log normal 0.609 9028 14828 
exponential Log normal Log normal 0.617 9163 14848 
Log normal Weibull Gompertz 0.666 9893 14860 
Log normal Log normal generalised 
gamma 
0.630 9459 15010 
Log normal exponential Gompertz 0.654 9848 15050 
Log-logistic Log normal Gompertz 0.652 9820 15061 
Log normal Log-logistic Gompertz 0.649 9835 15162 
Log-logistic Gompertz generalised 
gamma 
0.639 9696 15171 
Log normal generalised 
gamma 
Gompertz 0.631 9726 15405 
Log normal Weibull generalised 
gamma 
0.616 9595 15587 
exponential exponential Log normal 0.595 9325 15685 
Log normal Gompertz Weibull 0.601 9488 15796 
Log normal exponential generalised 
gamma 
0.604 9577 15843 
Log-logistic Log normal generalised 
gamma 
0.598 9552 15972 
Log normal Log-logistic generalised 
gamma 
0.596 9534 16007 
Log-logistic exponential Gompertz 0.612 9863 16111 
Log normal generalised 
gamma 
generalised 
gamma 
0.579 9398 16228 
Log normal Weibull Weibull 0.577 9527 16508 
Log normal Log normal Weibull 0.571 9420 16510 
Log normal Log normal Log-logistic 0.591 9783 16565 
Log normal exponential Weibull 0.573 9510 16602 
Log-logistic Gompertz Weibull 0.579 9741 16822 
Log-logistic generalised 
gamma 
Gompertz 0.581 9775 16836 
Log normal Log-logistic Log-logistic 0.577 9750 16910 
Log normal Log-logistic Weibull 0.551 9425 17118 
Log-logistic Gompertz exponential 0.557 9556 17144 
Log normal Weibull Log-logistic 0.568 9781 17214 
Log-logistic Log normal Weibull 0.546 9467 17344 
Log-logistic exponential generalised 
gamma 
0.547 9611 17556 
Log normal Log normal exponential 0.536 9435 17587 
Log-logistic exponential Weibull 0.539 9495 17604 
Log normal exponential Log-logistic 0.550 9703 17633 
Log normal exponential exponential 0.528 9352 17717 
Log normal generalised 
gamma 
Weibull 0.532 9426 17725 
Weibull Log normal Gompertz 0.569 10111 17781 
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Distribution used for:         
progression-
free -> 
progression 
progression-
free -> 
death 
progression-> 
death 
incremental 
QALYs 
incremental 
Costs (£) 
Cost per 
QALY 
gained 
(£) 
Log normal Gompertz exponential 0.521 9342 17917 
Log normal Log normal Log normal 0.529 9515 17993 
Log-logistic Gompertz Log-logistic 0.557 10080 18084 
Weibull Weibull Gompertz 0.551 10000 18157 
Log normal Gompertz Log-logistic 0.543 9876 18192 
Log-logistic Weibull Gompertz 0.546 9946 18219 
generalised 
gamma 
Gompertz Gompertz 0.558 10186 18270 
Log-logistic Log-logistic Gompertz 0.548 10033 18316 
Log normal Weibull Log normal 0.525 9633 18353 
Log-logistic generalised 
gamma 
generalised 
gamma 
0.512 9433 18424 
Log-logistic Log normal Log-logistic 0.524 9703 18514 
Weibull Gompertz Gompertz 0.542 10084 18615 
Log-logistic generalised 
gamma 
Log-logistic 0.528 9890 18741 
Log normal generalised 
gamma 
Log-logistic 0.524 9909 18897 
Log normal Log-logistic Log normal 0.502 9519 18948 
Log normal Log-logistic exponential 0.496 9416 18997 
Log normal exponential Log normal 0.498 9502 19095 
Weibull exponential Gompertz 0.530 10143 19127 
Log-logistic exponential exponential 0.491 9421 19200 
Weibull Log normal generalised 
gamma 
0.505 9713 19219 
Log normal Weibull exponential 0.489 9392 19219 
Log-logistic Weibull generalised 
gamma 
0.505 9726 19244 
generalised 
gamma 
generalised 
gamma 
Gompertz 0.523 10068 19250 
Log-logistic generalised 
gamma 
Weibull 0.480 9333 19442 
Log normal generalised 
gamma 
exponential 0.480 9350 19483 
Log-logistic Log normal exponential 0.483 9410 19489 
Weibull generalised 
gamma 
Gompertz 0.508 9983 19652 
Log-logistic Log-logistic generalised 
gamma 
0.495 9734 19658 
generalised 
gamma 
Gompertz generalised 
gamma 
0.501 9872 19693 
generalised 
gamma 
Log normal Gompertz 0.509 10029 19721 
Log-logistic Log-logistic Log-logistic 0.502 9899 19735 
Log-logistic generalised 
gamma 
exponential 0.471 9353 19862 
generalised 
gamma 
Gompertz Weibull 0.489 9753 19933 
Log-logistic Log-logistic exponential 0.481 9682 20125 
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Distribution used for:         
progression-
free -> 
progression 
progression-
free -> 
death 
progression-> 
death 
incremental 
QALYs 
incremental 
Costs (£) 
Cost per 
QALY 
gained 
(£) 
generalised 
gamma 
Weibull Gompertz 0.491 9908 20161 
Weibull Log normal Log-logistic 0.508 10285 20233 
generalised 
gamma 
Gompertz Log-logistic 0.508 10288 20244 
Weibull Log normal Weibull 0.477 9667 20256 
Log normal generalised 
gamma 
Log normal 0.470 9551 20303 
generalised 
gamma 
Log-logistic Gompertz 0.492 9989 20320 
Log normal Gompertz Log normal 0.472 9590 20330 
Log-logistic exponential Log-logistic 0.487 9911 20352 
Log-logistic Weibull Log-logistic 0.478 9747 20396 
generalised 
gamma 
exponential Gompertz 0.489 9983 20413 
Weibull Gompertz Log-logistic 0.502 10267 20470 
Weibull Weibull generalised 
gamma 
0.472 9693 20515 
Log-logistic Log-logistic Weibull 0.470 9721 20664 
Log-logistic Gompertz Log normal 0.476 9851 20686 
Weibull Gompertz generalised 
gamma 
0.468 9724 20788 
Weibull exponential Weibull 0.468 9774 20879 
Log-logistic Weibull Weibull 0.462 9653 20880 
Weibull Weibull Weibull 0.460 9642 20964 
Log-logistic Weibull exponential 0.456 9568 20969 
Weibull Gompertz Weibull 0.456 9733 21334 
Weibull generalised 
gamma 
generalised 
gamma 
0.448 9578 21364 
generalised 
gamma 
Log normal Log-logistic 0.477 10286 21555 
Weibull generalised 
gamma 
Log-logistic 0.465 10060 21636 
Weibull Log-logistic Gompertz 0.458 9986 21801 
Log-logistic Log normal Log normal 0.440 9625 21871 
Weibull exponential generalised 
gamma 
0.445 9759 21926 
Weibull exponential Log-logistic 0.466 10289 22065 
generalised 
gamma 
generalised 
gamma 
generalised 
gamma 
0.436 9648 22146 
generalised 
gamma 
Weibull Log-logistic 0.449 9990 22248 
Log-logistic exponential Log normal 0.439 9779 22289 
generalised 
gamma 
Log normal generalised 
gamma 
0.433 9649 22294 
Weibull Gompertz exponential 0.437 9754 22336 
generalised 
gamma 
generalised 
gamma 
exponential 0.433 9744 22479 
Weibull generalised 
gamma 
Weibull 0.435 9802 22513 
Weibull Log normal exponential 0.417 9440 22617 
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Distribution used for:         
progression-
free -> 
progression 
progression-
free -> 
death 
progression-> 
death 
incremental 
QALYs 
incremental 
Costs (£) 
Cost per 
QALY 
gained 
(£) 
generalised 
gamma 
Gompertz exponential 0.422 9575 22674 
generalised 
gamma 
Log-logistic Log-logistic 0.439 10002 22800 
Log-logistic Log-logistic Log normal 0.423 9664 22872 
generalised 
gamma 
Weibull generalised 
gamma 
0.421 9654 22956 
generalised 
gamma 
exponential Weibull 0.416 9612 23131 
Weibull exponential exponential 0.418 9740 23281 
generalised 
gamma 
exponential generalised 
gamma 
0.416 9693 23307 
Weibull Weibull Log-logistic 0.438 10203 23321 
generalised 
gamma 
Log normal Weibull 0.416 9740 23389 
Weibull Log normal Log normal 0.425 9988 23516 
Log-logistic Weibull Log normal 0.408 9630 23622 
generalised 
gamma 
generalised 
gamma 
Log-logistic 0.421 9941 23626 
generalised 
gamma 
Log-logistic generalised 
gamma 
0.407 9707 23869 
Weibull Log-logistic generalised 
gamma 
0.408 9746 23916 
Log-logistic generalised 
gamma 
Log normal 0.403 9635 23926 
Weibull Weibull exponential 0.393 9420 23949 
Weibull Log-logistic Log-logistic 0.422 10125 23985 
generalised 
gamma 
Weibull Weibull 0.394 9539 24237 
Weibull Gompertz Log normal 0.412 9995 24289 
generalised 
gamma 
generalised 
gamma 
Weibull 0.396 9633 24354 
Weibull Log-logistic exponential 0.394 9599 24377 
generalised 
gamma 
exponential Log-logistic 0.413 10106 24463 
Weibull exponential Log normal 0.404 9960 24676 
generalised 
gamma 
generalised 
gamma 
Log normal 0.394 9864 25031 
generalised 
gamma 
Log-logistic Weibull 0.379 9592 25281 
Weibull Log-logistic Weibull 0.380 9624 25342 
generalised 
gamma 
Log normal exponential 0.376 9624 25567 
generalised 
gamma 
Weibull exponential 0.370 9585 25896 
generalised 
gamma 
Log-logistic exponential 0.370 9621 26027 
generalised 
gamma 
Weibull Log normal 0.376 9833 26135 
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Distribution used for:         
progression-
free -> 
progression 
progression-
free -> 
death 
progression-> 
death 
incremental 
QALYs 
incremental 
Costs (£) 
Cost per 
QALY 
gained 
(£) 
generalised 
gamma 
Log normal Log normal 0.376 9882 26250 
Weibull generalised 
gamma 
exponential 0.360 9509 26402 
generalised 
gamma 
Gompertz Log normal 0.375 9913 26420 
Weibull generalised 
gamma 
Log normal 0.367 9702 26443 
Weibull Weibull Log normal 0.376 9955 26509 
generalised 
gamma 
exponential exponential 0.341 9481 27813 
generalised 
gamma 
Log-logistic Log normal 0.340 9686 28504 
generalised 
gamma 
exponential Log normal 0.349 9966 28583 
Gompertz Weibull Gompertz 0.340 10218 30056 
Weibull Log-logistic Log normal 0.318 9799 30769 
Gompertz Log-logistic Gompertz 0.316 10202 32299 
Gompertz Log normal Gompertz 0.314 10159 32353 
Gompertz exponential Gompertz 0.287 10097 35230 
Gompertz Weibull generalised 
gamma 
0.258 9860 38175 
Gompertz Gompertz generalised 
gamma 
0.251 9801 39043 
Gompertz generalised 
gamma 
Gompertz 0.252 10011 39781 
Gompertz Log-logistic generalised 
gamma 
0.230 9799 42651 
Gompertz Log normal generalised 
gamma 
0.219 9775 44704 
Gompertz Weibull Log-logistic 0.226 10279 45570 
Gompertz generalised 
gamma 
Log-logistic 0.220 10235 46418 
Gompertz Log-logistic Log-logistic 0.217 10244 47134 
Gompertz Gompertz Log-logistic 0.208 10191 48889 
Gompertz Weibull Weibull 0.194 9686 49907 
Gompertz Gompertz Weibull 0.188 9676 51582 
Gompertz exponential Log-logistic 0.197 10179 51781 
Gompertz exponential generalised 
gamma 
0.179 9666 53957 
Gompertz Log normal Log-logistic 0.180 10181 56610 
Gompertz Log-logistic Weibull 0.165 9707 58659 
Gompertz Log normal Weibull 0.164 9692 59199 
Gompertz Log-logistic exponential 0.159 9865 62101 
Gompertz Weibull exponential 0.156 9744 62327 
Gompertz Gompertz exponential 0.147 9686 65697 
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Distribution used for:         
progression-
free -> 
progression 
progression-
free -> 
death 
progression-> 
death 
incremental 
QALYs 
incremental 
Costs (£) 
Cost per 
QALY 
gained 
(£) 
Gompertz exponential Weibull 0.146 9668 66291 
Gompertz generalised 
gamma 
Weibull 0.144 9567 66552 
Gompertz generalised 
gamma 
generalised 
gamma 
0.143 9516 66668 
Gompertz Log normal exponential 0.128 9780 76128 
Gompertz generalised 
gamma 
exponential 0.120 9671 80492 
Gompertz exponential exponential 0.114 9635 84734 
Gompertz Gompertz Log normal 0.108 9938 92303 
Gompertz generalised 
gamma 
Log normal 0.091 9873 108802 
Gompertz Weibull Log normal 0.090 9882 109412 
Gompertz Log-logistic Log normal 0.087 9892 113980 
Gompertz exponential Log normal 0.079 9824 124952 
Gompertz Log normal Log normal 0.028 9781 344585 
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